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Key lectures
KL01
Adjuvant and neoadjuvant chemotherapy for osteosar-
coma of the extremity: Experience at Istituti Ortopedici
Rizzoli, in 1148 patients treated between 1972 and 1999,
with a 5 to 27-year follow-up
G. Bacci
(Department of Musculoskeletal Oncology, Istituti Ortopedici
Rizzoli, Bologna, Italy)
1148 patients with non-metastatic osteosarcoma of the
extremity were treated in a single institution between 1972
and 1999 with 4 protocols of adjuvant chemotherapy (248)
and 5 protocol of neoadjuvant chemotherapy (900). The
overall rate of limb-salvage was 71%, increasing from 20%
of the first adjuvant studies to 96% obtained with the last
neoadjuvant protocol.
5-year EFS and OS were 57% and 66% respectively, and
they were significantly related to serum values of alkaline
phosphatase, type of chemotherapy, and grade of histologic
response to preoperative chemotherapy (in patients treated
with neoadjuvant protocols).
The 61 local recurrences were significantly related to
surgical margins. The 5-year post-relapse EFS was 17%,
and it was significantly higher for patients relapsing with
lung metastases than for those with local recurrence. It was
also significantly related to the number of metastases and
duration of the disease-free interval.
In our experience, the combination of aggressive
chemotherapy and surgery can cure more than the 60%
of patients with osteosarcoma of the extremity, preserving
the limb in most patients.
KL02
Alveolar rhabdomyosarcoma: Molecular pathogenesis
and therapeutic implications
F.G. Barr, S.J. Xia
(Department of Pathology and Laboratory Medicine,
University of Pennsylvania, Philadelphia, USA)
Alveolar rhabdomyosarcoma is an aggressive soft tissue
cancer associated with the skeletal muscle lineage. These
cancers typically have a characteristic 2;13 chromosomal
translocation, which fuses the PAX3 and FKHR genes and
results in a chimeric PAX3-FKHR protein. Our studies
in NIH3T3 fibroblasts demonstrate that the fusion protein
has transforming activity at low expression level, but
suppresses growth at higher expression level. Using
PAX3-FKHR mutants with inactivating mutations in the
paired box or homeobox, we find that the homeobox is
required for transformation whereas the paired box is
required for growth suppression. Subsequently, we identi-
fied a vector that reduced PAX3-FKHR expression to a
level that does not cause growth suppression. In this
expression system, the paired box mutant demonstrates
substantially enhanced transforming activity. This finding
indicates that the paired box exerts an inhibitory effect on
PAX3-FKHR oncogenic behavior, and thus we hypothe-
size that events that interfere with PAX3-FKHR paired
box function, either by protein-protein interaction or
direct mutation, will promote tumorigenesis by increasing
oncogenic activity and decreasing growth suppressive
activity. Therefore, another avenue for therapeutic
strategies is to target these collaborating events that
permit the cell to tolerate the growth suppressive activity
of PAX3-FKHR or decrease its additional oncogenic
potency.
KL03
Experimental systemic therapies in bone tumors
M. Bernstein
(Department of Pediatrics and Oncology, Hopital Ste. Justine,
Montreal, Canada)
The most common bone sarcomas are osteosarcoma and
Ewing sarcoma, with 450 and 225 cases in North America
each year in those younger than 20 years. Osteosarcoma
occurs primarily in long bones, Ewing sarcoma also in the
pelvis, spine or chest wall. Localized disease confers a 65%
cure rate; initially metastatic disease, 25%. Management
includes systemic chemotherapy and local control mea-
sures for primary and metastatic sites. Complete surgical
excision is mandatory in osteosarcoma; in Ewing, radiation
can also be used.
Chemotherapy for osteosarcoma is based on a combina-
tion of cisplatin, doxorubicin and high-dose methotrexate.
Ifosfamide and etoposide, and alpha interferon, will be
further examined in the Euramos (European and American
Osteosarcoma) study. Ongoing investigations include the
fas, fas ligand pathway and anti-folates.
Systemic therapy for Ewing includes vincristine, doxo-
rubicin, cyclophosphamide, ifosfamide and etoposide.
The current Children’s Oncology Group (COG) protocol
studies increased dose density. High-dose therapy
with autologous stem cell reinfusion is being evaluated
in patients with intermediate prognosis disease (Euro-
EWING). The addition of the combination of vincristine,
topotecan and cyclophosphamide to standard therapy
will be assessed in the next COG study. Investigation
of mechanisms encouraging tumor development or
conferring resistance will lead to therapeutic innovation.
KL04
Radiotherapy and targeted radionuclide therapy in
osteosarcoma
Ø.S. Bruland
(Department of Oncology, The Norwegian Radium Hospital,
Oslo, Norway)
The lecture will focus on some tumour- and radio-
biological aspects of osteosarcoma (OS). It will present
our clinical experiences employing external beam radio-
therapy in primary inoperable or relapsing OS patients, and
aspects on the physical and biological optimization will be
discussed with inputs from members of the radiotherapy
task group within EUROBOSS. One goal is find options to
avoid conventional radiotherapy being used as an ultimate
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into the primary multimodal treatment. Cis-Pt based
chemo-irradiation might be one such option. Experiences
from a Scandinavian Sarcoma Group protocol (SSG XIII)
where high-risk soft tissue sarcoma patients were treated
post-operatively with a combination of doxorubicine and
ifosfamide-based chemotherapy and risk-adapted acceler-
ated/hyper-fractionated radiotherapy will be put forward
for discussion. Lastly, results from a dose-escalating
phase-I/II study using Samarium 153-EDTMP with
stem cell support in 15 OS patients will be presented.
The treatment was well tolerated and toxicity was mild.
At injected activity levels below 3.0mCi/kg, repeated
treatments were feasible without the need for PBCS.
The radiotherapy-boost from such bone-seeking targeted
radionuclide therapy resulted in long-tern local control
when given in combination with external beam irradiation.
However, it was seemingly not efficient to prevent growth
of chemo resistant micro metastases in the lungs.
KL05
Follow up
Sir A. Craft
(Department of Child Health, Sir James Spence Institute,
Royal Victoria Infirmary, Newcastle Upon Tyne, UK)
Follow up is essential following treatment for sarcoma.
There are several reasons for this. The most important is
the early detection of recurrence so that further potentially
curative treatment can be instituted. The other major
reason is for the detection of late effects of treatment and
if necessary institution of remedial treatment.
Detection of recurrence: Sarcomas have a particular pattern
of recurrence and this may be local, at the site of original
disease, or distant metastatic – usually to the lung.
Detection of local recurrence depends on the initial local
treatment. If this has involved amputation then it is much
less likely to happen although stump metastases do occur.
Regular clinical examination and imaging depending on
the site will be important. U/S, CT and MRI can all have
a part to play.
Metastatic disease will be detected by regular chest
imaging either with plain chest xray or with CT.
Further treatment may need any of the modalities of
surgery, radiotherapy or chemotherapy. The chances of
long term survival/cure depend on number of metastases,
surgical resectibility and the time of occurrence after the
end of treatment.
Detection of late effects: Chemotherapy as well as radio-
therapy and surgery can produce late effects and the
patient should be given a detailed follow up plan
depending on their particular risk of late effects. Many
centres now have late effects clinics often led by nurses.
KL06
Pediatric soft tissue sarcoma – dose, volume, and timing
of radiotherapy for local tumor control
S.S. Donaldson
(Department of Radiation Oncology, Stanford University,
Stanford, USA)
Purpose: To address issues of local tumor control
in rhabdomyosarcoma and non-rhabdomyosarcoma
(NRSTS) group of tumors.
Methods: A review.
Results/discussion: For NRSTS, histologic grade (tumor
biology) predicts outcome and patterns of failure. Surgical
excision is important for local management. Indications
for radiotherapy are a function of tumor grade, size, and
adequacy of surgery. Radiotherapy following marginal
excision for high-grade tumors improves local control.
Dose, volume, timing and type of radiation must be
individualized depending on clinical parameters, but
usually involves high radiation doses administered by
conformal techniques.
Radiotherapy is central to the multidisciplinary manage-
ment of most patients with rhabdomyosarcoma, a high-
grade tumor. Required doses and volumes vary with
histologic subtype, group/stage, age and primary site. The
estimated 5-year local control for IRSG IV patients with
gross disease at study entry (Group III) is 86%. Features
predicting local failure include: alveolar/undifferentiated
histology; truncal, extremity, and parameningeal sites;
T2, >5cm, and N1 status. Systematic chemo-radiotherapy
for patients with non-resected disease, as used in IRS IV,
appears to provide improved event free and overall
survival rates when compared with studies emphasizing
chemotherapy but reducing local radiation therapy.
The goal in pediatric sarcomas is high cure rate,
preserving form and function.
KL07
Sarcoma PET imaging
J.F. Eary
(University of Washington, Seattle, Washington, USA)
Sarcoma PET imaging has been explored by our group to
understand the contribution this imaging technique can
make to the diagnosis, treatment planning and follow-up
of sarcoma patients. We have used the radiotracer
[F-18]FDG to quantitate tumor metabolism in over 500
sarcoma patients. This imaging method, now used
clinically throughout much of the world, can be used to
determine sarcoma tumor grade. In a patient who is
receiving neoadjuvant treatment, the FDG PET derived
tumor metabolism data is a very sensitive means of
determining treatment response. This information also
can be used to predict patient outcome before, after, and
during therapy. Newer radiotracers will likely make an even
more significant contribution to sarcoma patient care by
providing a means of quantitating tumor cell proliferation,
cell population death, levels of regional tumor hypoxia, and
activity of drug resistance mechanisms to chemotherapy
agents. Many of these are being studied currently in
sarcoma patient imaging protocols. In this symposium
lecture, an overview with discussion of significant findings
from PET imaging in sarcoma studies will be presented.
Current clinically relevant findings as well as future
research directions will be presented to provide back-
ground for sarcoma issues to be discussed at this
symposium.
KL08
TNF-based isolated limb perfusion for locally advanced
extremity STS
A.M.M. Eggermont
(Department of Surgical Oncology, Erasmus University
Medical Center, Daniel Den Hoed Cancer Center, Rotterdam,
The Netherlands)
Isolated Limb Perfusion (ILP) with melphalan has a
successful track record as the treatment of choice of
multiple (small) melanoma in-transit metastases. The
application of Tumor Necrosis Factor-alpha (TNF) in
ILP has made it a successful modality to treat locally
advanced extremity soft tissue sarcomas and other large
tumors, and achieve limb salvage. TNF was approved in
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European trial that showed that ILP with TNFþ
melphalan resulted in a 76% response rate and in limb
salvage in 71% in patients with locally advanced soft
tissue sarcomas, deemed irresectable by an independent
review committee. Moreover efficacy of TNFþmelphalan
ILP was shown against various other limb threatening
tumors such as skin cancers and drug resistant
bone-sarcomas.
ILP models in the laboratory have provided a model
system to elucidate our insights in mechanisms of action
and develop new treatment modalities. These models have
identified TNF-mediated vasculotoxic effects on the tumor
vasculature and have shown that addition of TNF to the
perfusate results in a 3–6 fold increase in melphalan or
doxorubicin uptake in tumors. New (vaso-active) drugs
and new mechanisms of action are being discovered.
KL09
EUROpean bone over 40 sarcoma study (EURO-B.O.S.S)
A European treatment protocol for bone-sarcoma in
patients older than 40 years
S. Ferrari
1, S. Smeland
2, S. Bielack
3
(
1Italian Sarcoma Group,
2Scandinavian Sarcoma Group,
3Cooperative Osteosarcoma Study Group)
The trial EUROBOSS is a multicentre prospective study
for patients older than 40 years with highly malignant
sarcoma of bone: Osteosarcoma, Fibrosarcoma, Malignant
Fibrous Histiocytoma (MFH), Leiomyosarcoma,
Dedifferentiated Chondrosarcoma.
The present EUROBOSS protocol is based on the
experience of the participating intergroups in the treatment
of spindle cell bone sarcomas and their past and present
osteosarcoma protocols.
The study is a first step of a process to establish the
standard chemotherapy treatment with the aim to improve
outcome for patients with these rare tumours.
In this regard, the study aims to determine the feasibility
of intensive chemotherapy in this age group, and/or
separate efficacy analyses according to the different
histologic categories and whether the number of patients
recruited by the co-operating groups permits future
randomised studies.
Primary aim is to evaluate clinical outcome and
chemotherapy-related toxicity in patients 41–65 years
old with high-grade bone sarcoma treated with a three
drug chemotherapy regimen containing adriamycin
(ADM), cisplatin (CDP) and ifosfamide (IFO), and the
addition of methotrexate (MTX) to poor histologic
responders
The study is open to collaboration with other Groups or
Institutions, after agreement of all participating groups.
KL10
Treatment of adults according to pediatric protocols –
The Milan experience
A. Ferrari, M. Casanova, P. Collini, L. Gandola,
C. Meazza, A. Gronchi, P.G. Casali, F.F. Fossati Bellani
(Istituto Nazionale Tumori, Milan, Italy)
Purpose: Published series on adult rhabdomyosarcoma
(RMS) reported definitely worse results than in children,
casting doubts as to whether RMS is the same disease
in adults as in childhood patients. 171 RMS patients >18
years treated over a 25-year span were retrospectively
analyzed. Patients were stratified according to how much
they had been treated appropriately, in the light of current
treatment criteria for childhood RMS.
Results: In the whole series, 5yr-EFS and OS were 28% and
40%. Considering only patients with embryonal, alveolar,
or not-otherwise-specified RMS (n.110), 5yr-OS was 46%,
but was 61% in those cases (39% of the total) who scored
high for appropriate treatment.
Conclusions: Our series confirms a relatively poor outcome
for RMS in adults. However, outcome was similar to
childhood series for those patients whose treatment could
actually reflect the criteria currently employed in children.
In addition, the chemotherapy response-rate (85%) was
super-imposable to that usually observed in children.
These findings would suggest to treat adults with RMS
with intense approach mutated from pediatric programs,
but tailored for adults considering that these might tolerate
to a lesser degree treatments which have been designated
for children.
KL11
Tumor biology of bone sarcoma: Molecular pathogenesis
and therapeutic implications
R. Gorlick
(The Children’s Hospital at Montefiore and the Albert Einstein
College of Medicine. Bronx, NY 10467, USA)
All sarcomas can be characterized as those with recurrent
consistent chromosomal translocations and relatively
simple karyotypes and those with multiple tumor sup-
pressor gene abnormalities with complex karyotypes.
Osteosarcoma is an example of the latter category.
Multiple germ line alterations result in predispositions to
osteosarcoma including alterations in p53 in patients with
Li-Fraumeni syndrome, Rb in patients with hereditary
retinoblastoma, WRN in patients with Werner syndrome
and RecQL4 in patients with Rothmund-Thomson syn-
drome. In addition, environmental exposures to ionizing
radiation or increased bone turnover as observed in
growing patients or with Paget’s disease, predisposes
to osteosarcoma. This may suggest osteosarcoma is the
common endpoint of multiple genetic events but this is
refuted by the rarity of the disease. The genetic complexity
observed in tumors obtained from patients with sporadic
osteosarcoma makes it unclear which features are centrally
linked to tumor initiation and progression. Factors central
in the molecular pathogenesis are likely to be prognostic
and therapeutic targets. The identification of these events
is of critical clinical importance and likely will need to
include assessments of pathways and not just individual
genes. Our laboratories and the Children’s Oncology
Groups efforts to define prognostic factors and therapeutic
targets for osteosarcoma will be presented.
KL12
Local control in bone sarcomas
R.J. Grimer
(Royal Orthopaedic Hospital, Birmingham, UK)
Limb salvage surgery is now the standard treatment for
bone sarcomas. Amputation is still required for large
tumours which involve the neurovascular bundle or at
locations where complete resection of the tumour will
lead to a worse result than limb salvage. Limb salvage
is however associated with an increased risk of local
recurrence and the factors associated with this and the
significance of local recurrence are still not clear.
Margins of excision play a key role in determining
the risk of local recurrence, but the effectiveness of
neoadjuvant treatment is also highly relevant.
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but ineffective neoadjuvant the risk of LR is >10%. The
definition of what is a wide margin varies greatly between
institutions and attempts to clarify this are being made.
Once a patient has developed local recurrence, salvage
treatment is related to the site of the LR and the presence
or absence of disease elsewhere. In patients with metastases
as well as LR the prognosis is appalling but in patients
without metastases at the time of LR there is a 37%
chance of surviving 5 years and a 26% chance of surviving
10 years.
Whether local recurrence poses an increased risk to
overall survival is a difficult question to answer as the same
factors which lead to LR – poor response to neoadjuvant –
also lead to poor survival. A shared risk analysis will be
presented to estimate the significance of LR on survival in
bone sarcomas. Local recurrence is a devastating compli-
cation. Whether it is possible to predict patients at risk of
LR who may have a better prognosis if they undergo
primary amputation remains a subject of controversy!
KL13
Radiotherapy in the local control of soft tissue sarcomas
J.-L. Habrand, O. Oberlin, C. Lepechoux
(Institut Gustave Roussy, Villejuif, France)
Soft tissue sarcomas are rare conditions both in adults and
in children that represent approximately 1 and 5%
respectively of malignancies. They also comprise a wide
variety of pathological subgroups that are clearly different
in both age groups, along with different clinical behavior,
radio/chemosensitivity, and prognosis. On an other hand,
tolerance of normal tissues appears quite different in
both groups, with an exquisite sensitivity to radiations of
immature soft and bone tissues. All these factors explain
different treatment strategies, including divergences in the
management of similar tumors by pediatric and adult
oncological groups. Despite such a rarity and disparity,
considerable efforts have been made by large institutions,
as well as national and international groups in order to
clarify their management. As far as radiotherapy, its crucial
role has been evidenced relatively recently, mainly due to
the false reputation of radioresistance of the adult subtypes.
Nowadays, combined radio-surgical approaches have
become standardized in adults and chemo-radiations
in childhood. Evidence-based decisions become easier
with the accumulation of large clinical series, including
phases III. We will update projects that have evaluated
the role of local treatment with emphasis on radiotherapy.
KL14
mTOR – A major determinant of biologic behavior in
pediatric sarcomas
X. Wan, C. Yeung, B. Midura, C. Khanna, L. Helman
(Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA)
We recently identified ezrin as a determinant of metastatic
behavior in two independent mouse models of pediatric
sarcomas. Subsequently, we found an association of ezrin
with activation of mTOR signaling. Since mTOR is
targeted by rapamycin and analogs that are currently
undergoing clinical testing in patients with a variety of
tumors, we have continued to explore the possible role
of mTOR signaling in the biology of pediatric sarcomas.
We have demonstrated that inhibition of mTOR signaling
using rapamycin inhibits motility and invasion in vitro and
decreases experimental metastases in vivo. This appears to
be at least partially linked to inhibition of HIF1 and VEGF
expression in tumor cells. We also have used reverse phase
proteomic analysis of rhabdomyosarcoma tumors treated
on Children’s Oncology Group studies to analyze mTOR
activation prior to therapy. We found a strong correlation
between activation of mTOR pathways and poor outcome
in both embryonal and alveolar Stage III RMS patients.
We are currently attempting to validate these findings in
an independent group of Stage III RMS tumors. These
data strongly suggest that mTOR signaling is a significant
determinant of aggressive biological behavior and that
targeting this pathway may have significant therapeutic
benefit in pediatric sarcomas.
KL15
Tumor biology of bone sarcoma: Pathology and genetic
aspects
Pancras C.W. Hogendoorn
(Department of Pathology, Leiden University Medical Center,
Leiden, The Netherlands)
It has now been a well-recognised fact that a substantial
number of sarcomas harbour a tumour specific transloca-
tion. This notion has been initially forwarded by the
recognition of t(11;22) and its variants but now an array of
tumours such as myxoid liposarcoma, infantile fibrosar-
coma, aneurysmal bone cyst or desmoplastic small round
cell tumour can be characterised diagnostically at the
tumour genetic level. This conceptional recognition –
histomorphic and genetic tumour specificity – has lead to
the launching of the 2002 WHO classification of soft tissue
and bone tumours. While the majority of patients develop
their sarcoma de novo, a number clearly are part of a
congenital and inherited syndrome such as Familial
adenomatous polyposis, Beckwith-Wiedemann syndrome,
McCune-Albright syndrome, Multiple osteochondromas,
Li-Fraumeni syndrome, Retinoblastoma syndrome,
Rothmund Thomson syndrome, or Werner syndrome to
name a few. The recognition of these syndrome related
Total Intraleioal Marginal Wide
Osteosarcoma 16% 38% 26% 8%
OS >90% necrosis 4% – 18% 2%
OS  90% necrosis 19% 51% 24% 13%
Ewing’s >90% necrosis 1% 0 0 2%
Ewing’s <90% necrosis 17% 16% 28% 12%
Chondrosarcoma 24% 35% 26% 17%
Figure. Survival after local recurrence – all bone tumours.
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importantly alerts to the necessity to carefully examine
family members and opens screenings and prevention
discussion. Whether syndrome patients are having a
different prognosis per se and the tumour phenotype
is completely identical to their sporadic counterparts is
matter of intense research.
KL16
Rational diagnostics: Pathology and molecular biology
I. Leuschner
1, C. Poremba
2
(Institutes of Pathology,
1Christian-Albrechts-University Kiel,
2Heinrich-Heine-University Du ¨sseldorf, Germany)
Soft tissue sarcomas of childhood and adolescence include
a wide spectrum of entities. The so-called small round blue
cell tumors and spindle cell tumors are especially difficult
to classify based solely on conventional histology. To
identify different subtypes of tumors special histochemical
(e.g. PAS, Gomori, etc.) and immunohistochemical
techniques are necessary. Analysis of protein expression
by immunohistochemistry provides a helpful tool to
investigate the histogenesis of tumors. A basic spectrum
of antibodies should be included to study these tumors:
Desmin and myogenin (or MyoD1) for skeletal differentia-
tion; S-100, NSE, CD56, and synaptophysin for neural/
neuroendocrine differentiation; CD3, CD20, and CD 79
alpha for malignant lymphomas; CD 34, sm-actin, and
-catenin for spindle cell tumors; additional antigens, e.g.
Ki-67 and p53, for estimation of proliferation and tumor
suppressor gene malfunctions. Nevertheless, the molecular
analysis of tumors is necessary for demonstration of
specific translocations/gene defects to specify and prove a
diagnosis. For this purpose, RT-PCR for RNA expression
analysis of gene fusion transcripts and multi-color FISH
for analysis of chromosomal rearrangements are used.
Further investigations, using CGH or DNA microrrays
may help to sub classify such tumors, with respect to
prognosis or prediction of therapeutic response.
KL17
Systemic tumor control
W.H. Meyer
(Section of Hematology/Oncology, Department of Pediatrics,
OUHSC, Oklahoma City, OK, USA)
With modern treatment over 70% of children and
adolescents with rhabdomyosarcoma are cured.
Multidisciplinary therapy is necessary to maximize cure
rates. Chemotherapy is required for all patients. Local
control relies on complete surgical excision when possible;
those whose tumors are not completely excised and those
with alveolar histology tumors receive local irradiation in
COG studies. In North America vincristine, actinomycin
and cyclophosphamide are the standard chemotherapy
agents. In 2004 and 2005, COG initiates new studies for all
newly diagnosed risk groups. The low-risk patient subsets
receive four VAC cycles, followed by VA therapy.
The intermediate risk trial plans to test VAC vs. VACþ
irinotecan/vincristine, based on results from the D9802
window trial that demonstrates activity for this combina-
tion. The new high-risk study will use irinotecan/vincristine
followed by dose compression therapy with alternating
cycles of vincristine/cyclophosphamide/doxorubicin and
ifosfamide/etoposide. Both the intermediate and high
studies will evaluate irinotecan radiosensitization. New
advances in molecular characterization of tumors may
identify new therapeutic targets that can be exploited by
expanded preclinical drug discovery efforts, and hold the
promise to revolutionize risk based therapies.
KL18
Improved outcome in soft tissue sarcoma monitored by
the Scandinavian Sarcoma Group (SSG) register
S. Smeland
1, T.A. Alvega ˚rd
2, H.C.F. Bauer
3
(
1Department of Medical Oncology, Norwegian Radium
Hospital, Oslo, Norway,
2Southern Sweden Tumour Registry,
University Hospital, Lund, Sweden,
3Department of
Orthopedics, Karolinska Hospital, Stockholm, Sweden)
Purpose: Quality assessment of soft tissue sarcoma (STS)
treatment by the SSG registry
Patients: The SSG register contains data on 3634 patients
with STS diagnosed from 1986 to 2003.
Results: During this period the rate of primary referral
before surgery for deep lesions has improved from 73% to
93% and the use of adjuvant radiotherapy for deep-seated
STS from 24% to 44%. In the same period the 3-year local
control rate has increased from 73% to 88% whilst the
percentage of adequate margins did not change and the
amputation rate fell from 13% to 5%.
The preliminary survival rate for the SSG XIII study
for high-risk soft tissue sarcoma shows a projected 5-year
metastases-free survival of 57% (CI  15%) as compared to
38% in a previous population based study from Southern
Sweden. When including patients reported to the SSG
registry not recruited to the study the 5-year projected
metastases-free survival rate drops to 48% (CI  12%).
Discussion: The changes in referral patterns and increase
in adjuvant radiotherapy seem to contribute to the
improvement in local control. Population based materials
is important to assess the utilisation of the protocol and
improvement in outcome for the patients at risk.
KL19
Systemic treatment of soft tissue sarcoma with an
emphasis on local control
M.C.G. Stevens
(University of Bristol, Department of Oncology, Royal Hospital
for Children, Bristol, UK)
Multimodality therapy involving surgery, chemotherapy
and radiotherapy is important for the treatment of
rhabdomyosarcoma (RMS). Experience with this tumour
type is predominant in childhood soft tissue sarcoma
(STS) and whilst this may not always be appropriate for
treatment of non RMS STS, experience derived from
different approaches taken to the treatment of RMS
provides some insight into the role of systemic therapy in
local tumour control. There is a debate about the necessity
for radiotherapy (RT) in patients who achieve complete
remission with chemotherapy, with or without surgical
resection. The data show that when local therapy is
systematically delivered as part of primary treatment,
local control is generally more secure and the risk of
relapse less. However, the use of RT, particularly in very
young children, raises concern about its long term
consequences and there is experience to suggest that it
may be possible to avoid or reduce the intensity of local
therapy depending on response to surgery and primary
chemotherapy. Unfortunately, it is not yet possible to
reliably identify those patients who are most likely to be
cured without RT after achieving CR with chemotherapy
and conservative surgery but a synopsis of the current data
will be reviewed.
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Tumor biology of soft tissue sarcoma: Pathology and
genetic aspects
T.J. Triche
(USC Keck School of Medicine and Chair of Pathology,
Childrens Hospital Los Angeles, USA)
Diagnostic classification of soft tissue sarcomas in the
young readily divides into two main groups- rhabdomyo-
sarcoma and a diverse group of non-rhabdomyosarcomas,
including synoviosarcoma, extraosseous Ewing’s, malig-
nant peripheral nerve sheath tumor, fibrosarcoma, and
unclassified sarcomas. For therapeutic purposes, current
COG protocols largely follow this dichotomous classifica-
tion. We have been studying global gene expression
patterns in IRS-IV sarcomas for the past five years and
find that these tumors readily divide into these two main
groups as well. However, the classical subdivision of
rhabdomyosarcoma into embryonal and alveolar forms
is not substantiated. Instead, we find that only PAX-
FKHR translocated alveolar forms cluster together;
histologically alveolar un-translocated tumors are indis-
tinguishable from embryonal forms. Further, several cases
of embryonal rhabdomyosarcoma are non-myogenic
and indistinguishable from non-rhabdomyosarcoma
sarcomas, while other non-rhabdomyosarcoma sarcomas
are clearly myogenic and indistinguishable from embryonal
rhabdomyosarcoma based on patterns of gene expression.
Forty-eight selected prognostic genes predict highly favor-
able (94% 5-year survival), intermediate (75%), and
unfavorable (22%) survival cohorts of patients; even a
four-gene ‘‘sarcoma signature’’ performs nearly as well as
current risk stratification schemes. Prognostic genes are
highly enriched for MAP kinase signaling pathways,
suggesting a mechanism for aggressive vs. indolent
tumors and possible therapeutic targets for future drug
development.
KL21
Monitoring treatment and follow-up in bone and soft
tissue sarcomas
H.-J. Van der Woude
(Department of Radiology, Onze Lieve Vrouwe Gasthuis,
Amsterdam and Leiden University Medical Center, Leiden,
The Netherlands)
Modern imaging plays a pivotal role in the treatment
strategy of patients with high-grade bone and soft tissue
sarcoma. Various imaging modalities have been used to
monitor the effects of neoadjuvant chemotherapy in
osteogenic and Ewing’s sarcoma and to evaluate isolated
limb perfusion in high-grade STS. Currently, techniques
that focus on therapy-induced changes in tumorvascular-
isation and metabolism are most successful in predicting
histologic response. Dynamic contrast-enhanced magnetic
resonance (MR) imaging in particular allows detection of
and differentiation between residual viable tumor, granula-
tion tissue, edema and necrosis. A benefit of fast gradient-
echo sequences is that the entire tumor volume can be
evaluated with high spatial and temporal resolution,
opposed to single or double histopathologic section
examination which serves as gold standard for final
response. MRI as such aids in directing surgical strategy
and adjuvant treatment. Native and static contrast-
enhanced MR sequences are optimal for preoperative
assessment of tumor dimensions, margins and relationship
to viable structures and joints, but not for response
determination. Only an increase of tumor volume after
neoadjuvant therapy is indicative for poor histologic
response. FDG-PET imaging with or without CT applica-
tion has been found another promising tool with which to
predict the outcomes of patients with high-grade extremity
soft tissue sarcomas treated with chemotherapy.
KL22
EURAMOS 1: A model for the future of clinical research
in osteosarcoma.
J. Whelan
(UCLH, London, UK)
Randomised studies with sufficient power to define
improvements in survival or benefits of new treatments
are difficult to conduct in rare cancers. Recent trials for
osteosarcoma have been hampered by long accrual times
and few new therapeutic interventions. EURAMOS 1 is an
international randomised study for patients with resectable
osteosarcoma which is the result of co-operation between 4
clinical study groups in Europe and the United States. This
trial may prove to be a paradigm for future investigation
in osteosarcoma and other rare cancers. The advantages of
this joint venture are: rapid accrual times, harmonising
understanding of osteosarcoma and its treatment and
potentially rapid improvements in knowledge of osteosar-
coma biology. Meeting current clinical trial regulatory
requirements may be achieved more effectively by greater
co-operation between study groups. Finally, as the costs of
clinical trials soars, responsibility lies with investigators
to ensure that only scientifically valid, viable trials are
undertaken. However, recognition of both the importance
of such studies and the difficulties associated with
their execution is required by funding bodies and
regulatory authorities to ensure that investigators are
suitably supported.
KL23
Surgery for soft tissue sarcoma
H.C.F. Bauer
(Department of Orthopedics, Karolinska, Stockholm, SE-171
76 Stockholm, Sweden)
Surgery remains the most important part of the treatment
of patients with soft tissue sarcoma. In approximately half
of all soft tissue sarcoma patients control of the disease will
be achieved by surgery. Adjuvant radiotherapy has been
proven to improve the local control rate in combination
with surgery. Although the adjuvant chemotherapy is
increasingly used in soft tissue sarcoma the response rate
is low and there is no real convincing evidence that
adjuvant chemotherapy improves outcome to any large
extent.
Limb sparing surgery can be achieved in most patients,
and less then 10% have primary amputations, although the
amputation rate can increase after local recurrence. The
surgical classification system introduced by Enneking,
where intralesional or marginal surgery is considered
inadequate, and wide or compartmental margin is con-
sidered adequate, is in my opinion the most useful for soft
tissue sarcoma of the trunk wall or extremities. Clearly, it is
not applicable for intraabdominal or retroperitoneal
sarcomas.
Maybe the most important factor for achieving good
local control rates is to improve patient so that patients are
referred to a sarcoma center before surgery. It is not
enough to show good local control rates for patients treated
at a center, it has to be shown for a whole population area.
To highlight the effect of better management on outcome,
we have assessed how changes in referral, surgical margins,
48 Sarcoma Meeting Stuttgart Abstractsand use of radiotherapy have influenced outcome in soft
tissue sarcoma.
Methods: 869 adult patients with soft tissue sarcoma of
extremities or trunk wall were referred 1986–2004. For
comparison we have chosen three time periods: early
(1986–90), middle (1991–97), and late (1998–2004).
Results: Referral of patients before open biopsy or
excision improved from 64% to 66% and to 76% during
the late period. A wide surgical margin was achieved in
54%, 68% and 61%, respectively. Radiotherapy was
increasingly applied in the late period, from 29% to 42%.
In assessment of outcome only patients without metastases
and operated for primary tumor at the sarcoma center were
considered. The overall 5 years local control rate (Kaplan-
Meier) was 0.82, and for the three time periods 0.67, 0.83,
and 0.88. The 5 years metastases-free survival rate was
0.69, and for the three time periods 0.58, 0.71, and 0.73.
Conclusions: These results show a striking improvement
in local control and survival in soft tissue sarcoma. The
improvement was mostly a result of improved referral, but
also better margins and increased use of radiotherapy.
Whether local recurrence leads to metastases, or is only an
independent sign of malignant behavior, remains contro-
versial. Clearly better local control at least coincided with
better survival, and also leads to less surgery for recurrence
and to less morbidity.
KL24
MRI in sarcoma: Essential and advanced imaging
P. Winkler
(Radiologisches Institut, Olgahospital, Stuttgart, Germany)
MRI is the method of choice in imaging of primary,
recurrent or treated tumors, combined with plain x-ray
in malignant bone tumors. High resolution whole body
imaging might become the standard for evaluation of
metastatic disease and imaging of some complications
of therapy in the future.
There are three essential principles of MRI in soft
tissue sarcoma: 1. Fat suppression before and after
contrast administration; 2. High physical and contrast
in-plane resolution; 3. Lowest achievable volume
averaging.
It is my opinion, that fat suppression is mandatory for all
MR examinations in sarcoma. Fat has, however, been used
as ‘‘contrast medium’’ (T1-weighted non-fat-suppressed
sequence for estimation of bone marrow extension in
osteosarcoma). Imaging of peripheral nerves, dynamic
contrast studies, MR-guided biopsy and whole body MRI
are examples of advanced MR-applications. Imaging of
peripheral nerves is particularly relevant for surgical
planning in soft tissue tumors or for MR-guided biopsy.
Whole body MRI might have similar potential as PET-CT,
but is considerably less expensive. MR-guided precision
biopsy has proven to be an invaluable tool in primary
tumors or tumor-like lesions and potential recurrent
tumor, particularly in small, deeply situated sites. It
might be also used in future treatment of local small
metastases.
KL25
Going forward: The penalties of success and the tyranny
of numbers in childhood sarcomas
R. Womer
(Division of Oncology, Children’s Hospital of Philadelphia,
PA, USA)
Clinical research in pediatric sarcomas is in a difficult
position. Patients are divided into two groups: those with
localized rhabdomyosarcomas, osteosarcomas, and Ewing
sarcomas, whose prognosis is fairly good; and those with
desmoplastic small round cell tumors or disseminated
sarcomas, whose prognosis remains bleak. The first group
has a good supply of patients but few of the ‘‘events’’ that
make clinical studies statistically feasible, while the second
group has few patients, though most of them have events.
Rapidly accumulating biologic insights may eventually lead
to new treatments, but they also can make subclassification
irresistible, and thus make therapeutic studies more
difficult. There is a paucity of new therapeutic ideas, and
even fewer that have been tested adequately in pilot
studies. Thus there has been little therapeutic progress in
either group in a decade. Changes in our attitudes toward
clinical trials, as well as changes in the conception, design,
and coordination of clinical and translational research may
aid us in resuming therapeutic progress.
KL26
Local control of sarcomatous pulmonary metastases
A.A. Vaporciyan
1, J.B. Putnam Jr
2
(
1MD Anderson Cancer Center, Houston, Texas, USA,
2Vanderbilt University Medical Center, Nashville, Tennessee,
USA)
Isolated and resectable pulmonary metastases (PM) from
sarcoma represent a unique biology between the patient
and the tumor. However, resection alone for treatment of
sarcomatous PM will fail in a significant number of
patients. Various prognostic indicators (potential for
complete resection, fewer numbers of metastases, adequate
pulmonary reserve, etc.) and molecular characteristics may
assist the clinician in selecting patients who will have the
best potential for improved survival. These indicators may
better define the biological nature of the metastases, and
provide an estimate of post-resection survival. Use of
neoadjuvant or adjuvant therapy strategies may allow for
prolonged survival or cure
Other novel therapies such as regional delivery of
therapeutic agents to the lung (isolated lung perfusion)
may provide better and more directed therapy for PM.
Image guided percutaneous radiofrequency ablation,
although potentially less traumatic than thoracotomy,
may fail to identify, or treat occult PM frequently found
by manual palpation of the lung.
Today, the benefits of complete resection of sarcoma-
tous pulmonary metastases represents a unique and
serendipitous occurrence where the host biology, spread
of tumor, response to chemotherapy, and resection, render
the patient disease free. The best results of treatment of
sarcomatous PM await improved biological and molecular
therapies.
Oral
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Co-ordinated oncogenic transformation and inhibition of
host immune responses by the PAX3-FKHR fusion
oncoprotein
S. Nabarro
1,3, N. Himoudi
1,3, A. Papanastasiou
1,3,
K. Gilmour
2, A. Thrasher
2, M. Blundell
2 M. Hubank
1,
N. Sebire
3, H. Rees
1, G. Canderan
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3,
J. Anderson
1
(Units of
1Molecular Haematology and Cancer Biology, and
2Molecular Immunology, Institute of Child Health, London
Sarcoma Meeting Stuttgart Abstracts 49WC1N 1EH.,
3Department of Histopathology, Great Ormond
Street Hospital for Children, London)
Tumours have evolved elaborate mechanisms of evading
immune detection; for example, production of immuno-
inhibitory cytokines and down-regulation of MHC
expression. We have studied PAX3-FKHR as an
example of an oncogenic fusion protein associated with
aggressive metastatic cancer. We have shown that
PAX3-FKHR, as well as stimulating transcription from
its own target promoters, interferes with normal inter-
feron gamma signalling in tumour cells by means of
specific interaction with the STAT3 transcription factor.
This causes a dramatic reduction in tumour cells MHC
expression and an altered expression of a number of
cytokines and chemokines. For example PAX3-FKHR
downregulates the pro-inflammatory cytokines CCL5
(RANTES) and IP10 that have been shown to be
inhibited by STAT3, and it upregulates the known
STAT3 targets CXCR4 and IL10. Conditioned media
from cells expressing PAX3-FKHR has increased IL10
concentration which is reversed by a specific STAT3
blocker and inhibits dendritic cells maturation in vitro
and in tumour xenografts, also in a STAT3 dependent
manner. PAX3-FKHR also causes an increase in rate of
growth of xenografted tumours in immunodeficient mice
associated with decreased numbers of tumour infiltrating
inflammatory cells, and despite no differences in growth
characteristics in vitro between PAX3-FKHR expressing
and non-expressing isogenic cell lines. Supported by
Cancer Research UK and SPARKS)
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Significance of persistent rhabdomyoblasts in bladder
prostate rhabdomyosarcoma: Results from the fourth
intergroup rhabdomyosarcoma study
C. Arndt
1, S. Hammond
2, D. Rodeberg
1, S. Qualman
2
(
1Departments of Pediatric and Adolescent Medicine and
Pediatric Surgery, Mayo Clinic, Rochester Minnesota, USA,
2Department of Laboratory Medicine, Children’s Hospital,
Columbus, Ohio, USA)
Purpose: To determine the significance of residual
rhabdomyoblasts(RmyoB) in bladder prostate rhabdomyo-
sarcoma (BPRMS).
Patients/methods: 49 of 88 patients with BPRMS treated on
IRS-IV had at least one ‘‘second look operation’’ (SLO)
with tissue removal for evaluation (66 procedures in 49
patients). Slides from SLO’s were examined for viable
tumor (POS), no tumor (NEG), or RmyoB only. SLO’s
performed for documentation of clinical relapse were
excluded. Results of slide review were compared to results
obtained from chart review, and correlated with outcome.
Results: Slides were obtained from 41 patients (53
procedures). For 15 procedures, central review and
institutional pathology differed. Of 16 patients POS at
last evaluation, 7 failed (3 local, 1 distant, 3 second
malignant neoplasm (1 each osteosarcoma and leiomyo-
sarcoma in radiation field, 1 CNS glioma). Of 11 patients
with RmyoB at last evaluation 1 failed (local and distant); 3
underwent cystectomy/cystoprostatectomy despite RmyoB
only. Of 14 NEG 2 failed (1 toxic death, 1 local and
distant).
Conclusions: RMyoB often occur at SLO for BPRMS.
Persistence of RMyoB is not necessarily associated with
tumor recurrence and is not an indication for radical
surgery. Because RMyoB are difficult to discern from viable
tumor, review by experienced pathologist is indicated.
O03
New biological markers predicting outcome in Ewing
family of tumors
S. Avigad
1,2, A. Ohali
1, I.J. Cohen
2, S. Ash
2, Y. Goshen
2,
I. Meller
3, Y. Kollender
3, J. Issakov
3, R. Zaizov
1,2,
I. Yaniv
1,2
(
1Molecular Oncology, Felsenstein Medical Research Center,
2Pediatric Hematology Oncology, Schneider Children’s Medical
Center of Israel, Petah Tikva, Israel,
3Sourasky Medical
Center, Tel Aviv, Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel)
Purpose: In spite of advances in multimodal therapy, late
relapses of Ewing’s Sarcoma (ES) are frequent. Currently
accepted prognostic factors fail to classify ES patients’ risk
to relapse at diagnosis. Our aim was to search for novel,
reliable prognostic parameters.
Methods: Monitoring the chimeric transcripts and
telomerase activity at diagnosis and during follow up
in samples from 26 patients, and by gene expression
profiling of 20 tumors from patients with localized
disease.
Results: During follow up, but not at diagnosis, a highly
significant correlation between the presence of the chi-
meric transcript, high telomerase activity and progression
was detected (p¼0.007 and p<0.0001, respectively).
Molecular recurrences were identified prior to overt
clinical recurrence.
We identified two distinct gene expression signatures
distinguishing high risk ES patients that are likely to
progress from low risk patients with long term progression
free survival. The microarray-based classification was
superior to currently used prognostic parameters.
Conclusion: The presence of tumor cells or high telomerase
activity in BM/PBL are significant prognostic markers of
progression – during follow up. Gene expression profile
could identify high and low risk patients already at
diagnosis.
This may be useful in designing better risk group
stratified clinical protocols in ES.
O04
A single nucleotide polymorphism in the MDM2
promoter accelerates tumor formation in sporadic
human soft tissue sarcomas
P. Wu ¨rl
1, H. Taubert
2, G. I. Bond
4,W .H u
4,
H. Robinson
3, G. Lozano
5, A. Levine
3, F. Bartel
2
(
1Surgical Clinic I, Faculty of Medicine, University of Ulm,
Ulm, Germany,
2Institute of Pathology, University of Halle-
Wittenberg, Halle/Saale, Germany,
3School of Natural
Sciences, Institute for Advanced Study Princeton, New Jersey,
USA,
4Cancer Institute of New Jersey, University of Medicine
and Dentistry of New Jersey, New Jersey, USA,
5Section of
Cancer Genetics M.D. Anderson Cancer Center, University of
Texas, Houston, Texas, USA)
In a subset of tumors – especially in soft tissue sarcomas
(STS) – overexpression of MDM2 was found exclusive to
p53 mutation connected with negative prognostic rele-
vance, which could suggest that overexpression of MDM2
can substitute for inactivating p53 by mutation.
We have shown that a single nucleotide polymorphism
(SNP309) is found in the MDM2 promoter. It increases
the affinity of the transcriptional activator Sp1, resulting
in higher levels of MDM2 RNA and protein and the
subsequent attenuation of the p53 pathway.
105 patients who developed sporadic adult STS without
hereditary cancer predisposition and no germline p53
mutation were studied. Interestingly, independent of
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earlier age of onset of STS. Specifically, those individuals
homozygous for SNP309 were diagnosed on average
12 years earlier than those individuals without SNP309
(p¼0.01). The frequency of the SNP309 G allele was
greatly increased in those individuals who developed STS
at a young age. Those who developed STS below the age
of 41 years old had an allele frequency for SNP309
of 50%, while the allele frequency is only 33% for the
whole group (p¼0.0262). These data demonstrate that
SNP309 is associated with earlier formation of sporadic
STS in human adults.
O05
Improved outcome in soft tissue sarcoma through better
management
H.C.F. Bauer, O. Brosjo ¨, R. Wedin, M. Szeps
(Departments of Orthopedics and Oncology, Karolinska
Hospital, Stockholm, Sweden)
We have assessed how changes in referral, surgical margins
and radiotherapy have influenced outcome in soft tissue
sarcoma.
869 adult patients with soft tissue sarcoma
of extremities or trunk wall were referred 1986–
2004. For comparison we have chosen three time
periods: Early (1986–90), middle (1991–1997), and late
(1998–2004).
Referral of patients before open biopsy or excision
has improved from 64% to 66% and to 76% during the
late period. A wide surgical margin was achieved in 54%,
68% and 61%, respectively. Radiotherapy was increasingly
applied in the late period, from 29% to 42%.
In assessment of outcome only patients without meta-
stases and operated for primary tumor at the sarcoma
center were considered. The overall 5 years local control
rate (Kaplan-Meier) was 0.82, and for the three time
periods 0.67, 0.83, and 0.88. The 5 years metastasis-free
survival rate was 0.69, and for the three time periods 0.58,
0.71 and 0.73.
These results show a striking improvement in local
control and survival in soft tissue sarcoma. The improve-
ment was mostly a result of improved referral, but also
better margins and increased use of radiotherapy.
O06
Major organ toxicities after sarcoma therapy according
to the GPOH therapy trial protocols prospectively
evaluated in 760 children and young adults
J.D. Beck
1, M. Paulides
1, W. Sto ¨hr
1, S. Bielack
2,
H. Ju ¨rgens
3, J. Treuner
4, T. Langer
1
(
1LESS Centre, University Hospital for Children and
Adolescents, Department of Paediatric Oncology, Erlangen,
Germany,
2Osteosarcoma Trial Centre, University Children’s
Hospital Muenster, Department of Paediatric Haematology
and Oncology, Muenster, Germany,
3Ewing’s Sarcoma
Trial Centre, University Children’s Hospital Muenster,
Department of Paediatric Haematology and Oncology,
Muenster, Germany,
4Cooperative Soft Tissue Sarcoma
Study, Olgahospital, Department of Paediatric Oncology,
Stuttgart, Germany)
Background: Sarcoma treatment incurs a variety of
organ-specific toxicities.
Patients and methods: The Late Effects Surveillance System
(LESS) of the German Society for Paediatric Oncology
and Haematology (GPOH) prospectively monitors late
effects of antineoplastic treatment in patients treated for
Ewing’s, osteo- or soft tissue sarcoma within one of the
therapy trials of the GPOH. The aftercare is carried out
according to the published guidelines of LESS, using
examinations that are sensitive for the detection of major
toxicities and are efficient within the setting of a vertical
network.
Results: The cumulative incidences of studied major
toxicities in our relapse-free collective of paediatric
sarcoma patients are: Anthracycline-induced clinical
cardiomyopathy 2.0% (15/760), anthracycline-induced
subclinical cardiomyopathy 2.2% (12/548), severe
tubulopathy 6.2% (26/418), hearing impairment 52%
(39/72).
Discussion: Nephrotoxicity and cardiotoxicity are
moderate in our collective, while hearing loss in high
frequencies (>4kHz) is more common. Intervention
studies are an important step to be taken, in order to
develop strategies for the prevention and treatment of such
major toxicities.
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Cooperative Osteosarcoma Study Group trial COSS-96
of intensive, risk-stratified chemotherapy for
osteosarcoma
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16Berlin,
18Olgahospital Stuttgart,
20St. Anna-Spital Vienna,
2Institute
for Osteopathology, University Hamburg,
3Departments of
Orthopedics, Universities Vienna,
5Zu ¨rich,
4Heidelberg,
19Mu ¨nster,
10Klinikum Ingolstadt,
8Orthopedic Practice
Hamburg,
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Aims: To evaluate risk-adapted osteosarcoma chemother-
apy with doxorubicin (D), methotrexate (M), and
ifosfamide/cisplatin (IP).
Methods: Patients <40 years with nonmetastatic high-grade
extremity osteosarcoma eligible. Preoperative chemother-
apy (1 D, 2 M, and 2 IP) identical for all. Risk groups
stratified postoperatively by tumor volume and histologic
response.
Results: 442 eligible patients, 393 of these risk-stratified.
Median follow-up 3.6 years for all patients, 4.0 years for
373 survivors. Actuarial outcome at 4 years:
Group Postop chemo n Survival Event-free
All patients 442 84% 70%
Not stratified 49 71% 53%
Stratified 393 85% 71%
Lower risk 1 D, 1 IP, 4 M 65 87% 77%
Standard risk Randomized comparison S1 vs. S2
S1 3 D, 2 IP, 8 M 156 88% 72%*
S2 2 D, 1 IP, 10 M 157 85% 71%*
High risk 1 D, carboplatin
þetoposide 5
15 52% 41%
*Tendency towards late events beyond 4 years for S2 vs. S1: 5/62
vs. 1/56.
Sarcoma Meeting Stuttgart Abstracts 51Conclusions: Four-drug chemotherapy is highly effective
against osteosarcoma. A long treatment duration may
be needed even for presumed low-risk patients. The
outcome of high-risk patients remains poor despite salvage
treatment. A longer follow-up is required to determine
if S1 and S2 do equally well.
O08
The EpSSG RMS2005: A new stratification for the
first pan-European protocol for localised rhabdomyosar-
coma
G. Bisogno, A. Mattke, E. Koscielniak, C. Bergeron,
M. Jenney, R. Knietig, I. Brecht, S. Gallego, A. Schuck,
H. Martelli, A. Kelsey, R. Alaggio, A. Rosolen, A. Ferrari,
M. Carli, O. Oberlin, M. Stevens, J. Treuner
(EpSSG)
Introduction: The three Cooperative European Groups:
The SIOP MMT Committee, the CWS and the AIEOP
STSC recently decided to join together as the European
paediatric Soft tissue sarcoma Study Group (EpSSG).
As first step a common analysis has been performed
on localized rhabdomyosarcoma to identify prognostic
factors.
Methods: An analysis carried out by the CWS group using
the CWS/RMS 96 data and validated with data from
studies with longer follow up: The SIOP MMT-84 and 89,
the German CWS-81, 86 and 91 and the Italian RMS-79
and RMS-88 studies identified the following significant
prognostic factors:
. histology (alveolar vs. embryonal),
. post surgical status (IRS Group),
. tumour site,
. node involvement (N0 absent, N1 present),
. tumour size (> or  5cm),
. patient’s age (unfavourable if  10 years)
Combining these factors 8 subgroups of patients have been
identified:
Subgroup A: eRMS, IRS I, Any site, N0, favourable
age&size
Subgroup B: as subgroup A but with unfavourable age or
size
Subgroup C: eRMS, IRS II/III, favourable site, N0, any
age or size
Subgroup D: eRMS, IRS II/III, unfavourable site, N0,
favourable age&size
Subgroup E: eRMS, IRS II/III, unfavourable site, N0,
unfavourable age or size
Subgroup F: eRMS and N1
Subgroup G: aRMS, excluding N1
Subgroup H: aRMS and N1
Four risk groups have been identified with different
estimated 3-yrs EFS:
. Low risk: Subgroup A (EFS 90%)
. Standard risk: Subgroup B, C, D (EFS 70–80%)
. High risk: Subgroup E, F, G (EFS 50–55%)
. Very high risk: Subgroup H (EFS 30–40%)
Conclusions: Using data from across Europe 4 risk
categories for localized RMS have been identified.
Objectives and treatment plans have been elaborated for
each group in the EpSSG RMS 2005 protocol.
O09
Treatment of adult type sarcomas: The EORTC Soft
Tissue and Bone Sarcoma Group (STBSG) experience
J.-Y. Blay
(Centre Leon Barard, Lyon, France)
Historic background: The EORTC STBSG was founded
in 1976. The founding members came from Italy,
France, Germany, Belgium, Switzerland, UK and the
Netherlands.
Organization: The objectives were to develop, stimulate
and co-ordinate studies on all aspects of the treatment
of soft tissue sarcomas (STS) as well as to organise
congresses, symposia and conferences to promote these
studies. The Group has developed very strict quality
control procedures and played a major role in the
development of the RECIST criteria. The quality assur-
ance program involves a strict membership policy, central
review of responses, central review of pathology, use of a
systemic therapy checklist and on site monitoring visits.
Today the STBSG has members from 40 institutions from
13 countries.
Types of studies: The activities have primarily been within
the areas of standards for local and systemic treatment
strategies especially in advanced STS. So far, more than 45
clinical trials have been conducted and more than 200 pts
per year have been included. A unique database with over
2500 patients has been developed and based on this a
number of important studies have been published on
prognostic factors, long term survivors and new response
criteria. Several new drugs have been tested in STS
but doxorubicin and ifosfamide are still the most
effective agents. Other drugs with some first line activity
are dacarbazine, caelyx and possibly ET743. Imatinib
is very effective in GIST where it is now the treatment
of choice – a development in which the group has
played a very important role. Several phase 3 trials
have also been performed on both single agent
and combination chemotherapy. The group has also
participated in an osteosarcoma intergroup study.
Recently a phase 3 study on adjuvant doxorubicin and
ifosfamide in STS has been closed and awaits further
analysis. Presently the group is performing studies on
caelyxþifosfamide, high dose ifosfamideþdoxorubicin,
hyperthermia, exatecan, brostallicin, and gefitinib (Iressa).
The group also participates in the EE99 study of Ewing’s/
PNET. Finally studies on translational research have
been initiated, including a study of the molecular biology
of GISTs.
Intergroup co-operations: An increasing number of studies
have recently been performed in collaboration with other
groups such as SWOG, ECOG, NCIC, AGITG, FSG,
ISG and SSG.
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Why are age and size the most important risk factors
for further improvement of the risk stratification
for high risk rhabdomyosarcomas in children and
adolescents?
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52 Sarcoma Meeting Stuttgart AbstractsObjectives: To find possible reasons for the influence of
age and size being found to be the most important factors
for further improvement of the risk stratification for
children and adolescents with RMS.
Patients/methods: 1140 patients (CWS 81, 86, 91, 96
studies) were stratified according to the CWS-96 study.
779 defined high risk patients were analysed by COX-
regression. Age (p<0.001) and size (p<0.001) were
identified as additional factors influencing prognosis
significantly and were secondly correlated with tumour
and patients characteristics.
Results: 5-yr SUR (EFS) was in patients <1yr 62% (43%),
1–5yrs 74% (65%), 6–10yrs 75% (66%), 11–15yrs 67%
(52%), 16–21yrs 52% (47%). More RMA, tumours
>5cm, and nodal involvement were found in patients
>10yrs. The high number of events in large tumours
(>5cm) is especially seen in patients >10yrs (26%
metastatic relapses), but also in patients <1 year old
(24% progression). Patients <10yrs are less radically
operated, received lower doses of radiotherapy and
preoperative chemotherapy was preferred. There is no
better tumour response seen in younger patients (1–10yrs)
in comparison to patients >10yrs.
Conclusions: Though older patients receive a more intensive
treatment they show a worse outcome than younger
patients having a second chance after relapse. As we see
more alveolar histology, more nodal involvement, larger
tumours and more metastatic relapse in older patients
the reason may lie in a different tumour biology which
expression is still not found.
O11
Pyridinoline cross-links: Markers for primary and
secondary bone tumors
J. Bruns
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Introduction: Determination of hydroxylysylpyridinolines
(HP) and lysylpyridinolines (LP) in urine is a promising
method to determine bone resorption. This method is
independent from gender, diet, and kidney function
(creatinine clearance >25ml/min).
Material & methods: We evaluated the value of HP and LP
in urine from adult tumor patients suffering from primary
malignant bone tumors (n¼24), bone metastases (n¼38)
and soft tissue sarcoma with additional osseous involve-
ment (n¼13). The values were compared with those
obtained from 698 healthy controls (0.5 to 65 years old).
Results: Clearly exhibited a significant increase in HP
values (57.75nmol/mmol creatinine) in adult tumor
patients (aged 15 to 65 years) of all three subgroups
in comparison to the control group (22.23nmol/mmol
creatinine). Although LP is more specific for bone than
HP, the values of LP from all subgroups of the adult tumor
patients were less distinctly but significantly increased. In
the HP:LP ratio patients exhibited a distinctly increased
molar HP:LP ratio (12.0:1) in comparison to controls
(6.6:1). Linear correlation analysis between HP and LP
resulted in r¼0.98 for controls and r¼0.8 for tumor
patients.
Conclusion: Determination of HP and LP in urine obtained
from adult tumor patients suffering from malignant
primary bone tumors, metastases to bone and osseous
involvement in cases of soft tissue tumors is a useful
marker for bone resorption and can be indicative for an
osteolytic bone tumor. Further studies have to demonstrate
whether determination of HP, LP and its ratio can be
indicative for a relapse of the tumor.
O12
Improvement of local tumor control in retroperitoneal
soft tissue sarcomas (RSTS) – radiotherapy
W. Budach
(Department of Radiation Oncology, University Hospital
Du ¨sseldorf, Germany)
Most patients with RSTS are diagnosed with tumors larger
than 10cm. Complete resections are achieved in less than
50% of the cases. Local recurrences occur in 30–60% of
cases even after complete resections. Distant metastasis are
infrequent in liposarcomas, the most frequent histological
subtype of RSTS. Therefore, many patients die from
complications of the local tumor. External beam radiation
therapy (EBRT) is an effective pre- and postoperative
treatment in soft tissue sarcomas of the extremities. The
vicinity of relatively radiation sensitive organs like small
bowel and kidneys compromise the administration suffi-
cient radiation doses in RSTS. However, retrospective
data indicated some benefit from moderate dose EBRT.
Since better sparing of sensitive tissues can be achieved,
when the tumor is still in situ, preoperative RT appears
advantages. The use of intensity modulated radiotherapy
(IMRT) will markedly improve the ability to administer
higher doses to RPSTS resulting in better local tumor
control. Intraoperative electron beam radiotherapy
(IOERT) allows to keep sensitive tissues outside the
portals. A randomised trial comparing IOERT in
RSTS as boost before EBRT with EBRT alone (n¼87)
showed a clear benefit of IOERT in terms of local tumor
control. RSTS remain a interdisciplinary therapeutic
challenge.
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ICS-CWS RMS 96 – Early results of the Italian and
German Rhabdomyosarcoma (RMS) Cooperative Study
Groups
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Purpose: The ICS-CWS RMS 96, was addressed to
children <18yrs with localised RMS.
Methods: Treatment based on risk categories according to
histology, tumor site, lymph node (N) involvement, IRS
group (Gr). Chemotherapy (CT): ‘‘low risk’’; ‘‘standard
risk’’; ‘‘high risk’’: VAIA randomized vs. CEVAIE.
Delayed surgery after CT in Gr III. Radiotherapy: 32–
45Gy (pts in clinical CR or with residual disease or
ARMS). Between 1996 and 2003, 797 eligible pts entered
the study. Characteristics: sex: M 62%; age 74% <10yr;
site: orbit 10.7%, head-neck non PM 7,4%, PM 22%, GU
BP 11.8%, GU non BP 19.6%, extremity 10.7%, other
17.7%. Histology: alveolar 20.3%. Tumor size: >5cm
49%; N1 15%. IRS Group: I 16%, II 16%, III 68%. Risk
group: Low 10%, standard 22%, high 68%.
Results: 3-yr PFS and OS are 68.3% and 80.9% respec-
tively. According to risk group: Low risk 89.6% and
96.8%; standard risk 80.3% and 96.1%; high risk 61.4%
and 73.9%.
Conclusions: Low risk pts: Very good OS with an alkylating-
free regimen. Standard risk pts: Very good OS utilising
Sarcoma Meeting Stuttgart Abstracts 53a less aggressive treatment (9 vs. 12 cycles and no Doxo)
in comparison CWS 91 and ICS 88. High risk pts: No
improvement of OS and PFS.
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The orphan nuclear receptor DAX1 is expressed in
Ewing tumours and upregulated by the EWS/FLI1
oncoprotein
J. Carrillo
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Tumours of the Ewing family are sometimes difficult to
classify because of the highly similar appearance in routine
histology with other small round cell tumours, such as
rhabdomyosarcoma. To identify new marker genes of these
tumours, we analysed 22 Ewing’s sarcomas (ES) and 10
rhabdomyosarcomas (RMS) by CodeLink oligonucleo-
tides microarrays (Uniset I Human 20K). Genes specifi-
cally expressed for each tumour type were identified by
the statistical method Significance Analysis of Microarrays
(SAM). A total of 56 ES and 67 RMS specific genes
were identified. Amongst them, we focused on DAX-1
(NR0B1), an unusual orphan nuclear receptor involved in
gonadal development, sex determination and steroidogen-
esis. Quantitative real time RT-PCR, western-blot analysis,
and immunohistochemistry demonstrated that DAX1 was
expressed in Ewing cell lines and tumours, but not in
neuroblastoma or embryonal rhabdomyosarcoma. In
agreement with the transcriptional repressor activity
characteristic of DAX1, its expression was restricted to
the nucleus of Ewing tumour cells. We also analysed if
DAX1 expression was upregulated by the EWS/FLI1
fusion oncoprotein characteristic of Ewing tumours.
Using two unrelated cell systems, we demonstrated that
DAX1 mRNA and protein were upregulated by EWS/
FLI1, but not by native FLI1. These data show that
DAX1 could be a new target of the EWS/FLI1 oncoprotein
and open the possibility of its use as a Ewing molecular
marker in clinical routine diagnostic, at least in the
differential diagnosis with neuroblastoma and embryonal
rhabdomyosarcoma.
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The correlation between dose of follinic acid and
neurotoxicity in children and adolescents treated for
osteosarcoma with high dose methotrexate (HDMTX):
A neurophysical and psychosocial study
E. Boneda-Shkedi
1,2, D. Hoofien
2, M. Ben Arush-Weyl
3,
C. Kaplinsky
4,5, S. Ash
1, Y. Goshen
1, Y. Yaniv
1,5,
I.J. Cohen
1,5
(
1Department of Hematology Oncology Schneider Children’s
Medical Center of Israel,
2Hebrew University of Jerusalem,
Department of Psychology, Israel,
3Myer Children’s Hospital
Rambam Hospital, Israel,
4Tel Hashomer Hospital, Israel,
5Sackler School of Medicine, Tel Aviv University, Israel)
Introduction: Leukoencephalopathy occurs following
HDMTX with low dose follinic acid but can neurotoxicity
be prevented with adequate doses?
Objectives: To correlate follinic acid dose after MDMTX
and psychological and psychosocial status. 23 osteosar-
coma patients from three medical centers were evaluated 6
months – 20 years after therapy. 12 patients received 600–
800mg (one received 450mg) follinic acid (HDFA) and 11
patients received 120–220mg (LDFA).
Methods: 23 patients underwent extensive assessment
including neuropsychological measures of attention, work-
ing memory, visual perception, verbal memory, visual
memory, learning, executive functions, comprehension,
psychosocial measures of psychiatric status, self-esteem,
quality of life and social functioning. Both groups were
compared using parametric and non-parametric tests in the
relevant distributions and using the bonferroni method.
Results: 10 out of 18 equations in the neuropsychological
assessment significantly favored the (HDFA) group. No
psychosocial assessment showed a significance. Psychiatric
status and the social functioning were insignificantly better
in the (HDFA) group. Two measures of quality of life and
a measure of self esteem were insignificantly higher in the
(LDFA) group.
Conclusions: The (HDFA) group had a better neuropsy-
chological status. These findings have wider relevance
since the progressively lower follinic acid doses used in
leukaemia protocols may increase neurotoxicity.
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PET scanning in the orthopaedic population
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Introduction: Anatomic imaging modalities do not
accurately assess response of soft-tissue sarcomas to
preoperative radiotherapy and/or chemotherapy. [F-18]-
fluorodeoxy-D-glucose (FDG) positron emission tomo-
graphy (PET) predicts histopathologic response to therapy.
We use FDG PET to correlate between change in FDG
uptake and histopathologic response to preoperative
doxorubicin-based chemotherapy, risk of recurrence and
overall survival in patients with soft-tissue sarcomas. New
pilot data will also be included for total-joint and allograft
patients.
Methods: Retrospective analysis of thirty-eight patients with
intermediate-or high-grade, localized soft-tissue sarcoma
evaluated by FDG PET. Maximum standard uptake values
(SUVmax) of tumors were measured prior to treatment
with doxorubicin-based chemotherapy and prior to sur-
gery. Resected specimens were examined for residual
viable tumor using standard pathologic methods.
Association between change in SUVmax and residual
viable sarcoma was determined by Spearman rank correla-
tion. Patients were followed at least annually for evidence
of recurrence and survival. Kaplan-Meier analyses were
performed to determine whether the change in SUVmax to
chemotherapy correlated with risk of disease recurrence
after surgery and survival.
Results: The change in SUVmax of FDG inversely
correlates with the degree of residual viable tumor after
preoperative chemotherapy. Patients whose tumors have
40% or greater decline in SUVmax to chemotherapy are at
54 Sarcoma Meeting Stuttgart Abstractssignificantly lower risk of recurrent disease after complete
resection, and show a trend toward improved overall
survival.
Discussion/conclusion: FDG PET is a useful, non-invasive
measure of chemotherapy sensitivity of intermediate and
high-grade soft-tissue sarcomas. Soft-tissue sarcomas that
show response to doxorubicin-based chemotherapy by
FDG PET imaging have a lower risk of disease recurrence.
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Treatment results and prognostic factors in Ewing
sarcoma family of tumors in a Brazilian institution
C.M.L. Da Costa, A. Lopes, P.E. Novaes, B. De Camargo
(Pediatric Oncology Department, Hospital do Cancer AC
Camargo, Sa ˜o Paulo, Brazil)
The Ewing sarcoma family of tumors (ESFT) comprises a
group of neoplasms with aggressive behavior and definition
of prognostic factors is necessary to risk adapted therapy.
Prognostic factors in ESFT from a Brazilian institution
were analyzed. 110 consecutive patients with ESFT treated
from 1990–2001 were reviewed. 61% were male and 79%
were white. Median age was 12 years (range 3 months–19
years). Pelvic area (25 cases), femur (21 cases) and chest
wall (19 cases) were more often primary site. Thirty three
patients had detectable metastases at time of diagnosis.
There was a significant relationship between pelvic tumor
and metastases (p¼0.002). Five-year event-free survival
(EFS) was better for patients with age less than 12 years old
(63% vs. 34% p¼0.009), without metastases (66% vs. 12%
p<0.001),LDHlessthan300U/L(60%vs.38%p¼0.032),
good clinical response (63% vs. 9% p<0.001) and good
histological response (70% vs. 29% p<0.001). Metastases
(HR¼4.7 CI:5.51–22.61), clinical response (HR¼11
CI:2.36–9.62) and LDH (DHL¼2 CI:1.01–3.93) were
prognostic factors in multiple analysis (Cox). EFS was
influenced by age, metastases, clinical response LDH,
histological response. However only clinical response,
LDH, metastases were independent prognostic factors.
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Initial patient characteristics can predict pattern and risk
of relapse in localized rhabdomyosarcoma
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Purpose: Evaluation of primary tumor-, treatment-, and
patient-related factors predicting pattern and risk of relapse
in patients with localized rhabdomyosarcoma (RMS).
Methods: 1164 patients with RMS and a median follow-up
of 5 years achieved a complete remission after multimodal
therapy in the trials CWS-81, -86, -91, and -96 between
1980 and 2002. 336 of these developed either local (LR) or
metastatic (MR) relapse.
Results: Age, histology, tumor-size, -site (p¼0.07), IRS-
group, and radiotherapy were identified in multivariate
analysis as significant factors associated with increased
relapse risk. Relapse rates did not differ between the CWS-
trials. Median time to relapse was 1.43 (0.13–13.5) years.
LR (n¼217) the most common type of failure. Only 3 of
119 MR occurred >3 years after diagnosis and all those
were combined recurrences. Three patient subsets with
rather consistent pattern and risk of relapse could be
identified depending on the therapy-unrelated factors age,
histology, and tumor-size.
Conclusion: Initial patient characteristics can predict pattern
and risk of relapse. Screening for MR is not justified
>3 years after diagnosis. A risk stratification for follow-up
could be developed by means of three therapy-independent
factors. These results will form the basis of a new risk-
adapted follow-up for localized RMS in the CWS-trials.
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Role of radiotherapy in metastatic Ewing tumors
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Purpose: Primary metastatic disease is the main risk
factor in patients with Ewing tumors. We propose the
hypothesis that additional local treatment of
metastatic sites (especially by radiotherapy) may improve
outcome.
Materials and results: Bilateral lung irradiation (BLI)
is effective in controlling microscopic lung metastases,
but BLI was abandoned from treatment protocols with
the development of more effective chemotherapy regimens.
In the CESS-studies, BLI was a treatment option
for patients with lung metastases at diagnosis who
achieved a complete clinical response to chemotherapy.
A retrospective analysis demonstrated a dose-dependency.
In a multivariate analysis, lung irradiation was associated
with improved survival in patients with primary lung
metastases at diagnosis. Patients with bone metastases
( lung metastases) have a poor prognosis with
standard chemotherapy and local therapy. In phase-
II-trials, an aggressive approach including local irradiation
to clinically involved sites and additional high-dose
chemotherapy resulted in long-term remissions in about
40% of patients. Recent progress in diagnosis of metastases
(e.g. by PET) and local radiotherapy (e.g. 3D-conformal
or stereotactic radiotherapy) might further improve the
results.
Conclusions: BLI is an effective approach and currently
tested in the EURO-EWING-99-study. Local radiotherapy
to metastatic bone lesions is an attractive approach and
currently tested in ongoing trials.
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Topoisomerases I and II in high grade paediatric
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Sarcoma Meeting Stuttgart Abstracts 55Background: In the French Society of Paediatric Oncology,
patients with high grade osteosarcomas are treated with
OS94 protocol, including usually topoisomerase II
inhibitors. Antitopoisomerase I drugs were, only, used
in phase I studies. Considering these therapeutic
targets, our study was designed to investigate, firstly, the
status at loci 3p24, 17q21 and 20q11 and, secondly,
the candidate genes (TOP2B, TOP2A and TOP1,
respectively).
Patients and methods: We included 74 children treated
in OS94 protocol and systematically classified in good
(GR) and poor responders (PR) to neoadjuvant
chemotherapy. After DNA extraction, microsatellite
analysis was performed in paired blood and biopsy
samples at loci close to topoisomerase I, IIa and
IIb genes and was followed by QPCR targeting TOP1
and TOP2A comparatively to two different reference
genes.
Results: Our biopsies were highly rearranged at loci
20q11 (36.9%), 17q21 (47.6%) and 3p24 (69.7%).
Since TOP1 was amplified in a half of the rearran-
ged tumours, TOP2A was predominantly deleted
(27/34 abnormal cases). Furthermore, all the TOP2A
rearranged tumours were significantly correlated with
the GR subgroup without any consequence on survival
rate.
Conclusion: These results showed frequent rearrangements
of TOP1 and TOP2A in paediatric osteosarcomas, which
their role in oncogenesis should be studied.
O21
The role of surgical treatment in malignant vascular
tumours in children: A report from the Polish Paediatric
Rare Tumours Study
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The Polish Paediatric Rare Tumours Study registered
32 children (1992–2002) with angiosarcoma (ASA-10),
haemangioendothelioma (HE-7) and haemangioperi-
cytoma (HP-16) of infantile (7 pts) and adult-type (9 pts).
ASA: In 7/10 pts disease was local/regional, 8/10 tumours
infiltrated surrounding tissues. All 7 primary excisions
(PE) were incomplete. All pts received CHT, 5-radio-
therapy. 3/4 secondary resections were complete. 9/10 pts
died of relapse/progression.
HE: In all disease was local. 2/5 PE were complete.
2 patients received radiotherapy, 4–CHT. In 2 patients
secondary excisions were complete. 2/7 patients who had
incomplete PE died of disease.
Infantile HP: in all disease was local, 3 patients underwent
complete PE. 2/7 patients entered CR after CHT alone, 2/
7 after post-CHT surgery. All are in CR.
Adult-type HP: in all disease was local. 5/6 PE
were complete. 5 patients received radiotherapy, 6 CHT.
3 patients with macroscopic residues died of disease.
Conclusions: PE value in both HP subtypes and selected
HE: 10/14 excisions were complete vs 0/7 in ASA. Post-
CHT resections were complete in 7/9 cases improving
the outcome in HE and HP, but not in ASA. More
efficacious management of ASA should be searched for.
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Phase I – study: Exclusion of side-effects of the silver-
coated tumour endoprosthesis in 20 patients with bone
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The deep infection of tumour endoprosthesis is a serious
complication (10–20%). The silver-coated tumour endo-
prosthesis proved their effectiveness in a rabbit model
(7% infection versus 47% non-coated); toxicological side-
effects could be excluded (Gosheger et al., Biomaterials
2004). A prospective study is conducted including
230 patients in 2 phases: Phase I to exclude side-effects
(20 patients with bone metastasis) and secondly prove the
effectiveness.
Phase I consists of patients undergoing resection of large
metastasis with an impending (n¼7) or a diagnosed
fracture (n¼11) or an infected osteosynthesis (n¼2)
with progressive metastatic disease. The age ranged from
32–82, the mean follow up was 16 months.
The preliminary results did not show any side-effects
related to the silver-coating. Loosening, infection and
material failure could not be observed. The laboratory
parameters (GOT, GPT, creatinine, CK, etc.) did not
show pathologic changes due to the silver-coated endo-
prosthesis. In two performed sections analysing the
implant area no foreign body granuloma were found
and the surface was stable.
In summary, Phase I could exclude any side-effect of
the silver-coated endoprosthesis up to now so it can be
recommended in difficult patients suffering from an
infection, in an expected radiation therapy or in cases
with problematic soft tissue coverage.
O23
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Objectives: To explore the outcome of patients with primary
adult soft tissue sarcoma (STS) of the extremities under-
going re-excision following previous unplanned surgery.
Materials/methods: A total of 597 consecutive adult patients
with primary extremity STS were treated with conservative
surgery at our institution over a 20-year time span. Patients
referred after unplanned excisions were 318, while the
remaining 279 were primarily resected at our center. The
two groups significantly differed as far as size and depth
were concerned. The assessed end-points were sarcoma-
specific mortality, local recurrence and distant metastasis.
56 Sarcoma Meeting Stuttgart AbstractsUnivariable and multivariable analyses were performed in
the competing risks framework.
Results: At multivariable analysis, the 10-year cumulative
incidences in re-excised and primarily operated patients
were, respectively: 18.7 vs. 16.4% (P¼0.535) for local
relapse, 17.6 vs. 20.2% (P¼0.541) for metastatization,
20.4 vs. 22.4% (P¼0.645) for mortality. Amongst
re-excised patients, evidence of microscopic residual
disease on pathologic examination had a significant
prognostic impact at multivariable analysis for distant
metastases (P¼0.002), with a trend on survival detected
as well.
Conclusions: At a referral center carrying out a liberal policy
of re-excisions in adult, primary STS of extremities, the
outcome of re-excised patients was similar to primarily
resected patients. Evidence of microscopic residual disease
at re-excision was a marker of clinical aggressiveness.
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Overall survival after limb sparing or radical surgery for
malignant fibrous histiocytoma (MFH) of the extremity:
Analysis of prognostic factors by using SEER data
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Purpose: Limb sparing surgery followed by radiation
has emerged as standard management for extremity soft
tissue sarcoma. We examined factors associated with
overall survival in extremity MFH using NCI SEER
program data.
Patients and methods: 1043 SEER cases of soft tissue MFH
of the extremity (303 upper and 740 lower extremity) were
analyzed with median follow-up 5.2 years. Survival analysis
used Kaplan-Meier, log-rank test, and Cox proportional
hazards models.
Results/discussion: By univariate analysis, tumor size, grade,
age, SEER Stage, primary site, and type of surgery, were
significantly associated with overall survival (p<0.0001).
Five year overall survival was 64.8% (n¼588) for local
or wide resection and 56.9% for amputation (n¼204),
but only 16.9% (n¼60) for cases having had biopsy only.
Univariate significance was not achieved for the use of
radiation therapy treatment (p<0.9), or gender (p<0.4).
Race showed borderline significance (p<0.02) with
African Americans showing lower 5 year overall survival
(45.2%; n¼97) compared with Caucasian (60.0%;
n¼795). Multivariate analysis showed SEER stage
(p<0.00001), grade (p<0.00001), size (p<0.0001),
and type of surgery (p<0.0039) retained statistical
significance. Overall urvival for limb sparing surgery was
not different from amputation. The addition of radiation
therapy to limb sparing surgery did not impact on overall
survival.
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Postoperative hyperfractionated HDR-brachytherapy
with iridium-192 combined with external beam
radiotherapy for soft tissue sarcomas of the extremity
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Aim: A variety of radiotherapeutic approaches have been
used in the adjuvant local management of soft tissue
sarcoma. These include external beam irradiation, bra-
chytherapy, and intraoperative radiation therapy. In
appropriately selected patients, brachytherapy can be
used as monotherapy or as a boost to external beam
irradiation to treat possible microscopic residual disease at
the tumor bed. We analysed practicability, toxicity, local
tumor control and survival after hyperfractionated HDR-
brachytherapy with iridium-192 as adjuvant boost com-
bined with pre- or post-operative external beam irradiation
for marginal resectable intermediate or high grade primary
or recurrent soft tissue sarcomas of the extremity and
trunk.
Patients/methods: Median diameter of 13 primary and 10
recurrent soft tissue sarcomas was 10cm (range 3–20cm),
17x extremity, grading GIII in 45%, 4x R0-resection
(1–5mm in sano), 13x R1-resection, and 5x R2-resection.
Twenty patients received 23 courses of interstitial>HDR-
brachytherapy with iridium-192 1.5Gy BID, 15–30Gy
total dose, depending on resection margins. The median
brachytherapy volume of the 1.5Gy Isodose was 92ccm.
External beam irradiation was delivered to a median dose
of 50Gy (range 45–69Gy, re-irradiation in 5 patients).
Median follow up 27 months.
Results: Brachytherapy acute toxicity: 2x catheter disloca-
tion, 1x subfebrile temperature, 1x dermatitis CTC II.
External beam irradiation acute toxicity: 1x dermatitis
CTC II, 3x lymphedema CTC II. Actuarial 3-year
survival 83%, disease free survival 51%; 3-year overall
and extremity local tumor control was 78% and 87%,
respectively.
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Improvement of local control in retroperitoneal disease:
Surgical view
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(Division of Surgical Oncology and Thoracic Surgery,
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Retroperitoneal sarcoma, if treated with a primary surgical
approach offer exactly one chance for cure by R0 resection.
Liposarcoma of low grade as the type of tumor most often
diagnosed usually can be resected completely with
the retroperitoneal compartments providing surrounding
tissue and organs serving as margins of safety.
Unfortunately these characteristics are often neglected
during shelling-out procedures.
As in extremity sarcoma, high grade tumors and those
with extracompartmental extension should be treated
with a combined modality approach. After removal of the
sarcoma mass additional radiotherapy (RT) can applied
only with an increased risk of radiation enteritis. This hold
true also for completion-RT after IORT. According to
presently available data, there is no place for adjuvant
chemotherapy. Consequently, pretreatment biopsies (inci-
sional or CT-guided) need to representatives specimen
from those areas with different radiological appearance in
Gd-enhanced MRT. If a G3 lesion is detected, neoadju-
vant chemotherapy (alone or combined with hyperthermia
in the EORTC 62961 study, or combined radiochemother-
apy) or upfront radiotherapy (acc. ACOSOG trial) should
be the first step.
Any operative strategy aiming for cure should be as
radical as possible with resecting the total compartment if
required (including colectomy, nephrectomy, partial pan-
creatic resection or even part of the aortic wall). The kidney
Sarcoma Meeting Stuttgart Abstracts 57itself uninvolved by tumor and resected for invasion of the
ureter only can be reimplanted.
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Management, Translational Research Center, Kyoto University
Hospital, Japan)
Purpose: To disclose characteristics of rhabdomyosar-
coma in Japan and issues to discuss for future possible
international cooperative studies.
Patients: Three hundred and twenty rhabdomyosarcoma
patients treated from 1991 to 2002 in Japan.
Methods: Retrospective analysis for the outcomes of the
patients based on IRS-V risk-grouping.
Results: The 5-year survival were 86.2, 80.7, 61.7 and 38.1
percent for the low-risk subgroup A, the low-risk subgroup
B, the intermediate-risk group, and the high-risk group
patients, respectively. In the high-risk group, the patient
group that received high-dose chemotherapy (HDC) have
better survival (58.2%) than the other patient group treated
without HDC (18.4%) in significance (p¼0.019). There
was no significant difference between the survival of
embryonal (62.1%) and alveolar (58.5%) pathological
subtypes.
Discussion: The worse outcomes for Japanese patients in the
low-risk subgroup A and the low-risk subgroup B might be
caused by some difficulty in the differential diagnosis
between alveolar and embryonal subtypes. The better
outcome for Japanese patients in the high-risk group might
be due to the implementation of our original HDC
regimen followed by auto-peripheral blood stem cell
transplantation.
O28
Initial response and risk of early progression to regional
HT (RHT) combined chemotherapy among patients with
high-risk soft tissue sarcomas (HR-STS): A summary
report
L.H. Lindner
1,2, J. Braess
1, M. Schlemmer
1,
S. Abdel-Rahman
1, R. Issels
1,2
(
1Klinikum Grosshadern, University of Munich, Germany,
2GSF – National Research Center for Environment and
Health, Neuherberg, Germany)
Introduction: We analyzed the influence of grade (G)
on initial response and the risk of early PD during
RHT-combined chemotherapy.
Patients and methods: Doxorubicine based chemotherapy
in combination with RHT was performed in a total of 319
STS patients. For risk assessment of early progression 213
patients were analyzed.
Results: For all patients with measurable disease (n¼237/
319) the response rate (RR) was 33%. For G3, G2 and
G1 STS the RR were 32%, 33% and 37%, respectively.
RR was predictive for overall survival (OS) in patients with
G3 and G2 STS (5 year OS was 59% vs. 26% and 60% vs.
24% for responders/non-responders, respectively). But in
G1 STS 5 year OS was 85% for both. Early PD occurred
in 33/213 pts (15%) within the first 4 cycles of thermo-
chemotherapy. For the other 180 pts the 3-year local
progression free rate (LPFR), local progression free
survival (LPFS), and overall survival (OS) for E was
86.1%, 69.1% and 79.7% and for Non-E 48.0%, 38.1%
and 56.7%, respectively.
Conclusion: Response is independent from grading but is
predictive for OS in G2/G3 STS. The estimated prob-
ability for early PD is 15%. These pts do obviously not
benefit from the preoperative treatment regimen.
O29
Chemotherapy for primary osteosarcoma by intra-
arterial infusion
N. Jaffe
(Department of Pediatrics, University of Texas, M.D.
Anderson Cancer Center, Houston, TX, USA)
Therapeutic activity of an agent is related to mechanism of
action and concentration at the target organ. Higher
cytotoxic concentrations are achieved by the intra-arterial
as opposed to the intravenous route. Intra-arterial che-
motherapy for osteosarcoma has been administered with
Mitomycin C, 5-Fluorourcil, Methotrexate, Adriamycin
and Cisplatin. Cisplatin, 150mg/m
2 administered over
2 hour at 2 to 3 week intervals (4–6 courses) achieved
optimum results yielding tumor necrosis of 60–100%.
Systemic Cisplatin concentrations attained by the intra-
arterial route are similar to those attained by the
intravenous route. Differences in the local as opposed to
the peripheral vein concentrations, in the first 2 hours, are
highly significant: highest single concentrations in the local
draining vein at 60 to 90 minutes are 5–10mg/ml with a
steady state approaching 4mg/ml in the systemic circulation
(p<0.025). Tissue concentration in the tumor and
adjacent bone was 17 to 40mg/gm with tumor destruction
of 60–100%. Concentrations of 12mg/gm or less yielded
tumor destruction under 60% (p<0.025). Major prog-
nostic determinates of outcome were percentage of tumor
necrosis and tumor size (burden). Response in the primary
tumor to intra-arterial Cisplatin enhanced the safety of the
surgical procedure for limb salvage.
O30
Is more better? Lessons from consecutive Ewing tumour
studies
H. Ju ¨rgens
1, C. Liebscher
2, M. Paulussen
1, A. Schuck
3,
W. Winkelmann
4
(
1University Children’s Hospital, Department of Paediatric
Haematology and Oncology, Mu ¨nster, Germany,
2Coordinating Centre for Clinical Trials (KKS), University
of Mu ¨nster, Germany,
3University Hospital, Department of
Radiotherapy and Radiooncology, Mu ¨nster, Germany,
4University Hospital, Department of Orthopaedics, Mu ¨nster,
Germany)
Chemotherapy and local control with surgery and/or
radiation are essential in the treatment of Ewing tumours.
Results in patients below 25 years of age with biopsy-
proven osseous Ewing tumour and no visible metastases
were analysed with respect to the impact of trial (1981,
1986, 1992) and treatment strategy. A total of 400 patients
(pts) were analysed (CESS 81, 77 pts; CESS 86, 130 pts;
EICESS 92, 193 pts). The 5-year overall survival (OAS)
for the whole group is 0.70 with a plateau of 64% at 13.8
years. 5-year OAS has increased from 0.60 (CESS 81)
to 0.64 (CESS 86) and 0.79 (EICESS 92). This benefit
was seen in both small (<100ml) and large (>200ml)
tumours (small: 0.79, 0.68, 0.94; large: 0.31, 0.58, 0.69).
A particular benefit was seen in good responders to
chemotherapy (CESS 81, 0.79; EICESS 92, 0.95), in
patients <15 years where OAS rose from 0.61 to 0.85, and
in older patients (CESS 81, 0.33; EICESS 92, 0.62).
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chemotherapy intensity, i.e. substitution of cyclophos-
phamide by ifosfamide, and the extended use of surgery
for local control (CESS 81, 64%; EICESS 92, 82%).
O31
Early risk adapted radiotherapy improves prognosis in
children with primary nonresectable rhabdomyosar-
coma: Report of the German cooperative soft tissue
sarcoma studies
E. Koscielniak
1, A. Schuck
2
, B. Schmidt
3, T. Klingebiel
4,
C. Int-Veen
1, J. Treuner
1
(
1Olgahospital, Oncol./Haematol., Stuttgart, Germany,
2University of Muenster, Radiotherapy, Muenster, Germany,
Katharinenhospital, Radiotherapy, Stuttgart,
3University
of Frankfurt/Main, Oncol./Haematol., Frankfurt/Main,
Germany)
The major questions concerning radiotherapy in pts with
primary nonresectable rhabdomyosarcoma are: 1. Optimal
time and dose 2. Succession of RT and surgery 3. When
may RT be omitted? In the CWS-81 Study RT was
stratified according to the results of SL surgery at week
16–20, given only to pts who still had microscopic (40Gy)
or macroscopic (50Gy) residuals. In the CWS-86 Study
the RT stratification has been changed – the RT was given
in the majority of cases prior to SL surgery after one cycle
of CT (7–10 weeks) and stratified by the degree of tumor
volume reduction. The cumulative doses were: 32Gy
(favourable stratification criteria) or for patients with
unfavorable features 54.4Gy CWS-86, 48Gy CWS-91,
45Gy CWS-96. The single dose was reduced (1.6 Gy)
and given twice a day (accelerated hyperfractionation)
in the CWS-86, -91 and -96. This analysis included
429 pts with primary non resected localised RMS (Stage
III). The proportion of irradiated pts was similar in all
studies: 77% -79% -85%, -67%. The overall local tumor
control (LTC) in irradiated pts was 56%, 81%, 81% and
70% in the CWS-81, -86, -91 and -96 respectively
(p¼0.01). The median RT dose was 40Gy vs. 32Gy vs.
48Gy vs. 43.6 in the CWS-81, -86 and -91 Study
respectively. The prognosis improved dramatically in the
CWS-86, -91 and -96 Study in the group of pts who were
qualified as ‘‘good responders’’ after one cycle of the
neoadjuvant CT and had been irradiated mostly prior
to SL surgery (EFS-rate 69% vs. 46%, p<0.01. The
comparative dose of 40Gy conventionally fractionated was
given to 25 children in the CWS 81 Study (LTC¼48%)
Early, risk adapted irradiation given preoperatively and
concomitantly to chemotherapy improves prognosis in pts
with primary nonresectable RMS.
O32
Impact of EWS-FLI1 expression on the p53 pathway
in Ewing tumors
J. Ban, M. Kreppel, C. Siligan, G. Jug, H. Kovar
(Children’s Cancer Research Institute, Vienna, Austria)
P53 is a central regulator of cell cycle and death which
is impaired in the majority of human cancers. In Ewing
tumors (ESFT), however, p53 pathway alterations are rare.
ESFT are characterized by rearrangements of EWS with
the ETS transcription factor gene FLI1 in 85% of cases.
When introduced into primary cells of different origins,
EWS-FLI1 induces p53 dependent cell cycle arrest or
apoptosis while ESFT proliferation is dependent on
sustained EWS-FLI1 expression independent of the
presence of apparently fully functional p53. We tested
the hypothesis that EWS-FLI1 may functionally interfere
with p53 activity in the ESFT context. In reporter gene
assays, EWS-FLI1 partially suppressed the p53 promoter,
and suppression of endogenous EWS-FLI1 in ESFT cells
by RNA interference slightly activated p53 promoter
driven reporter gene activity. On the protein level,
endogenous p53 was significantly induced upon EWS-
FLI1 silencing in wildtype p53 ESFT cell lines. A similar
p53 inducing effect was observed upon cell cycle inhibition
or ectopic HEY1 expression in ESFT. In fact, HEY1,a n
established p53 regulator, was identified via chromatin
immunoprecipitation as a gene directly suppressed by
EWS-FLI1. Like EWS-FLI1 silencing, overexpression of
HEY1 resulted in ESFT growth arrest. Our results imply
that EWS-FLI1 suppresses basal p53 activity in ESFT.
O33
Comparison of treatment concepts for extraosseous
Ewing Tumours (EET) within consecutive trials of two
GPOH cooperative study groups
R. Ladenstein
1,U .P o ¨tschger
1,H .J u ¨rgens
2,
M. Paulussen
2, E. Koscielniak
3, J. Treuner
3
(The GPOH Cooperative Soft Tissue Sarcoma and Ewing
Tumour Study Group,
1St. Anna Kinderspital Wien, Austria,
2Universita ¨tskinderklinik Mu ¨nster, Germany,
3Olgahospital,
Stuttgart, Germany)
Purpose: Development of an effective strategy for patients
(pts) with EPMD.
Patients and Methods: Of 192 (pts) registered, 141 pts have
completed treatment. Median age is 15.8yrs (0.4–49.29).
Primary site was extremity in 57 pts and axial/other in
135 pts (40.6% in the pelvis). Tumour volume (TV) was
 200ml in 114 pts. Metastatic spread was bone marrow
(BM) only in 17 pts, bone only in 94 pts and bone&BM
in 79 pts. Additional metastatic sites were lungs (81 pts),
liver (7 pts), CNS (7 pts) and lymph nodes (11 pts). 123 pts
completed 6 VIDE induction cycles; reasons for <6VIDE
were toxicity(7), patient choice(2), progression(6). Local
treatments (surgery and/or radiotherapy) was documented
in 86 pts. Recommended HDT was busulphan 600mg/m
2
and melphalan 140mg/m
2 with PSCR. Median follow up is
2 years (range 0.0–4.6).
Results: Partial remission or better was achieved in 42% by
cycle 6. The 2 year overall survival (OS) for all 192 pts
is 32.8%. Only 84/141 pts received BuMel-HDT and
10 pts other HDT. BuMel pts achieved an OS of 30%.
Favourable OS factors at diagnosis are age <14yrs
(p¼0.0069), BM involvement only (p¼0.0057), single
bone lesions only (p¼0.0043), TV <200ml (p¼0.0004).
Conclusions: Further strategy refinement and validation of
HDT appears necessary within randomised trials.
O34
Expression profiles of osteosarcoma that can predict
metastatic potential
C.C. Lau
1, C. Man
1,J .G u
1, J. Visvanathan
1, J. Shen
1,
L. Perlaky
1, J. Hicks
1, M. Johnson
1, N. Davino
1,
J. Murray
2, L. Helman
3, W. Meyer
4, T. Triche
5,
R. Gorlick
6, K.-K. Wong
1, M. Chintagumpala
1
(
1Baylor College of Medicine, Houston, TX, USA,
2Cook
Children’s Hospital, Fort Worth, TX, USA,
3National Cancer
Institute, Bethesda, MD, USA,
4University of Oklahoma
Health Sciences Center, Oklahoma City, OK, USA,
5Children’s Hospital Los Angeles, Los Angeles, CA, USA,
6Memorial Sloan Kettering Cancer Center, New York,
NY, USA)
Using cDNA microarrays, we have analyzed the expression
profiles of 35 osteosarcoma cases consisting of 23 primary
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institutions. The expression profiles of these samples were
used to identify a set of significant predictor genes (n¼45),
a metastatic signature, for predicting the metastatic
potential of initial biopsies. This metastatic signature
correctly classified 34 out of a total of 38 initial biopsy
samples (correct classification rate¼89.5) and 22 of 26
initial biopsy samples in an independent validation set
(84.6%). The model correctly predicted all 10 metastatic
cases and 11 cases that initially presented with localized
disease at the time of diagnosis, but developed metastatic
disease later (sensitivity¼100%). Of the 17 cases that had
only localized disease, four of them were predicted as
metastatic (specificity¼76.5%) but two of these misclas-
sified cases have relatively short follow-up (<2 years).
In summary, we have used expression profiles to build a
model that can predict metastatic potential of osteosar-
comas at diagnosis. This model, together with our previous
chemo-resistant prediction model, will help to refine the
classification of osteosarcoma and ultimately impact the
stratification of these patients in future clinical trials.
O35
Antitumor effect of EWS/Fli-1 junction point targeted
antisense oligonucleotides by systemic injection in mice
A. Maksimenko
1, P. Couvreur
4, V. Polard
1, J.R. Bertrand
2,
M. Aboubakar
1, M. Gottikh
3, C. Malvy
2
(
1Bioalliance Pharma SA, Paris, France
2CNRS UMR 8121,
Institut G. Roussy, Villejuif, France,
3Belozersky Institute of
Physico-Chemical Biology, Lomonosov State University,
Moscow, Russia,
4CNRS UMR 8612, Faculty of Pharmacy
Paris sud 11, Chatenay Malabry, France)
The EWS/FlI-1 fusion gene, resulting from a t(11;22)
translocation, plays a key role in the pathogenesis of
Ewing’s sarcoma and the mRNA fusion point constitutes a
very specific target for therapeutic agents since it is only
present in cancer cells. We have therefore designed an
antisense oligonucleotide (ASO), made of 22 phosphodi-
ester bonds and 8 phosphorothioate bonds, protected by its
hairpin structure and complementary of type 1 fusion
point in EWS/Fli-1 mRNA. It inhibits with specificity the
expression of EWS/Fli-1 and cell growth when delivered by
cationic lipids in cell culture. We have shown previously
that this ASO inhibits with specificity the growth of a
tumor expressing EWS/Fli-1 in nude mice when delivered
intratumorally with bio-compatible polymeric nanospheres
coated with a cationic derivative, CTAB. However CTAB
could be toxic. We have now used chitozan for coating of
the same nanospheres. Chitozan can be either reversibly or
irreversibly bound to the nanospheres. In both cases these
nanospheres are efficient by intratumoral injection as was
CTAB. However when chitozan is irreversibly bound we
obtain tumor growth inhibtion after intraveinous injection
of the ASO-nanosphere complex.
O36
Conservative local treatment (surgery & brachytherapy)
for boys with bladder-prostate rhabdomyosarcoma
H. Martelli
1, C. Haie-Meder
2, O. Oberlin
2
(
1Ho ˆpital Bice ˆtre, Le Kremlin-Bice ˆtre Cedex, France,
2Institut
Gustave Roussy, Villejuif, France)
Objectives: to report the results of a conservative local
treatment (surgery and brachytherapy) for boys with BP
RMS, included in MMT 95 study.
Patients: From 1995 to 2003, 17 boys (14 were less than
6 years), were operated for a residual mass after
chemotherapy and 1 for local relapse after chemotherapy
alone. Patients underwent a partial prostatectomy or
cystectomy or both, with urethra preservation. All but
one patient had tumor cells in the resected specimen.
Surgery was never microscopically complete at the level of
the prostate. Brachytherapy was systematically performed
after tumor resection. The technique consisted of 2 loops
encompassing the prostate and the bladder neck area.
A dose of 60Gy was delivered with low dose rate.
Results: At a median follow-up of 4 years, 16 boys are alive
in first complete remission. One boy died from pulmonary
metastasis and another one from nodal and metastatic
relapse. Results in terms of urinary continence seem very
encouraging. Most of the boys are normally continent,
sometimes after perineal physiotherapy and have erections.
Conclusion: Even if very long term sequelae of brachyther-
apy cannot be evaluated, this method should be considered
in boys with bladder-prostate RMS.
O37
Detection and clinical significance of disseminated
tumour cells at diagnosis in bone marrow of children
with localised rhabdomyosarcoma
H.P. McDowell
1, A. Donfrancesco
2, G.M. Milano
2,
A. Clerico
3, O. Mannarino
2,3, P. Altavista
4, R. Boldrini
2,
R. Cozza
2, A. Inserra
2 C. Dominici
2,3
(
1Division of Oncology, RLCH NHS Trust Alder Hey,
Liverpool, UK,
2Laboratory of Oncology & Division of
Oncology, Bambino Gesu ` Children’s Hospital, Rome; Italy,
3Division of Oncology, Department of Paediatrics, La Sapienza
University, Rome, Italy,
4Section of Toxicology and Biomedical
Sciences, ENEA Research Center Casaccia, Rome, Italy)
Identification of poor prognosis patients with non-
metastatic rhabdomyosarcoma (RMS) remains a clinical
challenge. In an attempt to identify these patients a
prospective analysis for the presence of disseminated
RMS cells in bone marrow at diagnosis, using immuno-
cytochemistry, with MyoD1 and myogenin as markers, was
carried out. Thirty-seven patients treated on RMS88 and
RMS96 Italian protocols underwent staging investigations,
and in addition marrow examination for occult tumour
cells. All patients had negative marrow involvement using
cytomorphology, but 10/37 were positive with immuno-
staining. With a median follow-up of 30 months (range,
3–103), 7 patients are dead, 2 alive with disease and
28 disease-free. Marrow involvement was found to be
associated with a significantly higher risk of distant
recurrence (p¼0.014) rather than local and/or regional
recurrence. Overall survival probability was 91% in
patients with no marrow infiltration, 31% with marrow
infiltration (p¼0.001); event-free survival probability was
88% in the former and 48% in the latter (p¼0.01).
Disseminated tumour cells are indicative of disease spread
and are significantly linked to recurrence at distant sites
and poorer outcome. Marrow examination at diagnosis
using immunocytochemistry, a relatively low cost investi-
gation, may be an additional tool to modulate treatment.
O38
Children’s Kaposi’s sarcoma in an endemic area within
the ongoing AIDS endemic
B. Nkegoum
1, A. Gessain
2, P. Ndoumbe ´
3
(
1Pathology Service, University Teaching Hospital-Yaounde´-
Cameroon,
2Unit of Viral Oncology, Pasteur Institute-Paris,
France,
3Department of Pediatric Oncology-Faculty of
Medicine-Yaounde ´-Cameroon)
Background: Cameroon (Central Africa) was known to be
an endemic area of Kaposi’s sarcoma even before the onset
60 Sarcoma Meeting Stuttgart Abstractsof AIDS epidemic. Jensen and al reported 16 cases of
Kaposi’s sarcoma in Cameroonian children between 1968
and 1974. The aim of this study was to show the
anatomoclinical aspects of Kaposi’s sarcoma within the
ongoing AIDS epidemic in Cameroon.
Materials and methods: we carried out this retrospective
study over a period of 18 years (from 1987 to 2004). The
registers of the most important pathological laboratories
in Cameroon were retrieved.
Results: Among the 556 cases noted, 4% were aged 0–15
years. The youngest patient was aged 3 months and was
HIV positive. The male to female ratio was 3/1. The most
common site of involvement was cervical lymph nodes. All
the children presented with fever and weight loss. Skin and
lymph nodes were simultaneously involved in 2 cases. Only
4 cases of HIV positive serology were observed in this series
of children and the mother. The pathological aspect most
frequently observed was advanced stage Kaposi’s sarcoma.
Less than 10 children received full dose of chemotherapy
made up of cyclophosphamide, vincristine and prednisone.
Only one child survived 9 years after chemotherapy.
O39
Ifosfamide vs. cyclophosphamide: Long term gonadal
effects in male survivors of childhood cancer
O. Fawaz
1, V. Ridola
1, C. Schmitt
2, J.C. Gentet
3,
F. Aubier
1, D. Orbach
4, C. Bergeron
5, O. Oberlin
1
(SFCE (Socie ´te ´ Franc ¸aise des Cancers de l’Enfant):
1Institut
Gustave Roussy, Villejuif, France,
2Ho ˆpital Brabois, Nancy;
France,
3Ho ˆpital La Timone, Marseille; France,
4Institut
Curie, Paris; France,
5Centre Le ´on Be ´rard, France)
Purpose: To compare late effects of ifosfamide vs.
cyclophosphamide on fertility in males survivors of
childhood cancers.
Patients: 99 males were evaluated after treatment of a
soft tissue sarcoma (37), osteoasarcoma (25), Ewing (6),
lymphoma (28), other (3). Forty patients received
ifosfamide as unique alkylating agent and the other 59
received cyclophosphamide as unique alkylating agent.
Median interval after diagnosis was 9 years (4.5–19yrs),
median age at evaluation was 20 years (17.5–30.6yrs),
similar in the two groups. Median dose of ifosfamide was
54g/m
2 (30–96), median dose of cyclophosphamide was
8.3g/m
2 (4.6–22).
Methods: Evaluation was based on basal FSH measurement
known for its correlation with spermatogenesis. LH and
testosterone were also measured in most of the patients.
Results: Allmalesbutone(17.5yrs)hadnormaltestosterone
levels. FSH was above laboratories upper limit in 28 of the
59 males treated with cyclophospahmide and was within the
normal range in all the 40 pts treated with ifosfamide.
Conclusions: These results show a low risk of gonadal
dysfunction in men exposed to ifosfamide (median dose
54g/m
2) by contrast with the results for males treated
with cyclophosphamide. Additional patients are under
evaluation and will be presented.
O40
Cancer incidence in families of children with embryonal
and alveolar rhabdomyosarcoma included in the
Manchester children tumour registry
D. Pang, R. Alston, A. Kelsey, J.M. Birch
(University of Manchester & Cancer Research UK,
Manchester, UK)
Purpose: Histopathological subtypes of rhabdomyosarcoma
(RMS) in children including embryonal RMS (eRMS) and
alveolar RMS (aRMS) show distinct clinical features.
However the comparative cancer patterns among families
of patients have not been studied due to the rarity and
difficulties of differential diagnoses. We now compare
cancer incidences in relatives of children with these
subtypes of RMS.
Patients and methods: All children under 15 years old
included in the Manchester Children Tumour Registry
between 1 January 1954 and 31 December 2001 with
histologically confirmed RMS were eligible. All cases were
re-reviewed including immunohistochemistry and mole-
cular analysis. Families of cases were interviewed.
Reported cancers in relatives were verified from medical
records. Standardised incidence ratios (SIR) were esti-
mated from the age, sex, and calendar year specific
national cancer incidence rates. Results. For relatives of
children with eRMS, there were excesses of soft tissue
sarcoma (SIR¼5.6, p¼0.006), breast cancer (SIR¼1.8,
p¼0.03), and cervix cancer (SIR¼3.4, p¼0.009).
For aRMS families, there were excesses of soft tissue
sarcoma (SIR¼4.2, p¼0.04), stomach cancer (SIR¼2.5,
p¼0.04), and lung cancer (SIR¼1.8, p¼0.02).
Conclusions: For the first time we have demonstrated
distinct differences in cancer patterns between eRMS
families and aRMS. The role of germline mutations in
genes other than TP53 should be explored.
O41
DNA methylation abnormalities in rhabdomyosarcomas
D.M. Parham
1, B. Chen
2, C. Cooney
1, R.T. Kurmasheva
3,
C.A. Peterson
1
(
1Departments of Pathology, Pediatrics, Biochemistry,
Physiology, and Geriatrics, Arkansas Children’s Hospital,
University of Arkansas for Medical Sciences and Central
Arkansas Veterans Health Care System, Little Rock, AR,
USA,
2Division of Laboratory Systems, Centers for Disease
Control and Prevention, Atlanta, GA, USA,
3Department
of Molecular Pharmacology, St. Jude Children’s Research
Hospital, Memphis, TN, USA)
DNA methylation has been implicated in a broad array
of physiologic and pathologic processes. Because of its
association with genomic imprinting and epigenetics,
abnormal methylation holds great interest as a tumori-
genic mechanism in the origin and maintenance
of rhabdomyosarcoma (RMS). We have investigated
DNA methylation in a series of experiments that
demonstrate differences in methylation status among
embryonal rhabdomyosarcomas (ERMS), alveolar
rhabdomyosarcomas (ARMS), and normal tissues.
Using methylation-sensitive Southern blotting, our
results indicate that ERMS shows partial upstream
MyoD gene methylation, similar to normal embryonic
muscle and distinct from unmethylated MyoD in
ARMS and totally methylated MyoD of postnatal
tissues. Similarly, by methylation-sensitive PCR, the
upstream region of the PAX3 gene appears to be
hypermethylated in most ERMS and hypomethylated
in most ARMS and normal muscle. In contrast, the
cell cycle suppressor gene p16WAF shows hyper-
methylation in a subset of both ARMS and ERMS.
Analysis of global methylation shows a trend towards
global hypomethylation in a small number of
RMS, whereas semi-quantitative RT-PCR reveals that
DNA methyltransferase shows increased expression
in RMS, particularly ERMS, suggesting a misregulation
of enzyme activity. Our experiments demonstrate an
array of methylation abnormalities in RMS that correlate
with the known imprinting abnormalities of these
neoplasms.
Sarcoma Meeting Stuttgart Abstracts 61O42
Systemic therapy for refractory soft-tissue sarcomas
S.R. Patel
(Department of Sarcoma Medical Oncology, MD Anderson
Cancer Center, Houston, Texas, USA)
A limited number of systemic therapeutic agents have
some established activity in soft-tissue sarcomas.
Several histologies are considered primarily refractory
since no systemic therapy has been found to be effective
for these subsets, e.g. alveolar soft parts sarcomas
and clear cell sarcomas. For most of the other soft-
tissue sarcomas, conventional/standard agents include
doxorubicin, ifosfamide and dacarbazine. Patients
with disease that has progressed despite these agents
would be considered ‘‘refractory’’. With the rare
exceptions of long-term disease control after surgical
resections (mostly lung metastases), these patients are
very likely incurable. The primary therapeutic intent
in these patients therefore, is either palliation or
occasionally, extension of life. Therapeutic options
for these patients are also very limited and in many
instances, histology-specific, e.g. high-dose ifosfamide
for synovial sarcomas, taxanes for angiosarcomas,
topoisomerase 1 inhibitors for rhabdomyosarcomas/
Ewing’s sarcomas and gemcitabine/gemcitabine-
taxotere for leiomyosarcomas. Amongst agents still
undergoing investigations, ecteinascidin seems to have
some promising activity and is being pursued in
liposarcomas and leiomyosarcomas. The activity of
imatinib mesylate in GISTs and DFSP has fuelled
the interest in several other ‘‘targeted’’ therapeutic
agents, which are currently under investigation.
It is hoped that ongoing clinical trials will help
identify new agents with a better therapeutic ratio for
these patients with refractory soft-tissue sarcomas.
Continued efforts at development of new agents, and
enrolment of patients on clinical trials is strongly
recommended.
O43
Should adolescents with Ewing tumors be treated in
pediatric or non-pediatric oncology units? Data from the
GPOH CESS/EICESS studies
M. Paulussen, C. Liebscher, A. Hunold, D. Manner,
H. Juergens
(Department of Pediatric Hematology/Oncology, University
Children’s Hospital, Muenster, Germany)
Background: Adolescents with cancer have lower survival
rates than children. Ewing tumor patients treated accord-
ing to the same protocol in all age groups in Germany were
analyzed regarding age, treating institution, and outcome.
Patients: Data from 1426 patients treated on protocols
CESS81, CESS86, and EICESS92 were analyzed. The
treatment prescribed was indifferent of age. Patients were
registered in pediatric (73%), or non-pediatric, usually
(21%) medical oncology, institutions. Ten years event-free
survival (EFS) was analyzed.
Results: Patients aged  15 years achieved an EFS of 0.50,
EFS was 0.35 for patients >15 years, p¼0.0001. EFS was
0.49 for patients in pediatric, and 0.29 in non-pediatric
units, p¼0.0001. Patients aged >15 years achieved an EFS
of 0.41 in pediatric and of 0.29 in non-pediatric institu-
tions, p¼0.001. Patients aged 15–20 years achieved EFS
rates of 0.43 in pediatric and 0.24 in non-pediatric
institutions, p¼0.0002. In stepwise multivariate analyses,
older patient age lost significance, when the type of treating
institution was introduced into the model. Treatment in
non-pediatric institutions was an independent risk factor in
this model (RR1.43, p¼0.0006).
Conclusions: Adolescents with Ewing tumors should best
be treated in pediatric oncology institutions. Differences
in patient care between types of institutions should be
analyzed.
O44
Improving survival in Ewing tumors: A surgeon’s
contribution
A. Puri
1, M.G. Agarwal
1, C.N. Nair
2, P.A. Kurkure
2,
S. Banavalli
2, M.A. Muckaden
3, S. Laskar
3,
N.A. Jambhekar
4
(
1Department of Orthopaedic Oncology,
2Department of
Medical Oncology,
3Department of Radiotherapy,
4Department of Pathology, Tata Memorial Hospital,
Mumbai, India)
Our aim was to evaluate the role of adequate surgical
excision as part of the multidisciplinary management of
Ewing’s tumors.
From January 2000 to August 2004 a total of 104 biopsy
proven localised Ewing’s/PNET tumors were surgically
excised. Eighty five lesions arose in bone & 19 in soft
tissues. Surgery followed induction chemotherapy.
Wide excision with appropriate bone and soft tissue
reconstruction as required was attempted. Limb salvage
was accomplished in 92 cases and ablative surgery in
12 cases. Postoperatively the specimen was evaluated
for surgical margins and response to chemotherapy.
Patients showing residual viable tumor & those with
positive resection margins received postoperative
radiotherapy. All patients continued maintenance
chemotherapy.
Eighty four patients with a minimum follow up of 12
months (12–58 months) were available for evaluation.
Sixty six patients are alive without evidence of disease, 8
are alive with disease. Ten patients died due to progressive
disease. Both cases with intralesional margins, 1 of 7 cases
with involved margins & 5 of 75 cases with uninvolved
margins had local recurrence. Of the 9 cases with
inadequate margins 3 died and 2 have progressive disease.
Improving local control by adequate surgical excision
could ultimately contribute to increased long term survival
in Ewing’s tumors.
O45
Fusion gene dependent dissemination patterns of
alveolar rhabdomyosarcoma in the nude rat model
R. LeGallo
1, A. Burger
1, F.G. Barr
2, J.M. Gastier-Foster
1,
R.B. Fraser
3, W.E. Shiels
1, S.J. Qualman
1
(
1Department of Laboratory Medicine, Columbus Children’s
Hospital, Columbus, OH, USA,
2Department of Pathology
and Laboratory Medicine, University of Pennsylvania,
Philadelphia, PA, USA,
3Department of Pathology, IWK
Health Centre, Halifax, Nova Scotia, Canada)
The direct influence of PAX-FKHR fusion genes on
metastatic behavior of alveolar rhabdomyosarcoma
(ARMS) in vivo has not been tested. We hypothesize that
fusion gene presence is sufficient to alter the biologic
properties of an embryonal RMS (ERMS) cell line into
that of an ARMS-like pattern. The nude rat model was
manipulated using a human ERMS cell line transfected
with a construct containing the PAX3- or PAX7-FKHR
fusion gene. Three levels of gene expression (low, medium,
high) were studied. The ERMS cell line transfected with an
empty vector served as control. All animals received intra-
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controls showed a similar pattern of tumor dissemination
as the native ERMS cell line, involving lungs and adrenal
glands. The PAX3-FKHR transfected rats showed an
increase of bone involvement at all levels of expression
(p<0.05). Distant and disparate sites including the brain,
intraocular cavity, kidneys and lymph nodes were involved
only in the high expression group (p<0.05), suggesting
gene dose dependency. The PAX7-FKHR transfected
lines replicated the osteophilic deposition of the PAX3-
FKHR transfections. The PAX-FKHR fusion genes
determine the biologic dissemination patterns of ARMS
(versus ERMS) in the nude rat reflective of RMS behavior
in the human patient.
O46
Results of second-look operations in the intergroup
rhabdomyo-sarcoma study-IV, 1991–1997
B. Raney, J. Stoner, J. Anderson, C. Arndt, K. Brown,
W. Crist, H. Maurer, S. Qualman, M. Wharam, E. Wiener,
W. Meyer
(Children’s Oncology Group: Arcadia, CA. Division of
Pediatrics, UT MD Anderson Cancer Center, Houston, TX,
USA)
Purpose: To describe results of second-look operations
[SLO] and relate findings to outcome.
Patients/methods: 79 patients [pts] with gross residual
rhabdomyosarcoma had SLO after chemotherapy, with
[N¼65] or without [N¼14] radiotherapy. Primary tumor
sites were bladder/prostate [N¼27], orbit/head/neck
[N¼24], extremity/trunk [N¼16], and retroperitoneum/
pelvis [N¼12]. SLO was performed in 49 pts within 36
weeks after starting chemotherapy. Pts were grouped by
preoperative tumor response before SLO and pathology
results on SLO tissue.
Results: 15/18 pts [83%] without residual mass [‘‘complete
response’’] had no viable tumor at SLO. 26/61 pts [43%]
with residual mass had no viable tumor at SLO. The SLO
patients were compared with 328 similar patients without
SLO. 5-year failure-free survival [FFS] rates in those
having or not having SLO were 68% and 74% respectively
[P¼0.4]. The 5-year FFS rate in those without viable
tumor was 83% compared to 53% in those with viable
tumor [P<0.001].
Conclusions: Clinical/radiographic disappearance of tumor
usually correlated with no viable tumor at SLO. Clinical/
radiographic examinations detected residual masses, but
were non-specific regarding tumor viability. Nearly half
of the patients with residual masses had no viable tumor.
Patients without viable tumor had a much better outlook
for FFS than did those with persistent disease.
O47
Current status of systemic treatment of GIST
P. Reichardt
(Department of Hematology and Oncology, Charite ´ Campus
Virchow-Klinikum, Berlin, Germany)
Gastrointestinal stromal tumors (GIST) are the most
frequent mesenchymal tumors originating from the GI
tract. GISTs are strongly and uniformly positive for
CD117 (c-kit), a type III receptor-tyrosine kinase. Kit
mutations, leading to ligand independent constitutive
activation play a major role in the pathogenesis of GIST.
Until recently no active systemic treatment was available.
Imatinib, a specific inhibitor of the c-kit tyrosine kinase has
revolutionized the treatment of GIST with response rates
around 60% and progression arrest in 80 to 90% of
patients. Results from a large European trial show that
imatinib 800mg/day yields a 5 months advantage over
400mg/day in terms of progression-free survival, although
overall survival data are not yet mature. Once started,
treatment with Imatinib should not be terminated, even in
complete remission or after resection of residual disease.
The role of adjuvant treatment after potentially curative
resection of GIST is currently evaluated in ongoing
clinical trials. Patients with progressive disease while
under treatment with Imatinib should be enrolled in
studies testing novel treatment strategies as RAD001,
PKC412, AMN107, SU11248 or AMG706.
O48
Molecular imaging in the genomic age: The next big
thing
D. Rosenbach
(Tampa General Hospital, Affiliate Assistant Professor,
Department of Radiology, University of South Florida,
Florida, USA)
Traditional radiologic evaluation of malignancy focuses
by technological necessity on questions of anatomy and
morphology. Recent advances in the understanding of
genomics and proteomics have directed interest in
imaging, instead, to oncology’s underlying biological
behavior. Molecular imaging (MI) represents an emerging
discipline that aims to characterize and quantify the in vivo
actions of cellular and molecular events involved in normal
and pathologic processes, particularly malignancy. This
new paradigm heralds not only a growing insight into
human disease but also a shift from the anatomic and
morphologic determinism of traditional radiology. MI
probes, contrast agents in the broadest sense, interact
with specific target genes and proteins and manifest as
radioactivity, paramagnetism, fluorescence and acoustic
impedance that can be detected by appropriate scanning
modalities. By identifying the exact cellular events respon-
sible for malignancy, molecular imaging transcends the
demonstration of location and size and addresses the
questions of tissue differentiation, tumor expression,
metastatic disease, early response to treatment and
development and validation of novel therapies.
O49
Role of chimeric ETV6-NTRK3 transcript in diagnosis
and prognosis of congenital infantile fibrosarcoma
F. Sartori, R. Alaggio, P. Dall’Igna, B. Famengo, V. Ninfo,
M. Carli, A. Rosolen
(Clinica di Oncoematologia Pediatrica, Clinica di Chirurgia
Pediatrica and Istituto di Anatomia Patologica, Azienda
Ospedaliera-Universita ` di Padova, Padova, Italy)
Congenital Infantile Fibrosarcoma (CIFS) is a rare
myofibroblastic lesion, morphologically indistinguishable
from Adult Fibrosarcoma (AF) and Infantile fibromatosis
(IF). Until recently age was the only criterion to distinguish
CIFS from AF.
We investigated the diagnostic role of ETV6-NTRK3
transcript and its prognostic impact.
Hematoxylin-eosin stained slides and clinical reports
from 10 patients with CIFS were reviewed. Total RNA was
obtained from fresh or frozen samples and studied for the
chimeric transcript ETV6-NTRK3 by RT-PCR.
Patient median age was 4 months. Median follow-up
was 52 months. All cases were characterized by high
cellularity, high mitotic rate and features of immature
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Immunostains confirmed the myofibroblastic nature of
cells (vimentin and smooth muscle actin positive, desmin
and S100 negative). Four cases were positive for the
ETV6-NTRK3 transcript and were morphologically undis-
tinguishable from the 6 negative cases.
All ETV6-NTRK3 positive patients are alive and disease
free. Transcript negative cases had an aggressive clinical
course with multiple local relapses (6/6) and distant
metastases (3/6). One patient died of disease after two
years, the remaining are alive with disease.
Detection of ETV6-NTRK3 transcript is a useful
diagnostic tool and may identify different prognostic
groups within CIFS.
O50
Expression profiling of rhabdomyosarcoma: Increasing
reliability of target gene selection by combining expres-
sion data generated from different platforms
G.J. Schaaf
1, S. Gallego
2, P.D. Moerland
3,
D. Zwijnenburg
1, A. Llort
2, R. Versteeg
1, M. Kool
1
(
1Department of Human Genetics,
3Bioinformatics Laboratory,
Academic Medical Centre, University of Amsterdam,
Amsterdam, The Netherlands,
2Unitat d’Oncologia
Pediatrica, Hospital Universitari Vall d’Hebron, Barcelona,
Spain)
Rhabdomyosarcoma (RMS) is the most frequent soft
tissue sarcoma in children. Heterogeneity in response
to treatment still exists, in particular, the alveolar subtype
portends a very poor prognosis. We have employed
expression profiling analysis to select genes that are
differentially regulated in RMS as compared to normal
muscle, as well as genes that profoundly reflect the dif-
ference between alveolar (ARMS) and embryonal RMS
(ERMS), the major histological subtypes. To increase the
robustness of the candidate gene selection procedure, we
only select genes that show consistent differential expres-
sion in the analysis of 3 different profiling platforms,
including serial analysis of gene expression (SAGE),
cDNA and oligonucleotide microarrays. For the compar-
ison of RMS with normal muscle a large proportion of
the genes downregulated in RMS were found to encode
muscle-specific proteins (e.g. titin, troponin). Genes
consistently upregulated in RMS are committed to cell
cycle control. The comparison of ARMS to ERMS
identified several genes that are involved in disease
progression and metastatic disease. The relevance of
identified genes will be further analyzed using tissue
arrays that are generated in our departments. This will
allow us to combine gene expression data with clinical
parameters (e.g. age, histology, site, survival).
O51
Pharmacogenomic study on EWS-gene rearranged
sarcoma
K.-L. Schaefer
1, K. Brachwitz
1, Y. Braun
1, D. Wai
2,
H.E. Gabbert
1, C. Poremba
1
(
1Institute of Pathology, Heinrich-Heine-University,
Duesseldorf, Germany,
2Children’s Hospital Los Angeles,
Los Angeles, CA, USA)
The Ewing family of tumors (EFT) and clear cell sarcoma
of soft tissue (CCSST) both belong to the malignancies
of the musculoskeletal system which are characterized by
a chromosomal translocation involving the EWS gene on
chromosome 22. While for EFT neoadjuvant chemother-
apy is well established as an indispensable component
in the corresponding treatment protocols, for CCSST wide
chirurgical resection is the mainstay of tumor therapy.
To elucidate the molecular similarities and varieties
between these two tumor groups we sought to correlate the
susceptibility of EFT and CCSST to standard cytostatic
drugs with their respective gene expression pattern.
Seven CCSST and nine EFT cell lines were treated with
a panel of common chemotherapeutic agents and the
resulting LD50-values were correlated with their gene
expression pattern as measured by using Affymetrix HG
U133A microarrays.
In general, EFT are more sensitive to the most cytostatic
drugs in comparison to CCSST. However in both tumor
entities we also observed subsets of cell lines showing
exceptional patterns of drug resistance or drug suscep-
tibility respectively. These cell lines could be characterised
by a specific expression pattern of marker genes. We
therefore conclude that the functional analysis of
these marker genes may be helpful to understand the
individual differences in chemosensitivity in both EFT
and CCSST.
O52
Single-center experience with more than 800 soft tissue
sarcoma patients treated between 1993 and 2004:
Outcome and prognostic factors
P.M. Schlag, P.-U. Tunn, S. Koswig, P. Reichardt
(Clinic for Surgery and Surgical Oncology, Charite ´ Campus
Buch, Berlin, Germany)
Purpose: We report about our experiences of multimodal
therapy of more than 800 patients in a single institution
over a time-period of 12 years.
Patients and methods: 815 patients with soft tissue sarcoma
underwent surgical treatment between 1992 and 2004.
The average age was 51.5 years (10–82 years). 73.1% were
located at the extremities, 12.2% at the trunk and 14.7
in the retroperitoneum. The most frequent sarcoma
was liposarcoma (25.4%). High malignant sarcomas were
predominant (G3 42%). 60% percent of sarcoma were
greater than 5cm, and 74% were located extracompart-
mental. A multimodal therapy was applied in 52.4% of the
patients.
Results: R0 resection was achieved in 85%. Extremity
conserving surgery was performed in 85.3%. 5-year local
recurrence rate is 18.8%. Neoadjuvant therapy achieved in
41% a partial and in 11.1% a complete remission (isolated
limb perfusion, radiation, chemotherapy). The 5 year
overall survival rate is 66.9%. Patients with malignant
peripheral nerve sheath tumor had a significantly worse
overall survival (5-year SR: 49.9%). In contrast, patients
with liposarcoma (82%) and synovial sarcoma (84.5%) had
the best prognosis.
Discussion: Prognosis is dependent on R0 resection,
grading, size of the tumor, metastasis and tumor localiza-
tion. Additive therapy options within multimodal therapy
concepts are promising.
O53
Radiotherapy in parameningeal rhabdomyosarcoma:
Results of the CWS trials
A. Schuck
1, C. Int-Veen
2, S. Kirsch
2, T. Dantonello
2,
I. Brecht
2, B. Schmidt
3, E. Koscielniak
2, J. Treuner
2
(
1Radiotherapy Department, University Hospital Muenster,
Muenster, Germany,
2Department of Pediatric Oncology/
Hematology, Olgahospital Stuttgart, Stuttgart, Germany,
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Purpose: The role of radiotherapy in patients with localized
parameningeal RMS registered in the CWS trials was
analyzed.
Methods: 304 study patients were treated between 4/1980
and 12/2002. Treatment consisted of systemic therapy and
local therapy. The median follow up of surviving patients
was 73 months.
Results: There was 1 patient in group I, 18 patients in group
II and 285 patients in group III. EFS was 56% at 5 years
overall. In group II, local relapse free survival (LRFS) at
5 years was 72%. One local relapse occurred in13 patients
receiving radiotherapy and 3 in 3 patients without RT.
In group III, LRFS at 5 years was 76%. 255 of 285 patients
received radiotherapy. Median time from the start of
treatment to onset of radiotherapy was 104 days in group
III. No difference in local control was observed between
patients with onset of RT < or >104 days. In IRS group III,
8 of 42 patients (19%) relapsed locally following 28–36Gy
and 32 of 204 patients (15%) after >36Gy.
Discussion: Radiotherapy is essential in parameningeal
RMS. No clear correlation between onset of RT and
local control could be established.
O54
Prognostic significance of preoperative [18-F] fluoro-
deoxyglucose (FDG) positron emission tomography
(PET) imaging in patients with resectable soft tissue
sarcomas
M.H.M. Schwarzbach
1, U. Hinz
2, A. Dimitrakopoulou-
Strauss
3, F. Willeke
1 S. Cardona
1, G. Mechtersheimer
5,
T. Lehnert
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1
(
1Department of Surgery,
6Division of Surgical Oncology,
2Unit for Documentation and Statistics,
3Department of
Surgery, Clinical Cooperation Unit Nuclear Medicine,
German Cancer Research Center,
5Institute of Pathology,
University of Heidelberg, Germany)
Purpose: To evaluate the prognostic value of preoperative
PET using FDG calculating the mean Standardized
Uptake Values (SUV) in resectable soft tissue sarcomas
(STS).
Patients/methods: 74 patients with STS underwent pre-
operative FDG-PET with SUV calculation. Data were
analyzed for an association with the outcome. First and
third quartiles of the SUV distribution function were used
as cut-off values (1.59 and 3.6). Survival was estimated by
the Kaplan-Meier method. Uni- and multivariate analyses
were performed (log-rank test and Cox proportional
hazards regression model).
Results: In 55 cases, STS were completely resected
(follow-up 40 months): 5-year recurrence-free survival in
patients with SUV <1.59, 1.59–<3.6, and  3.6 was 66%,
24%, and 11% (P¼0.0034). SUV was a predictor for
survival (5-year rates: 84% [SUV <1.59], 45% [SUV 1.59–
<3.6], and 38% [SUV 3.6]; P¼0.057) and local control
(5-year rates: 93% [SUV <1.59], 43% [SUV 1.59–<3.6],
and 15% [SUV  3.6]; P¼0.0017). By multivariate
analysis, SUV predicted recurrence-free survival. The
differences were associated with grade (P¼0.002).
Conclusion: The FDG uptake, as measured by the mean
SUV in resectable STS, is a useful prognostic parameter.
SUV with cut-off values at the first and the third quartiles
predicted overall survival, recurrence-free survival, and
local control. Therefore, it can be used to improve the
preoperative assessment of resectable STS.
O55
Antiangiogenesis as an option for the treatment of
bone and soft tissue sarcoma?
L. Schweigerer
(Department of Pediatrics I, Children’s Hospital, University of
Go ¨ttingen, Germany)
Angiogenesis, the formation of new vessels, is indispen-
sable for tissue growth and expansion. On the molecular
level, relative tissue hypoxia or other situations generate
angiogenic triggers, including the activation of humoral
antiogenic stimulators and/or the suppression of antiangio-
genic stummuli and/or the corresponding signal
transduction systems in adjacent vascular endothelial
cells. Signalling results in endothelial cell proliferation
and the subsequent invasion of the cells into adjacent
tissues, eventually generating functional new capillaries.
Within the last decade, several angiogenic stimulators,
inhibitors and their receptors have been identified includ-
ing ‘‘vascular endothelial growth factor’’ (VEGF), the best-
known angiogenic stimulator.
Angiogenesis is seen under various physiological condi-
tions including pre- and postnatal growth. It is also seen
during regeneration, for example during uterine growth
and subsequent to cardiac infarction. Angiogenesis is also
casually involved in the progression of solid pediatric
malignancies. In contrast to malignancies prevalent in
adults, those presenting in children are extremely well
vascularized. Therefore, the inhibition of angiogenesis
by endogenous or synthetic antiogenesis inhibitors
could provide a means to improve conventional tumor
therapy. We have identified several molecules able
to inhibit experimental angiogenesis, including
2-methoxyestradiol, genistein and arginine deiminase.
These could have the potential for clinical application,
the most likely setting being additive to conventional
treatment modalities.
Antiangiogenesis is still in its infancy. However, recent
data have demonstrated its clinical potential in adult
tumors, suggesting that antiangiogenesis could be
feasible to improve outcome of children with solid
malignancies.
O56
Visualization of xenotransplanted human rhabdomyo-
sarcoma following transfection with red fluorescent
protein
G. Seitz
1, S.W. Warmann
1, R.M. Hoffman
2,
H. Heitmann
1, J. Mahrt
3, J.T. Wessels
3, J. Fuchs
1
(
1Department of Pediatric Surgery, University Children’s
Hospital, Tu ¨bingen,
2AntiCancer Inc., San Diego,
California, USA,
3Centre for Internal Medicine, Department
of Nephrology and Rheumatology, Go ¨ttingen, Germany)
Purpose: Discosoma sp. red fluorescent protein (DsRed2)
is a novel marker for in vivo labelling studies in different
biological systems. The aim of this study was to establish a
DsRed2-transfected human rhabdomyosarcoma cell line
and to perform xenotransplantation into nude mice for
in vivo imaging.
Materials and methods: The rhabdomyosarcoma cell line
(Rh30) was transfected with the pDsRed-N1 vector by
lipofection. DsRed2-positive cells were sorted by FACS
96h post transfection and selected in culture with G418.
After vector transfection, a pure and stable DsRed2-
positive clonal cell line was established. Expression of
DsRed2-mRNA was assessed using single-cell rT-PCR.
1 10
6 RFP cells were injected subcutaneous into nude
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growth through the mouse skin even at a very early stage.
Results/conclusion: Successful vector transfection was
achieved. After FACS followed by G418 selection and
monoclonal selection, a pure DsRed2-positive cell line
was established. rT-PCR revealed constant expression
of DsRed2-mRNA. After xenotransplantation of these
human cells, tumours could be detected and observed in
non-invasively through the mouse skin. This is a useful
tool for further investigations of the in vivo biology,
angiogenesis and metastasis of human rhabdomyosarcoma.
O57
E-cadherin mediates cell-cell adhesion and suppression
of anoikis during anchorage independent growth of
Ewing tumor cells
P.H.B. Sorensen
1,2, H.-G. Kang
1, J. Zhang
1,
N. Keshelava
1, C.P. Reynolds
1, T.J. Triche
1
(
1Childrens Hospital Los Angeles, University of Southern
California, Los Angeles, California, USA,
2University of
British Columbia, Vancouver, BC, Canada)
Ability to grow under anchorage independent conditions is
a hallmark of transformed cells. A key aspect of this process
is the suppression of anoikis, defined as programmed cell
death induced by detachment from the extracellular
matrix. To model this phenomenon, we analyzed Ewing
family tumor (EFT) cell lines growing as anchorage
independent multicellular spheroids lacking attachment
to underlying matrix. Not only do EFT spheroids show
reduced basal levels of apoptosis compared with adherent
cultures, but also demonstrate profound chemoresistance
to a wide range of agents. We therefore hypothesized that
cell-cell adhesions activate unique survival pathways in
EFT spheroids, and analyzed which proteins might under-
lie this process. We found that while EFT monolayers
utilize integrin-mediated adhesion to plastic, multicellular
spheroid formation is dependent on cell-cell adhesions
mediated by E-cadherin. Anti-E-cadherin antibodies
blocked spheroid formation and led to massive cell
apoptosis. Moreover, expression of dominant negative
E-cadherin reduced spheroid formation, restored their
chemosensitivity, and reduced cellular AKT activation.
Spheroid cells demonstrated increased activation of the
Rac1 and Cdc42 Rho family GTPases, and dominant
negative Rac1 or Cdc42 blocked spheroid cell survival.
These results suggest that anchorage independent Ewing
tumor cells suppress anoikis through E-cadherin cell-cell
adhesion and activation of Rho family GTPases.
O58
Results of osteosarcoma therapy without HD-MTX
between 1986 and 1992: A twelve year follow-up of
53 patients
J. Jakob
1, P. Reichardt
2, P.-U. Tunn
1
(
1Clinic for Surgery and Surgical Oncology, Robert-
Ro ¨ssle-Klinik, Charite ´-Campus Buch, Berlin,
2Clinic for
Hematology, Oncology and Tumor Immunology, Robert-
Ro ¨ssle-Klinik, Charite ´-Campus Buch, Berlin, Germany)
Background: We report about results of systemic
chemotherapy of osteosarcoma without HC-MTX.
Patients and methods: 53 patients with osteosarcoma of
the extremity, stage 2B, were treated between 1986 and
1992 (age 6–36 years, median 17 years). All patients
received a pre- and postoperative chemotherapy without
HD-MTX. 60.4% of the patients had a tumor volume less
than 150ml. 71.7% of the patients were treated by limb-
sparing therapy, 20.8 by amputation and 7.5% by rotation
plasty.
Results: The overall survival rate after 10 years was 67.2%.
The rate of local relapse was 11.3%. Without local
recurrence the 10 year survival was 74.2% (p¼0.002).
Pulmonary metastasis deteriorates the progtnosis, the
mean five year survival was 31.6%, a ten year survival
was not achieved. If the tumor volume was less than 150ml
a ten year survival of 71.1% was observed, more than
150ml led to 61.1% (p¼0.445) of 10 year overall survival.
Overall response to preoperative chemotherapy was
45.3%. The 10 year survival rate was 73.5% and 62.1%
for non responder.
Conclusion: The most important prognostic factors are
local and systemic progression of the tumor. Comparison
with the COSS protocol shows that therapy results without
HC-MTX are identical.
O59
Successful high resolution animal positron emission
tomography of human Ewing tumors and their meta-
stases in a murine xenograft model
C. Franzius
1, M. Hotfilder
2, C. Poremba
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1,
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3,H .J u ¨rgens
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1,
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(
1Department of Nuclear Medicine, University Hospital
Muenster, Muenster, Germany,
2Department of Pediatric
Hematology and Oncology, University Hospital Muenster,
Muenster Germany,
3Institute of Pathology, Heinrich-
Heine-University, Duesseldorf, Germany)
Purpose: A major advantage of small animal PET is its
capability to study molecular pathways in vivo non-
invasively and serially. As primary osseous metastasis is
the main adverse prognostic factor in patients with Ewing
tumors, a NOD/scid mouse model for human Ewing
tumor metastases has been established. The aim of this
study was to evaluate the feasibility of diagnostic molecular
imaging in this mouse model for human Ewing tumor
metastases.
Methods: Human Ewing tumor cells (VH-64, CADO-ES1,
TC-71) were transplanted into immune-deficient mice
via s.c. injection (n¼17) or via i.v. injection (n¼17).
To assess glucose utilization and bone metabolism,
mice were scanned after injection of 2-[18F]Fluoro-2-
deoxy-D-glucose (FDG) or [18F]Fluoride, respectively,
using a submillimeter resolution animal PET scanner
(quadHIDAC, Oxford Positron Systems Ltd, Oxford,
UK).
Results: Subcutaneously transplantated Ewing tumors
and metastases (lung, bone and soft-tissue) demonstrate
a moderately increased glucose uptake. Osseous meta-
stases are additionally visible on [18F]Fluoride PET
by demonstrating a decreased [18F]Fluoride uptake
(osteolysis). Hypermetabolic (FDG) and hypometabolic
([18F]Fluoride) metastases smaller than 10mm
3 were
depicted. Metastases were confirmed immunohistologi-
cally.
Conclusion: Diagnostic molecular imaging of Ewing tumors
and their small metastases in an in vivo NOD/scid mouse
model is feasible using a submillimeter resolution PET
scanner.
O60
Subgroup classification of rhabdomyosarcoma by
immunohistochemistry
M. Wachtel
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Zurich, Switzerland,
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Rhabdomyosarcoma (RMS) is the most common soft
tissue sarcoma in childhood. Based on histology, two
different RMS subgroups are distinguished, the embryonal
(ERMS) and the alveolar (ARMS) form. Due to a
higher rate of metastasis formation, the outcome of the
ARMS subgroup is much worse in comparison to the
ERMS, and a correct classification therefore has clinical
significance. However, classification solely based on
histology is not sufficient in many cases and requires
additional methods.
In the last decade, classification could be improved
by the finding that 80% of the ARMS carry specific
chromosomal translocations leading to the fusion of
PAX3 or PAX7 to FKHR or NCOA1. However
detection of the fusion-transcript needs high quality
RNA, which is not always available, as the complete
biopsy material is often needed for the initial histological
analysis.
Performing a tissue array on 252 RMS tumors
we demonstrate here that two translocation-dependent
marker proteins, AP2beta and P-Cadherin, allow indirect
detection of translocation-positive RMS by immunohisto-
chemistry with high sensitivity and specificity. Another
marker, the EGFR, shows high ERMS-specificity and
supplements the classification.
Our data therefore simplify diagnostic classification of
RMS on the level of immunohistochemistry.
O61
Role of plastic and reconstructive surgery in sarcomas
M. Greulich
(Centre for Plastic Surgery, Marienhospital, Stuttgart,
Germany)
Introduction: Local tumour control is a major problem in
sarcomas. Surgery therefore plays a key role in multimodal
therapy. But mutilating and radical surgery should be
avoided, especially in children and adolescents with respect
to quality of life and late effects.
Methods: Examples for resection by means of plastic-
reconstructive surgery and cosmetic and functional out-
come are presented. A short summary of the applied
techniques for coverage of major soft tissue defect is given
as well (e.g. transplantation, microvasular coverage, flaps,
vascular and neural reconstruction, microvascular bone
replacement, muscle- and tendon transfers, etc.). Plastic
surgery can be useful in reexision too. The difficulties
in determining the optimal timing of radiotherapy and
reconstructive surgery are considered. Radiotherapy can be
avoided in some patients by means of plastic surgery.
Conclusion: Plastic and reconstructive surgery offers
the possibility of resection without mutilation, but
also allows complete tumor resections that would not
have been possible with conventional surgery. Its use
should be an essential part of multidisciplinary and
multimodal therapy of sarcomas. Plastic-reconstructive
surgery does not only improve outcome and quality of
life, it can help to minimize the burden of therapy in
sarcoma as well.
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P001
Inflammatory Myofibroblastic Tumors (IMTs) in
children: Their relationship with HHV8 infection and
prognostic role of histology.
R. Alaggio, L. Calabro `, M. Barbierato, S. Bitetti,
G. Bisogno, E.S.G. d’Amore, P. Dall’Igna, G. Cecchetto
(Department of Oncology and Surgical Sciences, Pathology
and Oncology Section, University of Padua, Italy)
Introduction: IMTs can be neoplastic lesions, with clonal
rearrangements of ALK1, or infection-related.
Aim: To identify prognostic histological parameters and
investigate the role of human herpesvirus 8 (HHV8) in
pediatric IMTs.
Study design: 25 children (mean age 8 years) affected by
IMTs of lung (9), abdomen/pelvis (14), liver (1), spleen (1)
were analysed. Cellularity, flogosis, myxoid component,
necrosis, mitosis and cytologic atypia were evaluated,
as well as smooth muscle actin (SMA), desmin, ALK1
and clusterin (Clu) expression.
Ten cases were analyzed for the presence of HHV8
sequences by nested-PCR using ORF25 and ORF26-
specific primers, and 20 for LANA1/HHV8 immuno-
histochemical expression.
Results: All cases were Vimentin/SMAþ, Desmin/CD21/
CD23 , 7 ALK1þ, and 12 Cluþ. Among lung IMTs,
1 was ALK1þ, and 6 Cluþ. Among abdominal cases,
6 (1 liver) were ALK1þ, and 6 Cluþ. HHV8 sequences
and LANA1 expression were detected in 1 pulmonary
IMT. Abdominal involvement, mostly myxoid component,
atypias, poor inflammation and ALK1 expression were
found in 6/25 IMTs (2 AWD, 1 DOD).
Conclusions: Abdominal site, ALK1þ, myxoid component,
atypias might be unfavourable prognostic markers.
Lung IMTs might be infection-associated, as suggested
by the frequent Clu expression, involved in tissue
remodelling. However, HHV8 detection is only
occasional.
P002
Microsatellite instability is a rare event in Ewing’s
sarcoma
I. Alldinger, K.L. Schaefer, D. Go ¨dde, W.T. Knoefel,
H.E. Gabbert, C. Poremba
(Department of Pathology, University of Du ¨sseldorf;
Department of Surgery, University of Du ¨sseldorf)
We investigated paraffin-embedded tumor specimen from
63 patients with Ewing’s sarcoma. For microsatellite
analysis, we extracted DNA and performed PCR for 7
microsatellites. The PCR product was analysed in a
Genetic Analyzer. 8 patients (14.5%) were MSI-L; one
showed instability in D17S 250, 3 in BAT-25 and 4 in
D5S 346. No instability was detected in BAT-26, D2S
123, BAX and TGFBR2. LOH was detected in 9 patients
(16.4%), 6 in D17S 250, 3 in D2S 123 and 2 in D5S 346.
One patient had LOH in D17S 250 and in D5S 346.
The patient instable in BAT-25 had LOH in D2S 123.
We analysed protein expression of the mismatch
repair proteins MSH2, MSH6 and MLH1 by immuno-
histochemistry. In 54 of 59 patients (91.5%) we found
a nuclear expression. In three patients expression of none
of these proteins could be detected, with positive external
control. Three reactions could not be assessed due to
technical problems. One of the patients with no detected
expression was the patient with high-grade MSI.
We conclude that MSI is a rare event in Ewing’s
Sarcoma, and, unlike in HNPCC, MSI is not associated
with lost expression of MSH2, MSH6 and MLH1.
P003
En-bloc chest wall and vertebral resection for sarcoma
M. Incarbone
1, M. Alloisio
1, S. Luzzati
2 M. Infante
1,
U. Cariboni
1, A. Testori
1, G. Ravasi
1
(
1Thoracic Surgery Department, Istituto Clinico Humanitas,
Rozzano, Italy,
2Orthopedics Department, Ospedale di
Cremona, Italy)
Improvement of surgical techniques has resulted in
successful chest wall resection and simultaneous recon-
struction. We reviewed our experience with chest wall
sarcoma involving the spine, and verified 5-year survival
and feasibility of this aggressive surgery.
Thirteen patients underwent surgical en-bloc resection
for chest wall primary sarcoma involving the spine.
Concurrent pulmonary resection was performed in twelve
cases. A single hemi-vertebrectomy was performed in two
patients, a triple hemi-vertebrectomy in two, a complete
vertebrectomy in four, a triple complete vertebrectomy in
five.
Surgery includes three main steps: chest wall and
lung resection in posterolateral thoracotomy, spine section
in median posterior approach, en-bloc resection and
reconstruction.
Significative morbidity occurred in one patient who had
lower limbs paralysis (9%). Mortality occurred in two
patients (15.4%): One because of operative hemorrhage
and one because of ARDS. The overall 5-year survival was
30.8%. Excluding the two perioperative deaths, the 5-year
survival resulted 36.4%.
In spite of the limited number of patients, morbility and
mortality outcome and 5-year survival lead us to think that
surgery is the main therapy for primary sarcomas involving
the spine: en-bloc chest wall, lung and vertebral resection is
a safe and effective treatment.
P004
PKC412 induces cell death in alveolar rhabdomyo-
sarcoma cells
R.A. Amstutz, M. Wachtel. B.W. Scha ¨fer
(University Children’s Hospital, Division of Oncology, Zurich,
Switzerland)
Rhabdomyosarcoma (RMS) accounts for about 5% of
all childhood malignancies. Alveolar RMS (aRMS) is
more metastatic than embryonal RMS (eRMS) and is
therefore poorly prognosed. ARMS is characterised by
two translocations t(2;13)(q35;q14) and t(1;13)(p36;q14)
encoding for the transcription factors PAX3-FKHR
and PAX7-FKHR. These chimeric proteins activate
transcription at PAX binding sites more efficicently
than its wild type forms both contributing to the
malignant phenotype of aRMS cells including a
decreased apoptosis and an increased proliferation
rate. As shown earlier, the specific downregulation
of PAX3-FKHR by antisense oligonucleotides reduces
the cellular viability of aRMS cells. In this study,
we show that N-benzoyl- staurosporine (PKC412),
which was originallly identified as a Protein Kinase C
inhibitor, also induces cell death in aRMS but not in
eRMS cells. Furthermore, we show that PKC412
inhibits the transcriptional activity of PAX3-FKHR in
293T cells.
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PKC412 significantly reduced expression levels of several
target genes of PAX3-FKHR compared to untreated cells.
These results suggest targeting of PAX3-FKHR by
PKC412 which in turn breaks down the anti-apoptotic
pathways normally favoured by this transcription factor.
Therefore, PKC412 is a promising agent for the treatment
of alveolar rhabdomyosarcoma.
P005
Comparison of results of a pilot study of
alternating vincristine/doxorubicin/cyclophosphamide
and etoposide/ifosfamide with the fourth intergroup
rhabdomyosarcoma study for intermediate risk rhabdo-
myosarcoma
C. Arndt
1, J. Anderson
2, W. Meyer
3, D. Hawkins
4,
S. Sencer
5, J. Neglia
6
(
1Department of Pediatric and Adolescent Medicine, Mayo
Clinic, Rochester MN, USA,
2Preventive and Societal
Medicine, University of Nebraska, Omaha, NE, USA,
3Department of Pediatrics, University of Oklahoma,
Oklahoma City, OK; USA,
4Department of Hematology/
Oncology, Children’s Hospital and Regional Medical Center,
Seattle, WA, USA,
5Children’s Hospital and Clinics,
Minneapolis-St. Paul, MN, USA,
6Division of Pediatric
Hematology Oncology, University of Minnesota, Minneapolis
MN, USA)
Purpose: To compare the outcome of patients with
intermediate risk rhabdomyosarcoma (IRRMS) treated
on a doxorubicin containing pilot study (pilot) utilizing
alternating cycles of vincristine (V), doxorubicin (D),
cyclophosphamide(C) and etoposide(E), ifosfamide(I)
(Eur J Cancer 34:1224–29, 1998) with those of IRS-IV
using three drug therapy (VActinomycin(A)C, VIE, VAI).
Patients/methods: 46 patients with IRRMS were treated
on the pilot with doxorubicin. Their outcome was
compared to a similar subset of patients treated on
IRS-IV without doxorubicin. Because 22/46 pilot patients
had parameningeal primaries (PM), these were analyzed
separately.
Results: The 22 PM pilot patients and the 203 PM IRS-IV
comparison subset had comparable patient and disease
characteristics. Five year event free survival (EFS) and
overall survival (OS) for PM subset were: Pilot: 82% and
82%; IRS-IV: 72% and 76% (p¼0.42). When the 24 pilot
patients with other primary sites were compared to
similar IRS-IV patients, there was no statistically signifi-
cant difference in failure risk (p¼0.23). The estimated
failure relative risk for the pilot compared to IRS-IV was
0.54 (95% CI: 0.20, 1.47).
Conclusions: This non-randomized comparison of a small
(N¼46) pilot doxorubicin containing study of VDC/IE to a
similar group of VAC/VAI/VIE patients treated on IRS-IV
without doxorubicin showed no statistically significant
difference in outcome.
P006
Anti-antiogenic scheduling of gemcitabine vinblastine
carboplatin for relapsed and metastatic osteosarcoma:
A new therapeutic option
S. Ash
1, L. Kornrich
2, Y. Goshen
1, I.J. Cohen
1
(
1Department of Pediatric Hematology Oncology, Schneider
Children’s Medical Center of Israel,
2Department of Imaging,
Schneider Children’s Medical Center of Israel, Petah-Tikva,
Sackler School of Medicine, Tel Aviv University)
Objective: To report development of a protocol
for metastatic and relapsed osteosarcoma using an
anti-angiogenic schedule with Gemcitabine (known
to give palliation in osteosarcoma), vinblastine and
carboplatin (known antiangiogenic drugs) Y.O. a 10y
old boy received the protocol after a local femoral
relapse and lung metastasis with a pleural effusion.
He was first treated with weekly Gemcitabine 1gram/m
2
with a progressive improvement including pleural
effusion disappearance, decrease in size of lung
metastasis, negation of oxygen dependence and improved
well-being. 4 months later the lung metastasis grew
and 2 new lesions appeared. Additional vinblastine of
3mg/m
2 resulted in mild improvement and after 2
months additional carboplatin 50mg/m
2 (gemcitabine
500mg/m
2) improved his condition for a short period of
time. He died of disease after 10 months of weekly
Gemeitabine.
Another adolescent remained asymptomatic on this
protocol for 15 months after an almost complete resection
of a lung/chest wall relapse until anasarca and acute renal
failure developed. Spontaneous improvement occurred
but 5 weeks later she developed 2 brain metastases and
became moribund. Therapy was resumed and she became
asymptomatic again and returned to full activity for
3 months until abdominal progression occurred. Another
child received treatment for 3 months with only pain
improvement.
P007
Prognostic factors in Ewing’s sarcoma family of
tumors
S. Ash
1, T. Perri
1, S. Mor
2,*, G. Horev
3,7, I. Meller
4,7,
D. Loven
5,7, J. Isakov
6,7, Y. Kollender
4, Y. Yaniv
1,7,
R. Zaizov
1,7, I.J. Cohen
1,7
(
1Department of Hematology/Oncology,
3Department of
Radiology, Schneider Children’s Medical Center of Israel,
2Department of Pathology,
5Department of Oncology, Rabin
Medical Center, Petah Tiqva, Israel,
4National Unit of
Orthopedic Oncology, Israel,
6Unit of Bone and Soft
Tissue Pathology Sourasky Medical Center, Tel Aviv, Israel,
7Sackler Faculty of Medicine, Tel Aviv University, Israel
*deceased)
The study aim was to identify pre-treatment factors
that predict survival and to assess prognosis with a
more aggressive treatment protocol consisting of 4 courses
of IV-VACA (ifosfamide, etoposide, vincristine, cyclofo-
sphamide, actinomycin, adriamycin) radiation with
4000cGY before and 2000cGY after surgery, followed
by 2 courses of IV-VAC (without adriamycin). 75 patients
with Ewing Sarcoma admitted between 1972 and 1998
were reviewed.
Result: Metastatic disease, histologic subtype (PNET) and
higher I.DH levels at diagnosis worsen prognosis.
Response to treatment ( 40% reduction in tumor size
on imaging and  10% viable tumor at surgery after 2–3
chemotherapy courses) was a powerful predictor of
survival (p<0.05). Surprisingly, location of tumor at
diagnosis (for localized disease only) had no prognostic
significance (pelvic disease had the same prognosis as
limb disease). 42 of the 60 patients with localized disease
at diagnosis were treated with VACA or IV-VACA
protocols 15 (35.7%) survived with no progression of
the disease. Another 16 were treated with the new
modified IV-VACA protocol with a mean follow-up of
73 months, this protocol yielded a better prognosis
than the two previous protocols (P¼0.03 on
multivariate analysis). 11 (68.7%) are alive with no disease
progression.
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Alternative Lengthening of Telomeres (ALT) as a
predominant mechanism of telomere maintenance in
embryonal rhabdomyosarcoma
A. Ohali
1,2, S. Avigad
1,2, Y. Goshen
2, S. Ash
2,
R. Zaizov
1,2, I. Yaniv
1,2.
(
1Molecular Oncology, Felsenstein Medical Research Center,
2Pediatric Hematology Oncology, Schneider Children’s Medical
Center of Israel, Petah Tikva, Sackler Faculty of Medicine,
Tel Aviv University, Tel Aviv, Israel)
Purpose: The two major types of rhabdomyosarcoma
(RMS) are characterized by loss of heterozygosity (LOH)
at the 11p15 locus (embryonal) and translocations between
FKHR and PAX3 or PAX7 genes (alveolar). Telomeres,
the repetitive sequences at the end of eukaryotic chromo-
somes, shorten with each cell division. In cancer cells,
telomeres are maintained by activation of the telomerase
enzyme or by the ALT mechanism (alternative lengthening
of telomeres). Fifteen RMS tumors: 7 embryonal and
8 alveolar, were tested for telomere length (TRF) and
telomerase activity (TA).
Methods: TA was evaluated by the expression of hTERT,
using quantitative real time PCR. TRF was estimated
using Southern blotting, and the TRF of each tumor
sample was compared with matched peripheral blood
(PBL) from the same patient.
Results: 75% alveolar RMS expressed hTERT, and
heterogeneous telomere lengths: 4 tumors exhibited
shorter telomeres and 4 tumors longer telomeres. In
embryonal RMS, only 43% tumors expressed hTERT,
and 80% presented long telomeres.
Conclusions: These results suggest that ALT might be the
predominant mechanism of telomere maintenance in
embryonal RMS, while in alveolar RMS, both telomerase
dependent mechanism and ALT occur. The association
between presence of ALT and better prognosis in
embryonal RMS is currently being explored.
P009
Oncosurgical and reconstructive therapeutic concepts in
the treatment of soft tissue sarcomas of the extremities
H. Bannasch, G. Felmerer, A. Momeni, M. Fo ¨hn,
S.M. Ryu, G.B. Stark
(Department of Plastic and Hand Surgery, University Medical
School Freiburg, Germany)
Between 1994 and 2004 59 patients with soft tissue
sarcoma of the extremities underwent surgical treatment
in our department. The therapy of each patient was
sanctified by the interdisciplinary tumor conference of
the university medical school. The localisation showed
typical distribution patterns (upper extremity: n¼24
(41%) and lower extremity: n¼35 (59%). The most
common technique used for oncosurgical resection was
wide excision (70%), followed by compartment resection
(22%); whereas 3 patients (5%) had to be amputated
primarily (4 patients had to amputated secondarily due to
local relapse). All patients underwent single step recon-
struction of the defect according to the principles of the
so called ‘‘plastic reconstructive ladder’’. Beginning with
primary closure (20%) and skin grafts (24%), which were
suitable after wide excision of epifascial sarcomas, local
fasciocutaneous (8%) and myocutaneous (20%) flaps were
used for safe coverage of exposed neurovascular structures.
Free microvascular tissue transfer (fasciocutaneous, myo-
cutaneous and osteocutaneous flaps) was performed
in another 12 patients (20%) due to defects which could
not be closed by local techniques. In 5 cases (8%) with
significant functional loss due to compartment resection,
a single step local muscle transfer was performed.
The surgical therapy should include the armamentarium
of complex reconstruction to be able to achieve radical
resection and functional extremity preservation.
P010
The bioexpandalbe prosthesis: A new perspective after
resection of malignant bone tumors in children
R. Baumgart, P. Thaller, S. Hinterwimmer, D. Bu ¨rklein,
W. Mutschler
(University of Munich, Dept of Surgery, Germany)
Treatment of malignant bone tumors with prostheses in
skeletally immature patients is difficult because of reduced
stability and loss of growth plate in most cases. How can
stability be improved and limb-length discrepancy be
prevented?
Conventional expandable prosthetic devices cause an
increasing disproportion between bone and prosthesis.
To prevent such lack of correspondence of bone and
prosthesis, a bioexpandable prosthesis has been developed
which makes the bone to grow and not the prosthesis. The
stem of the modular implant consists of an intramedullary
nail with a smooth surface. When lengthening is necessary,
an osteotomy of the remaining bone will be performed and
the stem will be replaced by a fully implantable motorized
distraction nail. This construction allows limb lengthening
by callus distraction. External components are not
necessary. The first prototypes of such a bioexpandable
prosthesis have been clinically used following a 12cm
femoral resection in a 8 year old boy with osteosarcoma
and removal of a 13cm tibial segment in a 4 year old girl
with Ewing sarcoma. The postoperative clinical courses
were without complications.
Prosthetic joint replacement in combination with a fully
implantable motorized distraction nail makes it possible to
lengthen the remaining bone and increase stability.
P011
Non-metastatic osteosarcoma in children: Treatment
results and prognostic factors
Z. Bekic
1, V. Svesko
1, B. Sbutega
2, B. Dimitrijevic
2,
N. Lujic
2, M. Atanackovic
3
(
1Institute for Oncology and Radiology of Serbia, Belgrade,
Serbia & Montenegro,
2Institute of Orthopedic Surgery
‘‘Banjica’’, Belgrade, Serbia & Montenegro,
3Institute of
Pathology, Belgrade, Serbia & Montenegro)
Objective: The aim of our study was to evaluate results of
treatment and relevance of prognostic factors in patients
with nonmetastatic osteosarcoma.
Patients and methods: From 1988–2000 we treated 92
patients with osteosarcoma, median age 15 years (range
3–18). 76 pts had large tumors volume over 150ml.
Adjuvant chemotherapy after amputation was adminis-
tered in 29 pts and neoadjuvant in 63 (intravenous/
intraarterial in 47 and 16 pts, respectively), followed by
surgery (amputation in 32 pts, limb salvage in 27 pts,
resection in 3 pts) and postoperative chemotherapy. Two-
drug regimen (Adr-CDDP) was administered in 43 pts,
while 49 pts received chemotherapy by other protocols.
Results: During the 38–186 months follow-up period
(Me¼86) overall survival rate was 57% and disease-free
survival rate was 55.8%. Prognostic factors significantly
related to survival were tumor necrosis (p¼0.02), tumor
volume (p¼0.013), duration of symptoms <6 months
(p¼0.03), and value of laboratory parameters: alkaline
70 Poster Abstractsphosphatase (p¼0.036) and lactic dexogrenase
(p¼0.028).
There were no significant differences in survival in
relation to histopathological subtype, age, regimen or
mode of chemotherapy applied (two-drug/multi-drug,
i.v./i.a.).
Conclusion: Tumor load and responsiveness to chemo-
therapy are two major prognostic factors. The effects of
Adr-CDDP regimen are similar to other more complex
and toxic regimens.
P012
Phase II study of irinotecan in children with refractory or
recurrent sarcomas
G. Bisogno, R. Riccardi, A. Ruggiero, G. Surico, A. Prete,
M. Provenzi, P. Infolfi, L. Casula, M. Carli
(The AIEOP Soft Tissue Sarcoma Committee (STSC), Italy)
Background: Irinotecan is a novel antineoplastic agent that
works by inhibiting topoisomerase I. To evaluate its activity
against pediatric soft tissue sarcomas (STS) the Italian
STSC performed a multi-institutional phase II study.
Methods: Between 2002 and 2004, 32 heavily pre-treated
patients were treated with a 60-minute infusion of
20mg/m
2/day irinotecan for 5 days per week for two
consecutive weeks. The courses were repeated every 4
weeks for at least 2 courses, unless there were some toxicity
or disease progression. Overall 30 patients (12 rhabdo-
myosarcoma, 13 PNET, 3 Desmoplastic small round cell
tumor and 2 other STS) were evaluable for response.
Results: In all, 79 cycles were delivered. Major regimen-
related toxicity was diarrhrea present in 58% of cycles with
11% graded as 3–4. Grade 3–4 neutropenia was reported
in 10% of cycles. The response rate was 23% (2 CRþ5
PR) being 16% for rhabdomyosarcoma and 38% for
PNET. In addition 4 minor responses were noted.
Conclusions: Irinotecan used as single agent in the treat-
ment of recurrent/refractory STS showed an interesting
response rate in a population of heavily pre-treated
patients, especially in the subset of patients with PNET.
Its toxicity profile warrants further investigations in
association with myelotoxic agents.
P013
Parameningeal rhabdomyosarcoma: Improved survival
in the protocols coordinated by the Italian Soft Tissue
Sarcoma Committee (STSC)
G. Bisogno, C. De Rossi, Y. Gamboa, G. Scarzello,
E. Basso, S. Dallorso, C. Carollo, A. Scagnellato,
A. Ferrari, A. Prete, M. Carli
Purpose: We report a series of patients with non-metastatic
Parameningeal Rhabdomyosarcoma (PM-RMS), treated
between 1979 and 2002, to analyse survival and prognostic
factors.
Methods: 109 patients were enrolled in RMS-79, RMS-88
and RMS-96 studies. Biopsy or conservative surgery was
recommended as initial approach. Chemotherapy was
delivered according to the ongoing protocol: vincristine,
actinomycin-D/adryamicin, cyclophoshamide (VAC/CAV)
in the RMS-79 study (plus intrathecal therapy in case
of intracranial extension). Ifosfamide replaced cyclo-
phosphamide in the VAIA/IVA regimens used in the
RMS-88 study. VAIA randomized vs. CEVAIE in the
ongoing RMS-96 protocol. Radiotherapy (RT) was
recommended at the beginning of treatment in RMS-79
(dose: 55Gy), but was delayed to the 9th week in RMS-88
and RMS-96 (doses: 45–55Gy), adopting the accelerated/
hyperfractionated technique.
Results: For the whole population the 5-year overall
survival (OS) was 64%. The OS for RMS-79, RMS-88
and RMS-96 was 40%, 72% and 70%, respectively.
Protocol type was the most important prognostic factor.
The different parameningeal sites, tumor size, invasiveness
and histotype, and patient’ age resulted no significant as
well as known risk factors such as nerve palsy, skull base
erosion and intracranial extension.
Conclusions: Despite RT being delayed and doses reduced,
the outcome for PM-RMS patients has improved over
years. With the improvement of the treatment the known
prognostic factors have lost their impact.
P014
Malignant fibrous histiocytoma of bone after irradiation
for a myxoid liposarcoma in a 16 year old patient
B. Bode
1, U. Exner
2, S. Frigerio
1, J. Hodler
3,
B. Lombriser
4, H.P. Honegger
5
(
1Institute of Clinical Pathology, University Hospital, Zurich,
Switzerland,
2Clinic of Orthopeadics, Balgrist Hospital,
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3Radiology, Balgrist Hospital, Zurich,
Switzerland,
4Radioocology, Triemli Hospital, Zurich,
Switzerland,
5Oncology, Triemli Hospital, Zurich, Switzerland
Radiation associated sarcomas are rare complication of
adjuvant treatment. We present an unsual case of a short
interval between development of an intraosseous malignant
fibrous histiocytoma following irradiation for a mariginally
resected myxoid liposarcoma with supportive molecular
data.
16 year old male patient presented with a slowly growing
mass on the medial aspect of the knee. Radiologically,
a deep seated, partially intraarticularly growing tumor was
detected. Biopsy specimen showed a myxoid liposarcoma,
but the RT-PCR for the diagnostic translocation was
negative. The mariginal resection followed with histologic
confirmation of the myxoid liposarcoma. 70Gy irradiation
was applied to the operation field. In the follow up MRI
an intraosseous signal alteration of the distal femur was
detected 1.5 years later. At further follow up the change
was progressive and a biopsy was performed. Pleomorphic
malignant tumor without osteoid production, consistent
with malignant fibrous histiocytoma was diagnosed
histologically. The resection of the distal femur after neo-
adjuvant therapy was performed. The tumor was histo-
logically confined to the bone. Repeated RT-PCR on the
myxoid liposarcoma using own designed primers revealed
the diagnostic translocation t(12;22) with a unique break-
ing point, which was absent in all examined specinems of
morphologically different bone sarcoma.
Close follow up of the soft tissue sarcoma patient
allowed diagnosis of a unexpected bone sarcoma in the
irradiation field in an early stage.
P015
Evaluating the chemosensitivity of clear cell sarcoma of
soft tissue by an in vitro-assay
K. Brachwitz, K.L. Schaefer, Y. Braun, H.E. Gabbert,
C. Poremba
(Department of Pathology, Heinrich-Heine-University,
Duesseldorf, Germany)
Clear cell sarcoma of soft tissue (CCSST) represents a
rare, slowly growing tumor usually affecting adolescents
and young adults. CCSST demonstrates a fully malignant
neoplasm with tendency to metastasize, local recurrences
Poster Abstracts 71and 5-year survival rates of  50%. Retrospective data often
reveal few advantage of an adjuvant chemotherapy since
this tumor entity often shows resistance against the
majority of therapy schedules. In vitro cytotoxicity-assays
are not published for CCSST. Therefore we evaluated
the effectiveness of agents like adriamycine, ifosfamide,
etoposide, dactinomycine, irinotecan’s metabolite SN-38
and vincristine in CCSST cell lines compared to Ewing’s
tumor cell lines which are assumed to be chemotherapy-
sensitive. The growth inhibition was measured by an
MTT-assay. 6/7 cell lines were sensitive against adriamy-
cine, SN-38 and dactinomycine, and partly sensitive
against ifosfamide. Only 2/7 cell lines were sensitive against
etoposide, but all were resistant against vincristine.
In an ongoing project we are about to generate
expression profiles using DNA microarrays (Affymetrix
U133A) to identify critical differentially-expressed genes
in chemo-sensitive and chemo-resistant CCSST tumor cell
predicting characteristics for response to treatment.
P016
Combination telomerase inhibition therapy in Ewing
sarcoma cell lines
Y. Braun
1, A. Truck
2, I. Duran-Seuberth
2 C. Lanvers-
Kaminsky
2, A. Schuck
3, H.E. Gabbert
1, C. Poremba
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(
1Institute of Pathology, Heinrich-Heine-University,
Duesseldorf; Germany,
2University Children’s Hospital,
Department of Pediatric Hematology and Oncology,
Muenster; Germany,
3Department of Radiotherapy,
University Children’s Hospital Muenster, Germany)
Telomeres (the tips of chromosomes) shorten gradually
with each cell cycle due to the end–replication–problem
leading to growth arrest and apoptosis. Telomerase is a
ribonucleoprotein enzyme responsible for telomere main-
tenance. Inhibition of telomerase is a promising therapeu-
tic target, since it is required for the long-term proliferation
of most cancer cells but not present in most somatic cells.
Telomerase inhibitors by themselves will result in
telomere shortening, but it may take many cell replications
to achieve the benefit of such therapies. Combining
conventional therapies with a telomerase inhibitor may
accelerate the onset of proliferative deficiencies in cancer
cells.
To explore this hypothesis we inhibited telomerase
activity in two Ewing sarcoma cell lines, RM–82 and
STAET–1, by stable expression of a dominant-negative
mutant (DN) of the telomerase catalytic unit (hTERT,
human telomerase reverse transcritpase) and subsequently
treated these cells with several cytotoxic agents (vincristine,
doxorubicin and etoposide, respectively).
After transfection (up to three passages) hTERT
inactivation so far did not reveal an synergistic effect
on growth inhibition by treatment with doxorubicin,
vincristine, or etoposide in STA-ET-1 cells. Analysis of
RM-82 and long-term inhibition experiments for both cell
lines are ongoing.
P017
Localized peripheral primitive neuroectodermal tumors
(pPNET) and extraosseus Ewing’s Sarcomas (EES) in
children and adolescents: Results of the prospective
studies CWS 81, 86, 91 and 96 of the German cooperative
soft tissue sarcoma study group
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2Department of Paidopathology,
University of Kiel, Germany,
3Department of Radiotherapy,
University of Mu ¨nster, Germany,
4Department of Pediatric
Oncology/Hematology, University of Mu ¨nster, Germany,
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7Department of
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8Department of Pediatric Oncology/Hematology, University
Frankfurt, Germany)
Objectives: To show the results of the prospective CWS
81–96 studies for EES/pPNET, to evaluate prognostic
factors and to find a prognostic favourable subgroup in
order to adapt the therapy regime.
Patients/methods: 224 children and adolescents with loca-
lized pPNET (n¼152) and EES (n¼72) diagnosed
between 1981 and 2000 and registered with the CWS 81
(n¼13), CWS 86 (n¼43), CWS 91 (n¼77) and CWS 96
(n¼91) studies were analysed for risk factors and out-
come. The median age was 11 years, most tumours
occurred in extremities (28%), thorax (19%), trunk
(16%) and small pelvis (10%). Median follow-up was
54.9 months. All patients received chemotherapy, 162
received radiotherapy and 60 patients not. Primary
complete resection was performed, if possible (22 IRS I,
49 IRS II, 151 IRS III).
Results: 5-year EFS was 58.0% (EES 65.8%, pPNET
53.8%) and SUR 67.9% (EES 79.9%, pPNET
61.7%). 12.9% patients showed local relapses, 12.5%
metastatic relapses, 14% combined relapses and 4.9%
showed initial tumour progression. Risk factors
showing significant influence on the outcome are
invasiveness (p¼0.005), size (p<0.001), IRS group
(SUR IRS I 85.8%, IRS II 79.6%, IRS III 61.6%
p¼0.01). Prognosis in small and not invasive tumours is
excellent (EFS 89.6%, SUR 96.3%), but still bad for the
large group of T2b tumours (EFS 48.5%, SUR 59.6%).
Response to chemotherapy (p¼0.003) and radiotherapy
in IRS group II (p<0.001) have significant influence on
prognosis.
Conclusions: Prognosis in children and adolescents
with EES/pPNET is still not satisfactory, but an
especially favourable subgroup of patients with small
and non-invasive could be found, which might need
less therapy. Complete resection, response to
chemotherapy and radiotherapy are important factors for
prognosis.
P018
Leiomyosarcoma in children and adolescents: A retro-
spective analysis of the German and Italian pediatric
soft tissue sarcoma groups on prognostic factors and
outcome
I.B. Brecht
1, C. Int-Veen
1, A. Ferrari
2, G. Bisogno
3,
S. Kirsch
1, T. Dantonello
1, A. Schuck
4, M. Casanova
2,
T. Klingebiel
5, E. Koscielniak
1, M. Carli
3, J. Treuner
1
(
1CWS study group, Olgahospital Stuttgart, Germany,
2Paediatric Oncology Unit, Istituto Nazionale Tumori
Milano, Italy,
3Devision of Pediatric Hematology and
Oncology, Padova University, Italy,
4Radiotherapy
Department, University Hospital Munster, Germany,
5Department of Paediatric Oncology and Hematology,
University Frankfurt, Germany)
Objectives: To evaluate prognostic factors and outcome of
children and adolescents with leiomyosarcoma treated with
different therapy regimes.
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registered within the CWS and ICG studies between
1980 and 2003. Median follow up was 7.15 years. Male:
female ratio was 1.4, median age 8.8 years. Primary sites
were: other site (trunk, thorax, abdomen: 30) extremity
(20), head and neck (10), parameningeal (2). 14% were
lymph node positive, 39% showed invasive growth and
tumour size was >5cm in 39%. IRS group was IRS I
in 34, IRS II in 10, IRS III in 13 and IRS IV in
5 patients. The patients had different adjuvant therapy
(23 pts chemotherapy, 1 pt radiotherapy, 10 pts chemo-
and radiotherapy).
Results: Overall SUR was 80.7% and EFS 72.2% for all
patients. 5yr SUR (EFS) was 91.8% (84.5%) in IRS
group I, 76.1% (68.5%) in IRS group II, 74.1%
(66.6%) in IRS group III and 40% (20%) in IRS
group IV. 13% of all patients showed local relapse,
8% metastatic relapse and 3% initial progression. Age
( 10yrs, >10yrs) showed significance in the 
2-test, no
other risk factors could be found. Abdominal localisation
seems to be favourable. The influence of radiotherapy
could not been proven. Good response to chemotherapy
was seen in 43%.
Conclusions: Prognosis in children and adolescents with
leiomyosarcoma is very good, especially when completely
resected. Prognostically favourable is age less than 10 years
and abdominal localisation.
P019
Cardiac sarcoma in children and adolescents: Two cases
registered with the German pediatric soft tissue sarcoma
study
I.B. Brecht
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1
(
1CWS study group, Olgahospital Stuttgart, Germany,
2Department of Paidopathology, University of Kiel,
Germany,
3Department of Pediatric Cardiology, University
Children’s Hospital Muenster, Germany,
4Department of
Ped. Oncology/Hematology, University Children’s Hospital
Muenster, Germany,
5Gerhard-Domagk-Institut of
Pathology, University Munster, Germany)
Objectives: To show the outcome of two cases of the
extremely rare cardiac sarcomas in children and adoles-
cents registered with the CWS-study in 25 years.
Patients: A 16 year old girl with cardiac leiomyosarcoma
(G2) in the right atrium, 10cm, N0, M0 (patient 1) and an
8 year old boy with cardiac malignant mesenchymoma
(G3) in the left ventricle, >5cm, N0, M0 (patient 2) are
shown.
Results: The leiomyosarcoma of patient 1 was completely
resected and chemotherapy (vincristine, adriamycin,
actinomycin and ifosfamide) was given. The girl is still
alive in complete remission after 7 years. The cardiac
sarcoma of patient 2 was first resected in 2003, the
histology showed a liposarcoma (G1). After rapid
progression the patient received a heart transplantation
in 2004. The histology showed now a malignant
mesenchymoma (G3) with infiltration of the whole left
ventricle. The patient died in the same year of
transplantation.
Conclusions: Cardiac sarcomas are very rare in children and
adolescents. Though prognosis is known to be extremely
bad we can show a long term survivor with cardiac
leiomyosarcoma.
P020
Adherence to treatment protocols in Ewing’s sarcoma
and osteosarcoma in patients treated at the departments
of pediatric oncology and medical oncology
P. Brons, J. Boekhorst, Q. van Hoesel, H. Schreuder,
P. Hoogerbrugge
(Departments of Pediatric Oncology (PB, JB, PH), Medical
Oncology (QH) and Orthopaedics (HS), Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands)
Children treated for sarcoma have a better outcome as
compared to adults. Possible explanations for this include
intrinsic differences of tumor biology, clinical character-
istics or protocol adherence.
We compared the protocol adherence of patients with a
Ewing sarcoma (ES n¼27) and osteosarcoma (OS n¼42)
treated at the dept. of Pediatric Oncology (PO) and
Medical Oncology (MO), diagnosed between 1992 and
2002. Patients treated at the dept. of PO had a signifcant
shorter delay between time of diagnostic biopsy and start of
treatment. All patients but 3 were included in international
trials (EICESS 92; EORTC 80931 and Euro Ewing 99).
We found no difference in delay of surgery or neoadjuvant
chemotherapy and survival between patients treated at the
dept. of PO and MO. Protocol non-adherence was noticed
in 16/33 patients treated at the dept. of MO and 7/34
patients treated at the dept. of PO. Reasons for protocol
non-adherence were: Unknown (20% and 0%), lack of
response (80% and 46%), patient decision (0% and 23%)
and toxicity (0% and 30%) for patients treated at the the
dept. of PO and MO, respectively.
Conclusion: Protocol adherence was less at the dept. of MO
due to toxicity and patient decision.
P021
Fatal diagnosis: Dedifferentiated chondrosarcoma –
report on 13 patients
J. Bruns
1, W. Fiedler
2, M. Werner
3, G. Delling
3
(
1Department of Orthopaedic Surgery, University of Hamburg,
Germany,
2Department of Hematology & Oncology,
University of Hamburg, Germany,
3Institute for
Osteopathology, University of Hamburg, Germany)
Dedifferentiated Chondrosarcoma (DDCS) are one of
the skeletal tumors with the worst prognosis. It was the
aim of our study to get any hints regarding therapeutic
improvements.
Methods: Retrospectively, we analysed the data of patients
suffering from DDCS which were treated surgically in the
last 15 years. For staging the MSTS-Enneking system
was used; determination of the survival rate was done by
the Kaplan-Meier analysis.
Results: Between 1990 and 2003 13 patients suffering from
a DDCS were treated.
The mean age was 59.8yrs, (6 female, 7 male). The
location of the tumor was the pelvis 4X, proximal femur
3X, distal femur 4X, proximal humerus 2X. 9 patients
were staged IIB and 4 patients staged III. In all the
diagnosis was histologically confirmed either by biopsy or
complete histological analysis of the tumor. In all but one
the treatment was surgically. In 6 cases surgery was
accompanied by chemotherapy using holoxan and adria-
blastin. In 11 cases surgery was performed, in one patient
with a pelvic DDCS surgery was renounced, one patient
died during the preop. chemotherapy; in ten cases curative
resection was planned, in one patient a palliative intra-
lesional resection was done; in 6/10 cases with a curative
goal we achieved a wide resection, a marginal resection in
3/10 and an intralesional resection in 3 cases. The mean
Poster Abstracts 73time of survival was 9.6 months (2–26mo.) Local
recurrence was observed in 1 case. All dead patients died
due to metastasis to the lung. No obvious differences in the
time of survival were detectable depending on the use of
chemotherapy.
P022
Saving limbs with soft tissue sarcomas requires integra-
tion of plastic-reconstructive surgery into the interdis-
ciplinary treatment concept
Th. R. Bund, L.U. Lahoda, C. Choi, P.M. Vogt
(Klinik fu ¨r Plastische, Hand- und Wiederherstellungschirurgie
der Medizinischen Hochschule Hannover, Klinikum Hannover
Oststadt, Podbielskistraße 380, Hannover, Germany)
Soft tissue sarcoma of the extremities is a rare disease in
adults with an incidence of 2–3 per 100000 inhabitants.
Wide tumor excision (R0) is the most important factor for
local disease control. Limb sparing surgery combined with
adjuvant forms of therapy represents a preferable alter-
native to amputation even in advanced sarcomas if limb
function can be preserved. Plastic surgical and reconstruc-
tive procedures permit coverage of even major defects after
wide R0 excision and allow restoration of function even if
large bony defects and extensive loss of neuro-muscular
units occur. We present interdisciplinary concepts for limb
preserving therapy with soft tissue sarcomas formerly being
amputated. Due to the rareness of these soft tissue
sarcomas and the intricacy of therapy, patients should be
referred to centres of ‘‘excellence’’ offering interdisciplin-
ary, multimodular treatment options. Plastic and recon-
structive surgery is an integral part of these options. As
such plastic surgery needs to be involved from the start
when patients with soft tissue sarcomas are to be treated
emphasizing restoration of form and function.
P023
Immunohistochemical characteristics of uterine smooth
muscle tumors
G.M. Burkadze, G.A. Turashvili
(Department of Pathological Anatomy, Tbilisi State Medical
University, Tbilisi, Georgia)
Purpose: To explore more sensitive immunohistochemical
markers in differential diagnosis of uterine leiomyosarcoma
(LMS) and the specific subtypes of leiomyoma.
Patients: 14 cases of usual leiomyomas (UL), 16 cases of
cellular myomas (CL), 14 cases of bizzare leiomyomas
(BL), 15 cases of smooth muscle tumors of uncertain
malignant potential (STUMP), and 13 cases of LMS were
investigated.
Methods: Formalin-fixed paraffin-embedded surgical speci-
mens were immunostained for Ki-67, p53, Bcl-2, smooth
muscle actin (SMA), estrogen (ER) and progesterone
receptors (PR), and cathepsin D (CD) using avidin-biotin-
peroxidase method.
Results/discussion: The expression of Ki-67 was useful in
distinguishing CL from UL, STUMP from CL, and LMS
from STUMP. p53 expression was only seen in leiomyo-
sarcomas. Bcl-2 was expressed more frequently in UL
compared with LMS and STUMP indicating good
prognosis. The expression rates of SMA, ER and PR
in LMS were lower compared with CL and BL. CD
expression differed between LMS and STUMP, LMS
and UL, but not between STUMP and UL indicating
that CD expression might be a marker for invasion or
metastasis in LMS, and the expression of CD and ER/
PR may be an especially useful immunohistochemical
parameter to distinguish smooth muscle tumors in which
histological features are ambiguous or borderline.
P024
Tumors of the family of sarcomas Ewing’s/PNET. 1990–
2002
A.I. Caballero, A.Y. Sa ´nchez, C.J. Reno, S.D. Garcı ´a,
T.M. Pe ´rez, R. Ropero
(Oncopediatric Service of Cuban National Oncology Institute)
A total 30 patients (between 0 and 15 years of age) of
the pediatric Service of the Cuban National Oncologist
Institute were studied, with the diagnosis of Ewing/PNET
between 1990–2002. 22 patients (73.3%) had typical
Ewing’s Sarcoma, 4 patients with PNET (13.3%), and 4
(13.4%) Askin’s Tumors.
We intended to describe the clinical characteristics and
the main factors presage found in this series, besides
evaluating the results of the used different treatment
modalities. It prevailed the male (1.5:1), the white race
(98%) and the bony localizations. The main consultation
reason was the pain and the palpable mass. The size tumor
was one of the most significant factor worse presage (8cm).
The answer to the chemotherapy was also a factor
predictor for the survival. In this time the service has
been used 3 protocols (VACA-High Risk; VACA-Low
Risk; P-6). The disease-free survival (DFS) to 3 years
change in each one: 73%, 57%, 89% respectively. The
radical surgeries prevailed to the conservative treatment
being better the survival for these last ones. The global
survival and the DFS to 5 and 2 years respectively were of
49% and 76%.
P025
Quality of Life (QoL) in pediatric sarcoma patients:
What do we know?
G. Calaminus
(Department of Pediatric Oncology, Hematology and
Immunology, University Children’s Hospital, Duesseldorf,
Germany)
Background: Sarcoma cover a wide range of disease
(Ewing-, osteo- and soft-tissue sarcoma) with a specific
treatment according to site and stage. Additionally the age
of the affected patients within the pediatric population
varies widely. Therefore factors influencing Quality of Life
of the different disease groups are frequent.
Questions are: Are there disease specific QoL domains
affected? What is the role of stage, age, gender and
treatment ? How is long term QoL of these patients?
Osteo-and Ewing sarcoma: In the last year QoL research in
this group of patients has been started more extensively.
Investigators identified parameters such as treatment,
mobility, age, mutilation, control of pain, educational
status as factors influencing QoL after the end of
treatment.
Soft tissue sarcoma: Published series are very limited and are
mainly related to older children. Mutilation, pain, affection
of body image and treatment related (irradiation) long
term effects are described as factors influencing QoL in the
long run.
Standardized and prospective evaluation within disease specific
trials are needed: To determine the specific QoL areas
affected and to identify patients and families of risk who
need a more extensive psychosocial support and a more
specific mental and physical rehabilitation.
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Is the biopsy really the best choice in initially localized
unresectable rhabdomyosarcoma (RMS)? results of the
Italian studies
G. Cecchetto
1, F. De Corti
1, G. Bisogno
2, A. Ferrari
3,
P. Dall’Igna
1, G. Scarzello
4, R. Alaggio
5, I. Zanetti
2,
C. Boglino
6, M. Carli
2 for the Italian Cooperative Group
(
1Department of Paediatrics, Division of Pediatric Surgery,
University of Padua, Italy,
2Department of Paediatrics,
Division of Oncology, University of Padua, Italy,
3Pediatric
Oncology Unit, Istituto Tumori of Milan, Milan, Italy,
4Division of Radiation Therapy, General Hospital of Padua,
Italy,
5Department of Oncologic Sciences, Pathology Unit,
University of Padua, Italy,
6Pediatric Surgery Department,
Bambino Gesu, Rome, Italy)
Purpose: Analysis of impact on survival of initial
biopsy vs. macroscopic-residual resection (Debulking-
Operation¼DO) in IRS-Gr.III RMS, enrolled in the
Italian studies (1979–2003).
Patients/methods: Surgical guidelines recommended biopsy
and discouraged DO. Treatment after biopsy/DO was the
same. 394 patients were evaluable. 323 underwent biopsy.
Site: 34 Orbit, 31 HNnPM, 99 HNPM, 49 GUBP, 11
GUnBP, 27 extremities, 72 other. Histology: 84 Alveolar,
239 non-Alveolar. Tumor-size: 124  5cm, 199 >5cm.
71 underwent DO. Site: 20 Orbit, 11 HNnPM, 9 HNPM,
7 GUBP, 1 GUnBP, 4 Extremities, 19 Other. Histology:
22 Alveolar, 49 non-Alveolar. Tumor-size: 36  5cm,
35 >5cm.
Results: The 5-year OS is 68.7% after biopsy, 71.3% after
DO (p¼0.59); PFS 57.5% after biopsy, 61.9% after DO
(p¼0.56).
Patients NED after biopsy and after DO respectively:
SITE. Orbit 32/34 (94%) and 15/20 (75%); HNnPM
23/31 (74%) and 9/11 (82%); HNPM 69/90 (70%) and
40/9 (44%); GUBP 38/49 (77%) and 7/7 (100%); GUnBP
11/11 (100%) and 1/1 (100%); Extremities 16/27 (59%)
and 3/4 (75%); Other 36/72 (50%) and 10/19 (53%).
HISTOLOGY. Alveolar: 53/84 (63%) and 14/22 (64%);
non-Alveolar: 172/239 (72%) and 35/49 (71%).
TUMOR-SIZE.  5cm: 105/124 (85%) and 39/36 (83%);
>5cm: 121/199 (61%) and 19/35 (54%).
Remarks: No significant differences in outcome comparing
patients who had biopsy or DO. Since the biopsy is less
aggressive and dangerous, we believe it is preferable as
initial approach for Gr.III RMS.
P027
Ewing’s sarcoma in children and adolescent: A report
from a single institution in a developing country – 1970–
1999
A. Chandra, T.G. Sagar
(Department of Medical Oncology, Cancer Institute (WIA),
Chennai, India)
Background: Treatment outcome of malignant
bone sarcomas have changed over last three decades.
Few studies have been reported from less developed
countries.
Material and methods: We report here our experience
of 171 evaluable cases in last 30 years(1970–1999) at
Cancer Institute (WIA), a regional cancer centre in India.
Event free survival rates(EFS) and 95% confidence interval
were estimated by Kaplan Meier analysi and prognostic
factors by logrank statistics and logistic regression method.
Results: Prior to 1985 suboptimal drugs were available and
EFS was 6.3% at 5 years. During 1985–1999 with the
advent of neoadjuvant chemotherapy and local radio-
therapy/surgery, the survival improved to 53% in those
who completed therapy. Metastatic disease at presentation
and incomplete therapy are poor prognostic factors
(p¼<0.05).
Conclusion: Integrated multimodal care and achievement
of survival figures are a challenges in a developing
country.
P028
Vascular endothelial growth factor and matrix metallo-
proteinase-9 expression by tumour cells influence patient
survival in osteosarcoma
R.M. Charity, A.F. Foukas, N.S. Deshmukh, R.J. Grimer,
D.C. Mangham, S. Taylor
(Royal Orthopeadic Hospital, Birmingham, UK)
We investigate whether vascular endothelial growth
factor (VEGF) and matrix metalloproteinase-9
(MMP-9) expression in osteosarcoma influence patient
survival.
Fifty-five patients with stage II-B osteosarcoma of the
distal femur/proximal tibia were followed-up for a mini-
mum of 92 months. All had chemotherapy plus resection
of tumour. Tissue from resected tumours was stained for
VEGF/MMP-9 using immunohistochemical methods and
the percentage of tumour cells expressing VEGF/MMP-9
was assessed. The relationship between VEGF/MMP-9
expression and survival was assessed using Kaplan-Meier
survival curves.
At follow-up 33/55 (60%) patients were dead, all from
metastatic disease. 25/52 (50%) tumours expressed VEGF
and 37/51 (72%) expressed MMP-9. Patients with
tumours expressing VEGF in more than 25% of their
cells had significantly shorter overall (p¼0.019) and
disease free survival (p¼0.009). Patients with tumours
expressing MMP-9 also had significantly shorter
overall (p¼0.0042) and disease free survival
(p¼0.0004). There was an association between VEGF
and MMP-9 expression (p¼0.021). Poor post-
chemotherapy tumour necrosis did not significantly
influence survival and was a factor independent of
VEGF/MMP-9 expression.
VEGF and MMP-9 have roles in tumour
neoangiogenesis, invasion, and metastasis. We have
shown that they influence prognosis in osteosarcoma.
New therapies targeting their actions warrant further
study.
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A model for drug resistance in osteosarcoma
A. Marie Cleton-Jansen
1, C. Gomes
1,2, J. Anninga
3,
N.N. Henriquez
4, G. van der Pluijm
4, E. Pauwels
2,
P.C.W. Hogendoorn
1
(
1Departments of Pathology,
2Nuclear Medicine,
3Pediatrics,
4Endocrinology, LUMC, Leiden, The Netherlands)
Purpose: Resistance to chemotherapy is a problem in failing
treatment for osteosarcoma. Studies in other tumours
have identified multidrug resistance (MDR) genes, encod-
ing ATP driven cellular pumps as the cause of failing
chemotherapy. Due to pre-operative adjuvant chemother-
apy protocols and because this tumour is relatively rare the
role of these genes is unclear in osteosarcoma. To establish
the role of known mechanisms for multidrug resistance and
to identify new genes involved in osteosarcoma adjuvant
therapy response we have developed an in vitro/vivo model.
Methods: A panel of osteosarcoma cell lines has been
characterized for sensitivity to cytostatics. Dose dependent
cell death induced by cytostatics is determined by FACS
analysis. Expression of multidrug resistance (candidate)
genes is determined by quantitative PCR. The biological
activity of the MDR pumps is determined by radio-
pharmaceuticals (99mTc-Mibi and 99mTc-tetrofosmin)
and by fluorescent reporters.
Results: The osteosarcoma cell lines have different sensi-
tivity for chemotherapy. Cells can form tumours in nude
mice and tumor progression and metastasis can be
identified by a luciferase reporter gene using whole body
bioluminescent reporter imaging (BLI) and in vivo MDR
activity can be monitored by radiopharmaceuticals.
Conclusion: We have developed an in vivo model to study
drug resistance in osteosarcoma.
P030
Clinical and radiographic outcome of large segment
prosthetic replacement for tumors of the distal femur
and proximal tibia
H.D. Morgan
1, S.S. Leopold
1, D. Hawkins
2, V. Bolejack
3,
E. Conrad III
1
(
1University of Washington Orthopaedics and Sports Medicine,
2Children’s Hospital and Regional Medical Center,
1University
of Washington, Washington State, USA)
Purpose: Our purpose was to achieve clinical and radio-
graphic follow-up of patients who had modular distal
femoral or proximal tibial prostheses inserted following the
resection of a primary bone tumor around the knee.
Materials/methods: We retrospectively reviewed ninety-six
patients who had distal femoral or proximal tibial mega-
prostheses implanted between 1985 and 2002. Surviving
patients were followed for a minimum of two years; mean
follow-up of all study patients was 60 months (range 0–226
months). At each follow-up, patients underwent clinical
examination, Musculoskeletal Tumor Society (MSTS)
rating system evaluation, an SF-36 questionnaire, and
appropriate AP and lateral radiographs.
Results: The 96 patients ranged in age from 9–85 years,
with a mean of 33 years. Fifty-three patients had a
diagnosis of osteosarcoma, 32 had a non-osteosarcoma
malignancy, and 11 had a benign aggressive tumor. Sixty-
nine patients received a distal femoral prosthesis and 29
had a proximal tibial replacement. 79 of the prostheses
were Howmedica Modular Oncology Prostheses. The
overall patient survival was 84% at two years’ follow-up,
72% at five years, and 66% at ten years, with younger
patients having significantly better survival rates than
patients over 18 years of age. Implant survival was 79%
at two years, 66% at five years, and 51% at ten years, with
proximal tibial implants faring better than distal femoral
implants. Gender, length of resection, diagnosis (osteo-
sarcoma vs. other), and the use of allograft prior to
prosthetic implant did not significantly affect implant
survival. There were 80 total complications, with aseptic
loosening being the most common.
Conclusion: Modular prosthetic implants are a viable option
for limb salvage following tumor resection; however,
Implant survival at five and ten years may be lower than
previously described.
P031
Endoprosthetic vs. ‘‘Condyle-Sparing’’ intercalary allo-
grafts for distal femoral osteosarcoma: A comparison of
long-term follow-up
T.B. Rapp
1, M. Zimmel
2, E. U. Conrad III
3
(
1Loyola University Medical Center,
2University of Chicago
Medical School,
3University of Washington Orthopaedics and
Sports Medicine)
Introduction: Tumor resection and limb salvage reconstruc-
tion are commonly performed for distal femoral osteosar-
coma. No consensus exists regarding the optimal method
of reconstruction. Further, there is little published data
directly comparing different reconstructive techniques.
This study directly compares the long term oncologic
and functional results of two limb salvage techniques after
resection of distal femoral osteosarcoma.
Methods: A retrospective chart and radiographic review was
performed on patients treated for distal femoral osteosar-
coma at a single institution by one senior surgeon.
Results: Between 1989–2000, 45 patients were treated with
chemotherapy and limb salvage reconstruction for high
grade distal femoral osteosarcoma. 27 patients received
an intercalary ‘‘condyle-sparing’’ allograft, 18 received
primary endoprosthetic replacement. Average follow-up
was 6.5 years. The overall survival rate for the combined
groups was 84%. There were two local recurrences in the
allograft group, one in the endoprosthetic group. Ten
patients (37%) in the allograft group required revision to
an endoprosthesis. There was an average of 3.3 revision
procedures per patient performed in the allograft group
compared to 1.2 in the endoprosthetic group. There were
no significant functional differences between the groups.
Discussion/conclusion: Limb salvage with a ‘‘condyle-
sparing’’ intercalary allograft has the potential advantage
of preserving the knee joint. In our series there was no
significant difference in oncologic outcome when allografts
were compared to endoprosthetic reconstruction. However
37% of the allograft patients required eventual conversion
to an oncologic prosthesis and allograft patients had nearly
3  the number of revision surgeries. There were no
functional differences discernable between the two groups.
P032
The impact of surgery on outcome in pediatric non-
rabdomyosarcoma soft tissue
L.H.T. Sakamoto, C.M.L. da Costa, B. De Camargo,
C.B.G. Antoneli
(Pediatric Oncology Department, Hospital do Ca ˆncer AC
Camargo, Sa ˜o Paulo, Brazil)
Nonrhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
comprises a heterogeneous class of tumours which biology
is still not understood. Records of 32 NRSTS patients
from a single institution were reviewed from January 1995
to December 2000, regarding demographic data, TNM
staging, histological type and site of primary tumor.
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chemotherapy (ifosfamide, actinomicyn D, vincristine,
cyclophosphamide, doxorubicin, etoposide). Median age
at diagnosis was 10.7 years (range: 1.9–220.4 months).
Primary site was extremities (37.5%), head and neck
(28%), followed by pelvic area (12.5%). The most
common histological subtypes were fibrosarcoma (47%),
alveolar sarcoma (12.5%), leiomyosarcoma (9.5%).
Complete resection was performed in 65.5% of patients
as first treatment. Chemotherapy was done in 31.3% and
21.9% were irradiated. Five-year overall and event-free
survival were 80.3% and 76.5%, respectively. Patients
submitted only to surgery overall survival was statistically
higher than children treated with multimodal therapy
(88.9% and 63.6%; p¼0.03). The high survival of patients
submitted to complete tumour resection reveals the
importance of surgery for management of NRSTS.
Chemotherapy and radiotherapy had no influence in
improving surgery resection and in overall survival.
P033
Intensive chemotherapy is not better than VAC regimen
for rhabdomyosarcoma in children and adolescents
L.H.T Sakamoto, C.M.L. Da Costa, B. De Camargo,
C.B.G. Antoneli
(Pediatric Oncology Department, Hospital do Ca ˆncer AC
Camargo, Sa ˜o Paulo, Brazil)
Several studies have reported the efficacy of different
combinations of chemotherapy agents in the systemic
disease control. Intensive chemotherapy has been sug-
gested to improve prognosis.
To determine if intensive aggressive chemotherapy
scheme is better than pioneer regimen VAC records from
38 children and adolescents with rhabdomyosarcoma
admitted in our institution during the period 1995–2000
were reviewed. The median age at diagnosis was 7.6 years.
Local site was 8 cases head and neck, 7 parameningeal,
7 genitourinary, 7 extremity and 9 others. Histology was
alveolar in 15.5% of cases. Excluding 8 patients stage
IV, 15 (50%) received VAC (vincristine, actinomycin,
cyclophosphamide) and 15 (50%) received intensive
chemotherapy (VAC plus ifosfamide, doxorubicin, etopo-
side). Clinical and tumor characteristics were similar
among the both groups. (p>0.05). Five-year overall
survival and event-free survival were 55.5% and 54.1%,
respectively. Age more than 10 years, alveolar histology
and TNM stage constituted prognostic factors for overall
survival (p<0.05). Five-year overall survival was not
different between patients who received VAC vs. who
received intensive chemotherapy (72.7% vs. 58.3%,
respectively; p¼0.42). Despite choice of treatment was
not randomized VAC regimen suggests as good as
intensive chemotherapy with less toxicity and significant
less cost.
P034
Is early diagnosis an important prognostic factor in
osteosarcoma?
K.S. Rodrigues, C.M.L da Costa, M.R. Latorre,
B. de Camargo
(Pediatric Oncology Department, Hospital do Cancer AC
Camargo, Sa ˜o Paulo, Brazil)
Early diagnosis has been suggested as a factor that could
improve survival of children with cancer. One hundred and
sixty five children and adolescents with osteosarcoma were
referred to the Pediatric Department, Hospital do Cancer,
Sao Paulo, Brazil during 1991–2000. The M:F ratio was
1.2, mean age was 13.3. Interval between symptom onset
and diagnosis (lag time) vary from 7.5 days to 48 months
(ms) mean of 3.5ms. First symptoms were bone pain,
tumor mass, fracture with a mean lag time of 3.1, 5.0,
4.5ms respectively (p¼0.064). Age and bone pain as first
symptom was significantly correlated with lag time. When
bone pain was the first symptom there was a reduction in
lag time of 1.7ms (p¼0.031). The older the patient the
longer was the lag time. Lag time increased 1.9ms each
year of life (p¼0.024). Patients with localized disease had
a mean lag time of 3.2ms while metastatic disease 3.9ms.
(p¼0.303). There were no difference between 5-year
overall survival in patients with a shorter and longer
lag time (<3ms: 46.1% vs. >3ms: 47.5; p¼0.45). The
relationship between lag time and prognosis is complex
and many factors play important roles on survival.
P035
Osteosarcoma and Ewing’s sarcoma of the forearm and
hand
W. Daecke
1, A.-K. Martini
1,H .J u ¨rgens
2, S. Bielack
2,
L. Bernd
1
(
1Orthopa ¨dische Universita ¨tsklinik Heidelberg1, Schlierbacher
Landstraße 200 A, 69118 Heidelberg, Germany,
2Pa ¨diatrische
Haematologie und Onkologie, Westfa ¨lische Wilhelms
Universita ¨t, Mu ¨nster, Germany)
Introduction: Knowledge and prognosis of osteosarcoma
(os) and ewing sarcoma (ews) of hand and forearm is
limited.
Method: On basis of the Cooperative-Osteosarcom-Study-
Group (COSS) and the Ewing-Sarcoma-Study-Group
(EICESS) 39 patients with os and 33 patients with ews
of hand and forearm were assessed. Epidemiological,
clinical, histological data and the survival rates were
evaluated. For patients with os therapy consisted of
surgical tumour resection and (neo)-adjuvant chemother-
apy. Patients with low grade os received local resection
only. All patients with ews had neoadjuvant chemotherapy.
Local therapy in patients with ews was surgery in 7,
radiation in 7 and a combination of both 19 subjects.
Results: For 33 patients with high-grade central os 5-year
overall/event free survival was 86.2 6.4%/65.4 9.6%,
respectively. 5 of 8 patients with secondary metastasis were
in remission. 4 patients died of disease and two patients
died of chemotherapy related complications. In 33 patients
with ews 5-year overall/event free survival was 84.1 6.5%/
71.3 8.1%. Out of 7 patients with secondary ews
metastasis 6 died. Altogether 8 of 33 patients with ews
died of disease.
Discussion: By utilising current therapeutic protocols
in patients with os or ews of the hand and forearm
survival-rates are remarkably high.
P036
Epithelioid sarcoma with SYT-SSX1 fusion gene
expression. Molecular and cytogenetic analysis
C. de Torres
1, T.M. Cardesa
2, V. Cusı ´
3, S. Rodrı ´guez-
Perales
4, J.C. Cigudosa
4, J. Mora
2
(
1Laboratori de biologia molecular dels tumors del desenvolupa-
ment,
2Oncologia Pedia `trica,
3Anatomia Patolo `gica, Hospital
Sant Joan de De ´u, Barcelona, Spain,
4Centro Nacional de
Investigaciones Oncolo ´gicas, Madrid, Spain)
Epithelioid sarcoma (ES) is a rare malignant soft tissue
tumor of unknown histogenesis, characterized by an
epithelioid morphology of tumor cells, and co-expression
of epithelial and mesenchymal lineage proteins.
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differentiation of tumor cells have similar 18q11 break-
points: mesothelioma t (3;18)(p14;q11); t (5;18)(p15;q11),
synovial sarcoma (SS) t (X;18)(p11.2;q11.2) and ES
18q11 breakpoint. Expression of SYT-SSX fusion genes
has been previously investigated in ES with negative
results.
A 14-year-old male presented with a painful, slowly
growing mass on the anterior aspect of his right forearm.
Histopathologic evaluation of the excised lesion demon-
strated the presence of epithelioid cells exhibiting slight
nuclear atypia and a nodular growth pattern of the tumor.
Immunohistochemical staining was consistent with the
diagnosis of ES (positive for vimentine, cytokeratins, EMA
and CD34).
Expression of SYT-SSX fusion genes was analyzed by
conventional and real-time RT-PCR analysis. Both showed
a low level of SYT-SSX1 amplification in ES, when
compared to the positive control (synovial sarcoma). FISH
analysis was performed on paraffin sections of the tumor
and confirmed the presence of the SYT-SSX1 fusion
gene in a small proportion of tumor cells. This finding
supports a likely common histogenetic background
between SS and ES.
P037
Experiences with the ‘‘clavicula pro humero’’ operation
in malignant bone tumors of the proximal humerus in
adolescents and adults
P.M. de Zwart, F. Maurer, K. Weise
(BG-Unfallklinik Tu ¨bingen, Germany)
Malignant tumors in the proximal part of the humerus can
nowadays be treated by a limb saving procedure in many
cases, because of improved regimen of chemotherapy,
radiotherapy and because of better reconstruction of the
defect by arthroplasty or by using bone transplants, such as
the clavicula pro humero operation, firstly presented by
Winkelmann.
An 18-year-old young man presented with shoulder
pain. The diagnosis was osteosarcoma of the left proximal
humerus. After neoadjuvant chemotherapy a wide resec-
tion of the sarcomatous proximal humerus was done. The
defect was bridged by a clavicula pro humero operation.
Internal fixation from the clavicle to the distal humerus was
made with an AO plate and screws. No complications were
observed during the postoperative period. A good bone
healing and even an enlargement of the clavicula could be
demonstrated by X-rays. Range of motion of the shoulder
was 80 degrees flexion and abduction, 30 degrees external
rotation, and 80 degrees internal rotation. A comparison is
made between the functional advantages of this operation
and other forms of reconstruction like arthroplasty.
P038
The Ewing Tumour (ET)-antigen ETAA 16: Insights
in ET-specificity and functional evidence
U. Dirksen
1, A. Borowski
2, S. Borkens
1, C. Bury
1,
U. Go ¨bel
1
(
1Kinderonkologie, Ha ¨matologie und Immunologie,
Universita ¨tsklinikum Du ¨sseldorf; Germany,
2Anatomisches
Institut, Universita ¨t Bonn, Germany)
ETAA16 is a 60–95kD protein expressed on the majority
of Ewing-tumour-cells (ETC). Non-ETC obtained from
healthy tissues or tumour were tested negative for ETAA16
surface expression. Nothing is known about the biological
role of ETAA16 in ETC. An anti-ETAA16 antibody
is available. ETC have been shown to release Interleukin
(IL) 8, vascular endothelial growth factor (VEGF), IL6 and
monocyte chemotactic protein (MCP)-1. In order to test
the influence of AK16 on cytokine release in human ETC,
RDES- and VH64-celllines were cultured in the presence
or absence of different concentrations of AK16. Cytokine
release was tested by ELISA and cell death by propidium
iodine staining and binding of Annexin-V at 24, 48, 56
and 72 hours of culture. Our results indicate, that
anti-ETAA16 antibody inhibits the release of VEGF,
IL8, MCP-1 and IL6 after 48h of culture. Apoptosis
occured within 56–72 hours of culture. As controls
non-ET-celllines were treated equally.
Conclusion: ETAA16 is a ET-specific antigen. Binding of
AK16 to the ETAA16 antigen results in an impaired
function and earlys cell death in ET-celllines. Although the
apoptosis-specific signal appeared later than the down-
regulation of cytokine release, we can not exclude that the
impaired cytokine release is a secondary effect.
P039
Alveolar rhabdomyosarcoma with bone and bone
marrow involvement: The experience with diagnosis
and treatment
E. Drahokoupilova
1, D. Sumerauer
1, E. Kabickova
1,
O. Belohlavek
2, R. Kodet
3, L. Krskova
3, J. Stary
1
(
1Department of Ped. Hematology and Oncology Charles
University and University Hospital Motol, Prague, Czech
Republic,
2Department of Nuclear Medicine, Na Homolce
Hospital, Prague, Czech Republic,
3Department of Pathology
and Molecular Medicine, 2nd Medical School Charles
University Prague, Czech Republic)
Background: The bone marrow infiltration and bone
metastases are very unfavourable prognostic factors in the
treatment and survival of children with alveolar rhabdo-
myosarcoma. The treatment is very difficult and the chance
for achieving the long-term remission is very small.
Patients/Methods: We report three patients (age >10 years)
with alveolar rhabdomyosarcoma (diagnosis was confirmed
by imunohistochemical analysis of MYOD1 and PAX-
FKHR transcript by RT-PCR) and with diffuse bone
marrow involvement by neoplastic cells and bone metas-
tases (1 patient with and 2 without the evidence of primary
tumour by the using of FDG-PET and radiological
methods). Patients were treated with 9–11 cycles of
chemotherapy: topotecan, cyclophosphamide in alteration
with VAC (vincristine, actinomycin D, cyclophos-
phamide), followed by local radiotherapy and with
maintenance therapy by vinorelbine.
Results: Two patients achieved complete remission and 1
child achieved very good partial remission, median follow-
up was 15.3 months and median time to disease progres-
sion was 11.6 months (range 10–13 months). The toxicity
of this chemotherapy regimen was acceptable.
Conclusions: The regimen topotecan, cyclophosphamide
alterated with VAC is effective and good tolerated
combination for the treatment of poor-risk alveolar
rhabdomyosarcoma patients.
P040
Microarray analysis to identify target genes of PAX3-
FKHR in rhabdomyosarcoma after siRNA mediated
down-regulation
M. Ebauer, M. Wachtel, B.W. Scha ¨fer
(University Children’s Hospital Zu ¨rich, Division of Oncology,
Zu ¨rich, Switzerland)
Rhabdomyosarcoma is an aggressive childhood cancer
derived from skeletal muscle cells with two major
78 Poster Abstractshistological subgroups, the embryonal (eRMS) and the
alveolar (aRMS) form. ARMS is associated with the
chromosomal translocation t(2;13) or t(1;13) which gen-
erates the chimaeric transcription factor PAX3/FKHR.
Direct transcriptional targets mediating the oncogenic
effects of this fusion protein are largerly unknown.
In the present work, we analyzed the effect of PAX3/
FKHR downregulation by siRNA to identify novel targets
and characterize effects on cellular viability. Transfection
of small interfering RNA (siRNA) for PAX3/FKHR
reduced its expression on mRNA and protein levels and
resulted in decreased cellular viability.
To identify PAX3/FKHR target genes in RMS, the
alveolar line Rh4 was chosen as a model and microarray
analyses were performed after downregulation of PAX3/
FKHR. Numerous genes involved in muscle function such
as troponin C2 were induced by low levels of PAX3/
FKHR, suggesting that PAX3/FKHR was repressing their
expression. Several genes were downregulated, among
them are genes that play a role in apoptosis and cell growth
such as TFAP2beta and cannabinoid receptor 1.
The RNAi technique appears to be a promising tool for
analysis of PAX3/FKHR gene function and could also be
used to identify novel therapeutic targets for aRMS.
P041
Treatment of non-metastatic rhabdomyosarcoma and
other non-rhabdomyosarcoma soft tissue tumors of
childhood and adolescence
S. El-Badawy, H. Hussein, G. Attia
(National Cancer Institute, Cairo, Egypt)
Background: At NCI Egypt, soft tissue sarcoma represent
3.75% of total malignancies & 27.6% of these occur in
pediatric age group.
Methods: 56 children and adolescents, treated by upfront
chemotherapy and local treatment at week 9. Fifty four
patients received the high risk regimen of chemotherapy
consisted of alternating 6 drugs.
Results: Most common primary sites were the extremity
(28.6%), followed by orbit, trunk, parameningeal sites
(12.5% each), head & neck 10.7%, bladder & prostate
7.1%, retroperitoneal 7.1%. Tumor size more than 5cm
was encountered in 72.5%. Sixty two percent had
embryonal RMS and 27% were alveolar subtype. Forty
three percent of patients showed CR, 46% good PR, 7%
PR, while 2% SD. The 2-year OAS & DFS for the whole
group was 73 9% & 53 9% respectively. Sixteen
patients relapsed (7 locoregional, 6 distant & 3 both).
DFS was significantly affected by tumor size in favour of
those with tumors <5cm (P¼0.03). Local failure free
survival was 61 13%. On multivariate analysis radio-
therapy showed statistical significance (P¼0.04). Only one
patient died of fungal pneumonia.
Conclusion: Chemotherapy used in this study was well
tolerated. Radiation therapy is an effective modality should
be refined to reduce late sequlae by the use of IMRT &
brachytherapy.
P042
The significance of isolated limb perfusion with TNF-
alpha and melphalan in adults and children
S. Elezkurtay, P.-U. Tunn, P. Hohenberger, C. Kettelhack,
P.M. Schlag
(Clinic for Surgery and Surgical Oncology, Charite ´ Campus
Buch, Berlin, Germany)
Purpose: We report our 12-year experience with isolated
limb perfusion (ILP) for limb salvage therapy of locally
advanced soft tissue sarcoma.
Patients and methods: Between 1993 and 2004 105 patients
with soft tissue sarcoma (13% of all patients) received
isolated limb perfusion. Age was between 10 and 80 years
(Median 54 years) with a predominance of female
individuals (1.3:1). 3.8% of patients were children. ILP
was carried out most commonly in the lower limbs (84%).
Resection of the tumor was performed after a six week
period in 97% of patients.
Results: Limb salvage could be achieved in 78% of
patients after ILP. The response rate was 69%. Local
recurrence was seen in 11% of cases. The 5 year overall
survival was 68% in accordance with the survival of all
patients treated with soft tissue sarcoma (n¼815).
Secondary amputation was most frequently indicated
for synovial sarcoma of the foot. There was no case of
amputation, local recurrence or therapy related compli-
cations in childhood age.
Discussion: Isolated limb perfusion is the most effective
neoadjuvant limb sparing modality for locally advanced
soft tissue sarcoma in newly diagnosed as well as recurrent
lesions. First experiences in childhood conditions are
encouraging.
P043
Dose intensity of chemotherapy in osteosarcoma in
the Cooperative Osteosarcoma Study Group (COSS)
trials
M. Eselgrim
1, H. Grunert
1, M. Kevric
1,H .B u ¨rger
2,
H. Ju ¨rgens
1,T .K u ¨hne
4, R. Kotz
5, S. Lang
6, R. Mayer-
Steinacker
7, A. Zoubek
8, S. Bielack
1
(
1Universita ¨tsklinikum Mu ¨nster, Pa ¨diatrische Ha ¨matologie
und Onkologie,
2Institut fu ¨r Pathologie,
3Allgemeine
Orthopa ¨die,
4Universita ¨tskinderspital beider Basel,
Switzerland,
5Orthopa ¨dische Universita ¨tsklinik,
6Klinisches
Institut fu ¨r Pathologie, Universita ¨tsklinik Wien,
7Universita ¨tsklinikum Ulm,
8St. Anna-Spital, Wien,
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Background: The prognostic relevance of chemotherapy
dose intensity in osteosarcoma is still under discussion.
This analysis investigated whether higher dose intensities
correlate with better outcomes.
Procedure: Ninehundredseventeen COSS patients <40
years with primary, high-grade-central, non-metastatic
extremity osteosarcoma were evaluated for potential
correlations between chemotherapy dose intensity during
the first 200 days of treatment (DI200) and overall
and event-free survival. Scheduled therapy consisted
of intensive mutidrug chemotherapy and surgery. The
analysis focused on methotrexate, doxorubicin, cisplatin,
and ifosfamide, which were given to the majority of
patients. Multivariate analyses including well-known
prognostic factors were added to complete this investiga-
tion.
Results: Until day 200, patients had received
80684 26073mg/m
2 methotrexate, 242 69.2mg/m
2
doxorubicin, 324 133mg/m
2 cisplatin and 13880 
9802mg/m
2 ifosfamide (mean SD). After a median
follow-up of 6.6 (0.02–22.1) years, actuarial overall-suvival
(from day 200) was 77%, with an event-free survival
rate of 66%. There was no correlation between a higher
dose intensity of any particular agent or of overall
treatment and better outcomes in either uni- or multi-
variate analyses.
Conclusions: In an overall setting of intensive multi-
drug treatment for osteosarcoma, we could not prove
that higher dose intensities correlate with better
outcomes.
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Localized pelvic embryonal rhabdomyosarcoma with
bone invasion in a 14 y old girl. Ten year disease free
follow-up after multimodal treatment in the CWS 91
study
G.U. Exner, A.R. von Hochstetter, H.P. Honegger,
N. Lombriser, J. Streuli, E. Wight
(Uniklinik Balgrist, University of Zu ¨rich, and Stadtspital
Triemli, Zu ¨rich, Switzerland)
Rationale: Rhabdomyosarcoma of the pelvis has a very poor
prognosis. This case is presented to encourage multimodal
treatment and further evaluate the contribution of aggres-
sive extralesional surgery for such patients.
Patient and methods: At age 14 years the patient presented
with inguinal pain of 6 months duration considered
tendinopathy from horseback riding. At presentation she
had a large inguinal mass and a swollen right leg. Standard
X-ray showed destruction of the pubic and fracture of the
ischiac bone. The tumor volume was about 750ml from
MRI studies. Biopsy revealed a partially myxoid embryonal
rhabdomyosarcoma.
The patient was enrolled in the EVAIA branch of the
CWS 91 study. Following 30.1Gy of percutaneous radio-
therapy an extralesional resection of the affected pubic
and ischiac bones including the anterior part of the
acetabulum was achieved with min. margins of 6mm.
Islands of vital tumor cells were found in the largely
necrotic specimen. Postoperatively the patient completed
the full course of the CWS 91 regime and radiotherapy was
added to 52.8Gy.
At present at 10y f/u the patient is free of tumor. She has
lymph edema of the right leg, but otherwise is able to carry
out her daily activities; she continues horseback riding
including jumping despite complete loss of adductor
muscle function. She has no pain and has normal bladder
function. She is working as laboratory technician and is
presently pregnant in the 28th week of a so far uneventful
gestation. According to the patient she is highly satisfied
with the result and her quality of life.
P045
Adult-type soft tissue sarcomas in the pediatric age: The
experience of the Istituto Nazionale Tumori, Milan, Italy
A. Ferrari, M. Casanova, P. Collini, C. Meazza, R. Luksch,
M. Massimino, G. Cefalo, M. Terenziani, F. Spreafico,
D. Polastri, M. Podda, A. Rognone, D. Catania,
E. Zaffignani, O. Sironi, L. Gandola, A. Gronchi
(Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan,
Italy)
Introduction: In the heterogeneous group of non-
rhabdomyosarcoma soft tissue sarcomas (NRSTS), it
is important to identify groups as homogeneous as
possible; we define ‘‘adult-type’’ NRSTS those histotypes
typical of adulthood, definitely malignant, with morpholog-
ical features resembling differentiated/mature tissues
(excluding infantile fibrosarcoma, borderline tumors,
small-round-cell-tumors, i.e. RMS, extraosseus pPNET/
Ewing and DSRCT). Therefore, this definition includes
adult-type fibrosarcoma, MPNST, epithelioid-sarcoma,
leiomyosarcoma, clear-cell-sarcoma, liposarcoma, alveo-
lar-soft-part-sarcoma, malignant-fibrous-histiocytoma,
malignant-hemangiopericytoma, angiosarcoma, mesen-
chymal-chondrosarcoma, dermatofibrosarcoma.
Methods: We report on 179 patients <18yrs treated
over a 25-year period. Surgery was the mainstay of
treatment; 73 patients received radiotherapy, 114
chemotherapy (70 adjuvant). Results: 5yr-OS was 88%
in IRS Group I, 79% in Group II, 52% in Group III, 17%
in Group IV. Outcome was unsatisfactory in patients with
large and high-grade tumors even after gross resection
(MFS 36%) and adjuvant chemotherapy seemed to
improve the.
Results. In the group of initially-unresected cases (EFS
45%), patients who responded well to chemotherapy
and underwent complete resection had EFS  70%. The
chemotherapy response rate was 58% considering also
minor responses.
Conclusion: The identification of prognostic variables
should enable risk-adapted therapies to be planned.
Patients with initially-unresectable disease and those
with resected large and high-grade tumors are at high-
risk of metastases and might benefit of intensive
chemotherapy.
P046
Synovial sarcoma in adolescents and young adults. The
experience of the Istituto Nazionale Tumori, Milan, Italy
A. Ferrari, A. Gronchi, M. Casanova, C. Meazza,
L. Gandola, P. Collini, M. Massimino, R. Luksch,
G. Cefalo, M. Terenziani, F. Spreafico, D. Polastri,
M. Podda, R. Bertulli, P.G. Casali
(Istituto Nazionale Tumori, Milan, Italy)
Purpose: We previously reported on 271 SS patients of all
ages, treated at our institution over a 30-year period
(Ferrari et al., Cancer, 2004). Herein, we focus on the 83
AYA (age 17–30yrs), comparing clinical findings and
treatment results to those of younger and older patients.
Patients: Among the 83 AYA, 60 received initial macro-
scopic resection, 14 had locally-advanced disease and 3
had metastases at onset. Tumor size was >5cm in 60% of
cases (49% in children and 73% in older adults). Among
the AYA who had initial gross surgery, 45% received
radiotherapy (58% in children and 49% in older adults);
adjuvant chemotherapy was administered to 20% (78% in
children and 14% in older adults).
Results: For initially-resected AYA, 5yr-EFS was 40%
(66% for children, 31% older adults). For AYA with
advanced disease, 5yr-EFS was 55% and chemotherapy-
response rate was 60%.
Conclusions: Older age correlates with a worse prognosis
and this may be partially due to the greater use of
chemotherapy in the younger patients (treated by pedia-
tricians as rhabdomyosarcoma). Chemotherapy may play
a more important part in SS than in other adult sarcomas.
AYA could probably receive the better treatment within
experienced institutions that enrol patients into clinical
trails.
P047
Epithelioid sarcoma in children and adolescents:
A report from the soft tissue sarcoma Italian cooperative
group
M. Casanova
1, A. Ferrari
1, G. Bisogno
2, P. Collini
1,
R. Alaggio
2, A. Gronchi
1, C. Meazza
1, G. Cecchetto
2,
A. Garaventa
3, A. Di Cataldo
4, P. Indolfi
5, M. Carli
2
(
1Italian Cooperative Group on Soft Tissue Sarcoma, Milano,
2Padova,
3Genova,
4Catania,
5Napoli, Italy)
Objectives: To contribute further information to natural
history and management of epithelioid sarcoma in children
and adolescents.
80 Poster AbstractsMethods: We analyzed 24 patients (3–18yrs) treated
between 1988–2002. Primary site was extremity in
83%, size ranged between 1–10cm (median 3);
2 patients had nodal involvement, 1 lung metastases;
14 patients were IRSgroup I, 4 group II, 5 group III,
1 group IV.
Results: Radiotherapy was delivered to 6 patients,
chemotherapy to 7 (N1 and group III–IV patients).
Response to chemotherapy was achieved in 3/6
evaluable pts (2 pathological complete remission). Five
pts underwent delayed complete resection. Five-year
EFS and OS were 65.3% and 95.8% (median
follow-up 51mos). Nine patients relapsed (3–124mos,
median 12): 7 local (all alive after salvage treatment), 1
localþmetastases, 1 metastases (the 2 pts who developed
metastases died of disease). EFS correlated with age
(81.8%  10yrs, 52.7% >10yrs), site (70.0% extremity,
37.5% other), T-status (71.8% T1, 50.0% T2), but not
with size.
Conclusions: Despite the high rate of local relapse,
the prognosis was good. Chemotherapy may achieve a
response in unresectable disease and enhance surgery.
Unlike other pediatric soft tissue sarcomas, size seems to
be an unreliable predictor of prognosis. Pathological review
will be presented.
P048
The upcoming European protocol on pediatric non-
rhabdomyosarcoma soft tissue sarcomas
A. Ferrari, M. Casanova, I.B. Brecht, E. Koscielniak,
B. Brennan, N. Francotte, M. Van Noesel, D. Orbach,
G. Ljungman, A. Schuck, H. Martelli, A. Kelsey,
R. Alaggio, A. Rosolen, H. Brisse `, K. McHugh,
G.L. De Salvo, C. Bergeron, G. Bisogno, C. Int-Veen,
M. Carli, O. Oberlin, M. Stevens, J. Treuner
(European Pediatric Soft Tissue Sarcoma Study Group
(EpSSG) Pediatric Oncology Unit, Istituto Nazionale
Tumori, Milan, Italy)
Purpose: The three cooperative European groups
(SIOP-MMT, CWS and AIEOP-STSC) recently
joined together as the European paediatric Soft tissue
sarcoma Study Group (EpSSG). As concern Non-
Rhabdomyosarcoma-Soft-Tissue-Sarcoma (NRSTS), the
EpSSG is developing the first European study to
focus specifically on pediatric NRSTS.
Methods. The study includes two prospective clinical
trials, one on synovial sarcoma and one on ‘‘adult-type’’
NRSTS. Only general guidelines will be given for the so-
called ‘‘other histotypes’’. First objective of the study is
to make uniform the treatment of NRSTS patients in
Europe. Main objectives of the prospective trails are the
investigation of the role of an ifosfamide-doxorubicin
regimen in improving the response rate in patients
with unresectable tumors, the impact of the omission
of adjuvant chemotherapy in patients with low-risk
synovial sarcoma (IRS group I, tumour <5cm), the
role of adjuvant chemotherapy in IRS group I–II, G3,
size >5cm adult-type NRSTS patients in improving
the MFS and the OS, the prospective evaluation of
clinical/pathological prognostic factors (in particular
the tumour grade).
Conclusions: Increasing European collaboration should
allow the exploration of better treatment strategies
for children with NRSTS, for which in the past treat-
ments were generally adapted from those drawn up for
rhabdomyosarcoma.
P049
Could adjuvant chemotherapy have a role in surgically-
resected adult-type soft tissue sarcomas of children and
adolescents?
A. Ferrari
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3,
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2
(
1Italian Cooperative Group on Soft Tissue Sarcoma, Milan,
2Padua, Italy,
3The German Soft Tissue Sarcoma Study
Group (CWS), Olgahospital, Stuttgart, Germany)
Purpose: This analysis aims to evaluate whether adjuvant
chemotherapy can be recommended for high-risk,
surgically-resected, adult-type non-rhabdomyosarcoma
soft tissue sarcomas (NRSTS). The Italian and German
Cooperative Groups reviewed their databases, analyzing
patients classified as IRS group I–II, with high grade tumor
(G3) larger than 5cm in size.
Methods: The analysis included 36 patients (39%
MPNST), and compared the clinical features and outcome
of the group of 21 patients who received chemotherapy
versus the group of 15 patients treated with local therapies
only.
Results: For the series as a whole, 5yr-EFS, MFS and OS
were 26.2%, 34.0% and 37.5%, respectively. In patients
treated with chemotherapy, MFS and OS were 49.5% and
41.5% (median time to relapse: 13 months). In patients
who did not receive chemotherapy, MFS and OS were 0%
and 23.8% (median time to relapse: 3 months).
Conclusion: The role of adjuvant chemotherapy in NRSTS
is still uncertain, however the current analysis showed that:
(1) despite the globally good prognosis of grossly-resected
cases (5yr-EFS¼72%, OS¼86% [Ferrari et al., J Clin
Oncol 2005]), patients with G3 and large-size have a high
risk of metastatic spread, (2) MFS would seem better
in patients who had chemotherapy. Given these results,
and in accordance with some recent suggestions coming
from the literature on adult sarcomas, the new European
pediatric Soft Tissue Sarcoma Study Group (EpSSG)
NRSTS protocol will recommend adjuvant chemotherapy
in high-risk surgically-resected patients.
P050
Co-stimulation through CD137 enhances interleukin-2
driven immune response against Ewing family tumor
cells
J. Foell, C. Kuehnoel, O. Diwan, G. Horneff, S. Martin
(Martin-Luther-University Halle-Wittenberg, Department of
Pediatrics, Halle, Germany)
CD137 (4-1BB) is an inducible T cell costimulatory
receptor and a member of the tumor necrosis factor
receptor (TNFR) super family. It is mainly expressed on
activated T cells and activated natural killer (NK) cells.
Binding of CD137 to the natural ligand (4-1BBL)
or to agonistic monoclonal antibodies induces T cell
co-stimulation and leads to enhanced proliferation and
cytokine production. We report here that co-stimulation
with an monoclonal antibody against CD137 or transfec-
tion of tumor cells with human 4-1BBL enhances the
interleukin-2 (IL-2) induced immune response against
Ewing family tumor (EFT) cells in vitro. Additionally, the
incubation of circulating T cells from a patient with
progressively growing EFT with autologous tumor cells in
the presence of anti-CD137 mAb and IL-2 enhanced
the cytolytic T cell response against these tumor cells.
The stimulation of the CD137/4-1BBL pathway led to an
expansion and activation of CD8þ and CD4þ T cells and
Poster Abstracts 81NK cells. Under these conditions, growth of autologous
tumor cells was nearly completely suppressed. These data
suggest that in vitro stimulation of T and NK cells through
CD137 in combination with IL-2 followed by adoptive
transfer of activated T and NK cells might be an interesting
option for the treatment of patients with advanced
metastatic cancer including EFT.
P051
Topotecan monotherapy and Topotecan/Thiotepa com-
bination therapy with and without stem cell rescue in
patients with advanced malignant peripheral neuroecto-
dermal tumors (PNET): A pilot study of toxicity and
efficacy
S. Hess
1, C. Kuehnoel
1,J .F o ¨ll
1, A. Wawer
2, S. Burdach
1
(
1Martin-Luther University of Halle-Wittenberg, Division of
Pediatric Hematology/Oncology, Department of Pediatrics,
06097 Halle, Germany,
2Children’s Hospital, Medical
Center, Munich University of Technology, Munich, Germany)
A pilot study was designed to determine the toxicity of
topotecan (TPT) and to evaluate the efficacy of TPT in
combination with thiotepa in patients with advanced
malignant PNET.
Three patients were treated with TPT by interpatient
dose escalation with 1.2, 1.5 and 2mg/m
2 for 5 days
as continuous intravenous infusion (CIVI). All patients
received granulocyte-colony stimulating factor, one patient
received aPBSC. Thereafter five cycles of TPT 2mg/m
2 on
days  7t o 3 and thiotepa 100mg/m
2 on days  7t o 3
followed by aPBSC rescue on day 0 were given to three
patients.
Nonhematologic toxicity was mild to moderate, myelo-
suppression was the main toxicity. Grade 4 neutropenia
was seen in all patients. One of three patients with
monotherapy had no response, one became free of pain
for 14 days and the third showed stable disease (SD).
One patient received combination with thiotepa achieved
partial remission, one of three showed complete remission.
The third patient showed SD after first but progression
after 2 cycle.
TPT monotherapy is a palliative regimen with accep-
table nonhematologic and manageable hematologic toxi-
city. TPT/ thiotepa appears to be a tolerable myeloablative
regimen with antitumor activity. Hematologic toxicity is
reduced by use of cytokines and aPBSC rescue.
P052
Role of primary lung metastases in RMS-like tumors
in children and adolescents: Results of the CWS-study
group
G. Friedel
1
, S. Veit
1, S. Kirsch
2, T. Dantonello
2,
I.B. Brecht
2, C. Int-Veen
2, A. Schuck
3, P. Winkler
2,
I. Leuschner
4, S. Bielack
5, T. Klingebiel
6, E. Koscielniak
2,
J. Treuner
2, H. Toomes
1
(CWS Study Group:
1Department of Thoracic Surgery, Klinik
Schillerhoehe, Gerlingen, Germany,
2Department of Pediatric
Haematology and Oncology, Olgahospital, Stuttgart,
Germany,
3Department of Radiotherapy, University
of Mu ¨nster, Mu ¨nster, Germany,
4Department of
Paidopathology, University of Kiel, Kiel, Germany,
5Department of Pediatric Haematology and Oncology,
University of Mu ¨nster, Mu ¨nster, Germany,
6Department of
Pediatric Haematology and Oncology, University of Frankfurt,
Frankfurt, Germany)
Purpose: Analysis of data from patients with RMS-like
tumors and primary metastases confined to the lung
treated within the CWS 81–96 trials.
Methods: Evaluation of 75 completely documented patients
treated between 3/1981 and 10/2002. Median follow up
was 58 months (survivors). Treatment of the primary
tumor consisted of local and systemic therapy according
to the trial guidelines.
Results: The collective is composed of 38 patients with
RME, 6 with RMA, 2 RMS, 3 EES, 14 pPNET and 12
SySa patients with different localisation of the primary
tumor. Patients with pPNET had significantly more
pulmonary metastases than RME patients (p¼0.02). 26
patients are alive in complete remission, 2 showed partial
remission, 2 progressive disease, 1 relapsed and 42 died of
disease.
The 5-yrs OS and EFS improved significantly
from CWS-81 to CWS-96 (23% vs. 60% and 8% vs.
39%). Compared to all CWS-96 stage IV-patients
(OS 31%, EFS 25%) they showed better results
approximately to those in the RMS-like High Risk
group (OS 68%, EFS 57%). Younger patients or
those with small tumors had a significantly better
outcome (p¼0.01 and 0.03). The impact of lung
irradiation and resection of pulmonary metastases will be
discussed.
Discussion: Results of patients with RMS-like tumors
and with primary metastases only in the lung are
comparable to those in the High Risk group rather
than to stage IV-patients. Favourable risk factors
and adequate local and systemic control seem more
responsible for prognosis than the metastatic situation
itself.
P053
The use of a textile implant as artificial ligament to
prevent dislocation in THA due to pelvic resections
P.T. Funovics, M. Dominkus, C. Toma, F. Abdolvahab,
R. Kotz
(Department of Orthopaedics, Vienna Medical University,
Vienna, Austria)
Purpose: The risk of dislocation of THA after resection
of pelvic tumours is fairly high due to resulting soft
tissue loss. We report a procedure using a textile
implant (LARS ) to prevent dislocation of pedestrial cup
implants.
Patients/methods: In 7 consecutive patients (1 male; 6
female; average age 51 years) with skeletal malignancies
(osteosarcoma: 2; chondrosarcoma: 1; metastasis: 4;)
in whom resection of the acetabular pelvic bone was
indicated, reconstruction of the hip was performed by
use of a pedestrial cup (Scho ¨llner ) and a rectangular
femoral stem (Zweymu ¨ller ). Either primary (in 6) or
secondary (in 1) to this a textile LARS -ligament
was attached in a sleeve-wise technique around the
prosthetic femoral neck and periacetabular tissue
as a recontruction of joint ligaments. Post-operative
cast immobilization of the hip was performed for 6 to 12
weeks.
Results: Patients could be mobilized partially weight-
bearing starting at the fifth post-operative day, and
remained so according to subjective ability. There were
no cases of dislocation and ability to walk was rated
satisfying by all patients. At latest follow-up 5 to 14 months
post-operatively (average: 8.3 months) range of motion
averaged 84  in flexion (60  to 120 ).
Conclusion: The use of a textile implant in THA after pelvic
resections has shown to be a reliable instrument to prevent
dislocation due to large soft tissue defects with satisfying
functional results.
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A pilot trial of tumour-lysate loaded dendritic cell
vaccines in patients with primary and secondary skeletal
malignancies
P.-T. Funovics
1, M. Dominkus
1, R. Kotz
1, T. Felzmann
2
(
1Department of Orthopaedics, Vienna Medical University,
Austria,
2Childrens’ Cancer Research Institute, Vienna,
Austria)
Purpose: This study presents preliminary data of tumour-
lysate loaded dendritic cell-vaccination (DC) for recurrent
or metastatic skeletal malignancies.
Patients/methods: In 7 patients suffering osteosarcoma (1),
chondrosarcoma (1), Ewing’s Sarcoma (2), soft tissue
sarcoma (1) and metastasis of renal cell carcinoma (2),
DC-vaccination was administered additional to standard
treatment. DC precursor cells were generated from
peripheral blood mononuclear cells by leukocyte apheresis
and charged with lysed autologuous tumour cells obtained
by surgery. Each patient received 6 vaccinations of 1 106
cells (¼0.5ml) intranodally under sonographic guidance
in weekly intervals. Delayed Type Hypersensitivity (DTH)
testing for immune response against tumour antigens and
standard clinical and radiological examinations were
performed before and after treatment.
Results: No adverse side effects were observed in any
patient throughout treatment. Three patients died of
disease, 2 patients showed progressive disease, 2 revealed
stable disease for 15 and 21 weeks. Helper as well as
cytotoxic T-lymphocytes of 3 patients showed in vitro
reactivity in terms of CD4 expression.
Conclusion: The absence of adverse effects and uncompli-
cated therapeutic regimen together with promising immu-
nological responses, that can be correlated to clinical
outcome suggest that the use of DC-vaccination should be
investigated in earlier stages of disease to improve results.
P055
Clinical characteristics of aggressive fibromatosis in
children
J. Godzinski
1, K. Bronowicki
2, C.C. Flohil
3, F.W.J. ten
Kate
2, D.C. Aronson
2, H.A. Heij
2, E. Bien
1,
W. Madziara
1, D. Perek
1, A. Prokurat
1, M. Rapala
1,
W. Sulka
1, W. Wozniak
1, M. Wysocki
1
(
1Polish Paediatric Solid Tumours Study Group,
2Emma
Children’s Hospital AMC,
3Vrije Universiteit Medical Center,
Amsterdam, The Netherlands)
Background: Aggressive fibromatosis (AF) has different
characteristics in childhood and in adulthood. Its adequate
management is unclear.
Aim: To analyse AF behaviour and outcome after various
methods of treatment.
Patients: 45 patients (9 centres in The Netherlands and
Poland: 1988–2004). 29 boys (64%), 16 girls; age 0–17
years; locations: limbs/26 (58%), trunk & abdominal wall/
11 (24%), head & neck/8 (18%).
Results: 40/45 (89%) underwent surgery. 22 resections
(55%) were incomplete/marginal (15 relapsed 68%),
18 wide/compartmental and complete (2 relapsed 11%).
24 underwent surgery only (10 relapsed 42%). Surgery was
supplemented with CHT in 10 (5 relapsed), RTX in 3
(no relapse), RTXþCHT in 3 (2 relapsed). RTX & CHT
only were used in 1 (relapsed), CHT in 4 (2 CR,
2 progression-free).
Summary: In contrast to adults, AF of childhood is located
predominantly in the limbs and has a higher incidence
in boys. Wide/compartmental complete resection
(16/18 CR 89%) has good predictive value for outcome;
marginal/incomplete resections imply a high risk of relapse
(7/22 CR 32%). RTX seems of value (3/3 CR); good
responders to CHT occur (4/4 progression-free). 40%
relapse-rate indicates that the problem requires broader
studies.
P056
Extraskeletal osteosarcoma treated like conventional
osteosarcoma
S.Y. Goldstein-Jackson
1,2, G. Gosheger
3, G. Delling
4,
W.E. Berdel
5, G.U. Exner
6, G. Jundt
7, J.N. Machatschek
1,
A. Zoubek
8,H .J u ¨rgens
1, S. Bielack
1
(
1Universita ¨tsklinikum Mu ¨nster, Pa ¨diatrische Ha ¨matologie
und Onkologie, Mu ¨nster, Germany,
2University of Wales
College of Medicine, Heath Park, Cardiff, Wales UK,
3Universita ¨tsklinikum Mu ¨nster, Allgemeine Orthopa ¨die,
Mu ¨nster, Germany,
4Universita ¨tsklinikum Hamburg-
Eppendorf,, Institut fu ¨r Osteopathologie, Hamburg, Germany,
5Universita ¨tsklinikum Mu ¨nster, Medizinische Klinik und
Poliklinik A, Germany,
6Orthopa ¨dische Universita ¨tsklinik
Balgrist, Zu ¨rich, Switzerland,
7Universita ¨tsspital Basel,
Knochentumor-Referenzzentrum am Institut fu ¨r Pathologie;
Switzerland,
8St. Anna Kinderspital, Vienna, Austria)
Purpose: The aims of this analysis were to investigate the
clinical features of extraskeletal osteosarcoma (ESOS) and
examine the outcome after multimodal therapy.
Methods: The Cooperative Osteosarcoma Study Group
database was searched for patients with extraskeletal
osteosarcoma. Eligible patients were included in a retro-
spective analysis of patient, tumour, and treatment related
variables and outcome. Scheduled treatment included
surgery and multi-agent chemotherapy as for conventional
osteosarcoma.
Results: 17 eligible patients identified, median age 44 years
(3–65). The thigh was the commonest tumour site. Two
patients had a history of previous malignancies and two
had primary metastases. Median follow up was 3.2 years
(range: 0.6–7.4 years) and at last follow up, eleven patients
were alive in complete remission, three patients were alive
with disease and three patients had died of disease.
Actuarial 3-year overall and event-free survival rates were
77% and 56%, respectively. Patients with macroscopically
complete surgical remission had an improved overall
survival (p¼0.0004).
Conclusions: The patients in this retrospective study had
a surprisingly good survival rate. This may be due to the
combination of multi-agent chemotherapy with surgery,
and we recommend this approach in the treatment of
ESOS.
P057
Late effects of treatment in rhabdomyosarcoma (RMS)
Y. Goshen, I.J. Cohen, S. Ash, J. Stein, R. Zaizov, I. Yaniv
(Department of Pediatric Hematology/Oncology, Schneider
Children’s Medical Center of Israel, Petah Tikva, Sackler
Faculty of Medicine, Tel Aviv University, Israel)
89 RMS patients treated between 1974–2003. 66 are
survivors. Median follow-up 163 months (14–372).
Treatment included surgery, chemotherapy (VAC,
VACA, VACAIE, IRS III, V) and radiotherapy (30–
60Gy). Five survivors died, 4 of second cancer, 1
committed suicide. Radiotherapy related: 9/10 orbital
tumors received x-rays, 4 developed hypoplastic orbit and
severe retinopathy, 7 ptosis, 7 cataract, and 6 keratocon-
juctivitis sicca. In parameningeal RMS 8/11 developed face
disfiguration, 4 hypoplastic jaws and teeth, 2 hypoplastic
Poster Abstracts 83orbit with retinopathy, 2 hypoplastic pharynx/larynx
with speech/eating disorders and 2 GH deficiency.
Recurrent hemorrhagic cystitis occurred in 2/5 bladder/
prostate tumors. 7–13cm leg shortening was observed
in 3/10 extremities tumors irradiated at age <5 years.
Chemotherapy related. Cardiac: 48 survivors received
doxorubicin, 21 received 350–450mg/m
2, six developed
cardiomyopathy, 4 with CHF. None at doses<350mg/m
2.
Fertility: 14/24 males>21 years examined were azoosper-
mic, (cyclophosphamide doses were 10.2–24gr/m
2, some
received ifosfamide), 8 were pre-pubertal at treatment.
4/13 with paratesticular RMS, developed ejaculation
disorder (surgery related). 4/15 females, developed ovarian
failure, 3 after irradiation. Second tumors developed in 6,
two AML and one T-ALL (14, 46, 30 months from RMS).
One who developed osteosarcoma 7 years post RMS,
belonged to a cancer family (L-F), BCC in one and thyroid
adenomas in another.
Conclusions: 1. RMS survivors require prolonged follow-up.
2. New protocols must relate to previous late effects.
P058
Status of surgical margins and prognosis in
adult soft tissue sarcomas of the extremities: A
series of 911 consecutive patients treated at a single
institution
A. Gronchi
1, M. Fiore
1, P.G. Casali
2, L. Mariani
3,
R. Miceli
3, P. Collini
4, L. Lozza
5 P. Olmi
5
(
1Department of Surgery, Istituto Nazionale per lo studio e la
cura dei Tumori, Milano, Italy,
2Department of Cancer
Medicine, Istituto Nazionale per lo studio e la cura dei
Tumori, Milano, Italy,
3Department of Biostatistics, Istituto
Nazionale per lo studio e la cura dei Tumori, Milano, Italy,
4Department of Pathology, Istituto Nazionale per lo studio e la
cura dei Tumori, Milano, Italy,
5Department of Diagnostic
Imaging and Radiotherapy, Istituto Nazionale per lo studio
e la cura dei Tumori, Milano, Italy)
Purpose: To explore the prognostic effect of microscopic
marginal status after surgery for extremity soft tissue
sarcomas.
Patients/methods: 911 consecutive patients surgically treated
over a 20-year span at a single referral center were
analyzed. Six hundred and forty-two were first seen with
a primary, and 269 with a locally recurrent tumor. All
patients underwent macroscopically complete resection.
Microscopic marginal status was negative (tumor >1mm)
in 748 patients and positive ( 1mm) in 163. Median
follow-up was 107 months.
Results: Patients with primary disease had a lower
disease-specific mortality in comparison to those first
viewed for recurrence (25% vs. 37% at 10 years). Size,
malignancy grade, depth, histotype and local recurrence
had a statistically significant prognostic effect at multi-
variable analysis, while microscopically positive surgical
margins had not, though a trend in favour of negative
margins was observed. However, an extra risk was
observed for patients with positive margins after 3–5
years (HR¼1.8 after 5 years versus 0.8 before 5 years).
In patients treated for a local recurrence, the prognostic
impact of positive margins was higher (HR¼1.6).
Conclusion: Positive surgical margins had a weak adverse
prognostic effect, which was more pronounced for those
patients escaping an early relapse. This would seem to
justify a policy of surgical adequacy in adult soft tissue
sarcomas, though clinical decision-making in borderline
presentations for conservative surgery might be reasonably
flexible and shared with the patient. Once a local relapse
has occurred, the impact of local treatments seems more
critical.
P059
Targeting of pediatric embryonal tumors
K. Hajdin, H. Witt, F. Niggli, B.W. Scha ¨fer,
M. Bernasconi
(University Children’s Hospital Zurich, Division of Oncology,
Zurich, Switzerland)
Rhabdomyosarcoma (RMS) is a highly malignant tumor
in childhood. Existing chemotherapies can be improved
by delivering drugs specifically to the tumor or its
vasculature. For identification of a specific surface target
on RMS tumor cells we used in vitro phage display
with libraries coding for cyclic random peptides. A 80-fold
enrichment was observed after five rounds of panning
as compared to the nonrecombinant phage. Sequencing
of the enriched phage population identified
phages displaying the peptides CQQSNRGDRKRC and
CMGNKRSAKRPC. Phages carrying these sequences
were tested on RMS, neuroblastoma cells and fibroblasts.
Both peptides showed an over 400 fold increase in binding
to RD cells and bound with lower affinity to normal
fibroblasts.
The RGD containing peptide confirmed the efficacy of
our screening: This motif mediates the interaction between
fibronectin and integrins avb5 and avb6, which are
up-regulated in tumor cells. The second peptide contains
a motif that was previously identified in an in vivo
screening for breast tumor targeting peptides and showed
specificity for tumor lymphatics. These results demonstrate
that surface markers on tumor cells are shared between
different tumor types. Furthermore, specific targets for
RMS can be identified, examined and used to improve
targeting and efficiency of small anti-tumor molecules.
P060
The linear body growth in height and body weight in
children with sarcoma during the two years after
initiating oncological therapy
T.F. Hajnzic, G. Stipancic, M. Cuk, M. Mataija
(Department of Pediatrics, Hematology and Oncology Unit,
University Hospital Sestre Milosrdnice, Zagreb, Croatia)
We wanted to estimate the incidence of delay in linear
body growth and body growth velocity in children with
sarcoma during initial, aggressive therapy. We evaluated
the effects of therapy on body height (BH) and body weight
(BW) in sarcoma-patients during the first six months of
therapy and eighteen months after initiating therapy.
3–6 month after initiating oncological therapy (protocol
CWS-96 P-Treuner, Koscielniak 1995), we found a
decrease of growth velocity and stagnation of BH in 79%
(15/19) pts. 2/3 (9/15) pts with total growth failure had
significant catch up and equalize linear BH. The some
quantitative changes were found in the pace of BW
changes. After discontinuation of therapy 90% of pts
(17/19) had no further loss in BW.
The problem of late sequeles of cancer and chemo-
therapy during childhood is increasing. Acute toxic effects
of therapy are mostly expressed during aggressive multi-
agent induction of chemotherapy and radiotherapy.
Our results show that large decrease in linear BH and
BW during first months of treatment in most cases is
temporary. It is less expressed during less toxic main-
tenance therapy and it disappears after discontinuation
of the therapy.
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3480 Cases of Dermatofibrosarcoma Protruberans
P.J. Chuba
2, M.R. Hamre
1, M. Mott
1, R. Severson
1,
D. Lucas
3
(
1Department of Radiation Oncology, St. John Health
Systems, Detroit, MI,
2Departments of Pediatrics and
Orthopedic Surgery, Wayne State University, Detroit, MI,
3Department of Pathology, University of Michigan,
Ann Arbor, MI)
Purpose: Dermatofibrosarcoma protruberans (DMFP) has
low metastatic potential. We reviewed cases accessioned by
the NCI SEER program 1973–1999.
Patients/methods: 3480 cases of DMFP were identified with
median follow-up of 7.25 years. Tumors were head and
neck (n¼532; 15.3%), upper extremity (n¼791; 22.7%),
lower extremity (n¼654; 18.8%), and truncal (n¼1457;
41.9%).
Results/discussion: Overall survival for localized DMFP was
95%. Head and neck tumors were more common in males,
Caucasians, and the elderly. Distant metastasis was rare
(n¼15; 0.5%) with 5 year survival of 56.4%. Tumor size
(p¼0.007), and tumor site (p¼0.0009) were both
statistically significantly associated with overall survival.
Head and neck tumors showed 91.4% five year overall
survival compared with 96.2%, 96.7%, and 95.1% of cases
affecting the upper extremity, lower extremity, and trunk,
respectively.
Conclusion: These data provide an epidemiologic basis for
the conservative management of DMFP with wide local
excision. Head and neck and larger tumors may have
decreased overall survival.
P062
Late relapses in patients with osteosarcoma: Study of
clinico-pathological parameters
E.I. Hauben
1,8, S. Bielack
2, R. Grimer
3, G. Jundt
4,
P. Reichardt
5, M. Sydes
6, A. H. M. Taminiau
7, P.C.W.
Hogendoorn
1
(
1Department of Pathology, Leiden University Medical Center,
Leiden, The Netherlands,
2University Chidren’s Hospital,
Department of Pediatric Hematology and Oncology, Munster,
Germany,
3Royal Orthopaedic Hospital, Birmingham, United
Kingdom,
4Institute of Pathology, Bone Tumor Reference
Center, Basel, Switzerland,
5Charite Campus Berlin-Buch,
Robert-Ro ¨ssle Klinik, Berlin, Germany,
6MRC Clinical
Trials Unit, 222 Euston Road, London NW1 2DA, UK,
7Department of Orthopaedic Surgery, Leiden University
Medical Center, Leiden, The Netherlands,
8Laboratory for
Pathology, Stichting Pamm, Eindhoven, Netherlands)
Purpose: To identify characteristic clinico-pathological
features of osteosarcoma patients with late relapse.
Materials/methods: Late relapse was defined as first local
recurrence or metastasis 5 years or more after diagnosis.
Patient data on age, gender, location of the tumour and
histological subtype were retrieved from 557 patients from
the European Osteosarcoma Intergroup, 1136 patients
from the Cooperative OsteoSarcoma Study and 550
patients of one of the authors (RG). Patients without
relapse after 5 years acted as a control.
Results: Thirty-three patients had late relapse. Age and sex
distribution did not differ from the control. Eighteen
(54%) patients had their osteosarcoma located in the tibia
or the fibula versus 170 patients (31%) in the control
group. Thirteen (39%) patients had an osteosarcoma
subtype other than conventional versus 158 (29%) in the
control group. This was largely due to the higher incidence
of chondroblastic osteosarcoma subtype in the late relapses
patient group.
Conclusion: The occurrence of late relapse does not appear
to be associated with age or gender. Patients with a
chondroblastic subtype of osteosarcoma or a location of
osteosarcoma in the tibia or fibula are at higher risk to have
a late relapse.
P063
High prevalence of Simian virus 40 in human
osteosarcoma of hungarian origin
S. Heinsohn
1, M. Szendroi
2, U. zurStadt
1, H. Kabisch
1
(
1Centre for Women‘s and Children’s Health, Clinic and
Policlinic for Peadiatric Hematology and Oncology University
Hospital, Hamburg, Germany,
2Department of Orthopedics,
Faculty of Medicine, Semmelweis University Budapest,
Hungary)
Recent studies have detected Simian virus 40 (SV40)
DNA in specific human tumors albeit with significant
discrepancies in frequency.
The evidence that SV40 might play a role in some
malignancies is mounting. The major SV40 oncoprotein is
the large tumor antigen (L-Tag) due to its transforming
activity and the capability to bind and to inactivate p53
and pRB or exerting an oncogenic potential by another
mechanism. We analysed 130 paraffin embedded osteo-
sarcoma (OS) from Hungary by a recently established
real time quantitative (RQ-) PCR assay and 42 OS from
Germany by different methods. Peripheral blood samples
from healthy people of both countries served as a control
group.
The RQ-PCR assay allowed the linear amplification of
101 to 105 copies in 500ng of genomic DNA. More than
102 SV40 copies were detectable in 75% of the Hungarian
OS compared to less than 5% of the German OS samples
as shown in our recently published data.
We found a weak SV40 positivity (less than 101)
in 32/166 (19%) and 2/149 (1.3%) peripheral blood
samples from Hungarian or German healthy volunteers,
respectively.
Our data demonstrate remarkable differences in the
incidence of SV40 sequences in OS of different geographic
origin with an overall low frequency in samples from
peripheral blood of healthy volunteers.
P064
Is proliferative activity a useful diagnostic means for
low-grade chondrosarcoma?
A. Helfenstein
1, S.Frahm
2, M. Krams
2, W. Drescher
1,
R. Parwaresch
2, J. Hassenpflug
1
(
1Department of Orthopedic Surgery, University of Kiel, Kiel,
Germany,
2Department of Pathology and Lymph Node
Registry, University of Kiel, Kiel, Germany)
Distinguishing enchondromas from highly differentiated
chondrosarcomas is a common problem in bone pathol-
ogy. Even though proliferation activity is known to be a
prognostic factor in chondrosarcomas, it is not a major
grading criterion as in other tumors. One reason may be
the large number of grade 1 tumors and their extremely
low proliferation rates. Proliferating cells are too rare and
often cannot be detected by the established markers.
The present study focused on a new and very
sensible marker of proliferation, a monoclonal antibody
to the nuclear minichromosome maintenance protein
6, named Ki-MCM6. We studied 17 chondrosarcomas
(12 grade 1) and compared them with 14 enchondromas
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Ki-67 and Repp86. Ki-MCM6 proved most effective at
identifying proliferative activity in grade 1 chondrosarco-
mas. The MCM6 labeling index correlated with tumor
grade and was significantly increased in grade 1 chon-
drosarcomas compared with enchondromas. The 5 cases of
progressive chondrosarcoma also had a significantly higher
MCM6 labeling index than the nonprogressive cases.
Furthermore, by means of the MCM6 labeling index,
many cases of progressive disease were recognized among
those of uncertain malignant potential, justifying their
classification as low-grade chondrosarcomas.
P065
Topotecan and cyclophosphamide for Ewing tumour
relapse
A. Hunold
1, N. Boldering
1, C. Liebscher
2, M. Paulussen
1,
H. Ju ¨rgens
1
(
1University Children’s Hospital, Department of Paediatric.
Haematology and Oncology, Mu ¨nster, Germany,
2Coordinating Centre for Clinical Trials (KKS), University
of Mu ¨nster, Germany)
Background: Every third Ewing tumour patient relapses.
Prognosis in relapse is poor. Standard chemotherapy
regimens for this situation are lacking.
Patients: Fifty-seven patients aged 3.2–49.5 (median 16.9)
years were treated with the combination of topotecan
(0.75mg/m
2/day, days 1–5) and cyclophosphamide
(250mg/m
2/day, days 1–5) following first (42) or second
(7) relapse or progression under first-line therapy (8).
Results: A median of 3 (range 1–14) topotecan/cyclopho-
sphamide courses were given. Twenty-three patients
(40.4%) showed complete (6) or partial (17) response,
13/57 patients (22.8%) had stable disease, 15/57 (26.3%)
progressed. Two (3.5%) patients showed a mixed
response. At completion of relapse therapy, 26/57 patients
were in complete (20) or partial (6) remission. One had
stable disease, 26 showed progression, information was
unavailable in 4 patients. Of the 19 relapse patients
achieving CR, 11 maintained remission (57.9%). At the
time of evaluation, after a median follow-up for survivors of
23.1 (range 7.8–59.8) months from the event prompting
topotecan/cyclophosphamide treatment, 14/57 patients
(24.6%) were in continous complete (13) or partial (1)
remission. Overall survival after 1 year was 59% (95%
CI 48.1–73.7%), after 2 years was 31.7% (95% CI
18.1–45.3%).
Conclusion: Topotecan/cyclophosphamide is active in
relapsed Ewing tumours and warrants further evaluation.
P066
Vacuum-assisted biopsy of soft tissue tumors:
A minimal-invasive alternative to incision biopsy
J. Jakob
1,M .H u ¨nerbein
1, S. Gretschel
1, P.-U. Tunn
1,
W. Schneider
2, P.M. Schlag
1
(
1Clinic for Surgery and Surgical Oncology, Charite ´-Campus
Buch, Berlin, Germany,
2Institut for Pathology, Helios-
Klinikum Berlin-Buch, Berlin, Germany)
Purpose: To assess feasibility and accuracy of vacuum-
assisted biopsy of soft tissue tumors and to compare the
results with surgical biopsies.
Patients and methods: Vacuum-assisted biopsy (8G) was
performed in 39 Patients with soft tissue tumors in local
anaesthesia between April 2004 and January 2005. As a
control group we reviewed all patients who underwent
incision biopsy for soft tissue tumors in general anaesthesia
between 2003 and 2004 (n¼42). Tumor localisation, size
and histology were similar in both groups.
Results: Vacuum-assisted biopsy was technically sucessful
in all patients and provided high quality specimen. All
specimen were adequate to make a diagnosis including
malignancy, tumor subtype and grade. Sensitivity and
specificity for malignancy were 100% and accuracy of
diagnosis was 96.7%. Incision biopsy provided adequate
specimen in all cases and sensitivity and specificity for
malignancy also were 100%. Accurate histologic diagnosis
was obtained in 97.5%. No relevant complications
occurred related to either biopsy. Regarding the effective-
ness of both techniques there were no differences.
Conclusion: Vacuum-assisted biopsy provides accurate
specimens for the diagnosis of soft tissue tumors and may
be considered as minimal-invasive alternative to incisional
biopsy.
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Osteosarcoma in children in Slovakia 1995–2004:
Diagnostics, treatment and results
I. Jenc ˘o
1,V .Z ˇilinek
2, P. Bician
3, I. Oravkinova ´
1,
E. Buba ´nska
3, E. Kaiserova ´
2
(
1Department of Children’s Oncology, Kosice, Slovakia,
2Clinic
of Children’s Oncology Bratislava, Slovakia,
3Department of
Children’s Oncology, Banska Bystrica, Slovakia)
The authors present a review of 66 patients with the
diagnosis of osteosarcoma at the age of up to 18 years,
treated in the Slovak Republic in three children’s
oncological centres (Bratislava, Banska ´ Bystrica and
Kos ˇice). They analyse the epidemiology and incidence of
osteosarcoma in this age group, they show the summary of
used chemotherapeutic regimes and the ways of local
treatment, showing EFS and OS results of the mentioned
group of patients.
P068
Reconstruction of a foot by free musculocutaneus
Latissimus dorsi flap and free tendon transfer after
resection of a large congenital fibro sarcoma in a
15-week-old infant. A case report
A. Jester
1, K.-L. Waag
2, B. Selle
3, G. Germann
1
(
1Klinik fu ¨r Rekonstruktive, Plastische- und Handchirurgie, -
Schwerbrandverletztenzentrum, BG-Unfallklinik Ludwigsha-
fen, Plastische und Handchirurgie der Universita ¨t Heidelberg,
Germany,
2Klinik fu ¨r Kinderchirurgie, Klinikum der Stadt
Mannheim GmbH, Mannheim, Germany,
3Klinik fu ¨r Kinder
und Jugendmedizin, St. Annastiftskrankenhaus Ludwigshafen,
Germany)
Purpose: To present the case of a 15-week-old infant after
microsurgical reconstruction of a large defect of the lower
leg due to fibro sarcoma.
Patient/method: After birth a 5.5 4cm large tumor was
observed on the dorsum of the right foot. Biopsy showed a
congenital fibro sarcoma. After four cycles of chemother-
apy a radical excision of the tumor at the age of 14 weeks
followed. The defect was temporarily covered. Histology
showed a complete excision of the tumor. To cover the
defect a musculocutaneus latissimus dorsi flap was taken,
the cutaneus part being large enough to cover the defect.
Extensor tendons were reconstructed with free tendon
transplants.
Discussion: Being confronted with a soft tissue tumor in
extremities, oncologists and surgeons have to decide, what
kind of strategy to follow. Radical excision usually involves
amputation or mutilation, or on the other hand, with the
86 Poster Abstractsaim of preserving extremities compromises oncological
principles of surgical radicality. Microsurgical techniques
are rarely applied to infants. This case shows that
reconstruction is rewarding. Plastic surgery adds an
important factor to pediatric oncology and surgery and
should be routinely integrated in oncological concepts.
P069
Cell surface charge modification by lipopolysaccharides
from rhodobacter capsulatus
D. Kabanov, S. Prokhorenko, I. Prokhorenko
(Molecular Biomedicine Laboratory, Institute of Basic
Biological Problems RAS, Pushchino, Russia)
The antineoplastic activities of bacterial lipopolysacchar-
ides (LPS) have been severely limited by the systemic
toxicity. LPS from Rhodobacter capsulatus (LPSRb.cap) is
nontoxic. The LPS intercalation into a cell membrane via
lipid A part is capable to disturb tumor homeostasis,
leading to tumor accessibility of immunological defence
mechanisms. Since malignant cells carry a higher density of
negatively fixed charges on their surfaces we have chosen
human erythrocytes (HE) as a model for our investigation.
We compare the influence of LPSRb.cap and LPS from
Escherichia coli O55:B5 (S-LPSE.coli) intercalation into
the erythrocyte membrane on HE electrophoretic mobility
(HEEM) at the saturation thereshold. HE (5 106/ml)
were incubated with corresponding LPS in PBS solution
(pH 7.4) at 37 C for 1h. The HEEM was measured with a
‘‘Parmoquant-2’’ device. The incubation with LPSRb.cap
and LPSE.coli (35mg/ml) decreased the HEEM by 5%
( 1.23 0.01; p<0.001) and ( 1.22 0.01; p<0.001)
respectively, as compared to the control ( 1.29 0.01).
The HEEM decreased by 11% ( 1.15 0.02; p<0.001)
at the LPSE.coli concentration of 70mg/ml, whereas the
same LPSRb.cap concentration decreased HEEM only by
5%. These results indicate that the effect of LPS on the
HEEM depends on the lipid A intercalation capacity and
the total charge of the LPS molecule. We suppose to test
LPSRb.cap for tumoricidal activity in tumor models in
vitro and in vivo.
P070
In vivo proton magnetic resonance spectroscopic
(PMRS) evaluation and its histopathological correlation
for characterisation of soft tissue sarcomas
Kar-Madhabananda
1, S.V.S. Deo
1, N.K. Shukla
1,
N.R. Jagannathan
2, U. Sharma
2, V. Kumar
2,
S. Datta Gupta
3, Dr. V. Deo
3, S. Thulkar
4
(
1Department of Surgical Oncology,
2IRCH, N.M.R,
3Department of Pathology,
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Purpose: To correlate in vivo proton MRS findings with
histopathological features of various soft tissue sarcomas.
Patients/methods: PMRS Study was performed at 1.5T with
a surface coil appropriate for the location of the lesions in
16 patients. Single-voxel (SVS) study has been done in 10
cases and chemical shift imaging (CSI) study characterised
the heterogeneity of the tumor in 6 cases by using point-
resolved spectroscopic sequence (PRESS) with echo
time TR¼2000/TE¼30 & 270msec. The choline peak
was identified at 3.2ppm in spectra. MRS results and
histopathologic findings were correlated and P<0.001,
considered being significant.
Results/discussion: Choline peak was found in 11 out of 11
patients with malignant soft tissue tumours where as one
patient with benign and four treated malignant soft tissue
tumour patients with no residual disease did not show any
choline. In vivo spectroscopy here shows sensitivity,
specificity, (p<0.001), positive predictive value, negative
predictive value and accuracy of 100% each. In vivo PMRS
study can differentiate the malignant from benign soft
tissue tumor, tumour heterogeneity (especially CSI) and
tumour activity in recurrent and/or residual soft tissue
sarcoma.
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Genitourinary soft tissue sarcomas located outside
bladder and prostate in children treated according to
the CWS-96 Protocol: Report from the Polish Paediatric
Solid Tumours Study Group
E. Bien, T. Stachowicz-Stencel, B Kazanowska,
A. Balcerska, W. Balwierz, A. Chybicka, A. Dluzniewska,
E. Drozynska, A. Kurylak, M. Matysiak, M. Krawczuk-
Rybak, M. Rychlowska, E. Solarz, B. Sopylo, D. Stencel,
J. Wachowiak, M. Wieczorek, W. Wozniak, M. Wysocki
(Oncological Centres of the Polish Paediatric Solid Tumours
Study Group: Gdansk, Wroclaw, Krakow, Bydgoszcz,
Warszawa, Bialystok, Poznan, Chorzow)
Aim: Analysis of therapy efficacy in non-bladder/prostate
genitourinary sarcomas in children treated from I’1997 to
VI’2003 with CWS-96 protocol in Poland.
Material and methods: 19 children (M/F: 15/4, age: 3mo–
17.5y; median 7.2y). Histopathology: RMS – 15 pts (RME
– 13), non-RMS – 4.
Results: Primary site: Testes – 9 pts, paratesticular region –
6, uterus – 2, vagina and ovary – 1 each. 63% presented
with low stage neoplasm (I – 7, II – 5). Primary tumour
exceeded 5cm and/or invaded surrounding tissues in 7 pts
(37%). 3 pts had regional, 2 pts – distant lymph nodes
metastases. Primary excision: complete in 7 pts, incom-
plete – 12 (microscopically – 5, macroscopically – 7). 10
pts received chemotherapy for high risk group, 5 –
standard, 4 – low. 6/7 pts with macroscopic tumour
residues responded to chemotherapy (CR – 4, GR – 2). 1
pt (stage III triton tumour of uterus) did not, entering CR
after mutilating delayed surgery. No other patient required
delayed tumour resection. Radiotherapy (23.5–54Gy) was
given to 8 pts. 3 pts developed local relapse (non-RMS
histology and incomplete primary excision in 2). 3 pts died
(16%): 2 due to neoplasm progression, 1 of neutropenia-
related sepsis. 16 pts are alive (84%) with mean follow-up
48months. The only permanent complications result
from surgery (uterus and bladder removal – 1 NR,
bladder resection after relapse – 1). Chemotherapy and
radiotherapy were accompanied by severe but transient
myelosuppression in HR group.
P072
Soft tissue sarcomas of bladder and prostate in children
treated according to the CWS-96 protocol: Report from
the Polish Paediatric Solid Tumours Study Group
T. Stachowicz-Stencel, E. Bien, B. Kazanowska,
A. Balcerska, W. Balwierz, A. Chybicka, A. Dluzniewska,
E. Drozynska, K. Katski, J. Kowalczyk, A. Kurylak,
J. Peregud-Pogorzelski, D. Stencel, B. Zalewska-
Szewczyk, J. Wachowiak, M. Wysocki
(Oncological Centres of the Polish Paediatric Solid Tumours
Study Group from Gdansk, Wroclaw, Krakow, Lublin,
Bydgoszcz, Szczecin, Poznan, Lodz, Poland)
Aim: Analysis of course, outcome and therapy complica-
tions in bladder/prostate soft tissue sarcomas in children
treated from I’1997 to II’2003 according to CWS-96
protocol in Poland.
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17y2mo; median 5.3y). Histopathology: RMS–20 pts
(RME–14), non-RMS – 2 pts. Results: 96% presented
with advanced neoplasm (III – 14, IV – 7). In 18pts (82%)
primary tumour exceeded 5cm; in 17 (77%) extended
beyond site of origin. Lymph nodes metastases were stated
in 6 (27%), distant metastases in 7 pts (32%). No patient
underwent primary complete tumour excision. All received
chemotherapy for high risk group. Response to chemother-
apy after 3 cycles: CR – 2 pts, GR – 6, PR – 3, OR – 2, PD –
4, missing data – 5. Delayed resections were performed
in 11 pts (mutilating – 7) proving complete in only 5.
Radiotherapy (32–50.4Gy) was given to 16 pts, mainly after
delayed incomplete surgery. 5 pts developed local relapse,
4 – continual PD. None of these 9 pts had ever complete
tumour resection. 9 pts died: 7 due to neoplasm progres-
sion, 2 of therapy complications (septic shock, ARDS). 13
ptsarealive(59%)withmeanfollow-upof42months.8had
bladder removed with continent ileal pouch formed in 4.
Chemotherapy and radiotherapy were accompanied
by severe but transient myelosuppression and infections.
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Young patients with metastatic soft tissue sarcomas:
Retrospective multicenter study of the polish pediatric
solid tumors group
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8Department of Pediatrics,
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9Department of Oncological Surgery in Children and
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11Department of Pediatric Oncology, Chorzo ´w,
Poland,
12Department of Pediatric Oncology, University of
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Objectives: The aim of this study was to present the 10-years
experiences of the Polish Paediatric Solid Tumors Group
in the treatment of children suffering from metastatic soft
tissue sarcomas.
Material and method: All included patients were treated
between 1991 and 2002 in 11 centres belonging to the
PPSTG. The children were treated according to
SIOP-MMT-91 protocol (23 patients), and according to
CWS-96 protocol (35 patients). Their age ranged between
1 and 217 months. In 4 patients undifferentiated rhabdo-
myosarcoma, in 23 embryonal rhabdomyosarcoma, in
18 alveolar rhabdomyosarcoma, in 9 PNET, in 1 EES,
and in 3 SS was diagnosed.
Results: Estimated 5-years event free survival for all patients
was 0.26 and estimated 5-years overall survival was 0.33.
Complete remission achieved 37 patients (63.8%). The
comparison of EFS between the patients treated with
different protocols revealed significantly better results of
therapy in the group treated according CWS-96 protocol
(p<0.005). The diagnosis, patient’s age, tumour’s locali-
sation and number of metastases significantly influenced
the prognosis when considered together (p¼0.03).
Conclusions: A good stratification system for disseminated
soft tissue sarcomas is still lacking. Patients with very poor
prognosis need a new therapy strategies as a currently
employed regimens are totally uneffective.
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Second recurrence of osteosarcoma: An analysis of 249
COSS patients
B. Kempf-Bielack
1, S. Bielack
1, D. Branscheid
4,
Th. Ku ¨hne
2, A. Zoubek
3,H .J u ¨rgens
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(
1Departments of Pediatric Hematology and Oncology,
University Children’s Hospital, Muenster, Germany,
2University Hospital Basel, Switzerland,
3St. Anna-
Kinderspital, Vienna, Austria,
4Thoraxklinik Grosshansdorf,
Germany)
Background: Information about the presentation and out-
come of second and subsequent osteosarcoma recurrences
is limited to case reports and small series.
Patients: 249 consecutive patients with second osteosar-
coma recurrences from the COSS trials were evaluated for
history, presentation, and outcome.
Results: Second recurrences occurred a median of 2.7/0.8
(min-max 0.5/0.1–15.9/9.8) years after the initial biopsy
and first relapse, respectively. After a median of 1.0
(0–16.8) years from the diagnosis of second recurrence
for all patients and 2.2 (0–16.8) years for 52 survivors,
5 and 10 year actuarial survival rates were 19%/12%.
The corresponding rates were 32%/24% for 119 patients
with a third surgical CR and 2%/0% for the others
(p<0.0001). The length of the second relapse-free interval
also correlated with outcome (p<0.0001). 24 patients
remained in third CR at last follow-up.
Conclusions: A subgroup of patients with second osteosar-
coma recurrences achieves long-term survival. A longer
second relapse-free interval and a third surgical remission
are positive prognostic indicators.
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Sixteen children with pleuropulmonary blastoma:
Results of the cooperative soft tissue sarcoma group
S. Kirsch
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Purpose: Analysis of data from patients with the extremely
rare pleuropulmonary blastoma (PPB) treated within the
CWS 81–96 trials.
Methods: Evaluation of 16 patients (8 boys and 8 girls)
with a median age of 3 years treated between 7/1982 and
88 Poster Abstracts10/2000 according to the CWS studies. Median follow up
of was 71.67 months (survivors).
Results: Initial resection of the tumor was carried out in 14
patients, which resulted in complete excision in 7 cases (3
IRS I, 4 IRS II), but macroscopic tumor residuals (IRS III)
in 8 patients. The subsequent chemotherapy consisted
of the typical treatment scheme for high risk sarcoma.
4 patients were irradiated with dosages between 18 and
45 Gray and 6 patients underwent a secondary resection.
The 5-years overall and event free survival of the collective
are 70.1%. Both patients with progressive disease (one of
them initial stage IV) died of disease, but 12 of the 14
patients, who reached complete remission did not develop
local recurrence and are alive (75%).
Discussion: Pleuropulmonary blastoma is a very rare lung
malignancy in children. Though prognosis is reported to be
very poor, the outcome of patients treated according to the
CWS-guidelines shows promising results.
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Pulmonary nodule at fluorine-18 deoxyglucose positron
emission tomography (FDG-PET) in a child with Ewing’s
Sarcoma
1E. Kısmet
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(
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Ewing’s sarcoma is one of the childhood tumors that may
metastasize to the lungs. The pulmonary metastasis may be
the first presenting sign of the tumor or encountered
during chemotherapy or at follow-up. Positron emission
tomography (PET) using the glucose analogue F-18-
Fluorodeoxyglucose (FDG) is a promising new method
for non-invasive differentiation of benign and malignant
solitary pulmonary nodules in patients with malignancy.
We report a patient with Ewing sarcoma with a pulmonary
nodule without abnormal accumulation of FDG and
pulmonary fibrosis with false positive accumulation.
A 4-year-old boy who had been treated for Ewing
sarcoma had pulmonary nodule considering metastasis at
follow-up by computed tomography. FDG-PET scan was
negative but there was abnormal accumulation at the other
lung where a pulmonary nodule excised before and proven
histopathologically benign. Although the nodule that was
negative at FDG-PET disappeared in a one-month-period
there was no change on CT at the lung where accumula-
tion of FDG was detected. We conclude that FDG-PET is
helpful to differentiate malign pulmonary nodules from
benign ones but false positive results should be kept in
mind especially if there are fibrotic changes secondary to
recent pulmonary operation.
P077
Role of caspase 8 in death receptor-mediated apoptosis
in Ewing’s sarcoma
U. Kontny, A. Lissat, R. Klein, T. Vraetz, R. Klein,
C.M. Niemeyer
(Division of Pediatric Hematology and Oncology, Department
of Pediatrics and Adolescent Medicine, University of Freiburg,
Germany)
Purpose: The prognosis for patients with metastatic or
relapsed Ewing’s sarcoma is poor. Characterizing the
pathways leading to cell death in this tumor could lead to
the development of new rational therapeutics. In this study
we have analyzed the death receptor pathways in Ewing’s
sarcoma.
Methods: Nine Ewing’s sarcoma cell lines were incubated
with the death ligands Fas ligand or TRAIL. Apoptosis
was measured by flowcytometry. Expression of caspases,
bcl-2 and IAP-family members was studied by RNA-
multitemplate protection assay and immunoblot. Transient
and stable transfection of caspase 8 were done using
lipofectamine.
Results: Seven out of nine Ewing’ sarcoma cell lines studied
were sensitive to TRAIL-mediated apoptosis. The two
TRAIL-resistant cell lines were found to be caspase 8-
deficient. Incubation of resistant cell lines with interferon-
gamma could restore sensitivity to TRAIL-mediated
apoptosis. Interferon-gamma induced expression of cas-
pases 1, 7, 8, bak, and downregulated the expression of
surviving. TRAIL-induced apoptosis could be inhibited
by a caspase 8-specific inhibitor, however, transfection of
caspase 8 into caspase 8-deficient Ewing’s sarcoma cells
did not restore sensitivity to TRAIL-mediated apoptosis.
Discussion: While the expression of caspase 8 is essential for
death-receptor mediated apoptosis, the sensitizing effect
of interferon-gamma goes beyond the induction of caspase
8-expression.
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Outcome of patients with pulmonary metastasis of soft
tissue sarcomas following surgical resection
R. Kopp
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Introduction: Pulmonary metastasis are observed in patients
with soft tissue sarcomas (STS). Surgical resection of
pulmonary metastasis is still the most promising treatment
based on the minor response of soft tissue sarcomas
following radio- or chemotherapy.
Patients and methods: Between 1990 and 2003 we have
treated 55 patients (25 female, 32 male; mean age: 48
years) for pulmonary metastasis of soft tissue sarcomas with
the intention of curative resection. The following para-
meters were retrospectively analysed: age, gender, primary
treatment, tumor localisation, histopathological type
and grading, size and number of metastasis, tumor-free
interval, multiple resections and adjuvant chemotherapy.
Results: Complete resection of pulmonary metastasis
detectable at the time of operation was achieved in 44
patients (80%). Overall-survival after 5 years was 37.1%
(follow-up: 27.8 months). Perioperative mortality was
2.6%. Minor complications including wound infection,
hematothorax or pneumonia were observed in 5.2%.
Survival was associated with evidence of complete tumor
resection (43% vs. 18%; p<0.004), size of metastasis
(<4cm) and less invasive operative procedures.
Conclusions: Operative treatment of pulmonary metastasis
in patients with soft tissue sarcomas is an important
therapeutic option associated with low perioperative
morbidity and mortality and acceptable survival.
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Primary malignant sarcomas of the heart and great
vessels – a single center experience
H. Aebert, B. Kosan, M. Rudert, R. Teichmann,
W. Budach, J.T. Hartmann
(Medizinische Klinik II, Universita ¨tsklinikum Tu ¨bingen,
Germany)
Sarcomas of the heart are very rare entities. The most
common subtypes included leiomyo- and angiosarcoma.
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locally advanced or metastatic stage at diagnosis.
Between 6/2001 and 10/2003 12 pts with primary
sarcoma of the heart or great vessels have been identified
in the local sarcoma registry. Median age was 43 years
(22–72). The majority of pts have been referred to
the University Hospital after initiation of treatment, e.g.
surgical incomplete resection. All pts were symptomatic
with reduction of vitality, anorexia, dyspnoea, or neurolo-
gical symptoms at the time of reception. Tumors were
located in atrium [(n¼5), left (3)/right (2)], Art. pulmo-
nalis (n¼3), Aorta (n¼2), pericardium, left chamber,
(n¼1 each). Six pts presented with localised disease and
5 pts underwent curative intended resection. One pt was
considered locally irresectable. Six pts had advanced
disease including brain mets (4 pts), lymph nodes involve-
ment (2), lung mets (3) and liver mets (2). Five of these
6 pts underwent palliative (incomplete) resection to relieve
the physiologic effects of the tumor on the heart or the
arteria. Three out of 5 pts with curative intended surgery
have developed local recurrence within 6, 8 and 25 mos
despite adjuvant treatment. One single pt with an PNET
sarcoma subtype is still alive without relapse after comple-
tion of pre- and postoperative chemotherapy and another
pt with a paraganglioma is still disease-free after tumor
resection only.
Palliative chemotherapy including adriamycin and
ifosfamide has been applied in 7 pts and 4 pts responded
to treatment (1 PR, 3 SD). Palliative radiation included
3 pts with brain metastases and a single pt with progressive
primary tumor. At a median follow up 13 mos (2–28) 2 pts
had NED, 3 pts are alive with disease and 7 pts have died
due to tumor progression.
In conclusion, pts with primary sarcomas of the heart
and the great vessels were of young age, and half of
them presented with locally or distant advanced disease.
These pts should preferentially be referred to a tertiary
Cancer Center immediately after diagnosis without
preceding treatment attempts. Although the majority of
pts cannot treated curatively due to the delay in diagnosis,
an optimized treatment approach including neoadjuvant
chemo-/radiotherapy might enhanced the rate of
complete resection depending on the histologic subtype
and responsiveness to treatment.
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New pulmonary nodules in patients with malignancies:
An retrospective analysis
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Introduction: In patients with a malignant disease newly
discovered pulmonary nodules are highly suspected of
metastases or lung cancer. The purpose of our retro-
spective study is to determine the proportion of primary
and secondary malignant pulmonary lesions.
Patients: Between 1995 and 2003 87 patients (33 male,
54 female), mean age 64 years (range 29–78) underwent
surgery because of suspected lung metastases in our
hospital. The underlying malignancies were breast cancer
(25%), colorectal cancer (18%), prostate cancer (11%),
renal cancer (8%), melanoma (7%), sarcoma (5%) and
others (26%). Seven patients had two and one three
malignancies in their medical history. According to
oncologic standards surgery was performed in VATS
technique in (44%) cases. The remaining patients (56%)
underwent thoracotomy.
Results/discussion: Histology showed malignancy in 37%.
In 26% primary lung cancer was diagnosed, only 11% had
metastases and 63% had benign or inflammatory nodules.
65% of the lung cancer cases and 78% with metastases
were asymptomatic. The lung lesions were accidental find-
ings due to examinations or follow-up. Lung cancer was
associated with colorectal cancer in 5, breast cancer in 4,
prostate cancer in 3 patients. No perioperative mortality
occurred. We conclude that newly diagnosed pulmonary
nodules should be resected and histologically examined.
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Limb salvage by plastic reconstruction in patients with
soft tissue sarcoma of the lower extremity
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Introduction: Reconstruction of the body surface is a major
focus in modern surgery for soft tissue sarcoma (STS).
Plastic reconstruction often facilitates radical oncologic
resection and conservation of extremity function.
Methods: Analysis of prospectivly collected data from adults
with STS of the lower limb and plastic reconstruction
(1988–2004). Assessment focused on type of reconstruc-
tion, tumor manifestation, oncologic outcome and extrem-
ity function (MSTS-score). SAS for statistical analysis.
Results: 45 (mean age 48 years, 1.5:1 male:female) of 128
patients needed 52 plastic reconstructions after STS-
resection. 46% presented with local recurrence, 54% with
primary tumors. Histologically liposarcoma and malignant
fibrous histiocytoma dominated. Defects were located
at groin and thigh (64%), knee (21%) and lower leg
(13%). Reconstruction was achieved by pedicled flaps
(36%), random pattern flaps (25%), split-thickness
grafts (18%) and free microvascular transplantations
(6%). 62% received intraoperative radiotherapy. 8%
major, 34% minor complications, 27% reoperations and
no lethality or major amputation were observed. Local
tumor control was 81%. At a mean follow-up of 73 month
49% died. Functionality was high (MSTS-score 70.3%)
Discussion: Plastic reconstruction was necessary in 1/3 of
patients after limb preserving STS-resection. Long-term
functional results and good local tumor control underline
the importance of plastic surgery in a multimodality
treatment strategy for STS of the lower limb.
P082
The relationship of cytogenetics findings with clinical
outcomes in Ewing sarcoma
J. Kruseova ´, E. Stejskalova ´, R. Kodet, D. Sumerauer,
J. Stary ´
(Departments of Pediatric Hematology and Oncology and
Pathology, Motol Hospital, Prague, Czech Republic)
Purpose: To show the relationship of cytogenetics findings
with clinical outcomes in Ewing sarcoma.
We analysed eleven patients. Four of them had a trisomy
of chromosome 8 and one a trisomy 12: primary disease
1x scapula (4.5ml), 2x pelvis (114, 283ml), 2x chest (423,
1036ml). One patient had metastatic dissemination in his
skeleton and died of disease progression. Others didn’t
have metastases and achieved CR (median follow-up 43
months). A patient with chest tumours relapsed 13 months
after the end of treatment, tumours appearing in his
90 Poster Abstractslungs. He is currently undergoing second line treatment.
Unbalanced t(1.16) was ascertained in two patients – one
had shoulder blade involvement (2578ml), with general-
isation into lungs and upper-clavicular lymph nodes. He
had only two copies of the der(16) t(1.16) but no other
aberration. He died during treatment of disease progres-
sion. The other one had primary disease in his femur
(1165ml) with pulmonary metastasis. He is alive with
untreatable disease progression. Along with the t(1.16)
he had a modal number of 51–56 chromosomes, two
markers, a deleted 5p and 22q chromosome and gains of
chromosomes 8 12 20 and 21. We found no correlation of
trisomy 8 and 12 and clinical outcome, but the presence
of the t(1.16) in our patients karyotype predicted refractory
disease.
P083
Comparison of treatment concepts for extraosseous
Ewing Tumours (EET) within consecutive trials of two
GPOH cooperative study groups
R. Ladenstein
1,U .P o ¨tschger
1,H .J u ¨rgens
2,
M. Paulussen
2, E. Koscielniak
3, J. Treuner
3
(The GPOH Cooperative Soft Tissue Sarcoma and Ewing
Tumour Study Group,
1St. Anna Kinderspital Wien, Austria,
2Universita ¨tskinderklinik Mu ¨nster, Germany,
3Olgahospital,
Stuttgart, Germany)
Purpose: Comparison of strategies in EET patients (pts)
treated within two GPOH Cooperative Study Groups
(CSG).
Patients/methods: 236 pts with EET are evaluable: 113 pts in
CWS and 123 pts in ETS studies. The median age at
diagnosis is 15 years (6 months–58yrs); 133 pts are males.
Primary sites were extremities in 62 pts and central sites
in 174 pts. Chemotherapy was VACA/CE-VAIA(VIDE)
based in both CSG. 85 pts had initial surgery (Sx), 56 pts
later Sx. Radiotherapy (median dose 45Gy) was given in
141 pts (in 87 pts in addition to Sx).
Results: The 5 year overall survival rate (OS) of 236 patients
is 60% (EFS 49%). OS in non-metastatic disease (NMD)
is 70% and 33% with metastases at diagnosis (60 pts)
(p<0.001). Age significantly influenced OS rate: pts
<14yrs (103 pts) 70%, 14–18yrs (54 pts) 57%, >18yrs
(79 pts) 47%. Best outcome in NMD was observed in
studies CWS91 (OS 84%) and EuroEwing99 (OS 75%)
followed by CWS-concepts (study 96: OS 71% and studies
81/86: 69%) and earlier ETS-concepts (studies 91/92: OS
67% and studies 81/85/86: OS 38%)
Conclusions: Induction treatment intensity (EuroEwing99)
and early local control measures (CWS concepts) appear
equally important.
P084
Nephrotoxicity of platinum derivatives in paediatric
sarcoma patients
T. Langer
1, W. Sto ¨hr
1, M. Paulides
1, S. Bielack
2,
H. Ju ¨rgens
3, J. Treuner
4, R. Rossi
5, J.D. Beck
1
(
1LESS Centre, University Hospital for Children and
Adolescents, Department of Paediatric Oncology, Erlangen,
Germany,
2Osteosarcoma Trial Centre, University Children’s
Hospital Muenster, Department of Paediatric Haematology
and Oncology, Muenster, Germany, Ewing’s Sarcoma Trial
Centre, University Children’s Hospital Muenster,
3Department
of Paediatric Haematology and Oncology, Muenster, Germany,
4Cooperative Soft Tissue Sarcoma Study, Olgahospital,
Department of Paediatric Oncology, Stuttgart, Germany,
5Hospital for Children and Adolescents, Klinikum Neuko ¨lln,
Berlin, Germany)
Background: Platinum derivatives are known for their
nephrotoxicity. They can impair, to a different degree,
glomerular function and induce renal magnesium loss.
There are only a few prospective studies with repeated
measurements following cessation of antineoplastic therapy
in children and adolescents.
Patients and methods: 651 sarcoma patients were investi-
gated prospectively for nephrotoxicity in a multicentre
trial. The mean period of follow-up was 2.1 1 years.
Renal function was examined by testing plasma
magnesium, plasma creatinine and GFR estimated by
the Schwartz formula. We evaluated the incidence,
dependencies and the course of impairments.
Results: We found no platinum-induced impairments of
glomerular function. Frequency of hypomagnesaemia after
cisplatin therapy was 12.9% (95%-CI: 7.4–20.4%) and
after carboplatin therapy 15.6% (95%-CI: 5.3–32.8%),
in comparison with 5.1% (95%-CI: 2.4–9.5%) in patients
without any treatment with platinum derivatives. In all
patients the frequency of impairments decreased with
further follow-up, but the mild decrease of plasma
magnesium in platinum-treated patients persisted through-
out the study period.
Conclusion: Nephrotoxicity after treatment with cisplatin
and carboplatin was mild in our study. Further studies
have to show if hypomagnesaemia is permanent and if it
will result in any clinically relevant impairment.
P085
Response rate of fibrosarcoma cells to cytotoxic drugs
on the expression level correlates to the therapeutic
response rate of fibrosarcomas and is mediated by
regulation of apoptotic pathways
M. Lehnhardt
1, L. Klein-Hitpass
2, C. Kuhnen
3, H.H.
Homann
1, A. Daigeler
1, H.U. Steinau
1, L. Steinstraesser
1,
O. Mu ¨ller
4
(
1Department of Plastic Surgery, Burn Center, Hand surgery,
Sarcoma Reference Center BG University Hospital
Bergmannsheil, Ruhr University Bochum, Germany,
2Institute of Cell Biology (Tumor Research), IFZ, University
of Essen, Germany,
3Institute of Pathology, BG University
Hospital Bergmannsheil, Ruhr University Bochum, Germany,
4Tumor Genetics Group, Max-Planck-Institut fu ¨r molekulare
Physiologie, Dortmund, Germany)
Background: Because of the high resistance rate of
fibrosarcomas against cytotoxic agents clinical chemother-
apy of these tumors is not established.
Methods: HT1080 fibrosarcoma cells were exposed to the
chemotherapeutic agents doxorubicin, actinomycin D or
vincristine. Gene expression patterns were analyzed by
microarray analysis and validated by quantitative real-time
PCR.
Results: The analysis of the microarray data resulted in
3.309 (actinomycin D), 1.019 (doxo) and 134 (vincristine)
probe sets that showed significant expression changes. For
the RNA synthesis blocker actinomycin D, 99.4% of all
differentially expressed probe sets were down-regulated. In
comparison, probe sets down-regulated by doxo comprised
only 37.4% of all genes effected by this agent. Closer
analysis of the differentially regulated genes revealed
that doxo induced cell death of HT1080 cells mainly
by regulating the abundance of factors mediating the
mitochondrial apoptosis pathway.
Conclusions: The response rates on the gene expression
level, i.e. the number of genes regulated by the drugs
correlate to the clinical effectiveness of the drugs. Doxo
seems to exert its cytotoxic mechanism by regulating genes,
which are involved in several different apoptosis regulating
Poster Abstracts 91pathways. The exact knowledge of the genes affected by the
drugs will help to understand the diverse modes of soft
tissue sarcoma cell death in response to cytotoxic therapies.
P086
Feasibility of chemosensitivity testing in soft tissue
sarcomas
M. Lehnhardt, A. Daigeler, L. Steinstraesser,
H.H. Homann, H.U. Steinau
(Department of Plastic Surgery, Burn Center, Handsurgery,
Sarcoma Reference Center BG University Hospital
Bergmannsheil, Ruhr University, Bochum, Germany)
Background: The role of chemotherapy in soft tissue
sarcomas is not clearly defined and is largely restricted
to clinical trials.
Methods: The objective of this study was to gain additional
information about the chemosensitivity of soft tissue
sarcomas to seven 7 different chemotherapy agents as
single drugs and 4 combinations. Therefore we used an
established ATP based in-vitro testing system and
examined 50 soft tissue sarcomas. Chemosensitivity was
assessed using a luciferin-luciferase-based luminescence
assay providing individual chemosensitivity indices for
each agent tested.
Results: The sensitivity varied widely according to the
histological subtypes. The tumors state of cellular dedif-
ferentiation played a crucial role for the efficiency of the
chemotherapeutic agents. The sensitivity also depended on
the presentation of the sarcoma as a primary or recurrent
tumor. The highest sensitivity was demonstrated for
actinomycin D. The combination of actinomycin D and
ifosfamide yielded a high sensitivity in 76%. Doxorubicin
as a mono-therapy or in combination with ifosfamide
achieved high sensitivity in 70% and 72%, respectively.
Conclusions: Chemosensitivity testing is feasible in soft
tissue sarcomas. It can be used to create sensitivity and
resistance profiles of established and new cytostatic agents
and their combinations in soft tissue sarcomas.
P087
Allocation of soft tissue sarcoma patients of extremities
and wall: 10 years overview
S. Leinung, P. Wuttke, M. Scho ¨nfelder, P. Wu ¨rl
(Surgical Clinic, University of Leipzig, Germany)
Patients and methods: Over a 10-year period, the patients
referred to us with a soft tissue tumor (suspicios of soft
tissue sarcoma only) of the extremities and wall of the
trunk were analyzed retrospectively. The aim of the present
study was to investigate the differential diagnoses, the
number of incompletely operated soft tissue sarcoma
(STS), and local recurrences.
Results: A total of 490 patients with an soft tissue tumor
(STT) were referred to our department, and of these
patients 55% were diagnosed with an STS. In addition to
STS, the differential diagnoses for STT included 2%
lymphomas, 18% isolated carcinoma metastases, 18%
benign mesenchymal tumors, 5% inflammatory processes,
and 2% old hematomas. Only 45% of the STS had not
undergone previous surgery. Of these, 15% had been
incompletely resected, while 39% of the STS patients were
admitted with a local recurrence.
Discussion: In view of the numerous differential diagnoses
of an STT, both the possibility of an STS and also
carcinoma manifestations in the soft tissues should receive
more attention. With the aim of reducing the relatively
high number of STS re-resections and local recurrences,
the treatment of patients with suspicious STT should be
reserved for a specialized center.
P088
Gastrointestinal stromal tumours: Results of surgical
therapy
C. Leowardi, U. Hinz, M.N. Wente, T. Kremer,
G. Mechtersheimer, H. Friess, C. Herfarth,
M.W. Bu ¨chler, M.H.M. Schwarzbach
(Department of Surgery and Institute of Pathology, University
of Heidelberg, Germany)
Purpose: Surgical treatment is the standard therapy for
resectable gastrointestinal stromal tumours (GIST). The
aim of this study was to analyze the results of surgical
therapy under consideration of histopathological reclassi-
fication of this tumour entity.
Patients/methods: Observational study from a single center
during a representative period. All patients who underwent
surgery for primary or recurrent GIST between 1992 and
2004 were included. Immunohistochemical reclassification
was performed. Clinical data were gathered prospectively
in a computerized registry and subjected to univariate and
multivariate analyses together with the follow-up results.
Results: With a median age of 57 years, 49 male and 36
female patients (n¼85) were referred for 71 primary
tumors and 14 recurrences. Primary tumours were mainly
located in the stomach (n¼41) and in the small bowel
(n¼18). According to Fletcher-classification high-risk
tumours dominated (53%), only in these tumours recur-
rent disease was observed after surgery (19%). Complete
resection could be achieved in 84.5%. With a median
follow-up of 50 months, 5-year-survival-rates of patients
with complete resected tumours (91.5%) and patients
with primary tumours at first presentation (84.5%) were
significantly better than those of patients with incomplete
resected tumours and those who presented with recurrent
disease (p<0.0001, p¼0.0004).
Discussion: Complete surgical resection is of decisive
prognostic relevance and represents a potentially curative
treatment for the majority of patients with resectable
GIST.
P089
Malignant vascular tumors: Clinical presentation,
surgical therapy and long-term prognosis
C. Leowardi
1, U. Hinz
2, M.N. Wente
1, T. Kremer
1,
G. Mechtersheimer
3, F. Willeke
1, H. Friess
1, C. Herfarth
1,
M.W. Bu ¨chler
1, M.H.M. Schwarzbach
1
(
1Department of Surgery,
2Unit for Documentation and
Statistics,
3Institute of Pathology, University of Heidelberg,
Heidelberg, Germany)
Purpose: Clinical knowledge of malignant vascular tumors
(MVT) in adults is limited. The aim here was to analyze
clinical presentation, surgical therapy, and prognosis.
Patients/methods: Observational study from a single center.
Patients with primary or recurrent MVTs between 1988
and 2004 were included.
Results: Of 568 sarcoma patients 43 presented with a MVT
(7%). With a median age of 53 years, 24 males and 19
females were referred for 30 primary tumors and 13
recurrences. Tumors were diagnosed in the extremities
(n¼16), trunk (n¼3), abdomen (n¼15), retroperito-
neum (n¼7), and thyroid gland (n¼2). Subgrouping
revealed 22 angiosarcomas (51.2%), 9 malignant heman-
giopericytomas (20.9%), 8 malignant epiheloid hemangio-
endotheliomas (18.6%), and 4 lymphangiosarcomas
92 Poster Abstracts(9.3%). Median overall survival was 21.4 months with 2-,
5-, and 10- year overall survival rates of 41.5%, 38.3%, and
18.8%, respectively. Patients with tumors of the extremities
and trunk and patients without metastasis at presentation
had a better prognosis than those with abdominal or
retroperitoneal tumors (p¼0.0122) and patients with
metastasis at presentation (p¼0.0187).
Discussion: MVTs are rare, presenting with various clinical
symptoms and an ubiquitous occurrence. Their clinical
course is aggressive and thus prognosis is poor. Complete
surgical resection represents a potentially curative treat-
ment, especially for tumors of the extremities and trunk.
P090
Survival and prognostic factors in patients with
pulmonary metastases from soft tissue sarcomas
K.A. Gawad, L. Liebl, F. Elson, J. Kaifi., E. Yekebas,
J.R. Izbicki
(Department of General-, Visceral- and Thoracic Surgery,
University Medical Center Hamburg-Eppendorf, Germany)
Background/aim: Few studies on the role of pulmonary
metastasectomy in patients with soft tissue sarcomas (STS)
are currently available. The small number of such studies is
mainly noncontemporaneous and predate a more radical
approach including metastasectomy in cases of multiple
metastases as well as repeat resection. The aim of our study
was to evaluate the overall prognosis after such surgery and
to identify clinically relevant prognostic factors.
Patients/methods: Of 475 STS patients prospectively fol-
lowed in our database 48 patients underwent 67 metasta-
sectomies. Further studies were limited to such patients
with at least 3-years follow up.
Results: 26 patients (12 female/14 male) underwent 37
metastasectomies between 1990 and 2002. 7 (27%) of
those patients underwent at least one repeat resection for
recurrent metastases. 19 were more than 2cm whereas 18
were less than 2cm in diameter. Size of metastases, extent
of resection and extension of disease (solitary or multiple
metastases) were identified as possible independent prog-
nostic factors. The data suggest tumor size as one relevant
prognostic factor: Patients with a maximum metastasis size
of 2cm or less with a longer disease free interval.
Conclusion: Detailed subgroup analysis may isolate
patients with particular benefit of resection of pulmonary
metastasis.
P091
Prognostic relevance of FDG-PET in patients with
malignant peripheral nerve sheath tumors (MPNST)
and neurofibromatosis type-1 (NF-1)
K.A. Gawad, L. Liebl, W. Brenner, R. Buchert,
A. von Daimling, C. Hagel, R.E. Friedrich, V.F. Mautner
(Departments of General-, Visceral- and Thoracic Surgery,
Nuclear Medicine and Mund-, Kiefer-, Gesichtschirurgie,
University Medical Center Hamburg-Eppendorf, Germany)
The aim of this study was to assess the potential of FDG-
PET for risk assessment and outcome prediction in NF1
patients with MPNST.
Methods: F-18-fluorodeoxyglucose-PET imaging was per-
formed in 17 patients with NF-1 and MPNST prior to
therapy. The mean follow-up time was 18 (2–53) months.
SUV was calculated for each tumor and correlated to
tumor grade and patient outcome.
Results: 10 of 17 patients died within 11 (4–14) months.
3 patients had an SUV <3 (2.1–2.8; tumor grade II
each). None of these patients developed metastases during
follow-up (31–53 months). 14 patients had an SUV >3,
4 of which had a tumor grade II (SUV 4.0–11.0). 3 of these
4 died, 1 patient is still alive (follow-up: 2 months).
The remaining 10 patients had a tumor grade III (SUV
3.2–11.6). 7 of these 10 patients died, 3 are still alive
(follow-up: 10, 20 and 41 months). In Kaplan-Meier
analysis, patients with an SUV >3 had a significantly
(p¼0.034) shorter mean survival time of 15 compared to
45 months in patients with an SUV <3. Tumor grading
did not reveal differences in survival time between grades
(p¼0.249).
Conclusion: Pretherapeutic tumor SUV obtained by FDG-
PET was a significant parameter for risk assessment and
prediction of survival in NF1 patients with MPNST.
P092
Chemotherapy in alveolar soft part sarcoma: Single
institution experience and review of the literature
T. Lindner, D. Pink, P.-U. Tunn, P.C. Thuss-Patience,
A. Kretzschmar, P. Reichardt
(Department of Hematology and Oncology, Charite ´ Campus
Buch, HELIOS-Klinikum Berlin-Buch, Berlin, Germany)
Background: Alveolar soft part sarcoma (ASPS) is a rare
tumour. Published series about treatment and outcome are
scarce. Conclusive data about response to chemotherapy
are not available.
Results: From our registry containing 830 patients, we
identified 9 patients with ASPS. From the literature 100
cases of adult patients and 15 children with sufficient data
about chemotherapy were identified. Response to 1st-line
chemotherapy in 124 patients was: CR 2%, PR 4%, SD
44%, PD 49%. 316 patients with stage IV disease were
evaluable for the metastatic sites. The incidence of brain
metastases is 30.7% (97/316). Brain metastases were
detected at a median interval of 37 months (range 0–396
months) after primary diagnosis. The median survival after
diagnosis of brain metastases is 19 months. The median
survival for patients with metastases disease treated by
chemotherapy is 45þ months.
Conclusions: ASPS shows a high incidence of brain
metastases, at least 3 times higher than that of other soft
tissue sarcomas. Chemotherapeutic regimens well estab-
lished for the treatment of soft tissue sarcomas lack efficacy
in ASPS. Staging of metastatic ASPS should routinely
include imaging of the brain. ASPS should not be treated
with chemotherapy outside of controlled clinical trials.
P093
Geldanamycin induces growth arrest and apoptosis of
embryonal and alveolar rhabdomyosarcoma cells
M. Majka, E. Lesko, M.Z. Ratajczak
(Department of Transplantation, Jagiellonian University
Medical College, Cracow, Poland)
Geldanamycin (GA) is a new potential drug that has been
shown in various cell systems to inhibit tumour cells
proliferation, survival and motility by binding to various
proteins including heat shock proteins that play critical role
in tumor cells growth.
In this study we looked at the GA effect on rhabdo-
myosarcoma (RMS) cell lines. In our study we used
embryonal (ERMS) and alveoral (ARMS) cell lines. We
assessed effect of GA on RMS cells proliferation,
apoptosis, cell cycle and motility.
We found that GA had an anti-proliferative effect on
RMS cells by inducing their apoptosis and causing cell
Poster Abstracts 93cycle arrest. The ERMS cells were more susceptible to
GA treatment.
RMS often gives distant metastasis to various organs
including bone marrow. RMS cells respond to HGF with
increase motility and chemotaxis. We tested if GA could
inhibit HGF-induced chemotaxis of RMS cells. We found
that GA was able to inhibit strongly chemotaxis of RMS
cells toward HGF gradient in dose dependent manner.
New therapies are still needed in RMS disease. Our data
shows that GA could be a potential new drug in RMS
treatment. It blocks RMS proliferation, decreases its
survival and what is very important inhibits chemotaxis of
tumour cells.
P094
TNM staging in Ewing tumors: A recommendation
from the (EI)CESS/EE 99 studies
D. Manner, C. Liebscher, A. Hunold, M. Paulussen,
H. Juergens
(University Children’s Hospital, Department of Ped.
Hematology and Oncology, Mu ¨nster, Germany)
Background: Tumor size and metastases are known risk
factors in Ewing tumors. Adequate staging is essential to
stratify treatment intensity, but TNM staging is not
established.
Patients and methods: The validity of TNM staging was
tested based on tumor volume (T1  200ml; T2 >200ml
 500ml; T3, >500ml), the presence or absence of lymph
node metastases (N0, N1), and distant metastases (M0, no
metastases, M1 lung/pleura metastases; M1a  5 nodules;
M1b >5 lesions; M2 bone metastases, M2a, 1 lesion; M2b
>1 lesion and/or microscopic bone marrow contamination;
M3 multi-system metastases). 1371 patients from con-
secutive studies (1981–2003) were analyzed.
Results: Ten-year event-free survival (EFS) was 0.46. EFS
in patients without metastases (T1-3N0M0) was 0.61
compared to 0.32 in metastatic patients (T1-3N0,1M1-3),
p¼0.0001. In non-metastatic patients, tumor volume
discriminated EFS: T1:0.67; T2:0.50; T3:0.44,
p¼0.0001. Lymph node metastases correlated to unfavor-
able prognosis (N0:0.54, Nn1:0.28, p¼0.0008). The
difference in EFS between pulmonary, skeletal and
multi-system dissemination was significant: M1:0.47,
M2:0.29; M3:0.17, p¼0.0001. The discrimination of
M1 subgroups (M1a/M1b) was of prognostic relevance
(p¼0.0313); M2 subgroups (M2a/M2b) discriminated
outcome less clearly (p¼0.0657).
Conclusion: TNM staging is appropriate in Ewing tumors
and should be incorporated in future trials.
P095
IGF1R pathway blockage: A new strategy in ewing
tumour (ET) treatment?
A.S. Martins
1, C. Mackintosh
1, D. Herrero Martı ´n
1,
T. Herna ´ndez
2, E. de Alava
2
(
1Laboratory of Molecular Pathology,
2Tumor Bank, Centro
de Investigacio ´n del Ca ´ncer, Universidad de Salamanca,
Salamanca, Spain)
ET cell survival and proliferation depends on several major
autocrine loops. Its blockade is a promising therapeutic
approach. We analyzed the in vitro impact of IGF1R
pathway blockade by ADW742, a specific inhibitor of this
receptor, on ET cell line proliferation, apoptosis, cell cycle,
pathway phosphorylation, colony formation and motility,
alone and in combination with Vincristine (VCR) or
Doxorubicin (DXR).
IGF1R expression, constitutive, and ligand-inducible
phosphorylation of IGF1R were detected in 4/4 ET cell
lines, indicating a functional pathway. Combined treat-
ments showed a reduction of the proliferative rate ranging
50–85%, and isobolograms showed synergy. Apoptotic
rates reached nn%-80%. Interestingly, IC50 of phosphor-
ylation of AKT plummeted below 0.25mM in combined
treatments (5mM with ADW742 alone), suggesting that
this molecule could be an interesting surrogate marker of
tumor response to therapy. Combined therapy strongly
inhibits colony formation and mobility of ET cells.
Inhibition of ET cell proliferation by ADW742 is
mediated through blockade of IGF1R signaling. A
significant reduction of tumor cell growth and increase
in apoptosis, mainly by blocking both IGF1R-AKT/
MAPK pathways was seen, supporting a potential role
for ADW742 in combined therapies of ET, and the use of
p-AKT as an early marker of response to treatment.
P096
Phase II study of dose-intensive chemotherapy with
adriamycin and ifosfamide followed by high-dose ICE
with PSCT in locally advanced soft tissue sarcomas
F. Mayer
1, W. Brugger
2, H.G. Mergenthaler
3, H. Aebert
1,
R. Teichmann
1, M. Rudert
1, P.M. de Zwart
1, W. Budach
1,
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1
(
1Medical Center and Interdisciplinary Sarcoma Center,
University of Tuebingen, Germany,
2Klinikum, Hematology
and Oncology, Villingen-Schwenningen, Germany,
3Katharinenhospital, Hematology/Oncology, Stuttgart,
Germany)
Background: To determine whether dose-intensive neoad-
juvant chemotherapy is a feasible and effective approach in
patients (pts) with unresectable soft tissue sarcoma (STS).
Patients/methods: Treatment consisted of 3 cycles of
adriamycin (75mg/sqm) on day 1 and ifosfamide 12g/m
2
as 72h continuous infusion (AI) followed by one cycle
of high-dose chemotherapy (HD-ICE), etoposide
500mg/sqm, carboplatin 500mg/sqm and ifosfamide
4g/m
2, applied on day  4 through  2, and retransfusion
of PBSC on day 0. Presence of distant metastases deemed
resectable was allowed.
Results: Between 11/97–2/00 and 4/01–6/04 20 pts, median
age 45 (21–62) years, with high grade STS and different
locations (retroperitoneum, trunk, extremity) have entered
into this prospective trial, either with primary locally
advanced STS at primary diagnosis (65%) or with local
recurrences (35%). Four pts had additional single resect-
able metastases in the lung (3) or the liver (1). Fifteen pts
(79%) have completed all 3 planned AI cycles and attained
a disease stabilisation/minor (47%) or partial remission
(32%); one pt is still ongoing. The other 4 pts revealed
disease progression after the first (n¼1) or second AI cycle
(n¼3). Two pts did not receive HD-ICE because of
ineffective apharesis and grade III neurotoxicity. HD-VIC
was well tolerated without dose reduction in the remaining
10 pts (2 pts still ongoing). Non-haematological grade III
toxicity consisted of emesis in 2 pts (22%), and mucositis
as well as neurotoxicity in one pt each (11%). After PSCT
leucocytes and thrombocytes counts recovered on day 10
and 12, respectively. Tumor assessment revealed one
additional PR following HD-ICE. After completion of
AIþHD-ICE 3 pts without significant tumor shrinkage
underwent preoperative radiation according to protocol.
In total, 11 of 17 currently evaluable pts (65%) were
allocated to surgery. R0 resection was performed in 9 of
11 pts (82%). In one pt a lung metastasis has been
removed simultaneously. After a median follow up time of
94 Poster Abstracts18þ mos (range, 4–72þ) the 1-yr PFS rate is 26% and the
1-yr survival rate 76%. Depending on the resection status
median survival is 38 or 18mos (p<0.01).
Conclusion: Neoadjuvant AI plus HD-ICE with autologous
PSCT is a feasible regimen with an acceptable toxicity
profile in pts with locally advanced STS. R0 resection as
the primary end point was realised in 65% of the pts.
P097
Metastatic rhabdomyosarcoma report: SIOP trial
MMT 98
H.P. McDowell
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(
1RLC NHS Trust, Liverpool, UK,
2Royal Hospital for
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3Centre Leon Berard, Lyon, France,
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5Institut Gustave Roussy,
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The SIOP metastatic sarcoma protocol MMT98 ran from
July 1998 until November 2004. Patient stratification was
standard risk, (SR) <10yrs old, no bone marrow and/or no
bone involvement, and poor risk (PR), >10yrs old or with
marrow and/or bone involvement. SR patients received a
6 drug regime for 27 weeks with local treatment, followed
by 9 courses of low dose vincristine, actinomycin D and
cyclophosphamide (VAC). PR patients entered a window
study of either carboplatin or doxorubincin followed by
high dose sequential monotherapy using cyclophos-
phamide, etoposide and carboplatin, local treatment and
then VAC 9. Centres unable to undertake high dose
monotherapy administered SR treatment.
There were 38 SR, 74 PR patients, 28 on the SR
protocol, 46 on the PR protocol. Median follow up SR is
13.89mths, 2year EFS 54.05%, OS 63.43%, for PR is
11.40 months, 2 year EFS 4.26% OS 37.69%. PR patients
on the SR protocol, 2 year EFS 42.11%, OS 51.07% vs.
11.98% and 30.33% for the PR protocol.
This initial analysis shows survival comparative to other
studies for the SR patients. Use of high dose monotherapy
has failed to provide a beneficial effect for PR patients.
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Effectiveness of ICE-CAV in high risk Ewing sarcoma
family tumors: A single institution study
G.M. Milano, R. Cozza, L. De Sio, I. Ilari, A. Castellano,
P. Fidani, A. Serra, A. Jenkner, C. Dominici,
C. De Laurentis, A. Donfrancesco
(Bambino Gesu ` Children’s Hospital IRCCS, Rome, Italy)
Purpose: Ewing’s sarcoma (ES) and extraosseous Ewing’s
sarcoma/PNET (EES) share histopatologic characteristics,
constituting the Ewing’s sarcoma family. Risk factors are
volume >200ml, site, bilateral pulmonary metastasis,
EWS-FLI transcript and bone marrow involvement.
Methods: ICE regimen was active and well tolerated in
phase I/II studies, both in Ewing/PNET. The induction
regimen consisted of 2 ICE (Ifosfamide 1800mg/m
2/d 
5 days. Carboplatin 400mg/m
2/d 2 days, Etoposide
100mg/m
2/d 5 days), 2 CAV (Cyclophosphamide
1500mg/m
2/d 2 days plus Doxorubicin 75mg/m
2 and
Vincristine 1.5mg/m
2 continuous infusion over 72hrs);
courses were repeated every 21–28 days, G-CSF was
administered.
Patients: Eleven ES and 8 EES, median age 107 months,
were enrolled. 5/19 had bilateral lung metastasis and 3/19
bone marrow involvement. 38 courses of ICE-CAV were
administered. Grade 3–4 hematological toxicity occurred
in all ICE courses.
Results: Objective response-rate (CRþPRþMR) after
ICE-CAV was 94.7% (3CR, 15 PR, 1PD). 17/19 pts
completed protocol (total 7 courses): after a median follow
up of 23 months (range 6–91) 13 pts are DF, 1 AWD after
relapse and 5 DOD. Over 90% CR rate and 63% 5 years
OS seem promising and we plan to enrol additional
patients.
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Profile of children with bone and soft tissue sarcoma
admitted with febrile neutropenia
R. Mittal, H. Mottl, J. Nemec
(Department of Medical Oncology, Kuwait Cancer Control
Centre, Kuwait)
Objectives: To study the incidence and outcome of children
who were admitted with febrile neutropenia after receiving
chemotherapy for bone and soft tissue sarcomas.
Methodology: The clinical data of all the cases of bone and
soft tissue sarcomas, who were admitted with febrile
neutropenia (from 1.1.2003 to 31.12.2004) was recorded
in a pre formed Performa.
Results: A total of 10 patients of bone and soft tissue
sarcomas received 80 courses of various chemotherapies
during the study period. Various chemotherapy protocols
(mainly European) were used according to the primary
lesion. Fifteen of the 20 episodes were recorded in children
with diagnosis of ES/PNET. Prophylactic growth factors
were used in all except one patient. The median day of
onset of fever was day 9 (range 5–15), Median days for
ANC recovery was 5 days (range 3–8), and for platelets 7
days (range 5–10). Fever was the only presenting symptom
in majority of the case. No microbial positivity was recoded
in any case. Empirical antibiotic given was Fortum/
amikacin, which was changed to Tazobactum/amikacin
from April 2003. In only 4 episodes second line antibiotics
were used. Antifungal (ampho-B) were used in 2 episodes.
All patients recovered without any significant morbidity.
There was no fatal episode, and none of the patient
required admission to ICU.
Conclusions: There is high incidence of febrile neutropenia
in children who receive chemotherapy for sarcomas. But all
the incidences can be safely managed by using a standard
protocol without any serious consequences.
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Needle biopsy vs. open biopsy: Is it useful in soft tissue
and bone tumors?
E. Moessinger
1, F. Laenger
2, E. Hesse
1, L. Bastian
1
(
1Klinik fu ¨r Unfallchirurgie, Medizinische Hochschule
Hannover, Hannover, Germany,
2Pathologisches Institut,
Medizinische Hochschule Hannover, Hannover, Germany)
The aim of this retrospective study was to evaluate the
results of pathological findings in patients with soft tissue
and bone tumors, who were first treated with needle
biopsy.
Between January 2002 and December 2003. 100
patients underwent biopsy in our clinic because of soft
tissue or bone tumors.
56 bone tumors, including secondary bone tumors, and
44 soft tissue tumors were treated with biopsy during their
diagnostic algorhythm. Needle biopsy (NB) was performed
in 70 patients and open biopsy (OB) was performed in
30 patients. The NB group was treated in our outpatient
clinic and was operated under local anaesthesia while the
OB-group was admitted in our clinic for at least 2 days.
There was no significant difference in the results of
pathological findings between the NB an OB groups.
Poster Abstracts 95Especially in soft tissue tumors, the needle biopsy
has become an alternative treatment in the diagnostic
algorhythm.
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It could be difficult to remain blind to molecular
diagnosis of EWS-FLI 1 gene rearrangement during the
treatment of Ewing Sarcoma/PNETs
P. Mudry
1, J. Sterba
1, V. Bajciova
1, J. Berkovcova
2,
J. Skotakova
3, P. Gal
4, P. Janicek
5
(
1Department of Pediatric Oncology, Children’s Hospital Brno,
Czech Republic,
2Department of Internal Medicine -
Haematooncology, University Hospital Brno, Czech Republic,
3Department of Pediatric Radiology, Children’s Hospital
Brno, Czech Republic,
4Department of Pediatric Surgery,
Traumatology and Orthopedics, Children’s Hospital Brno,
Czech Republic,
5Department of Orthopedics, St Anna
Hospital, Brno, Czech Republic)
Evaluation for the presence of Ewing sarcoma/PNET (ES/
PNET) cells using RT-PCR for EWS-FLI 1 fusion
products is possible, however the clinical utility of such
studies is still matter of controversy and ongoing ran-
domized clinical trials. We believe, that there are some
clinical situations, where the patient could benefit from
such information. As an example of positive role of
molecular diagnosis we present two ES/PNET patients
with complicated clinical course and another two patients
with their molecular relapse detection from peripheral
blood prior diagnostic imagines. We can document
feasibility of EWS-FLI 1 detection in all our specimens –
tumor tissue, peripheral blood, bone marrow, all suspi-
cious tissues biopsies, incl. CSF and stem cells. PCR
methods could be used for molecular relapse detection,
and both confirmation of negativity of surgical specimens,
or revealing of positivity in the tissue sample, or minimal
residual disease (MRD) detection could be useful for
clinicians. Despite the prognostic role of such testing
remains to be established, for some patients (e.g. poorly
tolerating standard treatments) the use of PCR results
could be of benefit to while considering experimental
therapies like targeted or antiangiogenic maintenance
therapy with acceptable toxicity profile to retain remission
and/or quality of life.
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Plastic-surgical management of patients with sarcoma
of the forearm and hand
M. Mu ¨ller, G. Germann, B. Bickert, M. Sauerbier
(Department of Hand-, Plastic and Reconstructive Surgery -
Burn Center -, BG Trauma Center Ludwigshafen, Plastic and
Hand Surgery of the University of Heidelberg, Germany)
Radical tumor resection is main therapeutic goal for
treatment of sarcomas of the forearm and hand.
Reconstructive procedures play a key role in coverage of
defects and prevention of problems due to wound
infection. If localized within the periphery of the upper
limb the vast majority of cases require sophisticated
techniques to achieve salvage of forearm and hand.
Besides local cutaneous, muscle and fascia – flaps,
pedicled and free microvascular transplantations are used.
In special instances ablative surgery may become
necessary. The purpose of this study was to evaluate the
outcomes of patients who underwent radical resection of
sarcomas about forearm/hand. Between 1995 and 2005 15
sarcoma resections were performed. 9 patients were male,
6 female, average age was 52 years. After biopsy 7 fibrous
histiocytomas, 2 leiomyosarcomas, 2 synovial cell carci-
nomas, 2 osteosarcomas, 1 epitheloid sarcoma, 1 chon-
drosarcoma were diagnosed. 2 patients were treated with
primary closure or mesh graft transplantation. 1 patient
received a local flap, 6 patients needed free microvascular
transplantations to cover the defect. It was impossible to
preserve the limb 6 times, 3 patients had tumor recurrence.
Our results show the necessity of plastic-surgical recon-
struction as an integrative component of modern sarcoma
therapy.
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Results of Spanish Cooperative Protocol SEOP-95 for
non metastatic osteosarcoma of the limbs in children
A. Mun ˜oz, M.S. Maldonado, J. Alfaro, T. Contra,
P. Garcia-Miguel, M.J. Antun ˜a, A. Cantalejo, N. Pardo,
C. Melero, L. Gros, J. Heras, J. Huguetet, M. Ruiz-Portal,
G. Ocete
(Spanish Society of Pediatric Oncology (SEOP), Servicio de
Pediatria. Hospital Ramon y Cajal, Madrid, Spain)
Objectives: To improve survival and the rate of limb salvage
procedures, we started a protocol in which from 1995 to
2000, 99 patients with non metastatic osteosarcoma of the
limbs were enrolled.
Methods: The protocol consisted of preoperative che-
motherapy with ifosfamide doxorubicin, cisplatin and
high dose methotrexate. After surgery patients received
postoperative chemotherapy with the same drugs.
Results: Median age was 12 years. Femur (50%) was the
most common primary site. Limb salvage procedures were
performed in 85% of patients. Good histologic response
was observed in 67 cases. There were 7 local relapses (7% )
and 4 toxicity-related deaths. One patient developed a
second neoplasia (AML). No significant sequelae were
observed. With a follow up of 42 to 118 months (median
83 months) the 5 years event-free-survival is 67%.Survival
for good histologic response patients was 73% versus 52%
for poor responders (P¼0.011).Survival for patients with
tumor volume <100ml was 80% versus 68% for the rest
(P¼0.12).
Conclusions: This protocol led to good oncologic results,
with a significant toxicity rate. Our current protocol SEOP-
2001 has shortened the post-op chemotherapy in order to
reduce treatment-related toxicity.
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Spanish cooperative study SEOP-EW 95 for the treat-
ment of children with Ewing sarcoma and primitive
neuroectodermal tumors of bone
P. Garcia-Miguel, A. Sastre, A. Alfaro, M.J. Antun ˜a,
A.. Cantalejo, T. Contra, J.V. Hernandez, A. Mun ˜oz,
N. Pardo, M.J. Torres, M. Ruiz-Portal, J. Heras, G. Ocete,
J. Huguet, A. Santos, M.S. Maldonado
(Spanish Society of Pediatric Oncology (SEOP), Hospital
Infantil La Paz, Madrid, Spain)
Purpose: To improve survival of children with Ewing
sarcoma and PNET.
Methods: From 1995 to 2001, 132 patients were included.
Non axial tumors received preoperative and postoperative
chemotherapy with Vincristine, Adriamycin, Ifosfamide
and Actinomycin if tumor volume <100ml, plus
etoposide for >100ml tumors. Axial tumors received
same chemotherapy, irradiation and/or surgery for primary
and high-dose Busulfan–Melphalan. For metastatic
patients treatment was as above plus irradiation of
metastases.
96 Poster AbstractsResults: There were114 Ewing and 18 PNET: Median age
was 10.5 years; 51% of patients had pelvic or metastatic/
multicentric tumors. EFS at 63 months is 56%. Pelvic
primary tumors had a EFS of 17% versus 63% for the rest
(P¼0.001). Patients with good response to preoperative
chemotherapy had an EFS of 79% versus 49% for the rest
(P¼0.002). Patients with lung metastases had an EFS of
63% versus a 17% for multicentric (P¼0.001). There were
2 secondary neoplasias (1 ALL and 1 AML).
Conclusions: In our series, with an elevated rate of high risk
patients, this protocol was found to be effective in disease
control and survival.
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‘‘SOS Desmoide’’ A French patient group for desmoid
tumor promoting research, supporting patients
M. Podevin
1, L. Mignot
2, M. Lemarchand
1,
E. Taugourdeau
1, P.H. Cottu
3, O. Oberlin
4
(
1SOS Desmoide Association,
2Hopital Foch, Suresnes,
France,
3Clinique des diaconesses, Paris, France,
4Hopital
Pitie ´-Salpe ´trie `re, Paris, France,
5Institut Gustave Roussy,
Villejuif, France)
‘‘SOS desmoide’’ is an association created in 1998 by a
patient in partnership with a doctor with several aims:
. To break the loneliness of the patients and their
family.
. To enhance exchange networks between patients,
between doctors, between patients and doctors, and
between doctors and researchers.
. To sort and synthesize existing publications.
. To promote research.
Since that date, the association has grown up and has now
250 members of whom 60 are patients – adults and
children.
‘‘SOS desmoide’’ has set up a website for the patients
and the doctors (http://www.sos-desmoide.asso.fr/).
It has edited information booklets for patients and
doctors and is editing a newspaper.
It has launched a tumor bank to collect tumor samples
that will be used for research, with the strong wish to
remain in close contact with the researchers.
It has set up supportive group discussions.
The association is in relationship with many patients and
doctors from France and are trying to promote a network
of doctors in France who would join their efforts to
increase their expertise on this rare disease.
As the association had also contact with patients from
the entire world, it would like to make itself known and to
promote similar associations in other countries.
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Desmoid tumors in childhood: Place of radiation therapy
and chemotherapy
C. Oudot
1, P. Marie
2, D. Orbach
3, G. Raimondo
1,
M.J. Terrier Lacombe
1, O. Oberlin
1
(
1Institut Gustave Roussy, Villejuif, France,
2Ho ˆpital
Trousseau, Paris, France,
3Institut Curie, Paris, France)
Purpose: Retrospective study to define the efficacy and
places of surgery, radiation radio therapy and chemother-
apy.
Patients: Between 1982 and 2003, 71 children were treated
in 3 French hospitals.
Results: There was a male predominance (41 boys/
30 girls). Median age at diagnosis was 6.7 years [0–16].
Localizations were various: head and neck (32%), limbs
(30%). Only 3 had intra-abdominal localization (4%).
Three cases are associated with Gardner’s Syndrome.
The first line of treatment was surgery in 56/71 cases
(79%) and chemotherapy in 10 cases (14%) because of
unresectable lesions. When surgery was performed first,
free margins were described in only 8.5%.
Local radiotherapy was given in 22 cases after surgical
resection. Persistent complete response has been obtained
in 12 cases (55%).
36 children received a total of 60 various chemotherapy
lines (either vinblastinþmethotrexate, or actinomycin
based regimens) at diagnosis or for relapse. Complete
and partial responses was obtained after 21/60 (35%).
8 patients have presented a spontaneous regression.
Conclusions: Despite heterogeneous treatments, encour-
aging results have been observed after chemotherapy or
radiation therapy. Prospective studies according to
European recommendations will give us additional data
on therapy and epidemiology of this rare disease.
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Ewing’s sarcoma of the pelvis: 62 patients of the French
Society of Pediatric Oncology (SFOP)
E. Mascard
2, P. Wicart
2, C. Carrie
1, J. Dubousset
2,
O. Oberlin
2
(
1Hospital Saint Vincent de Paul, Paris, France,
2Institut
Gustave Roussy, Villejuif, France)
We aimed to evaluate the role of surgery and/or radiation
therapy in pelvic Ewing’s sarcoma.
Sixty-two patients were treated, from 1984 to 1993,
according to three successive chemotherapy protocols of
the SFOP. There were 35 females and 27 males, aged 5 to
28 years. Sixteen patients had metastases at diagnosis. The
modality of local treatment was not randomized. Surgery
was performed alone in 18 cases, surgery plus radiation
therapy in 15 cases, and radiation therapy alone in 25
cases. Four patients had no local treatment. High-dose
chemotherapy with stem cell transplantation was used in
14 patients.
The results were retrospectively assessed at mean 6.6
years follow-up: 29 patients had no evidence of disease,
6 had an evolutive disease, and 27 were deceased. Two
patients developed a radio-induced sarcoma. Overall
survival was 55 6% at five years FU and 53 7% at
10 year FU. There was no significant difference in survival
or local control related to the chemotherapy protocols.
There was a significant improvement in overall survival
(68% vs. 43%, p¼0.007) after surgery compared with
radiation therapy alone. Only two patients with metastases
at diagnosis had no evidence of disease at last F.U.
There was a significant improvement in pelvic Ewing
sarcoma outcome, with chemotherapy, and surgical treat-
ment when feasible. The prognosis of such lesions was,
in our experience, not so worse from other locations.
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Alveolar soft part sarcoma: A difficult and rare tumour
in oncology
J. Vermeulen, P. Freneaux, S. Helfre, V. Laurence, F. Doz,
H. Pacquement, J. Michon, D. Orbach
(Institut Curie, Paris, France)
Aim: To retrospectively review the presentation and
outcome of 5 patients treated between 1990 and 2004 for
alveolar soft part sarcoma (ASPS) in our institution.
Patients: Median age was 9 years [6–36]. Primary was limbs
(3 pts), orbital (1 pt) or non parameningeal head and neck
Poster Abstracts 97(1 pt). Histological diagnosis was initially wrong in 4 pts.
2/2 tumor had a TFE3 expression and TFE3/ASPL
transcript was present in 1/1 case.
First treatment was inadequate surgery (4 pts) or biopsy
(1 pt). IRS groups distribution was: IRS-I 1 pt, IRS-II
2 pts, IRS-III 1 pt, IRS-IV 1 pt (pulmonary). Complete
remission (CR) was achieved with surgery alone 1 pt,
surgery with chemotherapy and radiotherapy 2 pts. The
2 children with evaluable tumor were progressive after
chemotherapy. One child was lost of follow up (FU) during
treatment with progressive disease. One child is in late
second CR after a surgery of a distant solitary pulmonary
metastasis. At end of FU, 3 children are in CR (at 2
months–3 and 9 years).
Conclusions: 1. ASPS is a very rare tumor; 2. Local therapy
should be maximum; 3. Histological diagnosis is difficult
and may be helped by the TFE3 nuclear expression and the
presence of TFE3/ASPL fusion transcript. 4. Long term
metastasis may be curable with surgery only.
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Role of MLL4 in sarcomagenesis
M.J. O’sullivan, N. Melnyk, P.H.B. Sorensen
(University of British Columbia, Vancouver, BC, Canada)
We identified a novel non-constitutional chromosomal
translocation, t(17;19)(p13;q13), occurring as solitary
karyotypic abnormality in an intracranial, extra-axial
undifferentiated sarcoma presenting in a 12-year-old girl.
Two-colour FISH analysis using overlapping BACs,
showed localization of the 19q13.12 breakpoint to the
region harbouring the MLL4 gene.
This is the first tumor showing translocation involving
MLL4, and only sarcoma with a translocation involving
an MLL gene family member. Although there has been
no prior report of involvement of the MLL4 gene in
chromosomal translocation, the closely related MLL gene
is frequently involved in translocations in leukemias, with
adverse prognostic implications.
Aberrations of 19q13, the region harboring MLL4, are
common in undifferentiated sarcomas and osteosarcomas.
FISH analysis of an additional 47 cases of undifferentiated
sarcomas and osteosarcomas obtained from CHTN using
overlapping BACs showed only fused signals, suggesting
that none of these cases bears a translocation involving
MLL4. Ten cases showed amplification of MLL4, 17
showed 2–4 signals, possibly indicating duplication or
polyploidy. The remaining 10 cases were normal. This is
provocative in light of the identification of partial tandem
duplication of MLL in many hematopoietic neoplasms
lacking translocation of MLL.
We hypothesise that MLL4 plays a role in sarcoma-
genesis, analogous to the role of MLL in leukemogenesis.
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Neoadjuvant chemotherapy for osteogenic sarcoma:
Results of a single institute from Turkey
A. Ozkan, T. Celkan, H. Apak, S. Ocak, M. Hız,
S. Dervis oglu, F. Dincbas, S. Karaman, I. Yildiz
(Department of Pediatric Oncology, Cerrahpasa Medical
Faculty, University of Istanbul, Turkey)
Purpose: The aim of this study is to describe the outcome
of neoadjuvant chemotherapy for osteogenic sarcoma.
Patients and methods: Between November 1990 and
November 2004, 27 patients with osteosarcoma were
treated according to a protocol of neoadjuvant chemother-
apy with Cooperative Osteosarcoma Study Group (COSS)
or combination of cisplatin and doxorubicin. The median
age at diagnosis was 12 years (range, 5–16 years). A total of
25 (92.6%) primary tumors were located in an extremity,
whereas 2 (7.4%) occurred in the axial skeleton. Surgery
was limb salvage in 17 patients and amputation in 3
patients. The proportion showing a good histopathological
response (>90% tumour necrosis) to preoperative che-
motherapy was about 55%.
Results/discussion: The 5-year overall survival was signifi-
cantly related to the degree of histologic response to
preoperative chemotherapy (81.82% for good responders
versus 55.56% for poor responders). 20 (74%) patients had
localized disease, while 7 (26%) had metastases at
diagnosis. In 6 patients (22%), no surgical treatment was
performed. Thirteen patients (48.1%) received radio-
therapy (3 patients for tumor control of unresectable
primaries).The mean follow-up of all patients was 75
months (range 2–117 months). The 5-year event-free
survival (EFS) and overall survival (OS) rates were 52.58
and 57.52% respectively.
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All-trans retinoic acid, interferon-a and zoledronic acid
in the treatment of a patient with resistant metastatic
osteosarcoma
A. Ozkan
(Department Of Pediatric Oncology, Cerrahpasa Medical
Faculty, University of Istanbul, Turkey)
Purpose: Alternative approach in the treatment of patients
with resistant metastatic osteosarcoma.
Patient and methods: The patient, a girl 14 years of age, was
first admitted to the hospital for right knee and left jaw pain
and mass. A high grade osteoblastic osteogenic sarcoma of
the right distal femur and left mandibula’ was diagnosed
after an excisional biopsy. Bilateral micronodular lung
metastases were present at diagnosis.
The patient was initially treated according to the
Cooperative Osteosarcoma Study Group (COSS 96)
protocol for osteogenic sarcoma. We detected tumour
progression on the 10th and 18th weeks of protocol.
Despite the administration of second line (high dose
ifosfamideþetoposide 2) and third line (doxorubicinþ
cisplatin 2) of chemotherapy, combined local radio-
therapy, which couldn’t achieve the control of the
tumour. The patient was then treated with a combination
of oral ATRA (90mg/m
2 for 3 days per week), subcuta-
neous IFN (3 106U/m
2 5 days per week), intravenous
infusion zoledronic acid (4mg per months) and CAM
(complementary and alternative medicine: diet, vitamine,
melatonin, antioxidan therapy, mistletoe, green tea,
curcuma). Treatment was well tolerated, and the patient
is in stable disease for 8 months.
Results/discussion: ATRA/interferon /zoledronic acid
treatment may be considered as an alternative approach
in the treatment of patients with metastatic osteosarcoma
who have disease that is resistant to conventional
chemotherapy
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Ewing’s sarcoma: Results of a single institute from
Turkey
A. Ozkan, T. Celkan, H. Apak, S. Ocak, M. Hız,
S. Dervis oglu, A. Canpolat, S. Karaman, I. Yildiz
(Department of Pediatric Oncology, Cerrahpasa Medical
Faculty, University of Istanbul, Turkey)
Purpose: The aim of this study is to describe the outcome of
therapy for Ewing’s sarcoma.
98 Poster AbstractsPatients and methods: Data on 25 patients with Ewing’s
sarcoma of bone treated at a single institution between
January 1983 and January 2003 were retrospectively
considered (median age, 9.0 years; range, 3.0–15.0
years). All patients received primary treatment with
chemotherapy and surgery and or radiotherapy as local
modality treatment.
Results/discussion: At diagnosis, 16 patients had local-
regional disease, and 9 had distant metastases. The mean
follow-up of all patients was 50 months (range 4–108
months). The 4-year event-free survival (EFS) and overall
survival (OS) rates were 24.64 and 24.89% respectively.
The 4-year overall survival (OS) rate for patients with
local-regional disease is 42.86%; the 4-year OS rate for
patients with distant metastases is 0%. All patients with
distant metastases had progressive disease during therapy,
and 9 patients with local-regional disease experienced
disease progression during therapy. Despite significant
progress with the use of intensive multiagent chemotherapy
and local control measures, a significant proportion of our
patients die of disease progression.
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Malignant degeneration to osteosarcoma in a patient
with heterotopic ossiffication
C. Pacheco, M.D. Albala ´, M. Torres, A. Benı ´tez,
M.C. Pe ´rez, J. Garcı ´a, J.M. Latre
(Department of Nuclear Medicine, Reina Sofı´a Hospital,
Co ´rdoba, Spain)
Heterotopic ossification (HO) is an extra-osseous non
neoplastic growth of new bone. The clinical impact of HO
depends on the clinical setting, location and extent of
disease. The treatment is generally conservative. Malignant
degeneration to osteosarcoma has been reported but is
extremely rare.
We present a 56 years old woman with an HO at the
right calf since November-1990. That lesion presented a
rapid enlargement and significant pain during last months.
X-rays planar showed an increase in soft tissue
mass respect to the previous. MRI demonstrated a large
image with heterogeneous high T1 and T2 signal and
heterogeneous gadolinium enhancement.
Three-phases-bone-scan showed an increased activity in
soft tissues, due to hyperemia and ossification. Delayed
scan showed increase uptake of affected adjacent bones,
without another pathologic uptakes justified by metastases.
The final diagnostic confirmed by biopsy was well-
differenced osteosarcoma with rapid growth of its cartila-
ginous component, and the patient was put to amputation
of the leg with definitive treatment.
The contribution of the bone-scan in this case resides
in the visualization of the lesions’ hyperemia in the early
phases, the demonstration of the bone involvement in
delayed images and the importance of discarding bone
metastases in one unique study.
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No increased cancer risks in relatives of children with
Ewing’s sarcoma: A population-based family study
D. Pang, R. Alston, A. Kelsey, J.M. Birch
(University of Manchester & Cancer Research UK,
Manchester, UK)
Purpose: To determine whether there are increased risks of
cancer among relatives of children with Ewing’s sarcoma,
to assess the possible role of cancer predisposition.
Patients and methods: All children under 15 years old
included in the Manchester Children Tumour Registry
between 1 January 1954 and 31 December 2001 with
histologically confirmed Ewing’s sarcomas were eligible.
Families of cases were interviewed. Reported cancers in
relatives were verified from medical records. Standardised
incidence ratios (SIR) were estimated from the age, sex,
and calendar year specific national cancer incidence rates.
P-values were calculated assuming occurrence of cancer
follows a Poisson distribution.
Results: The study has sufficient statistical power (99%) to
detect a 2 fold increased risk. There is no overall cancer
excess in relatives of cases (O¼65, SIR¼0.8, p>0.05).
There are no discernible excesses in any specific common
cancers in relatives, including breast, CNS, lung, colo-
rectal, stomach, cervical, melanoma, prostate and bladder
(all SIRs <1.5, all P-values >0.05).
Conclusion: The study does not support a general role of
cancer predisposition in Ewing’s families. However the
results do not rule out a genetic role in certain rare families.
Further studies on subgroups of Ewing’s incorporating
molecular analyses would be helpful to clarify this.
P117
Correlation between histology and PAX/FKHR fusion
status in alveolar rhabdomyosarcoma
D.M. Parham
1, S. Qualman
2, L. Teot
3, F.G. Barr
4,
W.H. Meyer
5
(Soft Tissue Sarcoma Committee of the Children’s Oncology
Group:
1Departments of Pathology and Pediatrics, Arkansas
Children’s Hospital and Arkansas for Medical Sciences, Little
Rock, AR, USA,
2Children’s Hospital, Columbus, OH,
USA,
3Children’s Hospital of Pittsburgh, Pittsburgh, PA,
USA,
4University of Pennsylvania, Philadelphia, PA, USA,
5Children’sHospitalofOklahoma,Oklahoma City,OK,USA)
At the molecular level, alveolar rhabdomyosarcoma
(ARMS) is characterized by three mutually exclusive
PAX/FKHR conditions: PAX3/FKHR fusion (present
in 65% of cases), PAX7/FKHR fusion (present in 20%),
and PAX/FKHR fusion negativity (present in 15%).
The possibility of morphologic variation among these
Poster Abstracts 99molecular subtypes has not been investigated. We under-
took a blinded retrospective study of 65 cases of ARMS
(16 PAX fusion negative, 36 PAX3/FKHR positive, and
13 PAX7/FKHR by routine RT-PCR). We evaluated
cytohistologic parameters such as microcyst formation,
solid foci, differentiation, giant cell formation, anaplasia,
nuclear grade, mitotis/karyorrhexis index, rosette forma-
tion, geographic necrosis, stroma production, and the
presence of foci resembling embryonal rhabdomyosar-
coma. We analysed the results using a simple chi-square
formula. Of these features, only lack of cyst formation
reached significance (p¼0.00014), with 7 of 16 PAX
negative cases lacking this feature, compared to 0 of 36
PAX3/FKHR cases and 2/13 PAX7/FKHR cases. More
investigation is indicated, but these preliminary results
indicate that in general, only lack of cyst formation in
ARMS would suggest the absence of a PAX fusion.
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A comparison of epirubicin- and doxorubicin-induced
cardiomyopathy in paediatric soft-tissue sarcoma
patients
M. Paulides
1, W. Sto ¨hr
1, I.B. Brecht
2, A. Kremers
1,
J. Treuner
2, E. Koscielniak
2, T. Langer
1, J.D. Beck
1
(
1LESS Centre, University Hospital for Children and
Adolescents, Department of Paediatric Oncology, Erlangen,
Germany,
2Cooperative Soft Tissue Sarcoma Study,
Olgahospital, Department of Paediatric Oncology, Stuttgart,
Germany)
Background: Epirubicin-induced cardiomyopathy has been
studied almost exclusively in adult cancer patients. The
aim of our study was to investigate epirubicin-induced
cardiotoxicity in comparison with doxorubicin in children
and adolescents.
Patients and methods: 172 soft tissue sarcoma patients
(mean age at diagnosis: 8.3 years), treated with epirubicin
(median cumulative dose: 450mg/m
2) or doxorubicin
(median cumulative dose: 240mg/m
2) within the high
risk group of the CWS-96 study, were examined in a
prospective multicentre study. Heart function was analysed
by echocardiography, measuring left-ventricular fractional
shortening. The median follow-up was 27.7 months.
Results: The cumulative incidence of clinically manifest
cardiomyopathy was 0% (0/60; 95%-CI: 0–6.0%) in
patients treated with epirubicin, and 0.9% (1/108; 95%-
CI: 0–5.1%) in patients treated with doxorubicin. Three
patients showed subclinical cardiomyopathy. There was
no difference in fractional shortening between the two
treatment arms.
Conclusion: Cardiotoxicity was low in this study. For the
short term, cardiotoxicity seems to be only a small problem
in epirubicin-treated patients, if applied as in this study.
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Ewing tumor with extrapulmonary metastases: Changes
in survival between 1981 and 1999. Data from the GPOH
(EI)CESS Group
M. Paulussen, N. Weddeling, C. Liebscher, A. Hunold,
D. Manner, H. Juergens
(GPOH (EI)CESS Group, Dept of Pediatric Hematology/
Oncology, University Children’s Hospital, Muenster,
Germany)
Background: Outcome of patients with extrapulmonary
metastatic Ewing tumor is commonly regarded fatal. Here,
outcome of patients registered to three consecutive
co-operative GPOH Ewing tumor treatment studies is
analyzed.
Patients: Patients were treated within CESS81 (n¼20),
CESS86 (n¼62), and EICESS92 (n¼164). Prescribed
treatment consisted of alkylator- and doxorubicin based
chemotherapy with local therapy of the primary tumor and
of metastases, where possible. In EICESS92, some patients
received high-dose therapy with stem cell rescue in
addition.
Results: Four-year survival was 0.10 in CESS81, 0.31 in
CESS86, and 0.32 in EICESS92. The improvement from
CESS81 to CESS86 was significant (p¼0.0152). There
was no significant further improvement from CESS86 to
EICESS92.
Conclusions: Since CESS81, the prognosis of patients with
extrapulmonary metastatic Ewing tumor has increased
to more than 25% of patients surviving. This outcome,
however, is still unsatisfactory and new treatment strategies
are warranted in this patient group.
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Epitheloid sarcoma: Single institution experience with
focus on chemotherapy
D. Pink, P.-U. Tunn, T. Lindner, P.C. Thuss-Patience,
A. Kretzschmar, P. Reichardt
(Department of Hematology and Oncology, Charite ´ Campus
Buch, HELIOS-Klinikum Berlin-Buch, Berlin, Germany)
Background: Epitheloid sarcoma (ES) is a very rare tumor
of children and young adults.
Results: No publications on chemotherapy of ES beyond
case reports were identified in PubMed. From our registry
of 830 patients, we identified 18 patients with ES (2 female,
16 male). Median age at primary diagnosis was 31 years
(range 18–56) with 9/18 patients under 30 years. 6/17
patients developed a local recurrence, 13/17 metastases.
4 patients had metastases at primary diagnosis. Metastases
occurred in lymph nodes (8/13), lungs (11/13), skin (5/13),
bone (2/13), muscles (1/13) and brain (1/13). 9 patients
were treated with first-line chemotherapy in advanced
disease: 6/9 Epi/Ifo (3xSD, 3xPD), 1/8 Doxo/Ifo (1xSD),
2/8 Doxo mono (2xSD). 2nd-line chemotherapy was used
in 5 patients: 2/5 patients HD-Ifo (1xSD, 1xPD), 1/5
Doxo/DTIC (1xPD), 2/5 Gem/Doce (1xPR, too early).
3rd-line-therapy: 1/2 Gem/Cis (1xSD), 1/2 Gem/Doce
(1xSD). 14/17 patients are alive at a median follow-up of
19 months.
Conclusions: Standard chemotherapy seems to be ineffective
(no responses to doxorubicin-containing therapies in 9
patients, no responses in 7 patients treated with high-dose
ifosfamide). In contrast, gemcitabine-containing therapies
showed promising activity.
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Chemotherapy in patients with high-grade or dediffer-
entiated chondrosarcomas: Single institution experience
D. Pink, P.-U. Tunn, T. Lindner, P.C. Thuss-Patience,
A. Kretzschmar, P. Reichardt
(Department of Hematology and Oncology, Charite ´ Campus
Buch, HELIOS-Klinikum Berlin-Buch, Berlin, Germany)
Background: Chondrosarcoma (CS) is a rare neoplasm,
but 2nd most common malignant bone tumor (10–20%
of cases). 40% of CS are low-grade (‘‘1/2’’, 1), 60%
high-grade (2, 3, dediff. CS) [dedifferentiated CS: 10%].
The 5-year OS for low-grade CS is 90%, for high-grade
(2, 3) 40–50% and for dedifferentiated CS 10–20%. Data
on chemotherapy in metastatic or unresectable CS are rare.
Results: Only 11 publications containing original data on
chemotherapy in CS were identified in PubMed. Some
responses to chemotherapies including ifosfamide, doxo-
100 Poster Abstractsrubicin, and cisplatin were reported. In dedifferentiated CS
chemotherapy seemed to improve the prognosis of the
patients. In our institution 19 patients with CS were
treated with chemotherapy. 4/19 patients responded to
chemotherapy (CR and PR; 20% RR). Most patients were
treated with high-dose ifosfamide, antracyclines and
cisplatin. 7/19 are alive; median OS was 36 months from
first-diagnosis (5þ to 125). 17 patients had metastatic
disease, 5 are alive; median OS was 20 months from
diagnosis of metastatic disease (3þ to 91).
Conclusions: In high-grade and dedifferentiated CS
chemotherapy with HD ifosfamide and antracyclines
or cisplatin and antracyclines seems to be effective
with response rates comparable to soft tissue sarcomas.
A prospective multicenter trial should be performed.
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Soft tissue sarcomas in children: 12 years data from a
single pediatric oncology center in Poland
K. Polczyn ´ska
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T. Stachowicz-Stencel
1, A. Szolkiewicz
1, M. Hennig
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A. Balcerska
1, P. Czauderna
2, L. Komasara
2,E .I _ z zycka-
S ´wieszewska
3
(
1Department of Pediatrics, Hematology, Oncology and
Endocrinology,
2Department of Pediatric Surgery,
3Department of Pathomorphology, University of Gdan ´sk,
Poland)
588 children with malignancies were treated in
Department of Pediatric, Hematology, Oncology and
Endocrinology in Gdan ´sk between 1992 and 2004.
In that group 62 (10.5%) patients suffered from soft
tissue sarcomas. The aim of the study was to describe
tumour histology, localization and clinical stage, treatment
protocols and results of therapy.
RMS was diagnosed in 33, non-RMS in 26 and RMS-
like tumours in 5 children. There were 35 girls and 27 boys
in age between 3 months and 23 years at the diagnosis.
Favourable tumour localization was found in 17,
unfavourable in 45 cases. Most of patients were in III
and IV (55%, 18%) clinical stage of disease.
Children were treated according to CWS-91, 96, 2002
and other (IRS) protocols.
R0 primary tumour resection was performed in 7, R1 in
15 and R2 in 40 patients (11%, 24%, 65%). Relapse was
observed in 19 (31%) patients. 27 children (44%) died
between 2 and 60 months from diagnosis – 3 of them
due to sepsis.
In 9 patients (16%) permanent consequences of treat-
ment are noticed. The mutilating surgery was done in
8 children.
Results of soft tissue sarcomas treatment are still not
satisfactory. Significantly high percentage of cases with
advanced stage of disease was found.
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Soft tissue sarcomas located in extremities: Review of
13 cases
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(
1Department of Pediatrics, Hematology, Oncology &
Endocrinology, University of Gdan ´sk, Poland,
2Department
of Pediatric Surgery, Gdan ´sk, Poland,
3Department of
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Introduction: Sarcomas having seats in extremities are
associated with a worse prognosis. This opinion caused
us to review results of therapy in patients treated in our
department between 1992 and 2004.
Objective: To describe clinical presentation, used therapy
and outcome.
Patients: In 13 of 62 children with sarcomas tumour was
located in extremities (21%). In this group were 6 girls and
7 boys in age from 3 months to 12 years.
RMS were recognized in 8 children (RMA–5, RME–3),
non-RMS in 3 (MFH–2, TT–1), and RMS-like in 1 child.
Advanced stages of disease were noted in 62% patients
(III–4, IV–4). The treatment was carried according to
CWS-91, 96, 2002 and other (IRS) protocols.
Results: 7 children are alive, 5 in complete remission with
time of observation 3–10 years from the end of therapy.
6 patients died (46%): 5 of disease’s progression. 1 child
died of treatment complications – sepsis. Relapse was
observed in 8 children. Among them 2 are in complete
remission for more than 5 years, 2 are still treated and
4 patient died during 7–35 months from diagnosis.
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Soft tissue sarcomas in children with neurofibromatosis
type 1: Four cases treated in a single oncological
institution
E. Bien,
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1, T. Stachowicz-Stencel
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(
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Endocrinology, Medical University of Gdansk, Poland,
2Department of Anatomopathology, Medical University of
Gdansk, Poland,
3Department of Paediatric Surgery, Medical
University of Gdansk, Poland,
4Department of Paediatric
Nephrology, Medical University of Gdansk, Poland)
Patients with neurofibromatosis type 1 (NF1) are predis-
posed to developing malignant neoplasms, including soft
tissue sarcomas (STS), mainly of neural origin. Herein we
report on 4 cases of STS occurring in children with NF1,
treated in a single oncological institution. Material and
methods: F/M: 3/1, age: 8mo–14years. Histopathology:
RME-2, MPNST-1, MTT-1. Primary tumour was
localized in minor pelvis in 3/4 children and left forearm
in 1. All patients presented with advanced, unresectable
tumours and received CWS-91, CWS-96 or CWS-2002
protocols for STS.
Both patients with RME entered CR. A girl with
forearm tumour developed lung metastases 1.5 year post-
therapy and died of progression despite complete excision
and magachemotherapy with autologous PBSCT.
8-month-old boy with bladder RME died in CR of
neutropenia-related sepsis. Patients with MPNST and
MTT of minor pelvis did not respond to therapy. 14-year-
old girl with huge unresectable tumour died of progression.
Another patient underwent mutilating MTT resection
with uterus and bladder. She is disease-free 6 years post-
therapy – the only one among presented patients.
Conclusions: Neural and non-neural STS in NF1 children
seem to display worse prognosis than appearing as sporadic
cases. Children with NF1 should remain under detailed
control of oncologist.
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Clinical characteristics of sarcomas of head and neck in
children
S. Postovsky
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2
(
1Pediatric Hematology Oncology Department,
2Maxillofacial
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Tel Aviv, Israel)
Background: Limited information is available about clinical
behavior and management of pediatric head and neck
sarcomas (PHNS).
Aim of study: To characterize presentation, treatment and
outcome of PHNS.
Patients: Fifteen children, 6 boys and 9 girls, median age
9.6 years (range, 3 months–17 years) were evaluated.
Diagnoses were as follows: Rhabdomyosarcoma – 5
patients (pts), osteosarcoma – 3 pts, Ewing’s sarcoma –
2 pts, mesenchymal chordoma, rhabdoid tumor, malignant
peripheral nerve sheath tumor, aggressive fibromatosis –
one pt each.
Results: Swelling was presenting sign in 9 pts. Other
symptoms were related to pressure, obstruction or bleed-
ing. The mean duration of symptoms before diagnosis
was 6 months (range, 4 days–18 months). The tumor
involved adjacent structures in 6 of 15 pts. There were no
metastases at diagnosis. Treatment consisted of surgery
(S) – 2 pts, Sþradiotherapy (RT) – 1 pt, Sþchemotherapy
(CT) – 1 pt, CTþRTþS – 11 pts. With median FU of
38 months, 3 pts – DOD, 10 pts – NED, two pts – AWD.
Three pts developed distant metastases (two – died).
Conclusions: PHNS are characterized by relatively low risk
for developing metastatic disease (20%). In 40% of pts,
there was extension to adjacent structures. The complete-
ness of surgical resection of PHNS is the main prognostic
factor.
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Survival of metastatic disease in children with bone
sarcomas and soft tissue sarcomas
S. Postovsky, B. Moaed, R. Elhasid, A. Ben Barak,
A. Khalil, I. Zaidman, M. Haimi, M. Weyl Ben Arush
(Pediatric Oncology/Hematology Department, Meyer
Children’s Hospital, Rambam Medical Center, Haifa, Israel)
Background: Metastatic disease (MD) is the main cause of
death in children with sarcoma.
Objectives: To evaluate the influence of MD on survival
among children wit bone (BS) and soft tissue sarcomas
(STS).
Patients and methods: Medical charts of twenty-six pts were
evaluated. There were 14 boys and 12 girls with median
age of 13.5 years (range, 1–19 years). Fifteen pts were with
BS (Ewing’s sarcoma – 8 pts and osteogenic sarcoma – 7
pts) and 11 pts – various STS. Seven pts developed bone
metastases (5 – isolated and 2 – combined with lungs) and
19 – metastases in other than bone location (lung – 15 pts
isolated or in combination with other locations).
Results: With median follow-up of 33.6 months, 19 pts are
DOD, 5 pts – NED, 2 pts – AWD. Median survival after
diagnosis of MD was 13.6 months for BS pts and 27.0
months – for STS (p¼0.049). Median survival did not
differ between group with bone MD (24.1 months) and
group with metastases in other locations (17.3 months),
p¼NS.
Conclusions: 19% of sarcoma pts with metastases are
currently NED. Survival depends on histological diagnosis
but not on location of metastases in studied cohort of pts.
More efficient methods of treatment of MD are required.
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Radiological pseudo-progression of primary pulmonary
metastases in osteosarcoma: A case report
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Metastatic progression during chemotherapy is generally
interpreted as chemotherapy failure associated with a
dismal outlook. We report a 15-year-old girl with conven-
tional osteosarcoma of the left distal femur. Initial chest
CT scans showed two lesions in the right lung suspicious
of primary pulmonary metastases. The patient received
induction chemotherapy with doxorubicin, high-dose
methotrexate, cisplatin and ifosfamide. Chest CT scans 9
weeks after the initial CT revealed a marked increase of
bipulmonal sclerotic lesions in size and number, which had
to be interpreted as progressive disease radiologically.
Surgery of the primary tumor was performed as
scheduled in week 10. Histologic analyses revealed a
good response (<10% viable tumor). Following week 13,
staged bilateral thoracotomies were performed. A total of
20 histologically confirmed metastases were removed from
both lungs, all void of viable tumor cells. Thus, a complete
surgical remission was achieved, which is still maintained
after 14 months of follow-up.
This case demonstrates that radiological ‘‘pseudo’’-
progression of sclerotic pulmonary osteosarcoma meta-
stases during early chemotherapy need not necessarily
indicate true disease progression, but might sometimes be
explained by reactive sclerosis of pre-existing metastases
not evident on initial imaging studies. This must be kept in
mind when deciding about further treatment.
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Autologous peripheral blood stem cell transplant in
paediatric patients with poor prognosis solid tumors
solid tumors in a developing country: A pilot study
S. Poyiadjis, L. Wainwright, G. Naidu, D. Mackinnon
(Paediatric Haematology-Oncology Unit, Chris Hani-
Baragwanath Hospital, University of the Witwatersrand,
Soweto, Johannesburg, South Africa)
Introduction: Cyropreserved autologous Peripheral Blood
Stem Cells (PBSC) have been used by our unit for
transplant in children with poor prognosis solid tumours
since 1999.
Method: Twelve patients underwent PBSC harvest with a
view to be transplanted in combination with high dose
chemotherapy. Seven patients never progressed to trans-
plantation due to failure of the initial ‘‘window’’ treatment.
Five patients had their PBSC transplant: four patients
with Rhabdomyosarcoma (RMS) and one with recurrent
Wilms tumour. The protocols used were the ones
recommended by the UKCCSG.
Results: One patient with RMS died six months after
transplant from progression of the disease. Three patients
with RMS and one with Wilms tumour are alive: 8, 23, 46,
52 months after completion of therapy.
The patient who died still had macroscopic disease
when entering the Sequential High Dose Monotherapy
programme, unlike the other four survivors.
The harvest of the PBSC, the CD34 yield and
engraftment were all satisfactory.
Discussion: Paediatric poor prognosis advanced solid
tumours in developing countries can be successfully
treated with aggressive therapy in combination with
autologous PBSC transplant. Macroscopic disease at the
time of transplantation is a poor factor.
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Rotationplasty: Is there still a role?
A. Puri, C. Anchan, M.G. Agarwal, Y. Panchawagh
(Department of Orthopaedic Oncology, Tata Memorial
102 Poster AbstractsHospital, Mumbai, India)
Due to the incidence of large tumors at index presentation
precluding conventional limb salvage and the high cost of
expandable prosthesis for limb salvage in the paediatric
population, rotationplasty continues to be an often used
procedure in the developing world.
35 patients underwent rotationplasty at our institute
from January 2000 to September 2004. The age ranged
from 6 to 25 years. Twenty nine patients had osteosar-
coma, 5 had Ewing’s sarcoma and 1 patient underwent
rotationplasty for failed megaprosthesis. The involved bone
included lower end femur in 28 cases, upper femur in
1 case, upper tibia in 4 cases and entire femur in 2 cases.
Two of these patients underwent an amputation follow-
ing post operative vascular compromise. Other compli-
cations included vascular congestion in 2 cases which
recovered after exploration, partially recovered nerve palsy
in 1, wound infection in 2, local recurrence in 1 and non
union requiring bone grafting in 1 case.
Functional evaluation was documented in 25 patients
with a follow up ranging from 3 months to 56 months.
Using the MSTS scoring system the score was 25 or
greater in 22 of 25 patients.
In appropriately indicated cases rotationplasty is an
option with excellent oncologic and functional results.
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Renal sarcomas in the intergroup rhabdomyosarcoma
group experience: 1972–1999
B. Raney, J. Anderson, S. Qualman, M. Wharam,
E. Wiener, W. Meyer
(The Children’s Oncology Group, Arcadia, CA, USA,
Division of Pediatrics at the UT MD Anderson Cancer
Center, Houston, TX, USA)
Purpose: To ascertain clinical characteristics, treatment,
and outcome of IRSG patients with renal sarcomas.
Patients/methods: The IRSG database includes newly
diagnosed patients <21 years old with rhabdomyosarcoma
[RMS] or undifferentiated sarcoma [UDS].
Results: Five of the 4514 IRSG patients [0.1%] were
diagnosed with renal embryonal RMS [N¼4] or UDS
[N¼1]. Patient ages ranged from 2 to 12 years; four were
female. Tumor diameters ranged from 8 to 15 centimeters.
One patient underwent complete removal of localized
tumor [Group I]; 1 patient had localized gross residual
tumor [Group III], and 3 had distant metastases in lungs
and bone [Group IV] at diagnosis. All patients received
vincristine, dactinomycin, and cyclophosphamide; 2 also
received topotecan. The 4 patients with residual disease
received radiotherapy. All 5 patients achieved a complete
response, but the 3 with Group IV disease recurred in lung
[N¼2] or brain [N¼1] and died within 13 months. The
Group III patient died of Aspergillus pneumonia. Only
the Group I patient survives, continuously disease-free,
at 17þ years.
Conclusions: Renal sarcomas enrolled on IRSG protocols
were large and often presented with advanced disease.
Removing all gross tumor at diagnosis may be the best
approach to curing these patients.
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Outcome of residual structures present at the end of
therapy in parameningeal rhabdomyosarcoma
J. Robertson, C. Int-Veen, T. Dantonello, I.B. Brecht,
S. Kirsch, E. Koscielniak, J. Treuner
(CWS-Study Group, Olgahospital, Stuttgart, Germany)
Introduction: Parameningeal rhabdomyosarcomas are diffi-
cult to treat surgically due to the proximity of vital
structures. Following radio- and chemotherapy, residual
structures often persist at the end of treatment, making it
difficult to rule out the presence of small residual tumors.
Patients: 141 patients registered with the German Soft
Tissue Trials (CWS) between 1991 and 1996 who had a
pm-RMS were evaluated. Inclusion criteria were: Intention
to treat, alveolar or embryonal histology, treatment in
Germany, diagnosis by December 31, 2001, under 22
years of age at the time of diagnosis and Stage II or III.
Results: 35 (25%) patients had an unclear residual structure
at the end of treatment. 37 (26%) had a residual tumor,
32 (23%) no residual structure and in 24 (17%) patients,
the residual structure was described as inflammation or
scar tissue. There was no information on 12 patients, and
one patient was lost. 7 (20%) patients with an unclear
residual structure had a relapse. 5 (14%) of the patients
with a residual tumor relapsed. Of the patients without a
residual structure, 7 (22%) relapsed. 13 (54%) patients
with a residual structure described as inflammation or scar
tissue had a relapse.
Discussion: Unclear residual structures do not have a
significantly higher risk of relapse compared to no residual
structure, residual tumors have similar rates of relapse if
full remission has been achieved, and residual structures
described as inflammation or scar tissue have an unusually
high risk of relapse.
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Adamantinoma: A new histological variant
N. Little, B. Rogers, J. Pringle, S.R. Cannon
(Royal National Orthopaedic Hospital, UK)
Adamantinoma is a rare low-grade malignant epithelial
bone tumour constituting up to 0.5% of all malignant bone
tumours. An expansile, osteolytic mid-diaphyseal tibial
lesion was found in a 12 year-old girl. An initial histological
diagnosis of basaloid-type adamantinoma was made.
Following excision, further histology demonstrated
basaloid cells and acellular matrix focally surrounded
by osteoclast giant cells with calcium deposits, features
consistent with pilomatrixoma. Several histological variants
of adamantinoma have been documented; this case details
a previously unreported histological adamantinoma
variant – pilomatrixoma-adamantinoma.
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Rb-Loss: A genetic event in high grade chondrosarcoma
with low relevance to clinical practice
M. Ro ¨pke, B. Meyer, R. Schneider-Stock
Poster Abstracts 103(Department of Orthopedic Surgery and Department of
Pathology, Otto-von-Guericke-Universtia ¨t Magdeburg,
Germany)
Loss of function of the human retinoblastoma gene (Rb)
is a frequent genetic abnormality in human malignancies
and causes a disturbance of cell cycle and loss of normal
proliferation and differentiation. We studied loss of
heterozygosity (LOH) of the Rb gene in 31 formalin-
fixed, paraffin-embedded cartilaginous tumors using
polymerase chain reaction. Both components of DD-
chondrosarcoma, the low grade component and the
anaplastic component, were separated by a microdissec-
tion approach. The genetic data were correlated with the
expression of the Rb protein examined by Rb-immuno-
histochemistry. We found Rb-LOH in one chondrosar-
coma grade 3, and in the anaplastic component in 7 of
8 cases of DD-chondrosarcoma (89% of all high grade
chondrosarcomas). All benign cartilaginous tumors (four
enchondromas and two chondroblastomas), low grade
chondrosarcomas and low grade tumor components of
DD-chondrosarcomas were negative regarding Rb-LOH.
We concluded that Rb-LOH predominantly occurs in
highly malignant chondrosarcoma. However, it is not a
marker for identifying low grade tumors with a tendency
towards progression or local recurrence. This was
confirmed by the evaluation of the complete clinical
histories and long-term follow-up data which was
available in 13 cases. Radical or strictly wide surgery
will still act as the guarantor for the successful treatment
of chondrosarcoma.
P136
Plakoglobin expression depends on DNA methylation
and acetylation in alveolar rhabdomyosarcoma
T. Gastaldi
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Plakoglobin and -catenin are pivotal components of
cell-cell adherent junctions. -catenin over-expression
induces cell proliferation and tumor formation whereas
high levels of plakoglobin suppress cell proliferation and
tumorigenicity.
-catenin and plakoglobin expression was studied in 5
alveolar (ARMS) and 4 embryonal (ERMS) rhabdomyo-
sarcoma (RMS) cell lines and 11 RMS biopsies by
Western-blot. -catenin was homogeneously expressed in
all samples, whereas plakoglobin was absent or barely
detectable in ARMS. Semi-quantitative RT-PCR analysis
confirmed this expression pattern. Cell fractionation
analyses demonstrated that both catenins localized in the
cytoplasm and in the nucleus.
Because aberrant methylation and/or acetylation of
promoter regions may silence gene expression, the
effects of the DNA demethylating agent 5-Aza-20-
deoxycytidine (5AzadC) and of the histone deacetylase
inhibitor Trichostatin-A (TSA) were studied in RMS
lines. We showed a partial dose-dependent restoration
of plakoglobin expression in 5AzadC treated ARMS
cells, whereas TSA-treatment caused a time-dependent
increase in plakoglobin expression. -catenin was not
affected by either 5AzadC or TSA. We observed a
synergistic increase of plakoglobin expression in ARMS
cells treated with both agents.
The methylation status of promoter-associated CpG
islands was also determined in ARMS and ERMS.
Our results may explain some of the biological and
clinical differences between ARMS and ERMS and
represent the basis for a wider functional characteriza-
tion of catenins in RMS and other solid tumors of
childhood.
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Optimization of a real-time RT-PCR assay for minimal
residual disease studies in rhabdomyosarcoma
F. Sartori, R. Alaggio, G. Albiero, L. Mussolin, A. Rosolen
(Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-
Universita ` di Padova, Padova, Italy)
Real time quantitative reverse transcription polymerase
chain reaction (RQ-PCR) is a powerful tool for measure-
ments of gene expression for diagnostic and prognostic
purposes in several malignancies. To this aim the establish-
ment of uniform methods for normalization of RNA input
is relevant.
In this study we searched for the most useful endogen-
ous control genes for normalization of the measurements,
based on their lowest variability among bone marrow (BM)
aspirates from different RMS patients.
We analyzed the RNA expression of 11 potential
endogenous control genes. The sensitivity of the method
was assessed by limiting dilutions of alveolar RMS tumor
cells RH30 in hematopoietic cells. Subsequently, we
studied the expression of the RMS markers MyoD1 and
Myogenin in 10 non-RMS cell lines and 5 BM aspirates
from non-RMS patients in order to define their specificity.
The GUS and HPRT genes exhibited the lowest
variability among the BM specimens. MyoD1 and myo-
genin sensitivity ranged from 10–5 to 10–6 and they were
never detected in specimens other than RMS.
Preliminary results from an ongoing study of 25 RMS
patients confirmed the potentials and advantages of the
RQ-PCR assay compared to standard RT-PCR.
QR-PCR appear a favorable option for the analysis of
specific transcripts for the study of minimal residual
disease in children with RMS.
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Comparative analysis of molecular and histological
features in Ewing family tumors of childhood
R. Alaggio, F. Sartori, S. Bitetti, V. Ninfo, G. Bisogno,
A. Rosolen
(Istituto di Anatomia Patologica e Clinica di Oncoematologia
Pediatrica, Azienda Ospedaliera-Universita ` di Padova,
Padova, Italy)
The Ewing family of tumors (EFT) harbors specific EWS/
ETS gene rearrangements.
We investigated the morphologic and immunohisto-
chemical features of 47 children with initial diagnosis
of EFT and determined possible correlations between
histology and molecular characteristics.
Chimeric transcripts, growth pattern (nested/solid),
stroma (absent/abundant fibrosis) and cytology (small or
epithelioid cells) were evaluated.
43 cases were EWS/ETS positive: They included
2 cases of ectomesenchymoma previously diagnosed as
rhabdomyosarcomas. Other 4 cases were negative for any
transcript: 2 were considered PNETs, 1 synovial sarcoma
and 1 undifferentiated sarcoma.
Of the 41 Ewing/PNETs EWS-FLI1 fusion type-1
transcript was detected in 21 cases, type-2 in 11, other
EWS-FLI1 variants in 6 and EWS-ERG in 3. Solid growth
pattern (31/41 cases), and absent stroma (24/41 cases)
were not associated with specific transcripts. Epithelioid
104 Poster Abstractscells and atypical PNET features were more frequent in
tumors carrying transcripts other than type-1/2 (prevalence
of 80 and 75%). These characteristics were associated with
weak CD99 positivity (60%). No differences were detected
in neural marker expression.
Morphology alone allowed a correct diagnosis in 95%
of cases. Detection of specific transcripts appeared critical
in the differential diagnosis. Uncommon variant chimeric
transcripts were associated more frequently with ‘‘atypical
PNET’’ features and weak CD99 expression.
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Gene expression profilino identifies potential relevant
genes in alveolar rhabdomyosarcoma pathogenesis and
discriminates PAX3-FKHR positive and negative tumors
C. De Pitta `
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1, G. Albiero
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1, A. Rosolen
1
(
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Azienda Ospedaliera-Universita ` di Padova, Padova, Italy)
Some morphological and biochemical characteristics are
common to alveolar (ARMS) and embryonal (ERMS)
rhabdomyosarcoma (RMS) and suggest that RMS
arises from a disturbance in the normal skeletal muscle
development.
To study the pathogenesis of ARMS we used the
expression profiling technology with cDNA microarrays
on 5 PAX3-FKHR positive and 5 negative ARMS.
Gene expression profiles allowed to successfully distin-
guish PAX3-FKHR positive and negative tumors and to
discuss the role of some genes that might be biologically
relevant for the two ARMS subtypes (RAC1, CFL1,
CCND1). Interestingly, the majority of ARMS examined
(9/10) could be correctly classified in two clinical groups
based on only 11 discriminating genes. We confirmed
the predictive value of this small set of genes analyzing
blindly 4 additional ARMS biopsies. All 4 patients were
successfully classified, with 100% accuracy.
Transcription profiles of tumor samples and normal
fetal skeletal muscle were also compared. 171 differentially
expressed genes were found in all of the 10 ARMS.
Of them, 53 (31%) were over-expressed and 118 (69%)
under-expressed. The functional analysis of altered genes
led to the identification of a group of transcripts (BCOR,
DDX5, LGALS1, BIN1) that may be relevant in the
tumorigenic processes leading a normal muscle cell to
become a malignant rhabdomyoblast.
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Response of progressive fibromatosis to therapy with
liposomal doxorubicin
J. Rossler
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Introduction: Patients with progressive, unresectable
fibromatosis may suffer from high morbidity. Various
chemotherapeutic regimens have been tried in these
patients with limited success. Here, we report on the
successful use of pegylated liposomal doxorubicin in the
treatment of 4 patients with unresectable fibromatosis
in unfavorable localizations.
Case reports: Three children and one adult with progressive
fibromatosis were treated with three-weekly cycles of
chemotherapy with liposomal doxorubicin (dose range
20mg/m
2 to 50mg/m
2 per day every 21 days). Tumors
were located at the nasal cavity, fossa infratemporalis, oral
cavity, abdomen and fossa supraclavicularis, and were
surgically unresectable. Three of the four patients had been
heavily pretreated with various chemotherapeutic agents.
Objective tumor response was monitored by magnetic
resonance imaging and possible cardiotoxicity by echocar-
diography at regular intervals. A tumor response was
obtained in all four patients. All patients showed normal
cardiac function after completion of chemotherapy as
evaluated by left ventricular shortening fraction. Following
chemotherapy cycles severe neutropenia was not observed.
Conclusions: Pegylated liposomal doxorubicin is a thera-
peutic option in patients with progressive unresectable
fibromatosis in unfavorable localizations.
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‘‘Other’’ localisations of rhabdomyosarcoma in children
in the PPGGL materials
A. Rybczyn ´ska, B. Kazanowska, A. Reich, A. Balcerska,
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E. Solarz, K. Stefan ´ska, D. Stencel, B. Szewczyk,
J. Wachowiak, M. Wieczorek, W. Wo_ z zniak, M. Wysocki
(Paediatric Haematology and Oncology Departments: Poznan ´,
Biaiystok, Bydgoszcz, Chorzo ´w, Gdan ´sk, Krako ´w, Lublin,
Io ´dz, Warszawa, Wrociaw, Poland)
The aim of the research was an analysis of RMS occurring
in children in so called ‘‘other’’ localisation. The object of
the analysis was children aged one month to seventeen
years and six months (median age 11 years 5 months).
The most common localisation were: chest wall (n¼11,
22.5%), pelvis (n¼10, 20.4%), abdominal cavity (n¼8,
16.3%), vertebral canal (n¼4, 8.2%), retroperitoneal
space (n¼3, 6.12%), mediastinum (n¼2, 4.1%). The
most common clinical stages were: III (n¼22, 44.9%),
IV(n¼17, 34.7%). The size of the tumor at the most of
the children was bigger than 5cm. In TNM, T2b changes
dominated. In 17 (34.7%) cases metastases were recog-
nised at the moment of diagnosis – in nodes, bones, pleura,
lungs and bone marrow. In 12 (24.5%)cases the tumor was
recognised as RMS and the rest was diagnosed as non-
RMS (PNET mainly). The first step of the treatment
was chemotherapy. In 38 (77.6%) cases R2 resection was
carried out and pT3b (¼27, 55.1) stage was the most
common. Remission was diagnosed in 71.4% of children,
especially those who under went combined treatment.
The treatment has been successfully completed in 38
(77.6%) cases, in 4 (8.2%) progression was diagnosed
(local progression in 3 cases). 13 children (26.5%), died
mainly because of progression (n¼6) and return of
the illness (n¼3). Localisation: Abdominal cavity (n¼3),
chest wall (n¼3), vertebral canal (n¼1), pelvis (n¼1).
The most common were non-RMS tumors. Period of
observation: 5 months to 6 years and 9 months.
Conclusions: 1. The patients with so called ‘‘other’’
localisation of RMS are a diver group. 2. Further detailed
analysis is needed.
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Stratified single and double autologous bone marrow
trasplantation for Ewing’s sarcoma family of tumors
A. Sawada, M. Inoue, M. Yasui, T. Hamazaki,
T. Kishimoto, I. Saitoh, T. Nakano, M. Koyama,
Y. Takeshita, A. Sakata, T. Okamura, N. Sakata, K. Yagi,
K. Kawa
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and Research Institute for Maternal and Child Health)
Purpose: We explored the efficacy and safety of single (for
standard-risk) and double (for high-risk) autologous BMT
for Ewing’s sarcoma family of tumors (ESFT).
Patient and methods: Eight patients (3 localized, 4
metastatic and one relapsed tumors) were treated in
our institute from 1993 to 1999. All but one were
treated at first with 3–5 courses of window chemother-
apy which consisted of cyclophosphamide, pirarubicin,
cisplatin, and vincristine or etoposide. The patients
with primary tumor of pelvis or bone were treated
with 1st BMT, and then the primary sites were
irradiated 30Gy. In other patients, the primary tumors
were resected and irradiated (if residual diseases were
presented), and then treated with 1st BMT. The
patients without favorable clinical setting (completely
resected primary tumor and no distant metastasis)
underwent 2nd BMT.
Results: Among 8 patients, five (two localized, two
metastatic and one relapsed diseases) are alive well for
5–12 years, and three (one localized and two metastatic
diseases) died.
Discussion: Chemo-resistance is the only adverse prognostic
factor, and we otherwise observed no late relapse. Thus,
autologous BMT appear to be feasible and effective
for ESFT. The latter patients may need other novel
therapeutic modality in combination with high-dose
chemotherapy.
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Long term survival (more than 10 years) of
patients with osteosarcoma and multiple synchronous
metastases
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Rationale: Few patients with osteosarcoma (OSA) and
multiple synchronous metastases survive longer than
10 years after first diagnosis. We present data of long
term survivors.
Materials and methods: 9 OSA patients with metastases at
3 sites (at least 2 histologically proven) ore more were
identified among COSS registry surviving more than 10
years. Median age was 20.2 (range 8–45) years. Primary
tumor sites were the femur (7) and pelvis (2). All patients
had synchroneous pulmonary metastases, 4 patients had
additional skeletal metastases (rib, vertebra, femur, pelvis).
All patients had intensive chemotherapy according to
COSS protocols, surgery when required and repeat lung
metastasectomies
Results: Two patients were lost to f/u after 10 years without
disease manifestation. Complete remission was achieved in
four patients with an average of 16.2 years without relapse.
One patient with multiple synchronous lung metastases is
alive with disease at 15.6 years. One patient with multiple
synchronous pulmonary metastases and multiple skeletal
metastases lives at 10.1 years with stable disease, but free
of symptoms. One patient died 14.4 years after diagnosis
from lung disease.
Conclusion: The data presented point to the fact that
some patients with extensive disease may survive for
long time if they undergo adequate treatment. Initially,
treatment in most of these patients was considered only
palliative.
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Radiotherapy in Ewing tumors of the vertebrae:
Treatment results and local relapse analysis of the
CESS 81/86 and EICESS 92 trials
A. Schuck
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Purpose: Treatment results in patients with Ewing tumors
of the vertebrae enrolled in the CESS 81, 86, and EICESS
92 trials were analyzed with special emphasis on radiation-
associated factors.
Methods: A retrospective analysis was performed on 116
patients with primary tumors of the cervical, thoracic, or
lumbar vertebrae treated between 1981 and 1999.
Furthermore, a relapse analysis was done on those patients
who underwent radiotherapy and subsequently had a local
recurrence.
Results: 64.6% of the patients received definitive radio-
therapy, 27.5% of patients had surgery and radiotherapy.
Only 4 patients underwent definitive surgery. 27 patients
presented with metastases at diagnosis. 22.4% of the total
group developed local relapses. Among the subgroup with
definitive radiotherapy local recurrence was seen in 17 of
75 patients (22.6%). Event-free survival and survival at 5
years were 47% and 58%. Of 14 evaluable local relapses
following radiotherapy, 13 were in-field. No correlation
between radiation dose and local control could be found.
Discussion: Local control is poor in vertebral Ewing tumors.
The results following definitive radiotherapy in vertebral
tumors are comparable to those of other tumor sites when
definitive radiotherapy is given. Nearly all local relapses
following radiotherapy are in-field.
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Radiotherapy in adult type soft tissue sarcoma (sts):
Results of the CWS trials
A. Schuck
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2, S. Kirsch
2, T. Dantonello
2,
I. Brecht
2, B. Schmidt
3, E. Koscielniak
2, J. Treuner
2
(
1Radiotherapy Department, University Hospital Muenster,
Germany,
2Department of Pediatric Oncology/Hematology,
Olgahospital Stuttgart, Germany,
3Radiotherapy Department,
Katharinenhospital, Stuttgart, Germany)
Purpose: The results of patients with adult type sts
registered in the CWS trials are analyzed.
Methods: All patients with ‘‘adult type’’ sts registered
between 6/1981 and 12/2002 in the CWS trials were
included in the analysis. Treatment consisted of local
therapy and in some cases chemotherapy. The median
follow up of surviving patients was 51 months.
Results: There were 274 patients with localized disease.
In IRS group I, 2 of 14 patients (14%) with radiotherapy
relapsed locally and 8 of 50 patients (16%) without. In IRS
group II, 8 of 33 patients (24%) with radiotherapy relapsed
locally and 8 of 18 patients (44%) without (difference
not significant). In IRS group III, 51 patients received
second surgery. 7 of the 25 patients (28%) with additional
radiotherapy and 1 of 16 patients without additional
106 Poster Abstractsradiotherapy (6%) relapsed locally. Patients with RT-doses
>45Gy experienced less local failures.
Discussion: Radiotherapy is essential in adult type STS IRS
group II and IRS group III without oncological radical
secondary surgery. It is still open questions whether
patients with primary or secondary resection with free
margins profit from additional RT.
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Complete recovery from severe methotrexate intoxica-
tion after high-dose methotrexate therapy for sarcoma
by early use of carboxypeptidase G2
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Purpose: Accumulation of methotrexate (MTX) after high-
dose MTX (HD-MTX) therapy is a life-threatening
complication. Carboxypeptidase G2 (CPG2) rapidly
cleaves MTX into non-toxic metabolites. Few data exist
on the efficacy of CPG2 in patients (pts) with excessive
MTX accumulation.
Patients/methods: We have identified 4 sarcoma pts
treated with CPG2 for very severe MTX-intoxication
in a nationwide survey.
Results: Four pts (20–35 years; 2 osteosarcoma, 2
chondrosarcoma) with renal failure (serum creatinine:
308–362mmol/l) and serum MTX levels of 567, 304, 158
and 292mmol/l were registered 19, 40, 48 and 48 hours
after start of HD-MTX (5464–12005mg/m
2, 4 hour
infusion), respectively. Risk factors were overweight
(n¼2), suboptimal hydration (n¼2), low urine pH
(n¼2), preexisting renal insufficiency (n¼2), relevant
comedication (n¼2) and urine flow obstruction (n¼1).
CPG2 (15–35units/kg/body weight) was given as a single
intravenous injection 28–61 hours after start of HD-MTX
and tolerated in all pts without side effects. Serum
creatinine levels returned to normal in all pts by days 23–
43 after CPG2 treatment.
Discussion: CPG2 is effective and well tolerated in patients
with excessive MTX-intoxication and facilitates complete
recovery from renal failure. Future studies might evaluate
the potential role of CPG2 as a standard rescue agent in
high-risk pts.
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Radiotherapy in axial osteosarcomas
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Purpose: Analysis of the Cooperative Osteosarcoma Study
Group (COSS) experience with radiotherapy of axial
osteosarcoma and review of the literature.
Patients/methods: 45 patients with biopsy-proven high-grade
axial osteosarcomas of different sites (pelvis 32, cranial 9,
others 4)and three with metastases in axial sites who had
received radiotherapy at some time during their treatment
course were identified from the COSS database. Median
age was 21 (5–63) years. All patients received chemother-
apy in accordance to COSS protocols. Radiotherapy
was decided individually. Indications were unresectable
primary tumor (24), preoperative (4), postoperative treat-
ment (4), local recurrence (10), and metastases (6).
Different modalities were used: photontherapy (31),
photons plus high-dose samarium-153-EDTMP (9), and
others (8). Median dose in curative treatment was 60Gy
(30–75), in palliative treatment 50Gy (30–60).
Results/discussion: Median follow-up was 1.7 (0.1–9) years.
27 patients died. 16 of 29 patients with curative treatment
and 5/19 patients with palliative treatment were alive.
In 16 patients tumors were locally controlled or showed no
further local progression. Prognosis of axial osteosarcoma
remains poor in spite of multimodality treatment. Surgery
remains the standard for local therapy. High-dose radio-
therapy in addition to chemotherapy and surgery may
contribute to treatment in selected patients.
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Clinical results in the treatment of primary and locally
recurrent retroperitoneal soft-tissue sarcomas
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Purpose: The impact of local control on prognosis in
primary (PT) and locally recurrent (LR) retroperitoneal
soft-tissue sarcoma.
Patients and methods: 110 adult patients underwent surgery
(1988–2003). Results were analyzed for prospectively
gathered clinico-pathological data. Kaplan-Meier estima-
tions and Cox regression analyses were performed.
Results: Resectability rate was 90%, being comparable for
PT (n¼71) and LR (n¼39). Morbidity, mortality, blood
loss, and operation time were comparable for PT and LR.
Follow-up was 89 months. Local 2-, 3- and 5-year control
rates after complete resection of PT were 66%, 66%, and
59% compared to 23%, 19%, and 9% for LR (P<0.001).
The mean number of operations differed: PT (1.4) versus
LR (2.4) (P¼0.0047). The 5-year survival after complete
resection were 51% for PT and 43% for LR (P¼0.39).
The 5-year survival were 65%, 29%, and 0% for complete/
incomplete resection and exploration (P<0.001).
High-grade and blood loss show a poorer prognosis.
Discussion: Comparable resectability, morbidity, mortality,
blood loss, operation time, and hospitalization were
observed for surgery of PT and LR retroperitoneal
sarcomas. Repetitive surgery leads to survival rates after
resection of LR as observed in PT. Survival improves with
radicality of local resection.
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Analysis peri-operative factors in sarcoma surgery
M.N. Wente
1, M.H.M. Schwarzbach
1, U. Hinz
1,
C. Leowardi
1, G. Mechtersheimer
3, J. Debus
4,
G. Egerer
5, H. Friess
1, M.W. Bu ¨chler
1
(
1Department of Surgery,
2Unit for Documentation and
Statistics,
3Institute of Pathology,
4Department of Radiology,
5Department of Oncology, University of Heidelberg, Heidelberg,
Germany)
Purpose: Few data are available about STS patient
population and peri-operative parameters of a specialized
surgical unit.
Patients and methods: Prospectively data of surgically
treated STS patients from 10/2001 to 10/2004.
Results: 159 patients underwent 179 operations (median
age: 60.2 years). Visceral STS (VIS) (35.7%), retro-
Poster Abstracts 107peritoneal STS (RET) (31.3%), and extremity STS (EXT)
(27.3%) dominated. GIST were seen in 65.7% of VIS,
liposarcoma in 47.6% of the RET, and either malignant
fibrous histiocytoma (30%) or liposarcoma (23.3%) of the
EXT. Recurrence was treated in about half of the RET and
one third of EXT. VIS were mainly primary disease.
Operation time was 240min, 210min, 120min for RET,
VIS, and EXT. Blood loss was 500ml, 210 and 50 for
RET, VIS and EXT operations. Morbidity was 26.6% for
VIS, 29.1% for RET and 34.7% for EXT. Lethality was
8.9%, 2.0, and 1.6 for RET, EXT and VIS operations.
Recurrence was resected with acceptable peri-operative
parameters and morbidity.
Conclusion: STS surgery has to be differentiated for VIS,
RET, and EXT tumors. Recurrence is often treated
in RET and EXT, while primary tumors predominate
as in VIS. Tumor type and peri-operative factors
vary with location. Monocentrical data are useful for the
peri-operative management.
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High-dose ifosfamide in relapsed or progressive Ewing’s
sarcoma
B.M. Seddon, A.M. McTiernan, M.P. Michelagnoli,
S. Gabbie, S. Daw, J.S. Whelan
(London Bone and Soft Tissue Sarcoma Service, UCL
Hospitals, London, UK)
Purpose: To determine the response rate and toxicity to
high dose ifosfamide (HDI) in patients with relapsed or
refractory Ewing’s Tumours.
Patients and methods: Between 1993 and 2003, 28 patients
(15 males) were treated with HDI 12–18g/m
2 (median
15g/m
2) as part of multi component treatment strategies.
Eleven patients were treated following disease progression
during first line treatment, and 17 for relapsed disease.
All patients had previously received ifosfamide. Twenty-
five patients proceeded to further treatment.
Results: A total of 57 cycles were given, median 2 (range,
1–4) per patient. The principle toxicity, evaluable in
26 patients, was haematological, with 20 patients (77%)
requiring admission for febrile neutropenia. Platelet and
blood transfusions were required in 27% and 62% of
cycles respectively. Ifosfamide-induced encephalopathy
was observed in 8 patients, severe in 2. Objective response
rate, measurable in 21 patients, was 19%, with 2 complete
responses and 2 partial responses. Fifteen patients (54%)
were judged to derive clinical benefit, (objective response,
stable disease, or reduction of non-measurable disease).
Median overall survival from the start of HDI was 10
months (95% Confidence Interval, 7–13).
Conclusions: HDI has activity in patients with relapsed or
refractory Ewing’s tumours who have been pre-treated with
standard dose ifosfamide.
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Imatinib is not an alternative treatment for uterine
leiomyosarcomas
C. Serrano
1, C. Mackintosh
1, D. Herrero
1, A.S. Martins
1,
T. Herna ´ndez
2,J .P e ´rez-Fonta ´n
2, A. Orfao
3, E. Serrano
4,
A. Bullo ´n
4, M. Abad
4, E. de Alava
1
(
1Laboratory of Molecular Pathology,
2Tumor Bank,
3Flow
Cytometry Lab, Centro de Investigacio ´n del Ca ´ncer,
Universidad de Salamanca, Salamanca, Spain,
4Department
of Pathology, Hospital Clı´nico Universitario de Salamanca,
Salamanca, Spain)
Background: Several studies reporting that KIT is
expressed in uterine leiomyosarcomas (UL), suggest a
chance for a treatment with tyrosine-kinase inhibitors.
Nevertheless, these drugs are effective only when KIT
signalling pathway is constitutively active.
Design: Immunohistochemistry on a Tissue-microarray
including 18 UL was performed with a KIT antibody
used in GIST international clinical trials (Dako A4502).
Western Blot (WB) with KIT and phospho 719Tyr-KIT,
WB for antityrosine residues after immunoprecipitation
with KIT, and flow cytometric studies were performed
on 5 frozen tissue samples corresponding to 4 UL and
1 GIST. Exons 11 and 9 of c-kit and exon 12 of PDGFRA
were sequenced in all cases.
Results: Only mast cells were immunoreactive in UL,
whereas neoplastic cells lacked KIT immunoreactivity.
Accordingly, flow cytometric studies showed that KIT
immunoreactive cells in UL had features corresponding
to mast cells. UL samples showed very faint KIT bands in
WB, but lacked KIT activation, as assessed by WB for
phospho 719Tyr-KIT, and WB for antityrosine residues
after immunoprecipitation with KIT. No KIT or
PDGFRA mutations were found.
Conclusions: Our results indicate that KIT is not involved in
UL pathogenesis, and is not likely a target for anti-tyrosine-
kinase drug therapy in UL.
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and assessment of therapy response in patients with
Sarcoma: Initial results of a prospective study
C. Furth
1,2, B. Spors
2, J. Ruf
2, T. Voelker
1,2, D. Misch
1,
B. Sto ¨ver
3, M. Gutberlet
2, R. Felix
2, G. Henze
1,
H. Amthauer
2
(
1Department for Pediatric Oncology,
2Clinic of Radiology,
Nuclear Medicine and Radiation Oncology,
3Clinic of
Radiology, Department of Pediatric Radiology, Campus
Virchow-Klinikum, Charite ´ – Universita ¨tsmedizin Berlin,
Germany)
Purpose: An adequate assessment of metastases is crucial
for the initial staging and the consecutive therapeutic
regimen but also for a reliable evaluation of response to
therapy. We compared the value of whole body MR and
FDG-PET for staging and therapy assessment.
Patients/methods: In this prospective pilotstudy we report
on 5 pts (3f, 2m; mean age: 10.7) with metastasized
sarcoma who, apart from conventional staging by bone
scan, x-ray and CT were also examined before and after
chemotherapy both by FDG-PET and whole-body
MR using STIR and T1-weighted ( contrast media)
sequences. Histology and/or clinical/imaging follow-up
served as a gold standard.
Results/discussion: Detection of nodal and visceral involve-
ment correlated well with conventional imaging modalities
(n¼4/5 pts) with exception of mediastinal and intrapu-
monal metastases (n¼2 pts). Bone and bone marrow
lesions (n¼2/5 pts) were detected with the highest
accuracy using FDG-PET, followed by MRI and bone-
scan. Therapy response was best predicted with PET.
Both whole body examinations might therefore be a great
asset to stage-adjusted therapy regimens, ultimatively also
influencing patient outcome.
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ease after Wilm’s tumor treatment case presentation
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Secondary neoplasms are a rare but difficult problem in
Wilms tumor treatment. The secondary neoplasm usually
decrease dramatically the overall treatment outcome.
Authors presented a 23 years old male who underwent
successful Wilms tumor treatment at age of 4 (III 
grade, mix type). Patient underwent chemotherapy,
left nephrectomy and radiotherapy. At age 13 this patient
was operated on because of pancreatic head benign
teratoma – local tumor excision was performed. At age
23 he suffered from pancreatic head osteosarcoma extra-
sceletale. Patient underwent pancreatoduodenectomy. He
died 6 months after the operation because of rapid local
and distant osteosarcoma progress.
Patients who underwent extensive anti-cancer therapy
are immuno-compromised and predisposed to second
malignant disease development. In young patients radio-
therapy may develop the malignant disease. Thus it seems
reasonable to focus attention on early secondary neoplasm
detection as well as in primary disease recurrence.
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Sarcomas as second malignant neoplasms after solid
tumours in children: One center experience
J. Stefanowicz, K. Polczyn ´ska, D. Sierota, B. Kaczorowska-
Hac ´, E. Dro_ z zyn ´ska, A. Balcerska
(Department of Pediatrics, Hematology, Oncology and
Endocrinology, Medical University of Gdan ´sk, Poland)
The second neoplasm occurrence is serious complication
of oncologic treatment reducing the probability of patient’s
survival. Risk of second and next malignancy in children
cured of neoplastic disease predominates about 15–20
times risk of cancer appearance in general children
population.
Among patients treated in our department between
1992 and 2004 second neoplasm was recognized in 13
cases. In 4 children there were sarcomas: Skeletal and
extraskeletal osteosarcoma in 2 cases, chondrosarcoma in 1
case and undifferentiated sarcoma in 1 patient.
Wilms tumour was the previous neoplasm in 3 children
and retinoblastoma was observed in 1 child. Second
tumour occurred from 7 to 19 years after the first disease.
Patients’ age in time of diagnosis was 9–23 years. 3
children died between 6 months and 2 years from
diagnosis. 1 male patient is alive, cured of undifferentiated
sarcoma post retinoblastoma.
There was evident relationship between radiotherapy
and second neoplasm in 3 patients. It is difficult to
univocally define factors predisposing to second malignant
tumours. The role of genetic agents is considered however
chemotherapy and radiotherapy are thought to be the main
causes of second malignancies.
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Neurofibromatosis type 1 as a risk factor of malignancies
in childhood. Prophylactic procedures in patients from
one institution in Poland
D. Sierota, J. Stefanowicz, K. Polczyn ´ska, J. Wierzba,
E. Bien ´, T. Stachowicz-Stencel, A. Szolkiewicz,
E. Dro_ z zyn ´ska, A. Balcerska
(Department of Pediatrics, Hematology, Oncology &
Endocrinology, University of Gdan ´sk, Poland)
Neurofibromatosis type 1 (NF1) is quite frequent disorder
of autosomal-dominant pattern.
The average incidence is about 1 per 3000 births.
In patients with NF1 malignancies such as soft tissue
sarcoma or leukemia are noted.
There are 61 children with NF1 suspicion observed in
our department. Each child is carefully controlled in every
6 months as a outpatient. Pediatric, neurological and
ophtalmological examination is performed during first visit
and in case of any symptoms. Number of Lisch nodules,
field of vision, visually evoked potential, audiogram and
dermatological evaluation of skin abnormalities and also
orthopedic examination are performed. In each case of
asymptomatic NF1, MRI of brain and medulla is done in
every 2 years.
Cafe ´-au-lait spots were observed in 61 children, freck-
ling of armpits in 40, neurofibromas in 6, Lisch nodules in
1 patient. Secondary symptoms and complications such as
mental retardation (5) and epilepsies (3 cases), benign or
malignant CNS tumours (8), scoliosis (32) were noted.
In 4 patients malignant neoplasms occurred (6.5%):
RMS – 2 cases, Triton tumour – 1 case, MPNST – 1
case. 1 child died of disease progression, 1 of treatment
complications (sepsis). 2 children are alive.
In our opinion patients with NF1 need permanent and
specialist medical care.
P156
Inverse prognostic impact of syt-ssx fusion type in
paediatric synovial sarcomas treated according to the
German cooperative soft tissue sarcoma study therapy
protocol
S. Stegmaier, I. Leuschner, J. Treuner, E. Koscielniak
(Olgahospital, Stuttgart, Germany)
Synovial Sarcomas (SS) are genetically characterized by the
chromosomal translocation t(X;18) generating syt-ssx1 or
syt-ssx2 gene fusions in more than 95%. Several studies
indicated with variable significance that tumours bearing
the ssx1 fusion transcripts have a worse outcome than
tumours with ssx2 fusion. To assess the prognostic value of
syt-ssx fusion type in patients treated in a prospective study,
we investigated a group of 46 paediatric (age: 1–25 years)
SS patients with syt-ssx positive tumours. All patients were
registered in the CWS (German Cooperative Soft Tissue
Sarcoma Study) between 1996 and 2002. All patients were
treated with adjuvant chemotherapy. Fusion type was
determined by RT-nested-PCR on RNA isolated from
fresh/frozen or paraffin embedded tumour tissue. Kaplan-
Meier analysis indicates significantly better event-free
survival for patients whose tumours contain syt-ssx1
(n¼26) compared to -ssx2 fusions (n¼14) for localized
disease (p¼0.03 log-rank-test), being at odds with other
studies. This is to our knowledge the only prospective
treated group with SS, which was analysed for the
prognostic relevance of the fusion type. All other published
results included retrospectively analysed patients treated
according to individual or institutional recommendations.
This may be the reason for our contrary findings in
comparison to other publications.
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Osteosarcoma: Experience with cisplatin and doxorubi-
cin in a pediatric institution
P. Streitenberger, L. Mora ´n, M. Garcia Lombardi,
P. Pesce, G. Rey
(Unidad de Oncologı´a, Hospital de Nin ˜os Ricardo Gutierrez,
Buenos Aires, Argentina)
The use of preoperative chemotherapy has been shown
to be of direct and significant benefit to the osteosarcoma
patient. There is virtually an immediate palliation of
Poster Abstracts 109symptoms, early treatment of the micrometastasis and local
control of the disease. We present our experience and
results with cisplatin and doxorubicin.
Methods: In the years 1997–2004 twenty six patients
with Osteosarcoma were treated. All children were given
preoperative chemotherapy one to three cycles of Cisplatin
100mg/m
2/day Day 1 and Doxorubicin 25mg/m
2/day
Day 1–3, then radical resection of primary tumor and
finally postoperative chemotherapy was given.
Results: There were 24 evaluables cases, 21 with localized
osteosarcoma, 3 with pulmonary metastasis. The age of the
patients ranged between 5 and 17 years, (mean 13 years),
half of them were males. The tumor was located in distal
femur (69.2%), proximal tibia (23.1%) and others (7.7%).
The pathology was conventional type in 88.5%. Surgery
limb-salvage was attemped in 13 patients and amputation
in 11. The overall survival was 54% and the event free
survival was 50%, with mediam follow-up of 30 months
(5 to 83 months). The outcome of localized osteosarcoma
was 61% of overall survival and 57% of event free survival.
All patients with metastasis died.
Conclusion: Despite the low number of evaluable cases, the
results shown us the efficacy of cisplatin and doxorubicin
in the treatment of localized Osteosarcoma. Multicentric
studies must be done in order to evaluate the outcome of
metastasic patients.
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Dose- and time-dependent apoptosis of human sarcoma
cells by ibandronate and clodronate in vitro
U. Stumpf
1, S. Goettig
2, M. Schoenherr
1, C. Eberhardt
1,
R. Henschler
2, A.A. Kurth
1
(
1Department of Orthopaedic Surgery Stiftung Friedrichsheim.
University Hospital Frankfurt/Main, Germany,
2Institut of
Transfusion Medicine and Immune Hematology, German
Red Cross Blood Center Johann Wolfgang Goethe University
Frankfurt/Main, Germany)
Introduction: Bisphosphonates are known to induce apop-
tosis in different cell types. We tested and compared
the effects the bisphosphonates Clodronate (CL) and
Ibandronate (IB) could have in a direct way on human
sarcoma cells in vitro.
Methods: Human osteosarcoma cells (SAOS2 and
791TMHOS) and Ewings’s sarcoma cells (RD-ES and
TC71) were treated with CL (2mM, 1mM-10–7M)
and IB (10–3M-10–7M) for 24, 48 and 72h. Cell
apoptosis was evaluated by fluorescent flow cytometric
analysis: quantification via FACS and PI staining.
Results: CL-treated osteosarcoma-cells show after 72h
incubation with 2mM 12.6% and 10–3M 8.7% apoptopic
cells. Ewing‘s sarcoma cells were evaluated after 72h:
2mM 10–25% apoptosis.
10–3M IB causes on osteosarcoma cells after 48h <10%
and 72h 10–25% apoptotic cells, Ewing sarcoma cells
incubated with IB showed at 10–3M and 10–4M 10–25%
and of 10–5M and 10–6M <10% of apoptopic cells.
Conclusions: Clodronate and Ibandronate have time-
and dose-related direct effects on primary bone tumor
cells: apoptosis and inhibition of cell proliferation, with
Ibandronate having larger effects. The use of Ibandronate
may be indicated as an adjuvant to existing chemo-
therapeutic protocols.
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Relapse of osteosarcoma in children: Treatment, results
and prognostic factors
V. Svesko
1, Z. Bekic
1, Lj. Poleksic
1, B. Sbutega
2, S. Savic
2,
R. Jakovic
3, M. Atanackovic
4
(
1Institute for Oncology and Radiology of Serbia, Belgrade;
Serbia & Montenegro,
2Institute for Orthopedic Surgery
‘‘Banjica’’, Belgrade; Serbia & Montenegro,
3Institute for
Pulmonary Disease, Belgrade, Serbia & Montenegro,
4Institute
for Pathology, Belgrade, Serbia & Montenegro)
Objective: The aim of our study was to evaluate results of
treatment and analysis of prognostic factors in patients with
the relapse of osteosarcoma.
Patients and methods: From 1990–2000, we treated
22 children with osteosarcoma relapse, median age 16.
All patients received aggressive multimodal therapy
(chemotherapy/surgery) in previous treatment for non-
metastatic osteosarcoma.
In 19 pts pulmonary metastases were detected
(6 solitary), while 3 pts had local relapse of disease.
Disease-free interval (DFI) was more than 1 year in 8
pts.
Surgery was performed in 16 pts (thoracotomy 13,
amputation 3).
Chemotherapy regimens were administered in all
patients: IFO-VP16 (10 pts); HDMth/IFO-VP16 (8 pts);
HDMth/Carbo-VP16 (4 pts).
Results: During 10–128 months follow-up period (Me¼
36mts) disease-free survival rate was 34.71%.
The most significant prognostic factors, that influenced
survival were: presence of a solitary metastases
(p¼0.0188), local relapse of disease (p¼0.026) com-
pleteness of resection (p¼0.039), DFI longer than 1 year
(p¼0.034), and the tumor necrosis over 90% in previous
treatment (p¼0.047).
There were no significant differences in survival in
relation to the type of chemotherapy regimen applied.
Conclusion: The use of aggressive multimodal therapy
(surgery/chemotherapy) and evaluation of prognostic
factors are necessary for successful treatment in patients
with osteosarcoma relapse.
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Lung metastases in patients with osteosarcoma:
Radiological examination and the reality
A. Szafran ´ski, M. Rychlowska-Pruszyn ´ska, W. Woz ´niak
(The Clinic of Oncological Surgery in Children and Adolescents,
Institute of Mother and Child, Warsaw, Poland)
In the Institute of Mother and the Child, 382 osteosarcoma
patients aged between 3 and 26 years were treated between
1985 and 2003. 117 patients had lung metastases.
Treatment started with chemotherapy. After obtaining
the stabilization or the partial regress of changes, metas-
tases were removed by surgery. Patients with lung
metastases which were treated by comprehensive treatment
during the last five years were analysed on-the-job.
Conclusions: (1) Profitable is the effacement of metastases in
the period of the stabilization after use of chemotherapy.
(2) Intervention by surgery ascertains on average about
10% more metastases than are visible under examination
by CT scan. (3) Any doubts concerning unspecific changes
in visible lungs under CT examination, should be
interpreted as disadvantageous to the patient and be
verified by histopathological examination. (4) A most
exact method of removing of metastatic changes in the
lungs seems to be classical thoracotomy. (5) Repeated
(2–3 times) excision of metastases seems to be advisable.
The effacement of metastatic focuses makes the
obtainment of the many years survival of patients possible.
28% patients obtained five year survivals.
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The significance of biopsy in the conservative treatment
of bone tumours
M. Rychlowska Pruszyn ´ska, A. Szafran ´ski, W. Woz ´niak
(The Clinic of Oncological Surgery in Children and Adolescents,
Institute of Mother and Child, Warsaw, Poland)
The authors demonstrate the significance of bioptic
examination in the diagnosis and treatment of bone
tumours. A well conducted biopsy not only aims to allow
a diagnosis to be made, but also determines the possible
pathways of operational treatment.
The material subject to analysis is 382 cases of patients
with malignant bone tumours who were treated at the
Institute of Mother and Child within the years 1985–2003.
In all the cases, neoplastic material was taken from the
patient and examined histopathologically. This analysis
includes the surgical technique used, the location from
which the material was taken, and the complications that
occurred.
The analysis of the material shows that the biopsy
should be conducted by the same surgeon responsible
for the eventual surgical procedure, which confirms the
opinions of other authors interested in surgical treatment
of bone tumours.
When performed correctly, a biopsy enables for a saving
procedure to be performed, and may limit the number
of local recurrences and complications in the form of
inflammation.
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Rhabdomyosarcoma in children: 10 year experience
from a single institution in a developing country
T. Priya Kumari
1, Dr. Ratheesan
2, V.G. Chellam
3,
B. Rajan
2, P. Kusumakumary
1
(
1Pediatric Oncology,
2Radiation Oncology,
3Pediatric
Pathology, Regional Cancer Centre Trivandrum, India)
Aim: Clinicopathological study and survival analysis of
Rhabdomyosarcoma (RMS) in children (0–14yrs).
Methods: Retrospective analysis – RMS children treated
between January 1992 and December 2001. Grouping by
IRS system and survival by KaplanMeier method.
Results: 80 children had RMS. Median age 5.5 years.
Primary sites were head and neck in 42.5%, extremity in
21.3%, genitourinary in 13.75%. IRS grouping showed
Group1 3.8%, Group2 16.5%, Group3 74.7% and
Group4 5.1%. 61.25% had embryonal RMS. 63 children
were evaluable for treatment outcome. Group1 received
chemotherapy (VAC 1 year). Gp2 received chemother-
apyþlocal RT. Gp3 and 4 were given VACAdr cisplatin
and etoposideþRT. 11 children developed progressive
disease. 7 died, 2 had progressive disease and 5 had
infections. Overall survival was 76% and disease free
survival was 80% at 13 years. Survival by stage was
statistically significant (p value¼0.02 by log rank test)
Gp1 (100%) Gp2 (78%), Gp3 (77% ) Gp4 (0%). Survival
by histology showed better survival for embryonal RMS
(85%) compared to alveolar RMS (69%) p value (0.05).
Conclusion: In our centre majority of children with RMS
presented with advanced disease. An overall survival of
76% at 13 years could be achieved at our centre despite
the limited resources available in our developing country.
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Therapy of aggressive fibromatosis is still an open
question: A series of patients treated at a single
institution
Z. Tomasevic, D. Ristic
(Institute for Oncology & Radiology of Serbia, Belgrade,
Serbia)
Background: In the absence of large, randomized trials,
the precise role of systemic therapy in this rare disease is
unclear.
Methods: We reported a series of patients with inoperable,
deep extra-abdominal aggressive fibromatosis, treated
with combination of chemo-hormonal therapy. Therapy
consisted of six cycles standard CVP regimen, followed by
tamoxifen, 20mg daily.
Results: During 1995–2004, nine patients, concomitantly,
without selection, were included in this investigation.
Median age was 24, with predominantly male sex (6/9).
Extremities, was the most frequent localization (5/9).
Three patients had bulky disease (over 10cm). Five
patients underwent previous surgery, 3 wide excisions
and 2 palliative interventions. Complete remission was
observed in one patient, partial remission in four and
stabilization of disease in four patients. In category of
responders, median duration to onset of response was
10 months (range 4–14); median response duration was
32þ months.
Conclusions: Systemic treatment should be considered in
patients with aggressive fibromatosis for whom local
treatment approaches are primary not possible or have
failed.
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The different responses to IGF-I stimulation for
myogenin induction and cell cycle progression between
human alveolar and embryonal rhabdomyosarcoma
cells in comparison with non-tumor myoblasts
K. Tsuchiya, H. Hosoi, T. Sugimoto
(Department of Pediatrics, Kyoto Prefectural University of
Medicine, Kyoto, Japan)
Purpose: Elucidation of specific abnormalities on the
signaling pathway in rhabdomyosarcoma (RMS) for
developing new therapeutic agent(s) in the future
treatment.
Materials: Rh30 and KP-RMS-MS human alveolar rhab-
domyosarcoma (ARMS) cell lines, and Rh30mTOR-rr cell
line stably expressing rapamycin-resistant mTOR mutants
(mTOR-rr; S2035I), and RD and KP-RMS-KH human
embryonal RMS (ERMS) cell lines.
Methods: Western blotting analysis to see myogenin
induction and the signaling downstream insulin-like
growth factor receptor (IGF-IR). FACS analysis for the
cell cycle progression. (Results) In the two ARMS cell
lines, IGF-I response for myogenin induction were well
preserved. Rapamycin inhibited myogenin induction, but
not in Rh30mTOR-rr cells, suggesting that the signal goes
mainly through IGF-IR/mTOR pathway. IGF-I, however,
did not cause G1 arrest as observed in non-tumor myoblast
C2C12 cells, bur rather stimulated the cell cycle progres-
sion. On the contrary, in the two ERMS cell lines, IGF-I
did not show any influence upon myogenin induction,
G1 arrest or cell cycle progression.
Discussion: These differences on responses to IGF-I among
human ARMS, ERMS and non-tumor myoblast cells
may give a clue to further understanding of their different
oncogenesis and clinical behaviors, and to discovery of new
possible therapeutic target(s).
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Free vascularized bilateral fibula graft: Biological
reconstruction following resection of malignant bone
tumors of the lower-extremity
P.-U. Tunn, K.T. Moesta
Poster Abstracts 111(Clinic for Surgery and Surgical Oncology, Charite ´ Campus
Buch, Berlin, Germany)
Purpose: We present the free vascularized bilateral fibula
graft as a method for reconstruction of long bones after
resection of malignant tumors.
Patients and methods: Between 11/2000 and 08/2003 five
patients (2 female, 3 male; average age: 15.2 years)
received a biological reconstruction following resection of
a malignant bone tumor (Ewing sarcoma: n¼4, osteosar-
coma: n¼1) using a free vascularized fibula graft and plate
fixation. Tumors were located in the femur (n¼3) and
tibia (n¼2). Defects of median 16.4cm (11.5–23cm)
had to be bridged. All Patients had multimodal treatment
according to the EURO-E.W.I.N.G or COSS-96 protocol
respectively. The median observation period was 52
months.
Results: R0-resection was achieved in all cases, none of
the patients had local recurrence. Radiographic signs of
osseous remodelling could be detected after two months.
Full weight bearing on the affected leg was permitted
after 6–10 months. Complications occurred in 3 patients
(haemorrhage: n¼1, pseudarthrosis: n¼1, fracture:
n¼1). None of the complications led to failure of the
reconstruction or to amputation. MSTS ranking was very
good in 3 and good in 2 patients.
Discussion: Biological reconstruction of osseous defects is
always desirable if possible. Good functional results can be
obtained by using free vascularized bilateral fibula grafts in
the lower extremity.
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Ewing’s sarcoma family of tumors and spinal cord
compression: The Pinda protocols experience
M. Villarroel
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(
1The Programa Infantil de Drogas Antineopla ´sicas (PINDA)
Ministry of Health, Chile: Hospital Luis Calvo Mackenna,
Santiago,
2Hospital Roberto del Rı´o, Santiago,
3Hospital
Exequiel Gonza ´lez Corte ´s, Santiago,
4Radiotherapy, Instituto
Nacional del Ca ´ncer, Santiago,
5Hospital So ´tero del Rı´o,
Santiago,
6Hospital Clı´nico, Valdivia,
7Hospital Van Buren,
Valparaı´so,
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Objectives: Report the experience of 35 patients with
spinal cord compression, among 161 patients treated for
Ewing’s sarcoma family of tumors according to 3 national
protocols (PINDA 87, 92, 98).
Material/methods: Fourteen males, median age 9 years; 16
patients had vertebral, 19 paravertebral tumors. Primary
sites: Cervical 6, thoracic 8, lumbar 13, sacral 8. Pain and
neurologic deficit was present in all patients. Twenty-six
patients had localized disease, 22 had tumors >8cm, 15
were PNET. All patients received chemotherapy.
Results: Laminectomy in 26 patients, 22 with neurological
recovery. Seven patients received radiotherapy only,
5 are disease-free. Twenty-three received RT median
dose 45Gy. Five patients didn’t receive RT (2 complete
resection, 2 pogressive tumors, 1 refused treatment), all
relapsed.
Median follow-up 102 months; 5-year overall survival
and EFS, for localized tumors: 51.6% and 66.1%,
(13 disease-free); 25% and 30% for metastasic tumors.
Relapses: local 7, distant 2, both 4. Five patients
progressed, 1 refused treatment, 1 had a secondary
malignancy.
Conclusions: Results are comparable to those of other
patients wit EFT and were not affected by treatment era,
primary site or tumor size. Early surgical debulking and
RT as local treatment, minimize neurologic sequelae and
improves EFS.
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Multimodal therapy for children and adolescents with
Ewing’s sarcoma family of tumors. Preliminary results
of Chilean National Protocol Pinda 98
M. Villarroel
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Ministry of Health, Chile: Hospital Luis Calvo Mackenna,
Santiago,
2Hospital Roberto del Rı´o, Santiago,
3Hospital
Exequiel Gonza ´lez Corte ´s, Santiago,
4Radiotherapy, Instituto
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Objectives: Evaluate a pilot trial, (high dose vincristine,
doxorrubicin, cyclophosphamide, and ifosfamide, etopo-
side), in the treatment of Ewing’s sarcoma and primitive
neuroectodermal tumor of bone or soft tissue. Estimate
5-year overall survival and event-free survival, improve
local control, identify prognostic factors and define
toxicity.
Methods: Fifty-four eligible patients were enrolled
April 1998–December 2003; 46 completed chemotherapy.
Local control: Irradiation to the primary tumor 55.6Gy,
complete surgical excision, or both.
Results: Thirty-three male patients, median age 10.5 years,
38 had localized tumors, 23 had tumors >8cm. Eight
patients had soft tissue tumors, 21 PNET. Twenty-one
of 32 patients with localized tumors, remain disease
free, median 44 months. Relapse: Local in 5 cases,
metastasic in 1 and both in 4. Nine patients died of
tumor progression, 1 of a secondary malignancy. At 5
years, OS was 69.7% and EFS 55.7%. One of 14 patients
with metastasic disease, remains disease free for 16
months.
Conclusions: There was an improval in survival for
patients with localized tumors (PINDA 92 EFS 5-years
47%). Relevant prognostic factors: extremities tumors
(EFS 5-years 88.9% vs. 38.7%), ES histology (71.5%
vs. 37.3% for PNET) and response to induction
chemotherapy (complete remission 5-year EFS 85.7%
vs. 34.4%).
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Value of FDG-PET imaging for primary staging of
malignant pediatric sarcomas within a prospective
multicenter study (PET 2003)
T. Voelker
1,2, D. Misch
1,2, B. Sto ¨ver
3, R. Felix
2,
H. Amthauer
2, G. Henze
1
(
1Department for Pediatric Oncology,
2Clinic of Radiology,
Nuclear Medicine and Radiation Oncology,
3Clinic of
Radiology, Department of Pediatric Radiology, Campus
Virchow-Klinikum, Charite ´ – Universita ¨tsmedizin Berlin,
Germany)
Purpose: Evaluation of FDG-PET in comparison to
conventional imaging modalities (CIM).
Patients/methods: In this prospective multicenter study,
20 pt (12f, 8m; mean age: 12.4y) with a histologically
proven, sarcoma (osteosarcoma n¼5, Ewing-sarcoma
n¼7, rhabdomyosarcoma n¼8) were examined by
FDG-PET for primary staging (n¼17) and for
detection of recurrence (n¼3) resp. The results
were compared with CIM (MRI, CT-thorax, bone-scan)
within a 10 day interval to the FDG-PET scan.
112 Poster AbstractsHistology and clinical/imaging follow-up served as gold
standard.
Results/discussion: FDG-PET and CIM correctly detected
the primary tumor in 17 pts 8/17 pts. had locoregional,
distant or mutiple metastases which were correctly
indicated by FDG-PET (lung n¼2, distant n¼4, multiple
n¼5) 5/8 pts. Concordantly showed metastatic disease in
CIM (lung n¼2, other n¼1, multiple n¼2). In contrast
to CIM, FDG-PET revealed a more extensive metastatic
disease in 7 patients (42%), resulting in upstaging with a
consecutive change of therapy. Concerning the detection
of local recurrences FDG-PET and CIM were true positive
in two, and false negative in 1/3 pts. FDG-PET and CIM
are suitable for the staging of primary and recurrent
sarcomas, however, due to its apparent higher sensitivity,
FDG-PET has a potential impact on further treatment
strategy.
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Retrospective analysis of FDG-PET for staging of
malignant childhood sarcomas
T. Voelker
1,2, T. Denecke
2, C. Furth
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2, G. Henze
1, H. Amthauer
2
(
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Klinikum, Charite ´ – Universita ¨tsmedizin Berlin, Germany,
3EMBL, European Molecular Biology Laboratory, Heidelberg,
Germany)
Purpose: Evaluation of FDG-PET in staging of childhood
sarcomas in comparison to conventional imaging
modalities (CIM).
Patients/methods: 22 pts (12f, 10m; mean age: 11.4y)
with a histologically proven, sarcoma (osteosarcoma
n¼12, Ewing-sarcoma n¼4, rhabdomyosarcoma n¼6)
were examined by PET for staging (n¼14) and recurrence
detection (n¼8). The results were compared with CIM
(MRI, CT-thorax, bone-scan) within 10 day interval to
the PET. Histology and clinical/imaging follow-up served
as gold standard.
Results/discussion: In 14 pts with sarcomas PET and CIM
correctly detected the primary tumor. 4/14 pts showed
metastases: Lung n¼1 (PET neg., CIM pos.), distant
n¼3 (2/3: PET pos., CIM neg. and 1/3: concordantly PET
and CIM false pos.)
In 5/8 pts with relapse, restaging by PET and CIM was
concordant. In one pt CIM correctly indicated a lung
metastasis, undetected by PET. In contrast, PET depicted
an additional axillary lymph node manifestation, unnoticed
in CIM. In 3/3 pts, a recurrence was correctly excluded by
both modalities. PET and CIM are suitable for the staging
of sarcomas and the detection of recurrences. However,
whereas PET appears to be superior to CIM in the
detection of distant metastases, its use for lung metastases
is limited.
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Functional expression of chemokine receptors in child-
hood osteosarcoma
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Osteosarcoma is the most frequent tumor of the bone
in childhood. The major cause of death in osteosarcoma
patients is tumour metastasis. Chemokines are small
chemotactic proteins initially characterized by their
ability to control leukocyte chemotaxis. These proteins
have been subsequently shown to regulate proliferation,
differentiation, migration and homing of diverse cell
types. Chemokines are also thought to be active
participants in malignant disease. All chemokines med-
iate their biological effects through a family of seven-
transmembrane G-protein-coupled receptors. The goal
of this study was to characterize the functional expres-
sion of chemokine receptors on childhood osteosarcoma
to identify potential roles for specific chemokines/
receptors in the development and progression of tumor
metastasis and micrometastasis. We demonstrate func-
tional expression of chemokine receptor CCR1, CCR4,
CCR7, CXCR4, CXCR5 and CX3 CR1 on the
osteosarcoma cell lines SAOS, HOS and U2-OS using
quantitative Taqman analysis, FACS and modified
Boyden chamber assays. In parallel, the expression of
these receptors was found on 20 pediatric osteosarcoma
tumor biopsy specimens. Our data suggest a potential
role for chemokines in the biology of childhood
osteosarcoma. Insight into mechansisms that underlie
metastasis may help facilitate novel therapeutic
approaches in future.
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Identification of specific markers for bone tumor
progenitor subtypes
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Osteosarcoma is the most common malignant bone
tumor in children and adolescents. Several subtypes of
osteosarcoma can be identified based on morphology.
Currently we lack a clear understanding of the intrinsic
properties that distinguish one subtype from another,
and how these differ in their response to similar
conditions in vitro and in vivo. Mesenchymal stem
cells have a multilineage differentiation potential and
are characterized by lack of the hematopoetic markers
CD45, CD14, CD11 and CD34, but express CD29,
CD73 (SH3), CD105 (SH2), CD166. To date, no
individual specific marker adequately identifies these
cells. The goal of this study is the development of
methods for identifying, isolating and characterizing
specific precursor populations at intermediate stages of
differentiation of osteocytes, and their relationship to
tumor-generating cells. To this end, SV40 large T
antigen was used to immortalize human mesenchymal
stem cells. These cells were then used as immunogen in
rat to generate a panel of monoclonal antibodies
directed against surface proteins of the progenitor cells.
These antibodies are largely negative for peripheral
blood cells, but positive for primary human mesen-
chymal stem cells. They show a dramatic variability in
positivity on the osteosarcoma cell lines U2-OS, HOS,
Poster Abstracts 113SAOS, MG63 and CRL and some have been adapted
for use in immunohistochemistry.
P173
Pediatric Soft Tissue Sarcomas (STS) in Iran
P. Vossough
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(
1Department of Pediatric Hematology and Oncology, Iran
University of Medical sciences, Aliasghar Children’s Hospital,
Iran,
2Department of Pediatric Hematology and Oncology,
Shahid Beheshti University of Medical Sciences, Shohada
Hospital, Iran,
3Department of Pediatric Hematology and
Oncology, Iran University of Medical Sciences, Aliasghar
Children’s Hospital, Iran,
4Department of Pediatric
Hematology and Oncology, Semnan University of Medical
Sciences, Amir Al Momenin Children’s Hospital, Iran,
5Department of Pediatric Hematology and Oncology, Tehran
University of Medical Sciences, Bahrami Children’s Hospital,
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Background: STSs account for 7% of all childhood tumors.
Our survey was an epidemiologic study on soft tissue
sarcoma in a single institution.
Methods and materials: In a cross sectional analytic study,
the patients were evaluated for age, sex, histologic type
of cancer, stage, primary site of tumor, chemotherapy
protocol and outcome.
Results: STSs were the fifth most frequent malignancies
amongst patients of this center (253 cases). The rate
was 4.7% and about 85% of them were rhabdomyo-
sarcoma. Others types were malignant fibrous histio-
cytoma 3.9%, angiosarcoma 3.13%, fibro sarcoma
2.34% and undifferentiated sarcoma 1.56%. M/F ratio
were 1.37. The average age of children was 5.3 
0.6yrs old. About 60.5% of patients were younger than
six years. Most patients were in stage I–II (81%).
Embryonal subtype was 75%. Primary site of involve-
ment were 57.98% in head and neck, 6.72% in
extremity and 35.29% in trunk. The overall 5 years
survival rate was 72%. Relapse occurred in 25% of
patients. Chemotherapy protocol included VCR/ACT/
CPA/ADR in 32.85%, VCR/ACT 35.42%, VCR/ACT/
CPA in 31.73% and IF/VCR.
Conclusion: The prognosis of STS varies greatly depending
on the age, primary site, tumor size, histologic grade
and extent of disease at diagnosis. The most patients in
stage I–II had good prognosis.
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L1 cell adhesion molecule (CD171) expression in gastro-
intestinal stromal tumors (GIST)
J.T. Kaifi
1, K.A. Gawad
1, A. Strelow
1, E.F. Yekebas
1,
R. Wachowiak
1, W. Schaefer
2, M. Schachner-Camartin
3,
J.R. Izbicki
1
(
1Klinik fuer Allgemein-, Viszeral- und Thoraxchirurgie,
2Institut fuer Pathologie,
3Zentrum fuer Molekulare
Neurobiologie, Universitaetsklinikum Hamburg-Eppendorf,
Martinistrasse 52, 20246 Hamburg, Germany)
Background: After surgical resection the outcome of
gastrointestinal stromal tumors (GIST) is hardly predict-
able. Cell adhesion molecules have an essential function in
tumor progression and recently this was demonstrated for
L1 cell adhesion molecule (L1CAM; CD171). The aim of
our study was to determine expression of L1CAM in GIST
and correlate expression with development of metastases.
Methods: We retrospectively analyzed L1CAM expression
in 55 surgically resected GIST (primary tumors or
metastases) by immunohistochemistry on paraffin sections.
Staining was performed by peroxidase technique with
monoclonal antibody UJ127.11 against L1CAM.
Expression results were compared with development of
metastases in these patients.
Results: L1CAM was detected in 36 (65.5%) of 55 GIST.
23 (41.8%) of 55 patients suffering from GIST developed
metastases and among these 13 were positive for L1CAM.

2 test did not show a significant association between
L1CAM expression and metastasizing GIST (p¼0.264
by Fisher’s exact test).
Conclusion: Our data suggest that L1CAM is expressed in
a high number of GIST and could potentially serve as a
marker for this tumor. L1CAM expression did not
correlate with development of metastases in GIST patients
and is consequently not a predictor for metastasizing
GIST.
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Chemosensibilization in patients with unresectable
soft tissue and osteogenic sarcomas by focused micro-
waves achieving intratumoral tissue temperatures of
42 to 44 C
R. Wessalowski
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4, R. Ladenstein
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(
1Clinic of Pediatric Oncology, Hematology and Immunology,
2Institute of Diagnostic Radiology,
3Department of Radiation
Oncology, Heinrich Heine University Dusseldorf,
4Clinic of
Pediatric Hematology and Oncology, Westfa ¨lische Wilhelms
University, Mu ¨nster, Germany,
5St. Anna Children’s Hospital,
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7Children’s
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Background: Multidisciplinary risk-adapted regimens have
achieved remarkable cure rates in sarcoma patients.
However, a number of patients still fail therapy due
to insufficient local tumor control. We and others
have previously shown that the application of heat at
temperatures of 40–44 C increases the cytotoxicities of
anticancer drugs including N-lost derivatives, cytotoxic
antibiotics and platinum analoga. Therefore, we investi-
gated whether thermochemotherapy (TCH) can be utilized
to facilitate surgical resection in otherwise nonresectable
sarcomas and whether this combination improve local
tumor control.
Patients/methods: This study enrolled 25 patients
(female¼9, male¼16, age 1–59 years), 5 osteogenic,
20 soft tissue sarcomas. Indication: loco-regional relapse
(n¼9), unresectable tumor (n¼16). Site: pelvis (17),
abdomen (1), head/neck (2), extremities (4), spine (1).
Hyper-PEI-protocol: 4 1800–2000mg ifosfamide/qm,
4 100mg etoposide/qm, 2 40mg cisplatin/qm plus
2 hyperthermia (42–44 C, 1h) or RHT-95-protocol:
1 50mg adriamycin/qm, 4 1500mg ifosfamide/qm,
2 100mg etoposide/qm plus 2 hyperthermia (42–
44 C, 1h).
Results: 141 TCH-courses (279 heat sessions) were
applied, 6 patients achieved CR, 12 PR. TCH was
followed by surgical resection in 15/25 and/or radiotherapy
in 6/25 patients. Outcome: 13NED, 2AWD, 10DOD.
Conclusion: TCH shows substantial therapeutic efficacy
and facilitates complete tumor resection in 11/15 operated
patients. Multimodal treatment including TCH leads to
sustained remission in about 50 per cent of patients.
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The value of positron emission tomography scanning
with fluorine-18 deoxyglucose in the detection of local
and metastatic disease in childhood soft tissue and bone
sarcomas and evaluation of response to chemotherapy
M. Weyl Ben Arush
1, R. Bar Shalom
2, S. Postovsky
1,
Z. Keidar
2, A. Ben Barak
1, R. Elhasid
1, I. Zeidman
1,
M. Haimi
1, I. Meller
3, Y. Kollender
3, O. Israel
2
(
1Pediatric Hematology Oncology Department, Rambam
Medical Center, Haifa, Israel,
2Nuclear Medicine
Department, Rambam Medical Center, Haifa, Isreal,
3Oncology Orthopedic Unit, Sorasky Medical Center, Tel
Aviv, Israel)
Aim: To assess the diagnostic value of positron emission
tomography with fluorine-18-deoxyglucose (FDG-PET/
CT) in the detection of local, recurrent and metastatic
sarcomas (S) in children and evaluation of response to
standard chemotherapy.
Patients/methods: 26 children, 14 boys, 12 girls, median age
12.7 years. FDG-PET scans were compared to surgical
pathology or clinical follow up (FU) for a median of
6 months (5m–48m). 8 pts performed FDG-PET at
diagnosis, restaging, and detection of recurrence, 11 pts
at diagnosis and restaging, 15 pts at restaging and FU.
Eleven pts were evaluated for response to chemotherapy.
Results: For detection of local disease, FDG-PET had a
sensitivity of 0.92, specificity – 0.94 and accuracy – 0.93,
detection of non pulmonary metastases: sensitivity – 100,
specificity – 0.50, accuracy – 0.70, detection of lung
metastases: sensitivity – 0.66, specificity – 0.91, accuracy –
0.86.There were 5 false negative, 5 false positive. FDG
uptake values decreased significantly for 6 pts with
favorable histological response to chemotherapy.
Conclusions: FDG-PET is a sensitive test to detect
local disease and non pulmonary distant recurrences of
sarcomas. In the future, FDG-PETscanning in childhood
sarcomas has to be directed to the clinical implication for
detection and treatment evaluation of childhood sarcomas.
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Differences in survival between study groups detected in
an international randomised study: Analysis of Eicess 92
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(
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Background: EICESS 92 was a randomised study involving
647 patients with Ewing tumours conducted by two study
groups, UKCCSG and GPOH, between 1992–8. Survival
at 5 years for all patients was 62.6% (95% CI 58.8–66.5);
for GPOH patients 66.5% (95% CI 62–71.1) and for UK
patients, 54.3% (95% CI 47.3–61.4, p¼0.009).
Methods: A detailed analysis of trial data to find cause for
survival difference.
Results: This could not be accounted for by differences
in patient baseline characteristics or differences in delivery
of chemotherapy. Differences were evident between the
frequencies of local treatment modalities. Surgery or
radiotherapy alone was more often used in UK patients.
Pre-operative radiotherapy was used often in the GPOH.
Local recurrence with or without metastatic recurrence was
commoner in the UK (21.4% vs. 7.1%). Survival differed
according to local treatment received (surgery alone best,
radiotherapy alone worst, p¼0.0001). Analyses of sub-
groups failed to identify a clear causative association
between local treatment modality and survival differences
between the 2 groups.
Conclusion: Differences in outcome can occur between
study groups within the same trial. Different approaches to
local treatment of Ewing’s tumours led to higher local
recurrence rates in UK patients and may have been
associated with inferior survival.
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Fibrodysplasia ossificans progressiva in children
A. Szymborska, T. Klepacka, M. Szeliga, W. Woz ´niak
(The Clinic of the Oncological Surgery in Children and
Adolescents, Institute of Mother and Child, Warsaw, Poland)
Fibrodysplasia ossificans progressiva (FOP) is rare genetic
disease, heredited by autosomal dominant way.
Characterized by heterotopic forming bone tissue in
subcutaneous and muscular tissue. In majority cases it
begins in the first decade of life. Growing pain symptoms
with oedema of soft tissue and limited joint mobility leads
to disability.
Localisation most often in skeletal muscles, muscles of
extremities and small muscles of fingers. In diagnosis
fundamental role plays the presence of abnormalities of
finger bones as halux, short halux, microdactylia and
different bone deformations. Histopathological features
often suggest osteosarcoma, scleroderm, fibrosarcoma,
osteodystrofia Albrighta, neurofibromatosis. Important
role in diagnosis seems to have BMP-4.
There are no elaborated standards for clinical treatment
in FOP. Also there is no effective method of treatment
FOP.
Gen therapy with BMP-4 raises the hope for effective
FOP management.
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Bone tumors in pelvis in children: Limb salvage
operations
W. Woz ´niak, M. Rychlowska-Pruszyn ´ska, M. Kuczabski,
T. Izbicki, T. Walenta, A. Szafran ´ski, K. Bilska, J. Kijowski
In the period of 1985–2003 more than 400 patients with
primary bone malignant tumors (osteosarcoma, Ewing
sarcoma, chondrosarcoma) were treated in the Institute of
Mother and Child in Warsaw. In all of them contemporary
methods of complex treatment were applied, including
chemotherapy, surgery and/or radiotherapy. Localization
of primary neoplasm’s focus in the pelvis is less common
and the radical surgery is problematic in children.
We present a group of 19 patients in whom following
operations were preformed: 2 ‘‘classical’’ hemipelvec-
tomies—excision of pelvis bone with exarticulation of
lower extremity; 17 internal hemipelvectomies—excision
of pelvis bone sparing the lower extremity; 3 patients, type
I—hip bone ala excision above the hip articulation; 2
patient, type II A—excision of the hip bone ala with the hip
articulation; 3 patients, type II B—ischiadic and pubic
bone excision with the hip articulation; 4 patients, type II
C—excision of the hip bone ala with the hip articulation,
public and ischiadic bones; 2 patients, type I/III; 3 patients,
type III—pubic and ischiadic bones excision under the hip
articulation.
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last four years. In reconstruction was use bone grafts metal
and endoprothesies plates. Ten pas are alive with the
follow-up of 20–60 months. The patients have been
rehabilitating the salved limb.
Conclusions: 1. The internal hemipelvectomy is a less
mutilating operational treatment, performed within the
complex therapy of malignant bone tumors in children and
youth. 2. The internal hemipelvectomy allows the limb
salvage and efficacious patient’s walk. 3. The internal
hemipelvectomy requires a very well prepared operation
team, good technical background allowing reconstruction
of the resected bones rehabilitation in the postoperational
time.
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Chemotherapy in osteosarcoma: Results of treatment in
own material by the Polish Pediatric Solid Tumor Group
W. Woz ´niak, A. Chybicka, J. Boguslawska–Jaworska,
J. Bohosiewicz, J. Kowalczyk, P. Kolecki, M. Korzon,
M. Liebhart, M. Rybak, M. Wysocki, W. Golebiowski,
B. Kazanowska, J. Kijowski, A. Szafran ´ski, M. Rychlowska,
T. Izbicki, M. Kuczabski, J. Weclawek-Tompol, K. Katski,
W. Madziara, M.S. Popadiuk, M. S. Boruczkowski,
M. Leda
(Polish Pediatric Centers for Osteosarcoma Treatment, The
Clinic of the Oncological Surgery in Children and Adolescents,
Institute of Mother and Child, Warsaw, Poland)
Objectives: In the analysis two chemotherapy regimes:
EORTC and the adopted French HD-MTX protocol
(HD-MTXþDOXO/IFOþ), which are using in the
treatment of osteosarcoma patients by Polish Pediatric
Solid Tumor Group, were presented.
Methods: According to results of treatment in osteosarcoma
patients, which were treated by these two chemotherapy
regimens, the primary analysis was made, to compare in
the standardized way the efficacy of two osteosarcoma
chemotherapy regimens.
Results: In the period 1998–2003, 111 patients with
osteosarcoma were treated in 6 Polish Pediatric
Oncological Centers. 56 patients were treated by
EORTC protocol, 24 by the adopted French HD-MTX
protocol (HD-MTXþDOXO/IFOþETO) and 15
patients by the SFOP/different protocols. After neoadju-
vant chemotherapy the surgical treatment was performed.
Limb salvage surgery was performed in 41 from 56 patients
which were treated by EORTC protocol, in 20 from 24
treated by SFOP protocol.
52 patients are alive from the group treated by EORTC
protocol. In the group which were treated by SFOP
protocol, 28 alive, in the group treated by SFOP/different
protocol, 11 alive from 15 patients, with mean follow-up
60 months.
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Clear cell sarcoma of soft tissues: An unexpected
diagnosis
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Clear cell sarcoma is a rare soft tissue neoplasm whose
clinical behaviour and outcome has not been previously
characterized in children. We report a case of clear cell
sarcoma of soft tissues, affecting the great toe.
Patients/methods: A four-year-old boy presented with pain
in a swelling overlying the terminal interphalangeal joint of
the great toe. This lesion had been present at birth and
had grown slowly, with no bleeding or colour change.
Examination showed a discoloured firm swelling measur-
ing 1 1.5 centimetre, over the proximal part of the hallux.
No other abnormality was detected.
Results: An ultrasound scan was suggestive of a well-
encapsulated haemangioma. After an initial observation
period of six months, a decision to excise the lesion was
taken in view of pain and difficulty wearing shoe, even
though size did not change significantly. Microscopically,
it was multinodular, intersecting and infiltrating tendinous
tissue, extending to the excision margins. Spindled cells
and multinucleated giant cells were present with melanin
deposition, mild pleomorphism and mitoses. On staining,
the cells were positive for vimentin, HMB45, NSE, S100
and negative for MNF 116, CD68, CD1a, ASMA and
desmin. CD34 highlighted vasculature and giant cells were
negative with Factor 13a. Ki67 showed mild proliferation.
The diagnosis was Clear Cell Sarcoma of soft tissues with
residual microscopic disease, categorised as stage 2 (IRS
grouping). There was no evidence of metastatic spread on
bone scan and CT of chest and abdomen. There was no
evidence of loco-regional spread on MRI scan of the lower
limb and inguinal region. In view of the residual micro-
scopic disease, amputation of the great toe was undertaken
to obtain clear margins. The functional outcome was
satisfactory.
Discussion: Clear Cell Sarcoma of soft tissues is a rare
tumour in children. There are only few reports among
children in literature.
(1,2) UKCCSG is developing a
protocol for the non Rhabdomyosarcoma Soft Tissue
Tumours (ESSG-NRSTS). Complete surgical resection
with negative margins is the most effective treatment for
this disease. Patients with metastatic disease are candidates
for multi-institutional chemotherapy trials.
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Identification of regulatory proteins critical for T-cell
activation in blood of sarcoma patients
E.M. Zadorin, K.V. Shevchenko
(Central Research Laboratory Centre, Kiev, Ukraine)
The activation of T cells, mediated by the T-cell receptor
(TCR), activates a battery of specific membrane-
associated, cytosolic and nuclear proteins. Identifying the
signalling proteins downstream of TCR activation will help
us to understand the regulation of immune responses and
will contribute to developing therapeutic agents that target
immune regulation. In an effort to identify novel signalling
molecules specific for T-cell activation we undertook a
large-scale dominant effector genetic screen using retro-
viral technology. We discovered molecules not previously
known to have functions in this pathway, including a novel
protein with a RING domain (found in a class of ubiquitin
ligases; we call this protein TRAC-1), transmembrane
molecules (EDG1, IL-10R and integrin 2), cytoplasmic
enzymes and adaptors (PAK2, A-Raf-1, TCPTP, Grb7,
SH2-B and GG2-1), and cytoskeletal molecules
(moesin and vimentin). Furthermore, using truncated
Lck, PLC1, EDG1 and PAK2 mutants as examples, we
showed that these dominant immune-regulatory molecules
interfere with IL-2 production in oncology patients
primary lymphocytes. This study identified important
signal regulators in T-cell activation. It also demonstrated
116 Poster Abstractsa highly efficient strategy for discovering many components
of signal transduction pathways and validating them in
treatment of oncology patients.
P183
Oxidative stress regulates the expression and activity of
transcription factor activator protein-1 in rat sarcoma
models
K.V. Shevchenko, E.M. Zadorin
(NBS, Kiev, Ukraine)
The transcription factor activator protein-1 (AP-1), com-
posed of the Fos and Jun families of proto-oncogenes, is
induced in response to extracellular signals as part of
an immediate-early gene response. We hypothesize that
teratogens such as oxidative stress induce AP-1 activity
in the rat conceptus and that this AP-1 response may
either trigger abnormal development or protect the
embryo against insult. To test this hypothesis, the AP-1
response was assessed in whole embryos in culture. There
was a significant elevation in the oxidized to reduced
glutathione ratio in the embryo and yolk sac within
0.25hr of the initiation of culture, peaking at 0.5hr;
this is indicative of heightened oxidative stress. Thus,
there are tissue-specific differences in the duration of
the AP-1 response in the conceptus. Addition of the
antioxidants catalase and superoxide dismutase, but not
vitamin E, prevented the rise in the oxidized to reduced
glutathione ratio and also inhibited the induction of AP-1
mRNAs and DNA-binding activity. The AP-1 response
to oxidative stress may determine how the conceptus
responds to sarcoma. These results can be used in
medicine.
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Reasons for medical facility visits for teenage & younger
European children with sarcomas attending Barretstown
Therapeutic Camp: A four year comparative study for
quality of life
E. Kinsella
1, T. Dignan
1, F. Breatnach
1, P. Zeltzer
2
(
1Barretstown Gang Camp, Dublin, Barretstown, Ballymore,
Ireland,
2Shilysca Inc. Los Angeles, USA)
Purpose: Assess medical facility visits (MFV) for children
with sarcomas (S)
Methods: Prospective collection of needs/events over 28,
10-day camps (1998–2001). Campers: (a) 7–13yrs, (b)
>14–17yrs. Teen Camp. Staff¼2 volunteer physicians,
3–4 nurses/75 campers. Collected data were demographics,
reason for visit (disease-related?).
Results: 2246 children ages 7–18, 26 countries, were
supported by 836 staff. Median age¼12; M/F¼1.3/1.
Most common diagnoses: Leukemia¼30%, lymphoma¼
15%, sarcoma¼13% (283); other¼42%. Subgroups:
Ewing-S¼100; osteo-S¼94; rhabdomyo-S¼48; S¼13,
soft tissue-S¼12; synovial-S¼4; other¼12. Age¼13þ3.
Countries of origin had different distributions than
other cancers: Spain, Hungary¼highest. Age distributions
differed. Total of 3378 MFV for campers and 1785 for
staff. Of 283 S pts, 119 were available to assess visit
frequency (yrs 2000–2001); S children made 227 visits
(range 0–10) x¼1.9. M/F visit freq¼1.0; other
diseases¼1.5. Most frequent MFV were misc. complaints
(50%), pain, headache, cuts/abdominal pain. 31%
MFV were disease/treatment related vs. 10% for other
cancers.
Conclusions: (1) With appropriate medical and staff
support, Barretstown demonstrated a high safety profile
for S pts. (2) Most medical interventions were related to
normal camp issues: bee sting, activity-related injury, etc;
69% MFV were not disease-related. (3) Staff account for
35% total visits.
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The EpSSG RMS2005: A randomized trial for localised
rhabdomyosarcoma
G. Bisogno, C. Bergeron, M. Jenney, E. Koscielniak,
S. Gallego, C. Rechnitzer, B. Kazanowska, A. Schuck,
A. Kelsey, V. Ninfo, G.L. De Salvo, A. Ferrari, J. Treuner,
M. Carli, O. Oberlin, M. Stevens
(EpSSG)
Introduction: RMS2005 is the first protocol launched
by the European paediatric Soft tissue sarcoma
Study Group (EpSSG). It addresses the treatment
of young people (<21 years) with non-metastatic
rhabdomyosarcoma.
The protocol comprises a randomised trial for ‘‘high risk
patients’’ and observational studies for patients categorized
in other risk groups.
Methods: The analyses of previous European studies has
identified a High Risk Group: patients in IRS group II or
III, with favourable pathology but unfavourable site and
tumour size or age; patients in IRS Group I, II or III with
favourable pathology, site, size and age but with nodal
involvement; all patients with unfavourable histology
except alveolar N1.
One aim of the study is to improve the outcome
of these patients by implementing two novel strategies:
(1) the intensification of initial chemotherapy adding
anthracyclines to the standard IVA regimen, (2) the
adoption of a low dose maintenance treatment after 1st
line chemotherapy.
Treatment: Patients will be randomized on day 0 to
receive IVA (ifosfamide, vincristine, actinomycin D) vs.
IVADo (IVAþDoxorubicin) over the initial 4 cycles.
This is followed by 5 IVA cycles for all patients. This
combination has been tested in a pilot study and judged
feasible. After the standard 9 cycles of chemotherapy
patients in complete remission will be randomised to stop
treatment or receive maintenance chemotherapy compris-
ing low dose cyclophosphamide and vinorelbine for
6 months.
Surgery will depend on initial IRS group staging.
All patients will receive radiotherapy with doses ranging
between 36Gy and 50.4Gy depending on histology,
resection margins and tumour response.
Conclusions: Increasing European collaboration should
allow the exploration of better treatment strategies for
children with RMS through randomised studies.
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Skip metastases in osteosarcoma. Experience of the
cooperative osteosarcoma study group
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Poster Abstracts 117Purpose: Detection of ‘‘Skip’’ metastases (SM) herein
defined as second, smaller foci of OS occurring in the
same bone or as second lesion(s) of OS on the opposing
side of a joint is rare in patients with high grade
osteosarcoma (OS). The prognosis for OS patients
presenting with SM is reported to be catastrophic.
Patients and methods: The authors surveyed the medical
records of 1765 consecutive collected patients with newly
diagnosed high-grade OS of bone registered in the neo-
adjuvant COSS studies and identified 24 patients (1.4%)
with unequivocally proven SM (radiographically by
progression in 1 and histologically in 23). All 24 patients
were treated by an aggressive surgical approach coupled
with polychemotherapy. Demographic, diagnostic, tumor,
and treatment related variables; response and survival data
were analyzed.
Results: SM were identified preoperatively in 11/24 (46%)
patients by bone scan, 8/22 (36%) by plain X-ray, 5/11
(45%) by CT, and 15/19 (79%) by MRI. A complete
surgical resection of all clinically detectable tumor sites had
been achieved in 22/24 patients (92%) during front line
therapy. With a median follow-up of 4.4 years (7 years for
survivors), 12 patients (50%) were alive, all in continuous
complete surgical remission. Prognosis was significantly
better in the 16 patients with SM occurring within the
same bone of the primary, when compared to the 8 patients
with transarticular SM (5-year survival 62%, SE¼12% vs.
25%, SE¼15%).
Conclusion: SMs are rare in osteosarcoma and preoperative
detection relies on appropriate diagnostic imaging.
Aggressive multimodal therapy holds the promise to
achieve cure, especially in those patients in whom SM
occur within the same bone of the primary lesion.
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The role of liposomal anthracyclines added to ifosfamide
in the treatment of advanced soft tissue sarcomas
J.M. Siehl, U. Keilholz, A. Schmittel, G. Hu ¨tter,
H. Szelenyi, E. Thiel
(Medizinische Klinik III, Charite ´ Universita ¨tsmedizin Berlin,
Campus Benjamin Franklin, 12200 Berlin, Germany)
Actually the standard chemotherapy for advanced
soft-tissue sarcomas is a combination of doxorubicin and
ifosfamide. For both drugs there is a dose-response
relationship. The main problem, however, is a high rate
of toxicities.
Liposomal encapsulation of anti-cancer drugs is a
strategy pursued to reduce toxicity and improve tumour
uptake. Liposomal anthracyclines are far less cardiotoxic as
the conventional formulations and they might accumulate
at the site of the tumour. So far there are little data on the
efficacy of liposomal anthracyclines in advanced soft-tissue
sarcomas when used as single agents. The role of liposomal
anthracyclines in combination with ifosfamide is yet to be
determined.
We combined in a phase II study liposomal dauno-
rubicine with ifosfamide in the treatment of advanced soft
tissue sarcoma. 40 patients were enrolled, 35 of them were
treated first line. In another 4 patients we combined
liposomal doxorubicine with ifosfamide.
The toxicity of these combinations was tolerable. The
response rate was 31% with a median overall survival of
14 months.
Therefore the combination of liposomal anthracyclines
with ifosfamide turned out to be a safe and effective
regimen in the treatment of advanced soft tissue sarcoma.
Further evaluation should be performed.
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Osteosarcoma treatment in children
V. Kobys, G. Klymnyuk, T. Tarasova, O. Balytskaya,
E. Shayda, N. Repina, A. Dedkov
(Institute of Oncology of the Academy of Medical Sciences of
Ukraine, (Kiev, Ukraine))
Introduction: Improvement osteosarcoma treatment results
in children still remains an actual problem despite achieved
survival rate within 70–80%. The application of preopera-
tive chemotherapy correction we consider to be promising
for the improvement of chemotherapy efficiency.
Material and methods: The chemotherapy scheme with
individual matching of preoperative therapy for osteo-
sarcoma local forms was developed and approved at the
Institute of Oncology from 1999. 28 patients were treated
with this scheme. The purpose of this work is to analyze
and summarize treatment results of this patients’ group.
The middle age was 12.5 years. The following drugs were
used: Methotrexate 12g/m
2, cysplatin 40mg/m
2 1–3 day,
doxorubicin 25mg/m
2 1–3 day. Holoxane was used when
inefficiency or low efficiency of previous drug combina-
tions was fixed by complex examinations: Extremity X-ray,
CT, Doppler US.
Results: According to pathohistology of the operating
material pathomorphism of III–IV stage (after Havos)
was in 17 patients (60%). 22 patients (79%) are alive from
16 months to 5 years. Survival cumulative index during
the period of 24 months is 79.2% (p<0.05). Thus, the
developed treatment protocol of osteosarcoma in children
using individual matching of preoperative therapy demon-
strated high efficiency, but small quantity of patients and
limited terms of observation require further investigations.
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